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ABSTRACT 
 
The Amyloid Cascade Hypothesis states that fibrillation of the amyloid beta (Aβ) 
peptide is the primary cause of Alzheimer’s pathology. The trigger for the fibrillation is 
a subject of much debate, although it is clear, oxidative stress is a key feature of 
Alzheimer’s aetiology. This thesis explores a possible role of oxidation of Aβ, in 
particular the effect of histidine and methionine side-chain oxidation, on Aβ fibril 
growth rates. Within chapters 2 and 3 of this thesis is a discussion of various approaches 
to chemical synthesis of 2-oxo-histidine with a view to the incorporation of the oxidised 
amino acids into Aβ peptide using Fmoc approaches. Chapter 2 describes attempted 
chemical transformation of (protected) L-histidine into L-oxohistidine. 
Dimethyldioxirane oxidised Boc-His-OMe yielded products containing isopropylidene 
groups, while oxidation using a Cu(II)/ascorbate generated 2-oxo-histidine but gave 
very low yields. Within chapter 3, a successful synthesis of protected 2-oxo-histidine is 
described, via the known imidazolin-2-one-4-carboxylic. Chapter 4 analyses Aβ(1-40) 
fibrillation kinetics by treating the intact peptide with various oxidants. Contrary to 
previous reports, hydrogen peroxide alone did not slow fibrillation rates. Cu(II)/Cu(I)-
catalysed oxidation increased the likelihood of amorphous aggregation over fibrillation. 
This thesis shows oxidation of Aβ has a profound influence on fibril growth and that 
incorporation of a stable oxidised histidine into Aβ is a realisable goal. 
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1.1. Alzheimer's Disease (AD)
 
 
Alzheimer's Disease (AD) was first characterised in 1906 by Alois Alzheimer upon 
examination of one of his patients, Auguste D, 55 years old. She had presented with the 
symptoms of disorientation, impaired memory, difficulties reading and writing, and 
hallucinations (Alzheimer, A., 1906). Upon post-mortem the cerebral cortex of the 
patient's brain was found to be thinning and, within the remaining tissue, two 
abnormalities were noted, co-localised with neuronal degeneration; intracellular 
neurofibrillary tangles (NFT) within cell bodies and proximal dendrites, and 
extracellular amyloid plaques within the blood plasma, cortical interstitium and 
cerebrospinal fluid (CSF) (Figure 1.1). 
 
 
 
In the 1960s, Terry et al. and Kidd found the main component of plaques to be amyloid 
fibrils (Kidd, M., 1964, Terry, R. D., et al., 1964) and further work in 1984 and 1985 by 
two groups, Glenner and Wong and Masters et al., identified the aggregated 
proteinaceous component of these plaques to be the ~4 kDa amyloid beta (Aβ) peptide 
Figure 1.1: Neuropathology of AD. Histological section of cerebral cortex showing both extracellular 
amyloid plaques and intracellular neurofibrillary tangles (Blennow, K., et al., 2006). 
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(initially named A4) (Glenner, G. G. and Wong, C. W., 1984, Masters, C. L., et al., 
1985). Around the same time, NFTs were found to be composed of paired helical 
filaments (PHFs) containing a hyperphosphorylated form of the microtubule-associated 
protein, tau (Grundke-Iqbal, I., et al., 1986). Further work in the 1980s and 1990s 
deduced more molecular mechanisms behind AD, culminating in the Amyloid Cascade 
Hypothesis in 1992 (see Section 1.3.). Since then research has strived to elucidate the 
exact aetiology of Alzheimer’s disease. 
 
1.2. The amyloid beta (Aβ) peptide 
 
1.2.1. Evidence for Aβ as the toxic species in AD 
 
Throughout the field of AD research there are currently two schools of thought as to 
what is the toxic species in the disease; the “tauists” who believe it is the intracellular 
protein tau and the “baptists” who propose it is the extracellular peptide, Aβ. 
There are several lines of evidence that Aβ is the primary toxic species in AD 
aetiology. Firstly, Aβ is directly toxic to neuronal cell cultures and causes both 
neurodegeneration and impaired learning and memory in animal models (Nakamura, S., 
et al., 2001, Zhang, Y., et al., 2002). Secondly, several mutations of APP, the precursor 
protein from which Aβ is derived, and related APP-processing proteins lead to 
early-onset familial cases of AD (fAD) (Lazo, N. D., et al., 2005). Such AD-causing 
mutations do not exist for the tau protein. Thirdly, Down’s Syndrome sufferers present 
with AD by 50 years of age and this is thought to be due to the increased gene dosage of 
APP on chromosome 21, which is trisomic in the disease.  Therefore, Aβ is likely the 
primary toxic agent in AD aetiology. It is likely that, although tau is not the primary 
toxic species in AD, it is still required for toxicity as a downstream mediator of toxicity, 
with several studies showing that without tau, Aβ toxicity it limited (Oddo, S., et al., 
2006, Rapoport, M., et al., 2002, Roberson, E. D., et al., 2007, Shipton, O. A., et al., 
2011). 
In the literature there is an “Alternative Hypothesis” of Aβ’s role in AD 
pathology that states that Aβ is either a bystander in AD or has a neuroprotective role in 
AD. Any proteinaceous deposits, be they amyloid plaques or neurofibrillary tangles, are 
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hypothesised to be simply downstream developments in the disease progression 
(Castellani, 2009). However, evidence for a neuroprotective role for Aβ is dependent on 
the peptide’s concentration and aggregation state, with picomolar and possibly 
nanomolar concentrations being neuroprotective while higher, disease-related 
concentrations proving neurotoxic (Puzzo, D., et al., 2008, Yankner, B. A., et al., 1990). 
At the Aβ concentrations seen in AD pathology, Aβ is the primary toxic species in the 
disease. 
 
1.2.2. Cleavage of the amyloid precursor protein (APP) generates the Aβ peptide. 
 
The Aβ peptide is not a primary translation product but is instead derived from the 
endoproteolytic processing of a ubiquitous cell-surface protein; amyloid precursor 
protein (APP) (residues 672 to 714, Figure 1.2(C)) (Kang, J., et al., 1987, Robakis, N. 
K., et al., 1987). APP is a type I membrane spanning glycoprotein of approximately 770 
amino acids with three main isoforms; 695, 751 and 770 and has an enriched expression 
in brain tissue. One fundamental event in AD aetiology is the cleavage of the APP 
protein to generate the Aβ peptide. 
Neurons are unique in that the APP they produce can be cleaved by two possible 
pathways; the amyloidogenic pathway (Figure 1.2(A)) and the non-amyloidogenic 
pathway (Figure 1.2(B)) (Busciglio, J., et al., 1993, Selkoe, D. J., 2001). Only the 
amyloidogenic pathway involving two cleavages by the β-and γ-secretases generates the 
Aβ peptide. The second cleavage by γ-secretase can occur anywhere between residues 
711 and 715 of APP leading to several isoforms of Aβ (Figure 1.3). however, 90 % of 
cleavages generate Aβ(1-40) or Aβ(1-42) (Thinakaran, G. and Koo, E. H., 2008). In the 
healthy brain the cleavage to generate Aβ(1-40) is more common leading to an 
abundance of Aβ(1-40) over Aβ(1-42), but this balance can shift in AD pathology 
towards more Aβ(1-42). Aβ isolated from plaques is also found with post-translational 
modifications which make Aβ both more resistant to proteolysis leading to increasing 
Aβ levels (Atwood, C. S., et al., 2002, Kuo, Y.-M., et al., 1998), and, in many cases, 
more liable to aggregate (Fabian, H., et al., 1994, He, W. and Barrow, C. J., 1999). 
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Figure 1.2:  The two pathways of proteolytic degradation of the amyloid precursor protein 
(APP). (A) Amyloidogneic cleavage pathway. (B) Non-amyloidogenic cleavage pathway. (C) 
Cleavage relative to sequence. Residues 670 - 770 of APP are shown. Blue numbers refer to codons in 
the APP sequence, whereas red numbers refer to codons in the holoprotein, Aβ. The neuronal cell 
membrane is illustrated in yellow. Note some minor secretase cleavage sites are not shown. Shown in 
green are the 16 kindreds currently known for familial cases of AD. Adapted from Kosik et al., 1999, 
Barrow 1999 and Lazo et al., 2005 (Barrow, C. J., 1999, Kosik, K. S., 1999, Lazo, N. D., et al., 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: The Aβ sequence can vary between 39 to 43 residues. The amino acid sequence of Aβ 
showing the differentiation between the hydrophilic region of Aβ and hydrophobic region. The most 
common isoforms are Aβ(1-40) and Aβ(1-42) as illustrated with *.  
 
Aβ(1-39) DAEFRHDSGYEVHHQ KLVFFAEDVGSNKGAIIGLMVGGV 
Aβ(1-40) DAEFRHDSGYEVHHQ KLVFFAEDVGSNKGAIIGLMVGGVV * 
Aβ(1-41) DAEFRHDSGYEVHHQ KLVFFAEDVGSNKGAIIGLMVGGVVI 
Aβ(1-42) DAEFRHDSGYEVHHQ KLVFFAEDVGSNKGAIIGLMVGGVVIA * 
Aβ(1-43) DAEFRHDSGYEVHHQ KLVFFAEDVGSNKGAIIGLMVGGVVIAT 
   Hydrophilic   Hydrophobic and amyloidogenic 
 
 
 
 
 
 
 
Chapter 1 
Introduction 
 
 
21 
 
1.2.3. Aβ(1-40) and Aβ(1-42) have different aggregation behaviours and toxicities. 
 
Aβ(1-42) is more hydrophobic than Aβ(1-40) due to the addition of two non-polar 
residues, isoleucine and alanine, at the C-terminus (Kuo, Y.-M., et al., 1998). This 
causes Aβ(1-42) to self-associate more than Aβ(1-40), leading to significantly faster 
fibrillisation rates than for Aβ(1-40) (Jarrett, J. T., et al., 1993) and deposition as 
plaques earlier in AD pathology (Saido, T. C., et al., 1996). Aβ(1-42) is more protease 
resistant and thus has extended longevity compared to Aβ(1-40). It forms larger 
intermediate species on the way to fibres, known as oligomers, than Aβ(1-40), with 
typical Aβ(1-42) species being pentameric and hexameric (paranuclei) and Aβ(1-40) 
oligomers exist as an equilibrium between monomers, dimers, trimers and tetramers 
(Bitan, G., et al., 2003, Chen, Y. R. and Glabe, C. G., 2006). Aβ(1-42) also exclusively 
forms aggregated species most associated with Aβ neurotoxicity – ADDLs and 
amylospheroids (see Section 1.2.8.) – which are not formed by Aβ(1-40) (Hoshi, M., et 
al., 2003, Lambert, M. P., et al., 1998). In general Aβ(1-42) is more neurotoxic than 
Aβ(1-40) and thus Aβ(1-42) is known as the ‘amyloidogenic species’ of Aβ. 
The estimated concentration of Aβ in healthy individuals is 0.2 ± 0.09  nM in the 
blood and between 0.6 nM and 8 nM  in the CSF, predominately as the Aβ(1-40) 
isoform (Gravina, S. A., et al., 1995, Mehta, P. D., et al., 2000, Seubert, P., et al., 1992, 
Vigo-Pelfrey, C., et al., 1993). In the AD brain the concentration of total Aβ increases 
approximately 6-fold to 75 nM soluble Aβ and 5 µM insoluble Aβ (Kuo, Y. M., et al., 
1996, Mclean, C. A., et al., 1999). The concentration of Aβ(1-42) increases 12-fold in 
overall brain tissue but decreases in blood plasma and CSF indicating increased 
sequestration in plaques (Kuo, Y. M., et al., 1996, Pesaresi, M., et al., 2006, Sjogren, 
M., et al., 2002, Tapiola, T., et al., 2009). These increases in Aβ concentrations in the 
AD brain relative to healthy brain are due to both greater production of Aβ coupled with 
impaired Aβ clearance (Lazo, N. D., et al., 2005). 
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1.2.4. Aβ structure 
 
The determination of the structure of full length Aβ has been complicated by the 
propensity of the peptide to form non-crystalline amyloid fibres preventing solution 
NMR studies and X-ray diffraction studies. However, solid-state NMR and site-directed 
spin labelling has enabled the structure to be determined (Roychaudhuri, R., et al., 
2009). 
 
The structure of monomeric Aβ 
 
The Aβ peptide is amphipathic with two distinct regions (Figure 1.3); the hydrophobic 
C-terminal (residues 16-42), which contains mainly non-polar residues, and the largely 
hydrophilic N-terminal (1-15). Within the C-terminus two regions control Aβ 
fibrillisation via the hydrophobic effect; residues 15 – 21 and residues 31 – 36 (Soto, C., 
2004, Wetzel, R., 2006). In particular the Met35 residue has been shown to be important 
to Aβ neurotoxicity, Aβ paranuclei formation, and thus subsequent fibrillisation 
(Nakamura, M., et al., 2007, Varadarajan, S., et al., 2001, Varadarajan, S., et al., 1999). 
This residue is also linked to oxidative stress induced by the peptide. The hydrophilic 
region of the peptide does not fibrillise in solution but instead forms the non-
amyloidogenic random coil conformation. This region contains all the metal binding 
sites, modulates pH-dependence of the peptide’s structure and controls the 
conformational state of the peptide (Barrow, C. and Zagorski, M., 1991). 
In aqueous environments, Aβ has a random coil structure with some bend and 
turn character (Riek, R., et al., 2001, Zhang, S., et al., 2000). In a membrane/micelle 
environment Aβ forms a predominately alpha helical structure with two helices; Helix 1 
from residues 15-24 and Helix 2 from residues 28-36 (Coles, M., et al., 1998, Shao, H., 
et al., 1999). In both environments Aβ can undergo a conformation change to a β-sheet 
form, which has a propensity to form amyloid fibres (Glenner, G. G., et al., 1972, 
Halverson, K., et al., 1990). The N-terminal residues 1-8 remains disordered throughout 
(Torok, M., et al., 2002). 
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The structure of fibrillar Aβ 
 
Site-specific spin-labelling and solid state NMR have shown that, within each β-sheet 
form of the Aβ monomer, residues 12-24 (β1) and 30-40 (β2) (Figure 1.4(A)) in 
Aβ(1-40) and residues 18-26 (β1) and 31-42 (β2) in Aβ(1-42) make up the β-sheets that 
are aligned perpendicular to the fibril axis in a β-strand-turn-β-strand motif, with the 
remaining residues being solvent exposed and random coil (Figure 1.4(A)) (Antzutkin, 
O. N., et al., 2000, Nelson, R. and Eisenberg, D., 2006, Tycko, R., 2006, Whittemore, 
N. A., et al., 2005). These two sheets are joined by a β-turn between residues 25-29, 
which is stabilised by a salt bridge between Asp23 and Lys28 in Aβ(1-42) 
(Figure 1.4(B)) (Luhrs, T., et al., 2005, Nelson, R. and Eisenberg, D., 2006, Petkova, A. 
T., et al., 2002). These β-strands self-assemble and are held together by intermolecular 
backbone-backbone hydrogen bonding in a cross-β structure (Figure 1.4(C)). Based on 
studies on other amyloid proteins this likely forms a steric zipper structure (Nelson, R. 
and Eisenberg, D., 2006, Sawaya, M. R., et al., 2007). This self-assembly leads to 
oligomers and then rod-like protofibrils (aka fibrils), which have a beaded appearance 
due to their formation via elongation of spherical aggregates (Blackley, H. K. L., et al., 
1999, Hartley, D. M., et al., 1999, Nybo, M., et al., 1999, Walsh, D. M., et al., 1999). 
Fibrils have been measured as 150 nm long with a 2.5 - 3.9 nm diameter for Aβ(1-40) 
and a 4 - 6 nm diameter for Aβ(1-42) (Kirschner, D. A., et al., 1986, Nelson, R. and 
Eisenberg, D., 2006). Five or six parallel fibrils around a hollow core make up a mature 
fibre (Burkoth, T. S., et al., 2000, Inouye, H., et al., 1993, Miyakawa, T., et al., 1986, 
Terry, R. D., et al., 1964). Atomic force microscopy (AFM) and transmission electron 
microscopy (TEM) show fibres are > 1 μM in length, 10-15 nm in diameter, un-
branched, twisted and have a regular periodicity in thickness of ~ 150 nm (Burkoth, T. 
S., et al., 2000, Roher, A. E., et al., 1996, Terry, R. D., et al., 1964). They are non-
crystalline and insoluble with the direction of the polypeptide backbone perpendicular 
to the fibril axis. They exhibit birefringence with Congo Red dye and bind the dyes 
thioflavins S and T (Atwood, C. S., et al., 2002, Sipe, J. D., 2000, Soto, C., 2004). 
Fibres aggregate together to form amyloid plaques. Amyloid fibres, across all 
amyloid diseases, share similar structural and spectroscopic characteristics. This 
hierarchical structure of Aβ fibres is built up linearly as shown in Figure 1.5 with an 
Chapter 1 
Introduction 
 
 
24 
 
initial conformational change in the Aβ peptide from its native form (see above) to a β-
sheet form (Halverson, K., et al., 1990). 
 
 
Figure 1.4: Models of the Aβ(1-40) protofilament. (A) Residues1-8 are disordered and not shown. 
Residues 9-40 form two β-sheets – 12-24 (orange) and 30-40 (blue) joined by a turn. The yellow arrow is 
the direction of the fibril long axis. (B) Residues 9-40 coloured based on residue side chain; hydrophobic 
(green), polar (magenta), negative (red), positive (blue). K28 (Lys28) and D23 (Asp23) form a stabilising 
salt bridge at the bend (Petkova, A. T., et al., 2002). (C) The β-strand is made up of parallel β-sheets in a 
cross-β arrangement (Tycko, R., 2006). 
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Unfolded Aβ monomer 
α-helical monomer 
β-sheet monomer 
Oligomers 
Protofibrils 
Fibrils 
Plaques 
Figure 1.5: Amyloidogenic pathway of Aβ aggregation. The electromicrographs are taken 
from Seilheimer et al., 1997 (Seilheimer, B., et al., 1997). 
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1.2.5. The kinetic models of Aβ fibrillisation 
 
The fibrillisation of Aβ is a ‘nucleation-dependent-polymerisation’ (NDP) event 
(Figure 1.6(A)) (Jarrett, J. T., et al., 1993, Wetzel, R., 2006). It involves three main 
stages; a nucleation or stationary lag phase, an elongation phase and a final plateau 
phase. These stages can be represented by a fibril growth curve (Figure 1.6(B)). 
Dynamic light scattering (DLS) studies at acidic pH allow slowed-down kinetics 
to be studied. These studies have shown spherocylinder micelles of Aβ to forming, 
which are seeds for equilibrium, in a constant pre-equilibrium with both monomers and 
further aggregating species. At a critical concentration these seeds form fibre nuclei 
(nucleation) (Lomakin, A., et al., 1997, Wetzel, R., 2006, Yong, W., et al., 2002). 
Nucleation is slow because it is energetically unfavourable with entropy outweighing 
enthalpic gains due to the need to bury hydrophobic residues (Bieschke, J., et al., 2006). 
This generates a lag phase in fibril concentration growth, although this lag phase can be 
removed if the concentration of Aβ is high and the Aβ culture is seeded with a 
nucleating species (Jarrett, J. T. and Lansbury, P. T., 1993). 
 
 
 
 
 
 
 
 
 
 
Figure 1.6: The kinetics of amyloid formation is 
a Nucleation Dependent Polymerisation (NDP). 
(A) Nucleation is thermodynamically unfavourable 
due to a decrease in entropy (kn<<1). However, the 
following elongation phase is thermodynamically 
favourable (ke>>1) because in a non-linear polymer 
monomers can add at multiple sites. (B)  Amyloid 
fibril growth follows a stereotypical sigmoidal 
growth curve. There is an initial stationary lag 
phase or nucleation phase, followed by a rapid 
increase in fibril concentration during an elongation 
phase and finally a plateau phase.   
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Once a critical concentration of nucleating seed species has formed elongation begins 
(Jarrett, J. T. and Lansbury, P. T., 1993). This leads to a rapid increase in fibril 
concentration (Walsh, D. M., et al., 1999). Elongation involves both monomers adding 
to the end of fibrils and fibrils themselves self-associating. In addition, fragmentation of 
fibres generates new fibril ends for monomer addition (Harper, J. D., et al., 1999, 
Nichols, M. R., et al., 2002). 
Finally a plateau phase follows where maximal fibril growth has occurred, 
monomer concentrations have fallen below the critical concentration and the fibres are 
in a thermodynamic equilibrium with the critical concentration of nucleating seeds. 
 
1.2.6. Factors that influence Aβ fibrillisation 
 
Thioflavin-T (Th-T) studies on in vitro Aβ(1-40) have shown that fibrillisation rates are 
dependent on several factors; temperature, pH, Aβ length and sequence, ionic strength, 
solvent hydrophobicity, Met35 oxidation, metal ions, seed concentration and Aβ 
concentration, which it follows with first-order kinetics (Khandogin, J. and Brooks, C. 
L., 3rd, 2007, Mclaurin, J., et al., 2000, Roychaudhuri, R., et al., 2009, Sarell, C. J., et 
al., 2010, Stine, W. B., Jr., et al., 2003). It should be noted when consulting literature 
studies that the in vivo environment experienced by Aβ is different to these in vitro 
environments because the former is influenced by molecular crowding; interactions with 
numerous metals, lipids, such as cholesterol and gangliosides, and proteins, such as 
Apolipoprotein E and laminin (Bronfman, F. C., et al., 1996, Hayashi, H., et al., 2004, 
Mclaurin, J., et al., 2000, Van Den Berg, B., et al., 2000, Yanagisawa, K. and 
Matsuzaki, K., 2002). This may explain why the critical concentration of Aβ for 
fibrillisation in vivo is so much lower (pM) than in vitro (nM) (Selkoe, D. J., 1994). 
However, studies on ex situ plaques combined with radio-iodinated Aβ have shown that 
the same first-order kinetics occurs in vivo (Esler, W. P., et al., 1996) and in vitro Aβ 
fibres have been found to have the same morphology, tinctorial, immunological and 
spectroscopic characteristics as fibres extracted from amyloid plaques, thus validating in 
vitro studies (Giaccone, G., et al., 2005, Soto, C., 2004). 
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1.2.7. Off-pathway Aβ aggregation 
 
As well as the classical polymerisation described above, several pathways, and hence 
several resulting structures, have been found for Aβ assembly. These pathways are 
distinguished as “on-pathway” if they result in fibres and “off-pathway” if they result in 
other structures (Figure 1.7). The folding pathways taken by Aβ depend on its 
concentration. Below 100 μM Aβ amyloid fibrils form, while above 100 μM Aβ 
micelles form (30-50 monomers) as Aβ begins to act as a surfactant (Westlind-
Danielsson, A. and Arnerup, G., 2001). At very high Aβ concentrations (300 – 600 μM) 
Aβ(1-40) only has been shown to spontaneously form highly stable, 20 – 200 μm 
diameter spheres from fibres (Hoshi, M., et al., 2003). 
Several “on-pathway” structures are reasonably stable and have been isolated 
from fibrillising Aβ cultures. They tend to be composed of either dimer and trimer or 
hexameric units of Aβ and include hexameric, 18-mer and 24-mer oligomers and the 
dodecameric species the Aβ*56 and amyloid derived diffusible ligands (ADDLs) 
(Bernstein, S. L., et al., 2009, Bitan, G., et al., 2003, Huang, T. H. J., et al., 2000, 
Roychaudhuri, R., et al., 2009). These last two structures are discussed more in Section 
1.2.8. as potentially toxic species of Aβ. 
Off-pathway species include pore-like structures called annuli (Lashuel, H. A., 
et al., 2003), and globular structures such as globulomers (dodecamer), the “Aβ 
oligomer” (octadecamer), amylospheroids (ASPDs) and amyloid balls, of diameters 10 
– 15 nm and 20 – 200 nm respectively (Hoshi, M., et al., 2003, Murray, M. M., et al., 
2009, Yu, L., et al., 2009). Several of these, especially the larger globular species, have 
only been detected in vitro, although they have been shown to be neurotoxic if their 
diameter exceeds 10 nm (Gellermann, G. P., et al., 2008, Kusumoto, Y., et al., 1998, 
Roychaudhuri, R., et al., 2009). One example of an off-pathway Aβ species, which has 
been detected in situ within brain tissue, is the unstructured amorphous aggregate. 
These aggregates are non-toxic to neuronal and glial cell cultures and this has led to the 
hypothesis that the neurotoxicity of Aβ requires an on-pathway fibril structure (Howlett, 
D. R., et al., 1995, Lorenzo, A. and Yankner, B. A., 1994). 
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1.2.8. Toxic species of Aβ 
 
Amyloid plaques are associated with dystrophic, dysmorphic and dead neurons in the 
AD brain (Benzing, W. C., et al., 1993, Spires, T. L. and Hyman, B. T., 2004). 
Therefore, initially it was thought that amyloid plaques, and the amyloid fibres they 
contained, were the toxic species in the disease (Lorenzo, A., et al., 1993, Pike, C. J., et 
al., 1991, Weldon, D. T., et al., 1998). However, subsequent studies, which inhibited 
plaque formation did not prevent the neurotoxic properties of the peptide (Bieschke, J., 
Figure 1.7: “On-pathway” vs. “Off-
pathway” Aβ(1-42) assembly. 
Adapted from Roychaudhuri et al., 
2009 (Roychaudhuri, R., et al., 2009). 
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et al., 2008, Forloni, G., et al., 1997, Lambert, M. P., et al., 1998). In addition, some 
studies found a lack of correlation between the prevalence of AD pathology and the 
concentration of amyloid plaques in AD patients and the occurrence of memory deficits 
and synaptic dysfunction in mice before amyloid deposition (Aizenstein, H. J., et al., 
2008, Giannakopoulos, P., et al., 2003, Katzman, R., et al., 1988, Mucke, L., et al., 
2000). Instead, plaque formation is now thought of as a neuroprotective mechanism 
which traps smaller toxic aggregates of Aβ, but unfortunately inadvertently causes 
further neurodegeneration through obstruction of axonal transport, activating microglial 
clearance mechanisms and recruiting cellular components (Frautschy, S. A., et al., 
1991, Kowall, N. W., et al., 1991, Meyer-Luehmann, M., et al., 2008, Zhang, Y., et al., 
2002). 
Current dogma now states that it is the smaller pre-fibrillar aggregates of Aβ 
which exhibit cellular toxicity. Freshly prepared Aβ kills fibroblasts (Klein, W. L., et 
al., 2004) and leads to the production of highly toxic substrates, such as hydrogen 
peroxide (H2O2). This production reduces as Aβ peptide cultures age and presumably 
form larger aggregates (Figure 1.8) (Lue, L.-F., et al., 1999, Mclean, C. A., et al., 1999, 
Tabaton, M., et al., 1994). In addition, the concentrations of soluble forms of Aβ 
correlate better with AD progression (Simmons, L. K., et al., 1994). 
 
 
 
 
 
Monomeric forms of Aβ are not neurotoxic (Chromy, B. A., et al., 2003, Ferreira, S. T., 
et al., 2007, Kagan, B., 2005, Kayed, R., et al., 2003), therefore toxic species of Aβ 
must be between monomeric and fibrillar size. The actual size of these neurotoxic Aβ 
species is yet to be elucidated, although there is literature evidence that the following 
Aβ aggregates are toxic species; oligomers (pentameric and hexameric) (Ferreira, S. T., 
Figure 1.8: Hydrogen peroxide production by Aβ(1-40) early in aggregation profile. (A) Curve a 
shows the aggregation profile of Aβ(1-40) as measured with Th-T fluorescence. Curve b shows 
hydrogen peroxide production as predicted by an EPR spectrum for DMPH-OH. Curve c shows the 
simulated hydrogen peroxide production. (B) This is an enlargement of the early part of Figure 1.14A 
(Klein, W. L., et al., 2004).  
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et al., 2007, Gong, Y., et al., 2003, Lambert, M. P., et al., 1998, Oda, T., et al., 1995), 
Aβ-derived diffusiable ligands (ADDLs) also known as Aβ*56  (dodecameric) (Klein, 
W. L., et al., 2004, Lacor, P. N., et al., 2007, Lacor, P. N., et al., 2003, Lambert, M. P., 
et al., 1998, Westerman, M. A., et al., 2002); dimers and trimers (Crouch, P. J., et al., 
2005, Shankar, G. M., et al., 2007), amylospheroids (ASPDs), the only non-β-sheet 
form of toxic Aβ recorded to date (Hoshi, M., et al., 2003),  and finally protofibrils 
(Haass, C. and Steiner, H., 2001, Hartley, D. M., et al., 1999, Nilsberth, C., et al., 
2001). Detection and correlation of Aβ oligomeric forms with toxicity is complicated by 
the fact oligomers are often transient intermediate species and hence oligomeric 
preparations of Aβ are unlikely to be homogenous. Therefore, smaller subsets of 
oligomers may actually be the most toxic form of Aβ. However, it is most likely the 
case that both oligomers and protofibrils are the neurotoxic Aβ species (Bhatia, R., et 
al., 2000, Hoshi, M., et al., 2003, Kayed, R., et al., 2003). 
 
1.3. The Amyloid Cascade Hypothesis 
 
In 1992 Hardy and Selkoe devised the Amyloid Cascade Hypothesis, which described 
how the intial misfolding of the Aβ peptide and its subsequent fibrillisation induced 
neurotoxicity via a cascasde of molecular events, including a loss of ion homeostasis, 
for important ions, such as the signalling ion Ca
2+
 and redox-active metal ions, and 
oxidative stress, eventually leading to neuronal apoptosis (Figure 1.9) (Hardy, J. and 
Selkoe, D. J., 2002, Hardy, J. A. and Higgins, G. A., 1992). 
Aβ exerts this toxicity by binding plasma membrane receptors and disrupting 
intracellular signalling pathways, damaging cellular membranes and thus altering 
neuronal conductance and initiating inflammation and reactive oxygen species (ROS) 
production  (Balleza-Tapia, H. and Pena, F., 2009, Snyder, E. M., et al., 2005, 
Velazquez, P., et al., 1997, Yankner, B. A., 1996). Its oxidation of lipids may also 
prevent tau dephosphorylation thus linking the two proteinergic agents of AD (Mattson, 
M. P., et al., 1997). In conclusion, the Aβ peptide mediates neurodegeneration via 
numerous different mechanisms complicating attempts to develop therapeutics against 
AD. 
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1.4. Current therapies 
 
The therapeutics for AD are currently lagging behind those for comparably common 
diseases such as cancer. It is still nearly impossible to detect pre-clinically with 
diagnosis relying purely on neurological tests that do not distinguish between different 
types of dementia and no confirmation of the disease until post-mortem. Current 
therapeutics, such as acetylcholinesterase inhibitors, are symptomatic only and often 
cause significant side effects (Nordberg, A., 2003). Therapeutics cannot simply reduce 
the concentrations of Aβ because the peptide is hypothesised to have cellular functions 
including as an initiator of neurite sprouting after neuronal lesions (Geddes, J. W., et al., 
1986), as an antioxidant (see Section 1.5.3.), as an apolipoprotein capable of controlling 
cholesterol homeostasis (Koudinov, A. R., et al., 2001) and as a modulator of 
neurotransmitter receptors and neuronal excitation, and thus controlling memory 
Figure 1.9: The Amyloid Cascade Hypothesis. The Amyloid Cascade Hypothesis states that it is the 
misfolding of Aβ and subsequent fibrillisation to oligomers which triggers neurodysfunction and 
neurodegeneration seen in AD pathology. Downstream targets include synaptic dysfunction, loss of 
ion homeostasis and tau hyperphosphorylation and subsequent aggregation to neurofibrillary tangles 
(NFTs) (Hardy, J., Selkoe, D. J., 2002).  
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forming processes such as long-term potentiation (LTP) (Wu, J., et al., 1995a, b). 
Indeed targeting Aβ itself with therapies, such as Aβ vaccination, can lead to 
detrimental side effects such as inflammatory responses (Orgogozo, J. M., et al., 2003, 
Senior, K., 2002). 
Therefore, ideally therapeutics should target the triggers of Aβ misfolding, of 
which there are several hypothesised in the literature. These include elevated levels of 
Aβ causing a concentration-dependent seeding effect (Hortschansky, P., et al., 2005, 
Lomakin, A., et al., 1996), changes in physiological condtions such as pH and ionic 
strength closer to the conditions e.g. pI (PH 5.3) of Aβ where fibrillisation is most rapid 
(Sarell, C. J., et al., 2010, Snyder, S. W., et al., 1994), metal ions binding Aβ and 
altering fibril growth rates  (Sarell, C. J., et al., 2010) and chemical modifications of 
Aβ, such as oxidation of the tyrosine, methionine and histidine residues in Aβ (see 
Section 1.5.3.), altering the net charge and hydrophobicity of the peptide and thus its 
fibrillisation rates. 
Interestingly, some of the most recent successful clinical trials have involved 
antioxidants, such as Vitamin E and α-lipoic acid (Grundman, M., 2000, Hager, K., et 
al., 2007, Sano, M., et al., 1997), and metal chelators,such as Desferrioxamine and 
Clioquinol (Crapper-Mclachlan, D. R. C., et al., 1991, Liu, G., et al., 2010, Ritchie, C. 
W., et al., 2003). This may indicate that metal-catalysed oxidation (MCO) may be very 
important in AD pathology. 
 
1.5. Oxidative Stress  
 
1.5.1. Oxidative stress increases with age. 
 
Oxidative stress relates to tissue damage caused by reactive oxygen species (ROS) 
when cellular antioxidant systems become overwhelmed. ROS include both radicals, 
e.g.superoxide O2˙
-
, hydroxyl radicals HO˙and peroxy radicals ROO−, and non-radicals 
e.g. hydrogen peroxide H2O2, peroxynitritie (ONOO
−
) and lipid-derived aldehydes and 
ketones (Berlett, B. S. and Stadtman, E. R., 1997, Butterfield, D. A. and Stadtman, E. 
R., 1997, Kowalik-Jankowska, T., et al., 2004, Wong, S. F., et al., 1981). These ROS 
are derived from several sources, including lipid peroxidation, ionising radiation and the 
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terminal respiratory electron chain of mitochondria (Halliwell, B., 1992, Olanow, C. 
W., 1993). However, the most frequent mechanism is metal-catalysed oxidation (MCO) 
and this generates the most reactive ROS, the hydroxyl radical (Stadtman, E. R. and 
Berlett, B. S., 1997). 
A consequence of living in an aerobic environment is that oxidation products 
accumulate over time, causing cumulative cellular damage, and these are the cause of 
several age-related disorders (Butterfield, D. A. and Stadtman, E. R., 1997, Zhu, X. W., 
et al., 2005). Indeed studies have shown that the greater the level of oxygen that an 
animal is exposed to, the shorter its lifespan (Halliwell, B. and Gutteridge, J. M. C., 
1985) and Stadtman et al. reported that protein oxidation, as indicated by measuring the 
protein carbonyl content of tissue, increases with age (Figure 1.10) (Stadtman, E. R. and 
Berlett, B. S., 1997). Several studies have shown oxidative stress and aging to be 
intricately linked (Agarwal, S. and Sohal, R. S., 1993, Edamatsu, R., et al., 1995, 
Forster, M. J., et al., 1996, Mecocci, P., et al., 1993, Smith, C. D., et al., 1991, Sohal, R. 
S., et al., 1995, Starke-Reed, P. E. and Oliver, C. N., 1989, Takahashi, R. and Goto, S., 
1990, Youngman, L. D., et al., 1992). Levels of antioxidants which scavenge ROS, such 
as vitamins A, C and E, bilirubin, superoxide dismutase and glutathione, tend to 
decrease with age (Halliwell, B., 1992, Perkins, A. J., et al., 1999, Stadtman, E. R. and 
Berlett, B. S., 1997). Thus it is an alteration in the balance between oxidant production 
and antioxidants that causes increasing oxidative stress with increasing age. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10: Increasing 
carbonyl content of proteins 
with age across numerous 
tissue types. Carbonyl 
content of: Triangles – 
Human dermal fibroblasts. 
Circles – Human occipital 
lobe tissue. Squares – Human 
eye lens cortex. Stars – Rat 
liver hepatocytes (Stadtman, 
E. R., and Berlett, B. S., 1997, 
Smith, M. A., et al., 1994, 
Garland, D., et al., 1988, 
Oliver, C. N., 1987).  
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1.5.2. Oxidative stress in the central nervous system (CNS) and AD 
 
Oxidative stress has been shown to cause synaptic dysfunction and apoptosis in neural 
cultures (Greenlund, L. J. S., et al., 1995, Kamsler, A. and Segal, M., 2004), although 
low levels of ROS are required for normal neuronal function such as LTP (Serrano, F. 
and Klann, E., 2004). The central nervous system (CNS) is particularly vulnerable to 
oxidative stress due to several properties. It has a high oxygen consumption rate i.e. 
20 % of body’s consumption by only 2 % of body weight, due to most energy being 
derived from oxidative metabolism (Coyle, J. T. and Puttfarcken, P., 1993, Jiang, D. L., 
et al., 2010). It has a high concentration of peroxidizable polyunsaturated fatty acid side 
chains present in membranes (Halliwell, B., 1992). With the exception of the liver, the 
brain has the highest concentration of redox active metals in the body (Popescu, B. F. G. 
and Nichol, H., 2011, Youdim, M. B. H., 1988), which coupled with low concentrations 
of iron-binding proteins, such as transferrin, in the cerebrospoinal fluid (CSF) leads to 
high concentrations of free iron (Gruener, N., et al., 1991).  Compared to other tissues, 
the brain tissue has low concentrations of antioxidant enzymes, such as catalase, 
superoxide dismutase and glutathione peroxidase(Coyle, J. T. and Puttfarcken, P., 1993, 
Halliwell, B. and Gutteridge, J. M. C., 1985), and high concentrations of reductants 
such as ascorbic acid (500 μM), 10-fold the level found in the blood and further 
concentrated in neural tissue to approximately 10 mM in neurons and 1 mM in glia 
(Halliwell, B., 1992, Spector, R. and Eels, J., 1984). Finally the low mitotic cellular 
renewal in brain tissue means oxidative damage is not compensated for with 
regeneration of neurons (Lee, H.-G., et al., 2007). 
A recurrent finding from analysis of the post-mortem AD brain is evidence of 
severe oxidative stress. This was first reported by Martins et al. in 1986 with the finding 
of increased activity of the hexose monophosphate pathway enzymes indicative of 
increased oxidative stress (Martins, R. N., et al., 1986). Oxidative stress starts early in 
AD pathology, preceding both Aβ fibrillisation and NFT formation, and continues 
throughout the disease progression, with neurons associated with NFTs and amyloid 
plaques found to contain oxidised nucleic acids (DNA and RNA), oxidised proteins and 
oxidised lipids (Castegna, A., et al., 2002, Ding, Q., et al., 2005, Nunomura, A., et al., 
1999, Sayre, L. M., et al., 1997, Smith, C. D., et al., 1991, Subbarao, K. V., et al., 1990, 
Sun, A. Y., et al., 2001). Markers of oxidative stress are found in regions of the brain 
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associated with neurodegeneration such as the inferior parietal cortex and hippocampus, 
frontal pole, inferior parietal lobe and superior middle temporal gyrus but not the 
cerebellum  (Figure 1.11) (Aksenov, M. Y., et al., 2001, Hensley, K., et al., 1995, 
Hensley, K., et al., 1998, Korolainen, M., A., et al., 2006). 
Further findings indicative of a role of oxidative stress in AD include elevated 
concentrations of redox active transition metals in the AD brain, especially within 
plaques (Markesbery, W. R., 1997, Smith, M. A., et al., 1997a), a lowered pH (6.6) in 
the AD brain, which promotes metal redox reactions required for MCO (Yates, C. M., et 
al., 1990), the concentration in plaques of numerous factors linked to oxidative stress 
e.g. Cu/Zn-SOD, Mn-SOD, catalase and AGE-modified tau (Grundke-Iqbal, I., et al., 
1990, Smith, M. A., et al., 1994a, Smith, M. A., et al., 1997b, Smith, M. A., et al., 
1994b, Smith, M. A., et al., 1994c), elevated concentrations of ROS in the AD brain 
(Atwood, C. S., et al., 2000, Giulian, D., et al., 1998) and upregulation of some 
antioxidant enzymes and metal-binding proteins in the AD brain in regions associated 
with AD pathology (Kish, S., et al., 1986, Lovell, M. A., et al., 1995, Martins, R. N., et 
al., 1986, Premkumar, D. R. D., et al., 1995, Smith, M. A., et al., 1994a). 
Both the tau protein and the Aβ peptide are found oxidised in AD pathology. 
Tau is found oxidised at Cys322 and this leads to protein dimerisation and 
polymerisation to insoluble filaments (Schweers, O., et al., 1995, Troncoso, J. C., et al., 
1993). Aβ is also found oxidised (Boros, S., et al., 2004) and itself is predicted to have 
many roles in the oxidative stress of AD (see Section 1.5.3.). 
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Figure 1.11: 
Markers of 
oxidative stress in 
the AD brain are 
in regions 
correlated with 
neurodegeneratio
n. Oxidative stress 
in AD occurs in the 
frontal cortex, 
hippocampus, and 
neighbouring 
entorhinal cortex, 
and areas of the 
temporal lobe. 
These are also 
areas of 
neurodegeneration 
in AD pathology 
(shown in red). 
Neither oxidative 
stress or 
neurodegeneration 
occurs in the 
cerebellum 
(Aksenov, M. Y., 
et al., 2001, 
Hensley, K., et al., 
1995, Hensley, K., 
et al., 1998, 
Korolainen, M., A., 
et al., 2006).  
 
Chapter 1 
Introduction 
 
 
38 
 
1.5.3. The role of Aβ in AD oxidative stress 
 
Aβ as a pro-oxidant in AD pathology 
 
The Aβ peptide may not just be toxic due to its aggregation state (see Section 1.2.8). It 
may also mediate toxicity by being a pro-oxidant in AD pathology. Several studies have 
correlated Aβ neurotoxicity with levels of cellular oxidants e.g. neurons depleted of 
antioxidants are more susceptible to Aβ-mediated toxicity (White, A. R., et al., 1999). 
In addition, Aβ neurotoxicity can be inhibited by radical scavengers and antioxidants 
such as catalase, vitamin E and gossypin (Behl, C., 1997, Yatin, S. M., et al., 2000, 
Yoon, I., et al., 2004). Targeting Aβ with antisense oligonucleotides reduces oxidative 
stress in transgenic mice models (Poon, H. F., et al., 2004) and in situ studies have 
shown that markers of oxidative stress are elevated in the tissues of animal models 
expressing Aβ and neuronal cultures exposed to Aβ (Akama, K. T., et al., 1998, Bondy, 
S. C., et al., 1998, Butterfield, D. A., et al., 1994, Della Bianca, V., et al., 1999, 
Klegeris, A. and Mcgeer, P. L., 1997, Matsuoka, Y., et al., 2001, Murray, I. V. J., et al., 
2005, Rival, T., et al., 2009, Smith, M. A., et al., 1998, Sultana, R. and Butterfield, D. 
A., 2008, Yatin, S. M., et al., 1999). 
Aβ has been proposed to promote oxidative activities in cells including 
stimulating RAGE receptors within neurons, which causes oxidative stress, stimulating 
nitric oxide and superoxide production by microglia, converting cholesterol to 
neurotoxic 7-hydroxycholesterol and entering mitochondria to induce ROS generation 
within these organelles (Li, M., et al., 1996, Mcdonald, D. R., et al., 1997, Meda, L., et 
al., 1995, Nelson, T. J. and Alkon, D. L., 2005, Pratico, D., 2008, Thomas, T., et al., 
1996, Yan, S. D., et al., 1996). It has also been reported to decrease the activity of 
endogenous antioxidants such as glutathionine peroxidase, superoxide dismutase, 
ascorbic acid, vitamin E and glutathione (Kato, M., et al., 1997, Melo, J. B., et al., 
2009, Wan, L., et al., 2011). 
In addition, to promoting oxidative processes, the Aβ peptide has been proposed 
to produce ROS itself. Hensley et al., first reported electron paramagnetic resonance 
(EPR) and mass spectrometric data, which seemed to show that Aβ produced radicals 
upon fragmentation (Hensley, K., et al., 1994). However, this spontaneous generation of 
ROS by Aβ was disputed by several studies which showed Aβ-induced radical 
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production required metals (Dikalov, S. I., et al., 1999, Huang, X., et al., 1999a, Huang, 
X., et al., 2004, Turnbull, S., et al., 2001) and thus Hensley’s initial study was explained 
as having involved trace metals in solution. 
Huang et al. reported Aβ to produce equimolar concentrations of hydrogen 
peroxide, by the reduction of molecular oxygen and either Cu
2+
 or Fe
3+
 (Huang, X., et 
al., 1999a, Huang, X., et al., 1999b). This hydrogen peroxide production was then 
correlated to the toxicity of the peptide and has been shown to be enough to oxidise 
other proteins (Antunes, F. and Cadenas, E., 2001, Harris, M. E., et al., 1995). The 
toxicity of Aβ can be inhibited by the hydrogen-peroxide scavenger catalase and 
neuronal cell clones, which are resistant to Aβ toxicity, are also often resistant to H2O2 
toxicity (Behl, C., et al., 1994), implying that the peptide’s toxicity is mediated by H2O2 
(Behl, C., et al., 1994, Huang, X., et al., 1999a, Rival, T., et al., 2009). Further studies 
reported that Aβ was capable of further reducing this H2O2 to generate hydroxyl radicals 
via Fenton’s chemistry (Dikalov, S. I., et al., 2004, Guilloreau, L., et al., 2007). 
This pro-oxidant activity of Aβ has been proposed to be mediated specifically by 
smaller aggregates of the peptide while plaques, which negatively correlate with 
oxidative damage, may be redox-silencing traps for the Aβ peptide (Cuajungco, M. P., 
et al., 2000, Smith, D. G., et al., 2007). There is some dispute whether monomeric Aβ  
or oligomeric/fibrillar Aβ is the more redox active (Drake, J., et al., 2003, Fang, C.-L., 
et al., 2010, Jiang, D. L., et al., 2010, Monji, A., et al., 2001).  The two major Aβ 
isoforms have been reported to have different pro-oxidant activity with the Aβ(1-42) 
peptide generating 5 times the concentration of hydroxyl radicals than the Aβ(1-40) 
peptide (Huang, X., et al., 1999a). 
 
Aβ as an antioxidant in AD pathology 
 
Despite evidence from the studies described above it is not current dogma in the field of 
Alzheimer’s research that Aβ is a pro-oxidant and in fact several studies have reported 
Aβ to be an antioxidant in the disease. Some of these studies have reported that 
antioxidants do not protect against the neurotoxicity of Aβ (Lockhart, B. P., et al., 1994, 
Lorenzo, A. and Yankner, B. A., 1994), and inconsistent results found by Zhang et al. 
for the action of H2O2 scavengers led this group to propose that inhibition of Aβ 
neurotoxicity by catalase was due to induction of a conformational change in the 
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peptide rather than ROS scavenging (Zhang, Z., et al., 1996). Further evidence against 
Aβ being a pro-oxidant is the fact oxidative stress occurs early in AD aetiology, prior to 
increases in Aβ concentrations and deposition (Drake, J., et al., 2003, Nunomura, A., et 
al., 2001, Pratico, D., et al., 2001). In addition, application of low concentrations of Aβ 
(0.1 – 1.0 nM) to cellular cultures has been shown to protect against certain types of 
oxidative stress e.g. ascorbate-stimulated lipid peroxidation (Kontush, A., 2001, 
Kontush, A., et al., 2001a). 
There are two mechanisms by which Aβ is hypothesised to act as an antioxidant 
against MCO; scavenging already formed ROS such as hydroxyl radicals or chelating 
redox-active metals and preventing ROS formation by MCO. Both are proposed to act 
via the Met35 residue, with Aβ rapidly chelating redox active metals and in doing so 
being oxidised to Met35 sulfoxide and then slowly scavenging ROS after this oxidation 
which leads to further oxidation of Met35-sulfoxide to Met35-sulfone (Baruch-
Suchodolsky, R. and Fischer, B., 2008). In terms of the second mechanism, the H2O2 
and hydroxyl radical production rates of Aβ-metal complex are less than for the free 
metal, for both Cu
2+
 (Guilloreau, L., et al., 2007) and Fe
3+ 
(Khan, A., et al., 2006). 
However, most redox active metals are not in a free form in physiological settings and 
Aβ-Cu produces more ROS than these other protein-Cu complexes (Guilloreau, L., et 
al., 2007, Hureau, C. and Faller, P., 2009). Therefore Aβ may not be as useful an 
antioxidant as previously hypothesised. 
It may be the case that Aβ has a dual-role of both pro-oxidant and antioxidant 
dependant on certain conditions; Cu
2+
 ions concentration (Hayashi, T., et al., 2007), the 
presence of ascorbate (Murray, I. V. J., et al., 2005, Zou, K., et al., 2002) or whether it 
binds Cu
+
 or Cu
2
 (Baruch-Suchodolsky, R. and Fischer, B., 2008, 2009). Finally Aβ 
concentration is thought to control the antioxidant behaviour of Aβ with high disease-
related concentrations i.e. μM concentrations rather than normal nM concentrations, 
needed for antioxidant behaviour (Baruch-Suchodolsky, R. and Fischer, B., 2008, 
Kontush, A., et al., 2001b). This is likely due to increased aggregation of Aβ at higher 
concentrations of the peptide and the increased redox metal ion binding affinity of 
aggregated Aβ compared to the monomeric peptide (Baruch-Suchodolsky, R. and 
Fischer, B., 2008). Several groups have proposed oligomeric Aβ to be antioxidant, 
whereas fibrillar and monomeric Aβ is pro-oxidant (Karr, J. W. and Szalai, V. A., 2008, 
Nadal, R. C., et al., 2008, Sponne, I., et al., 2003, Zou, K., et al., 2002). 
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This condition dependent behaviour of Aβ has led to the hypothesis that Aβ has a dual 
role in AD pathology; as an antioxidant in its monomeric form and as a pro-oxidant in 
its oligomeric form (Atwood, C. S., et al., 2003, Kontush, A., 2001, Nadal, R. C., et al., 
2008). A final consideration is that oxidative stress can control the production of Aβ, 
via H2O2 production damaging the APP promoter and peroxidation of phospholipids in 
the plasma membrane altering the activity of γ-secretase, degrading the enzymes which 
usually catabolise the peptide, all leading to further Aβ production (Frederikse, P. H., et 
al., 1996, Misonou, H., et al., 2000, Paola, D., et al., 2000, Shinall, H., et al., 
2005).Therefore, with oxidative stress controlling Aβ concentrations and high 
concentrations of Aβ becoming pro-oxidant, a positive feedback loop is set up in AD 
pathology of increasing oxidative stress. 
 
Aβ and metal catalysed oxidation (MCO) 
 
In AD there is a loss of metal homeostasis with altered concentrations of free metal ions 
in AD brains (Atwood, C. S., et al., 1999) and increased concentrations particularly in 
areas of neurodegeneration (Deibel, M. A., et al., 1996, Thompson, C. M., et al., 1988). 
These metal ions include the redox active Cu
2+ 
and Fe
3+
 ions (Cornett, C. R., et al., 
1998, Dong, J., et al., 2003, Lovell, M. A., et al., 1998). Metal ions have been found to 
alter APP expression and trafficking (Rival, T., et al., 2009, Venti, A., et al., 2004) and 
alter the fibrillisation properties of Aβ by binding the peptide, altering its net charge and 
encouraging amorphous aggregation instead of fibrillisation (Atwood, C. S., et al., 
1999, Chevion, M., 1988, Sarell, C. J., et al., 2010, Stadtman, E. R., 1990, Stadtman, E. 
R. and Berlett, B. S., 1991, 1997). However, one of the most likely effects of increased 
redox active metal concentrations in AD is an increased occurrence of metal-catalysed 
oxidation (MCO). 
Metal-catalysed oxidation is the production of reactive oxygen species (ROS) by 
the redox activity of metals such as copper ions and iron ions. These metals transfer 
single electrons and cycle between their reduced (Cu
+
 and Fe
2+
) and oxidised state (Cu
2+
 
and Fe
3+
). By transferring these electrons to species such as oxygen and hydrogen 
peroxide in reactions such as the Haber Weiss Reaction and Fenton’s Reaction these 
metals can generate ROS including the superoxide anion and hydroxyl radicals (Fifure 
1.9). MCO is a site-specific process thus these highly reactive hydroxyl radicals oxidise 
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neighbouring targets (Opazo, C., et al., 2002). Opazo et al. proposed Aβ to act as a 
metalloprotein, forming a complex with these redox active metal ions (Figure 1.12) 
(Baruch-Suchodolsky, R. and Fischer, B., 2008, Halliwell, B. and Gutteridge, J. M. C., 
1985, Huang, X., et al., 1999a). Indeed, the residues of Aβ involved in metal co-
ordination tend also to be the residues required for ROS production by the peptide 
(Figure 1.13). 
 
Figure 1.12: Metal-catalysed 
oxidation reactions. Aβ is 
hypothesised to act as a 
metalloprotein, forming a 
complex to a redox active metal 
(M
(n+1)+
). It can take on a 
radicalised form through the 
oxidation of metal ions such as 
Cu
2+
or Fe
3+
. (a) A metal ion 
transfers an electron to molecular 
oxygen leading to the production 
of the anionic radical superoxide. 
This is bound to the Aβ-Cu 
complex and thus is not itself a 
toxic ROS of Aβ-mediated 
neurotoxicity. (b) Superoxide is 
dismutised with another molecule 
of hydrogen peroxide to hydrogen 
peroxide. (c) Fenton’s Reaction. 
(d) Haber-Weiss Reaction. Both 
of these reactions lead to hydroxyl 
radical production, which can be 
free or metal bound (Opazo, C., et 
al., 2002, Hewitt, N., and Rauk, 
A., 2009). 
Chapter 1 
Introduction 
 
 
43 
 
(A) 
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGV 
 
(B) 
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGV 
 
 
Figure 1.13: A comparison of Aβ residues which bind copper and Aβ residues linked to ROS 
production. 
A summary of the literature reports of: 
(A) Residues potentially involved in Cu
2+ 
co-ordination (blue) and Cu
+ 
co-ordination (green). 
(B) Residues involved in Cu
2+ 
reduction (red) and ROS scavenging (yellow). 
 
Different types of MCO systems include Fenton’s Reagents (Cu2+/H2O2), Udenfriend’s 
Reagents (Fe
3+
/ascorbic acid) and the Cu
2+
/ascorbic acid system. Of the two redox 
active metals, the reduction of Cu
2+
 by Aβ is more efficient than the reduction of Fe3+, 
and Cu
2+
 ions generate hydroxyl radicals from H2O2 at several times the rate of Fe
3+
 
(Dikalov, S. I., et al., 2004, Guilloreau, L., et al., 2007, Jiang, D., et al., 2007). In 
addition, for redox cycling of the metal to occur, and hence greater than equimolar 
concentrations of H2O2 to be generated by the Aβ-metal complex, an external reducing 
agent is required of a lower redox potential that the Aβ-metal complex (0.28 – 0.34 V 
vs. NHE), e.g. ascorbic acid (0.051 – 0.058 V vs. NHE) (Khossravi, M. and Borchardt, 
D. R., 1998). It should be noted that ascorbate has a dual role as a pro-oxidant and an 
antioxidant. As a pro-oxidant it can reduce Cu
2+
 to Cu
+
 whereas as an antioxidant it can 
scavenge ROS (Stadtman, E. R. and Berlett, B. S., 1997). 
Because MCO is site specific, the binding of redox active metals to Aβ and 
subsequent production of ROS such as the hydroxyl radical likely leads to oxidation of 
the Aβ peptide itself. This oxidation could lead to peptide bond cleavage or peptide 
cross-linking leading to large-insoluble aggregates. However, another outcome of Aβ 
oxidation may be amino acid side chain modifications (Table 1.1), particularly of 
aromatic and/or metal binding amino acids, which alter the net charge and 
hydrophobicity of the peptide, thus altering its fibrillisation rate. Hence MCO may be 
one of the elusive triggers of the Amyloid Cascade. 
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Amino acid Products of oxidation 
Arginine Carbonyl derivatives 
Threonine 
Proline 
Lysine 
Leucine Hydroxyleucine 
Methionine Methionine sulfoxide/methionine sulfone 
Phenylalanine Hydroxyphenylalanine 
Tyrosine Dityrosine and nitrotyrosine derivatives 
Tryptophan Hydroxytryptophan, kynurenine derivatives, nitrotryptophan 
Cysteine Disulfide derivatives 
Histidine 2-oxo-histidine, 4-OH-glutamate, aspartic acid, asparagine 
Glutamic acid α-ketoacyl derivatives 
Table 1.1: Expected products of amino acid oxidation. 
 
Histidine, methionine and tyrosine residues of Aβ are likely oxidised by MCO 
 
Several factors determine an amino acid’s susceptibility to oxidation. Amino acids in a 
hydrophilic peptide environment are more readily oxidised than amino acids in a 
hydrophobic region, due to their greater exposure to the aqueous medium. In Aβ this 
would favour oxidation within the hydrophilic N-terminal (1-28) region rather than the 
hydrophobic C-terminus (29-42). In addition, the type of oxidising system can 
determine amino acid susceptibility to oxidation. As described above Aβ seems to be 
primarily involved in MCO, which produces highly reactive short-lived ROS which 
target their nearest neighbours. The redox active metal ion Cu
2+
 has been shown to bind 
the Aβ peptide via the three histidines (His6, His13 and His14) and the N-terminus as 
part of a square-planar complex (Figure 1.14) (Huang, X., et al., 1999a, Nakamura, M., 
et al., 2007, Smith, D. P., et al., 2006). These three histidine residues of Aβ are required 
for the reduction of Cu
2+
, as shown by comparison with rat Aβ, which contains one less 
histidine than human Aβ and is subsequently less redox active (Ali, F. E., et al., 2003, 
Inoue, K., et al., 2006, Kowalik-Jankowska, T., et al., 2004, Nadal, R. C., et al., 2008, 
Schiewe, A. J., et al., 2004, Schoneich, C. and Williams, T. D., 2002, Schoneich, C. and 
Williams, T. D., 2003). Therefore, these residues are the nearest targets of any ROS 
generated by MCO with the Cu
2+
 ion. 
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Indeed the three histidine residues of Aβ, in particular His13 and His14, have been 
identified as oxidised in several in vitro studies where the Aβ peptide has been exposed 
to MCO conditions such as Cu
2+
 ions and either H2O2 or ascorbic acid (Nadal, R. C., et 
al., 2008, Schoneich, C. and Williams, T. D., 2002). The product of this histidine 
oxidation is often identified as 2-oxo-histidine (Kowalik-Jankowska, T., et al., 2004) or 
asparate and asparagine (Uchida, K. and Kawakishi, S., 1989b), which are oxidation 
products derived from 2-oxo-histidine (Scheme 1.1(B))  (Giunta, S., et al., 2000, Nadal, 
R. C., et al., 2008, Nishino, S. and Nishida, Y., 2001, Schiewe, A. J., et al., 2004, 
Schoneich, C. and Williams, T. D., 2003). 
Several studies have found other residues in Aβ such as methionine (Met35) and 
Tyrosine (Tyr10) oxidised after MCO to the products given in Scheme 1.1(C), either in 
addition or instead of histidine residues (Head, E., et al., 2001, Shearer, J. and Szalai, V. 
A., 2008). In addition, although 90 % of Aβ isolated from amyloid plaques upon post 
mortem is found oxidised (Dong, J., et al., 2003), only the Met35 residue is found to be 
the likely target in the Aβ sequence (Atwood, C. S., et al., 2000, Baruch-Suchodolsky, 
R. and Fischer, B., 2008). 
Figure 1.14: Cu
2+ 
ions bind Aβ as part of a square planar complex. The first mole of Cu2+ ions is 
co-ordinated to Aβ via the three histidines of the peptide and its N-terminus amino groups in a square-
planar geometry. Modified from Syme and Nadal et al. (Syme, C. D., et al., 2004). 
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This finding might be due to the analysis techniques used, e.g.raman spectroscopy, 
being unable to detect certain oxidised residues. In addition, Aβ peptides isolated from 
AD plaques is found with both a 32 % histidine loss and a percentage gain in arginine, 
Scheme 1.1: Amino acid oxidation products associated with Aβ. Common oxidation products of the 
three most likely oxidised amino acids in the Aβ sequence; (A) methionine, (B) histidine and (C) 
tyrosine. For simplicity the amino acid backbone and β-carbon are not shown.  
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glutamate and glutamine, the end products of histidine oxidation (Nadal, R. C., et al., 
2008, Schiewe, A. J., et al., 2004). MCO may continue after production of 2-oxo-
histidine to provide these ring-ruptured products. Therefore, histidine oxidation in Aβ is 
a likely event in AD pathology. Aβ tends to be found di-oxidised at Met35 and one 
histidine residue (Sundberg, R. J. and Martin, R. B., 1974). Therefore, the two main 
residues found oxidised are histidine (His6, His 13 and His14) and methionine (Met35). 
 
The three histidines of the Aβ peptide 
 
Histidine (His or H) 5 is a 156 Da basic amino acid (pI 7.61) with a positively charged 
imidazole side chain (pKa 6.04) at neutral pH, meaning that at physiological pH 
histidine can act as a buffer. A pyridine-type nitrogen in the imidazole ring side chain 
allows histidine to bind metals, such as Cu
2+
 and Zn
2+
 ions (Fraser, P. E., et al., 1994). 
This property and the basic nature of the imidazole side chain give this residue its 
biological activity. 
The imidazole ring can be represented by two tautomers (Scheme 1.2).  The 
labelling of histidine is discussed further in Chapter 6. 
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As described above in Section 1.2.8., the Aβ peptide has a toxicity that is linked to its 
fibrillisation state, with oligomeric and protofibrillar forms being considered the most 
neurotoxic. Although, the histidine residues of Aβ are not important for determining the 
peptide’s pre-fibrillar β-sheet packing (Hou, L., et al., 2004), they are important for the 
process of fibrillisation and subsequent fibril stabilisation (Fraser, P. E., et al., 1994, 
Hilbich, C., et al., 1991, Mclaurin, J. and Fraser, P. E., 2000), with histidine 
substitutions leading to altered length and surface tension of Aβ protofibrils and the 
Scheme 1.2: The tautomeric forms of L-histidine 5 and 2-oxo-histidine 4. L-histidine has two 
tautomers of the imidazole ring, which exists predominately in the X tautomer but undergoes fast 
hydrogen atom exchange to the minor tautomer. 2-Oxo-histidine exists in a tautomeric state of three 
tautomers although it is primarily believed to exist in the cyclic urea tautomer Y. 
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formation of stable, amorphous, ribbon like-aggregates beyond the protofibrillar stage 
(Hou, L., et al., 2004). This is likely due to these histidines forming intramolecular 
interactions via glycoaminoglycans, binding metals, forming salt-bridges via their 
imidazole moieties to carboxylates in aspartate and glutamate residues, e.g. Asp23-
His13, (Figure 1.15) (Lazo, N. D., et al., 2005), and undergoing hydrogen bonding 
(Giulian, D., et al., 1998). These all contribute to an amorphous aggregate structure 
instead of the usual amyloid fibrillar structure. In general, as histidine is the only amino 
acid able to buffer at physiological pH, these three amino acids are very important for 
determining the electrostatic charge of the Aβ peptide in physiological environments. 
 
 
 
There are numerous mechanisms by which Aβ is proposed to exert its toxicity. One is 
the activation of microglia leading to brain inflammation seen in Alzheimer’s pathology 
and His13 and His14 in the Aβ sequence have been shown to be part of a HHQK (His-
His-Gln-Lys) tetrad which binds and activates these microglia (Smith, D. G., et al., 
2010). Another mechanism of Aβ toxicity, is the binding of Aβ oligomers to cellular 
membranes, and mutation studies have shown His14 to be vital for this binding and 
subsequent neurotoxicity, via electrostatic interactions between the charged head groups 
of phosphatidylserines and the imidazoles of histidines (Díaz, J. C., et al., 2006). The 
channels that are proposed to form when Aβ binds to these membranes are also reliant 
on His13 and His14 being present in the Aβ sequence, as shown by mutation studies 
(Nakamura, M., et al., 2007). The three histidines of Aβ have also been shown to be 
important in determining the antioxidant behaviour of Aβ, as these residues have been 
Figure 1.15: Modification of the histidines in Aβ promotes amorphous aggregation over 
fibrillisation.  
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implicated as scavengers of potentially harmful free radicals (Traore, D. A. K., et al., 
2009). 
Histidine oxidation in other proteins has been shown to alter metal affinities 
(Meister Winter, G. E. and Butler, A., 1996), alter protein function (Lewisch, S. A. and 
Levine, R. L., 1995) and alter protein turnover (Liaw, S.-H., et al., 1993, Schoneich, C., 
2004). Histidine oxidation in the Aβ sequence may be protective as oxidised Aβ has a 
lower affinity for Cu
2+
 ions and thus may be less likely to generate ROS by Cu
2+
 
reduction (Schoneich, C., 2000, Uchida, K. and Kawakishi, S., 1994). However, if 
histidine oxidation leads to greater Aβ fibrillisation rates, then such oxidation may not 
be protective at all and this is discussed more in Chapter 4. 
These effects of histidine oxidation in other proteins and the numerous roles of 
the histidine residues in the Aβ sequence on AD aetiology, indicate that oxidation of 
histidine residues could greatly alter this aetiology. 
 
The most likely product of histidine oxidation is 2-oxo-histidine. 
 
Histidine can be oxidised by MCO on either the imidazole ring or on the amino acid 
backbone (Scheme 1.3). Oxidation of the imidazole side-chain of N(α)-Bz-His-OH 5b 
has been shown by Uchida and Kawakishi to lead to 2-oxo-histidine 4, a 172.5 Da 
mono-oxygen C-2 adduct of histidine 4, also known as β(2oxoimidazolonyl)alanine 
(Uchida, K. and Kawakishi, S., 1989b, 1990b) or to ring-ruptured products such as 
asparagine 3, aspartate 2, aspartylurea 1, formylasparagine 8, 4-hydroxyglutamate 9 and 
glutamic acid 10 (Ali, F. E., et al., 2003, Levine, R. L., et al., 1996). Oxidation of the 
amino acid backbone involves hydrogen abstraction at the α or β carbon leading to 
compounds such as α-ketoacids, aldehydes, amides, imidazole acetic acids, imidazole 
lactic acids, imidazole acsetonitriles or carboxylic acids (Ali, F. E., et al., 2003). 
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Scheme 1.3: MCO of N(α)-Bz-His-OH can 
generate both ring-ruptured products and 
α, β-oxygen adducts. (A) Uchida and 
Kawakishi reported NMR evidence that 2-
oxo-histidine 4 could be further oxidised by 
MCO to form ring ruptured products such as 
formylasparagine 8 and aspartylurea 1 which 
decompose to asparagine 3 and aspartate 2. 
(B) Oxidation of histidine can also occur at 
the α or β position in the amino acid 
backbone, leading to products such as 
benzoate 11, benzamide 12 and 5-(2-
benzamididovinyl)imidazole 13 (Uchida, K., 
and Kawakishi, S., 1989, 1990).  
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Mono-oxygen addition to the imidazole ring is the main product of MCO, with oxygen 
addition at C-2 4, C-4 7 or C-5 6. Addition of oxygen at C-4 7 and C-5 6 has been 
detected by Schoneich using EPR studies (Lassmann, G., et al., 2000) and in some cases 
these adducts have been predicted to be the predominant form (Schoneich, C., 2000). 
However, these oxygen adducts are predicted not to be stable and are likely to either 
leads to ring fragmentation or conversion to 2-oxo-histidine 4 (Scheme 1.4) (Schoneich, 
C., 2000). The production of 2-oxo-histidine is also reported to be MCO system specific 
e.g. Uchida et al. found Fe
3+
-based redox systems, Fenton’s or Udenfriend’s, incapable 
of producing 2-oxo-histidine 4 (Uchida, K. and Kawakishi, S., 1989b). 
Oxo-histidine has also been detected following application in vitro of Cu
2+
 ions 
and ascorbate to numerous proteins.  Evidence includes addition of +16 mass units to 
proteins (Zhao, F., et al., 1997), amino acid analysis showing a decrease in histidine 
content of proteins (Lewisch, S. A. and Levine, R. L., 1995, Requena, J. S. R., et al., 
2001), detection of an earlier eluting amino acid in amino acid analysis  (Zhao, F., et al., 
Scheme 1.4: Oxygen addition to C5 during histidine oxidation. Hydroxyl radicals can  add at 
the C-5 position. They can then either react with molecular oxygen (B) to form a peroxy radical 
which will further react, or they can reduce Cu
2+  
(C), which will ultimately lead to the imidazole 
ring fragmenting (as shown by the dotted lines). One, theorised reaction of the C-5 adduct 6 is 
shown (A), where in the presence of transition metals or a basic environment, water elimination of 
the C-5 adduct 6 converts it to a radical precursor of the C-2 adduct 84. These reactions all apply 
to the C-4 adduct 7 (Schoneich, C., 2000). 
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1997), decreased C-2 
1
H-NMR peak intensities for histidine within proteins under MCO 
conditions (Khossravi, M., et al., 2000, Uchida, K. and Kawakishi, S., 1990c), 
1
H-NMR 
peaks that match those of the model N(α)-Bz-His-OH 5b (Meister Winter, G. E. and 
Butler, A., 1996, Retsky, K. L., et al., 1998, Uchida, K. and Kawakishi, S., 1993, 1994)
 
and co-elution of the oxidised amino acid isolated from HPLC columns with a known 
sample of 2-oxo-histidine 4 (Santa Maria, C., et al., 1995). 
Initially, there were concerns in the literature that, although 2-oxo-histidine 4 
could be detected in vitro after application of MCO, this form of oxidised histidine may 
not form in vivo. Studies on CuZnSOD isolated from liver that reported an age-
dependent loss of histidine (Ghezzo-Schoneich, E., et al., 2001) could not be replicated 
by later mass spectrometry studies (Atwood, C. S., et al., 2000). In addition, although 
Aβ released from brain tissue showed loss of histidine residues (Lee, J. and Helmann, J. 
D., 2006) it was not identified as containing 2-oxo-histidine 4. However, studies on the 
transcription factor PerR  have shown that after exposure to H2O2, histidine will 
incorporate oxygen in vivo (Traore, D. A. K., et al., 2009). Traore et al. advanced on 
this study by isolating 2-oxo-histidine 4 from PerR protein oxidised in vivo and 
providing a crystal structure of the oxidised amino acid (Figure 1.16) (Hovorka, S. W., 
et al., 2002, Schoneich, C., 2000, Schoneich, C. and Williams, T. D., 2002). Therefore, 
it is likely that 2-oxo-histidine 4 is a relevant form of oxidised histidine in vivo. 
 
 
 
Therefore the most likely product of histidine oxidation in Aβ exposed to MCO is 2-
oxo-histidine (Atwood, C. S., et al., 2002, Sayre, L. M., et al., 1997, Uchida, K. and 
Kawakishi, S., 1986, 1989b, 1993).  It contains a neutral cyclic urea rather than the 
Figure 1.16: Density map and corresponding crystal structure of the His37 residue in PerR-Zn 
after application of hydrogen peroxide. A crystal structure of His37 after application of hydrogen 
peroxide reveals the oxidation product is 2-oxo-histidine 4.  
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basic imidazole of histidine, at neutral pH, and hence is less nucleophilic than histidine, 
giving it a reduced proton affinity relative to histidine (Lewisch, S. A. and Levine, R. 
L., 1995) and causing it to exit later than histidine 5 from reverse-phase HPLC (RP-
HPLC) columns (Lam, A. K. Y., et al., 2010). DFT calculations predict that 2-oxo-
histidine exists as a mixture of three tautomers (Scheme 1.2) especially in an aqueous 
environment (Ren, Y., et al., 2005). The most stable tautomer is the cyclic urea form 
thus 2-oxo-histidine 4 has no aromatic character unlike histidine.  
2-Oxo-histidine 4 is stable in an acid environment e.g. at the 0.05 M HClO4 
(Traore, D. A. K., et al., 2009) and the 6 M HCl needed for amino acid analysis as long 
as dithiothreitol (DTT) is used (Lewisch, S. A. and Levine, R. L., 1995). However, it is 
not stable in a basic environment and thus its stability can be increased by keeping pH 
below 8.0 (Lewisch, S. A. and Levine, R. L., 1995, 1999). In addition, freeze drying at 
20 °C or storage as a protein hydrolysate has been shown to reduce the oxidised 
residue’s degredation rates (Ren, Y., et al., 2005). This must be considered when using 
this amino acid in solid phase peptide synthesis. 
2-Oxo-histidine can also form 2-oxo-His-2-oxo-His or Lys-2-oxo-His protein 
cross-links (Meister Winter, G. E. and Butler, A., 1996) thus promoting peptide 
aggregation. Therefore, the oxidation of histidines in the Aβ peptide to 2-oxo-histidine 
is highly likely to alter the behaviour of the Aβ peptide. 
 
Mechanisms of hidtidine oxidation to 2-oxo-histidine by MCO 
 
There is some debate in the literature regarding the mechanism by which histidine is 
oxidised by MCO. Scheme 1.6 shows the initially accepted mechanism; oxidation by a 
hydroxyl radical generated by single-electron reduction of a redox active transition 
metal followed by single-electron reduction of H2O2. This radical then attacks histidine 
at the C-2 position forming a radical species, which is oxidised to a carbocation. 
Subsequent proton loss leads to 2-oxo-histidine 4 (Uchida, K. and Kawakishi, S., 1986, 
1989b). There are some variations on this mechanism, such as the formation of the 
radical at a ring nitrogen instead of C-4 (Zhao, F., et al., 1997) and delocalisation of the 
radical and carbocation throughout the imidazole ring system (Garrison, 1987, Simic, 
M. G., 1978). This mechanism has been backed up by EPR studies showing hydroxyl 
radicals readily adding to the aromatic ring system (Lassmann, G., et al., 2000). Other 
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studies have also confirmed the action of H2O2, Cu
+
 ions and Cu
2+
 ions in this MCO 
reaction with the use of H2O2 inhibitos catalase and thiourea and the metal chelators 
BCA and EDTA (Khossravi, M. and Borchardt, D. R., 1998). H2O2 alone did not 
oxidise histidine, indicating that H2O2 must be reduced by MCO to form hydroxyl 
radicals before histidine oxidation can occur (Khossravi, M. and Borchardt, D. R., 1998, 
Stadtman, E. R. and Berlett, B. S., 1991, Uchida, K. and Kawakishi, S., 1990a, Zhao, F., 
et al., 1997). 
However, several studies dispute the hydroxyl radical mechanism with the 
findings that hydroxyl radical scavengers, e.g. mannitol, sodium formate, isopropanol 
and 5,5-Dimethyl-1-Pyrroline N-Oxide (DMPO), do not prevent oxidation of histidine 
by MCO (Stadtman, E. R. and Berlett, B. S., 1997, Vogt, W., 1995). In addition DFT 
calculations predict free hydroxyl radicals tend to add at the C-4 and C-5 position of 
histidine, not the C-2 position (Zhao, F., et al., 1997). Instead for C-2 oxygen addition, 
an alternative caged mechanism for MCO of histidine is predicted (Scheme 1.5) 
(Khossravi, M. and Borchardt, R. T., 2000), where an azametallacyclic complex forms 
between the imidazole of histidine, ascorbate, Cu
2+
/Cu
+
 ions and other compounds such 
as buffer salts and water (Uchida, K. and Kawakishi, S., 1994). This mechanism 
involves a single electron transfer from the imidazole to a bound Cu
2+ 
ion, leading to a 
ring radical. The His-Cu(I) complex then reacts with molecular oxygen to give a peroxy 
radical. An electron transfer then occurs from the bound Cu
+
, converting the ring radical 
into an anionic state. This then degrades to a hydroperoxy species which is reduced to 
2-oxo-histidine by Cu
2+
, as part of a oxocopper(III) species (Uchida, K., 2003) 
(Scheme 1.5) (Kurahashi, T., et al., 2001, Uchida, K. and Kawakishi, S., 1989a). The 
expected 2-hydroperoxy intermediate has been identified by 
13
C-NMR (Farber, J. M. 
and Levine, R. L., 1986). Other evidence for this mechanism include the detection of 
charge transfers with colour changes of N-benzoylhistidine-Cu
2+
 complexes after 
addition of ascorbate (Imanaga, Y., 1955) and calculations which show that histidine 
has a higher reactivity for electron transfer (6 × 10
7
 M
−1
 s
−1
)  than hydroxyl radical 
addition (5 × 10
9
 M
−1
 s
−1
) (Bernaducci, E., et al., 1981) and that metal charge transfers 
are energetically favourable (Uchida, K. and Kawakishi, S., 1989b). However, Imanaga 
et al. found no evidence for complexes of histidine and ascorbate (Hureau, C. and 
Faller, P., 2009). 
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In the Aβ peptide, oxidation by hydroxyl radicals is less likely than a charge transfer as 
Cu-Aβ has a much lower redox potential than either of the Tyr10 or Met35 residues and 
is relatively stable to electron transfers from endogenous versions of these residues 
(Schoneich, C., 2000, Zhao, F., et al., 1997). However, heavy-oxygen isotope studies 
have shown that the source of oxygen in 2-oxo-histidine formation during MCO is not 
water but ambient oxygen (Zhao, F., et al., 1997) and this means that the MCO 
mechanism involves a hydroxyl or peroxy radical and not an electron transfer 
mechanism (Cooper, 1985). 
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Scheme 1.5: Mechanism of MCO of histidine to 2-oxo-histidine via a hydroperoxy 
intermedate – a “caged” mechanism. Uchida and Kawakishi propose a mechanism of MCO of 
histidine 5 to form 2-oxo-histidine 4, which proceeds via a 2-hydroperoxy intermediate C as has 
been identified by Kurahashi et al., 2002 (Kurahashi, T., et al., 2002). This process starts with a 
one electron transfer from the imidazole to a bound Cu
2+ 
ion, leading to a ring radical bound to 
Cu
+
. Loss of H
+
 from C-2 leads to the radical intermediate A. The His-Cu(I) complex then reacts 
with molecular oxygen to give the peroxy radical B. An electron transfer then occurs from the 
bound Cu
+
 converting the oxygen radical into an anionic state C. This then undergoes a proton 
transfer to a hydroperoxy species D. An oxidation of Cu
2+
 to a Cu
3+
 species and loss of water gives 
2-oxo-histidine 4. In general, copper ions are considered complexed in an azametallacyclic 
complex (Uchida, K. And Kawakishi, S., 1994, Uchida, K., 2003). For simplicity’s sake only the 
five-membered ring of histidine is shown. In addition, the complex is only shown between Cu
2+ 
and imidazole, not ascorbate, water or any buffer salts. 
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Scheme 1.6: Mechanism of MCO of 
histidine to 2-oxo-histidine via 
hydroxyl radical production. For 
simplicity’s sake only the five-
membered ring is shown. 
(A) Histidine 5 binds a Cu
2+ 
ion and 
this metal is reduced by ascorbate to 
Cu
+
.  
(B) This then generates a hydroxyl 
radical by reducing hydrogen 
peroxide.  
(C) The hydroxyl radical attacks the 
C-2 of histidine giving a 
hydroxylated histidine radical. 
(D) Electron transfer then occurs 
from this histidine radical to Cu
2+
, to 
form 2-oxo-histidine. Cu
+
 then 
dissociates from 2-oxo-histidine 4 
(Schoneich, C., 2000, Schoneich, C., 
2000, Hovorka, S. W., 2002). 
There is some variation on the 
intermediates X and Y (Zhao, F., et 
al., 1997, Uchida, K., and Kawakishi, 
S., 1986, 1989). 
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The likely physiological effect of Aβ oxidation 
 
Due to the reversible oxidation of methionine this amino acid may act as a scavanger of 
ROS, preventing them reacting with other targets (Hou, L., et al., 2002, Johansson, A.-
S., et al., 2007, Maiti, P., et al., 2010). However, oxidation of histidine is irreversible 
and therefore can be considered as peptide damage. 
The effects of methionine oxidation in Aβ on the peptides solubility, 
neurotoxicity and fibrillisation has been previously studied using non-radical based 
H2O2 mediated oxidations (Barnham, K. J., et al., 2003, Bitan, G. and Teplow, D. B., 
2004, Yan, Y., et al., 2008). Aβ-Met35-Ox has been extensively analysed in the 
literature and has been found to have increased solubility in aqueous medium and thus 
dissociation from lipid membranes, to remain in a random coil form and not undergo the 
transition to alpha helix seen in wild-type Aβ and to not form the toxic paranuclei seen 
with Aβ(1-42) (see Section 1.2.8.) (Hureau, C. and Faller, P., 2009, Johansson, A.-S., et 
al., 2007, Naylor, R., et al., 2008, Pike, C. J., et al., 1995, Seilheimer, B., et al., 1997). 
There is some literature dispute over whether Aβ-Met-Ox is more neurotoxic than wild-
type Aβ  (Hou, L., et al., 2002, Johansson, A.-S., et al., 2007, Maiti, P., et al., 2010). 
There is also some literature dispute over whether Aβ-Met-Ox is more likely to fibrillise 
than normal Aβ (see Chaoter 4). However, in general the effects of Met35 oxidation on 
Aβ structure and fibrillisation can be easily studied by simply using a non-radical based 
oxidation system such as H2O2, without other residues within the Aβ sequence being 
oxidised, and this has been done by groups such as Hou et al., Johansson et al. and 
Maiti et al. (Sarell, C. J., et al., 2010, Syme, C. D., et al., 2004). 
In comparison, histidine cannot be oxidised selectively in the Aβ sequence, 
without oxidising other residues. Thus this PhD project proposed to synthesise oxidised 
histidine in a high yielding synthesis with a product which is both enantiomerically pure 
in the biologically-relevant L-enantiomer form and has appropriate protecting groups for 
solid peptide synthesis. This oxidised histidine could then be incorporated into the 
sequence for Aβ(1-42) to generate a form of the peptide where the oxidised residues are 
solely the three histidine; His6, His13 and His14 (Figure 1.17). 
 
 
 
DAEFRH-oxDSGYEVH-oxH-oxQKLVFFAEDVGSNKGAIIGLMVGGVVIA 
Figure 1.17: The location of oxidised histidines in solid-phase peptide synthesised Aβ(1-42)-His-ox.  
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Using literature methods (Gangopadhyay, S., et al., 1992, Garrison, 1987, Hureiki, L., 
et al., 1994, Karim, E. and Mahanti, M. K., 1992, Laloo, D. and Mahanti, M. K., 1990, 
Pereira, W. E., et al., 1973, Pinto, I., et al., 1990, Rangappa, K. S., et al., 1998, 
Satyanarayana, M. V., et al., 1993, Uchida, K. and Kawakishi, S., 1989b, 1990b, Yong, 
S. H. and Karel, M., 1978), a comparison could then be made between the native Aβ 
peptide and this synthesised Aβ-His-ox peptide in terms of both secondary structure 
changes, for example their propensity to refold to the amyloidogenic β-sheet form rather 
than the native α-helical or random coil form (Sections 1.2.4.), and altered fibrillisation 
behaviours, both in terms of overall changes in fibrillisation rate, effects on fibrillisation 
lag times and alterations in either the nucleation or elongation phases of the peptides 
aggregation behaviour (Sections 1.2.5.). Together this information should give a clearer 
insight into how histidine oxidation of the Aβ peptide alters the peptides amyloidogenic 
fibrillising behaviour, thus providing further evidence that oxidation is the elusive 
trigger of the Amyloid Cascade Hypothesis (see Section 1.3.).This may ultimatedly 
reveal how oxidation contributes to the aetiology of Alzheimer’s Disease. 
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2.1. Introduction 
 
Chapter 1 suggested 2-oxo-histidine 4 as the most physiologically relevant form of 
oxidised histidine in Aβ exposed to metal-catalysed oxidation (MCO). This Chapter, 
and Chapter 3, will discuss attempts to generate protected, enantiomerically pure 2-
oxo-histidine, starting in Chapter 2 with syntheses from L-histidine. 
 
 
2.1.1. Literature syntheses of 2-oxo-histidine from L-histidine 
 
Histidine 5 oxidation generally requires harsher conditions, i.e. metal-catalysed or 
radical-based oxidations, than methionine oxidation, which can be effected by H2O2 
alone (Tsuji, K., et al., 1992).  Histidine 5 exposed to H2O2 simply forms 1:1 
histidine-hydrogen peroxide hydrogen-bonded adducts, which are crystallise in 
aqueous solution (Ali, F. E., et al., 2003) and in vivo (Uchida, K., 2003).  
It was first shown in 1937 by Edlbacher and Segesser that the imidazole of 
histidine readily decomposes upon aeration with L-ascorbic acid in the presence of 
trace metals and in doing so generates ammonia (Lewisch, S. A. and Levine, R. L., 
1995, Von Edlbacher, S. and Von Segesser, A., 1937). Since then the most 
commonly quoted synthesis of 2-oxo-histidine in the literature has been the synthesis 
of N(α)-benzoyl protected 2-oxo-histidine 5b with an aerated Cu2+/Cu+/ ascorbate 
system (Scheme 2.2(A)) (Meister Winter, G. E. and Butler, A., 1996, Uchida, K. and 
Kawakishi, S., 1986, 1989, 1993). This is a metal-catalysed oxidation (MCO) which 
is mirrored by oxidising conditions in the Alzheimer’s brain (Ali, F. E., et al., 2003, 
Schoneich, C. and Williams, T. D., 2003). 
 A relatively recent literature synthesis of 2-oxo-histidine is that described by 
Saladino et al (Scheme 2.2(B)). They reported that the relatively mild oxidant 
dimethyldioxirane (DMDO) could be applied to N(α)-Boc protected histidine methyl 
ester 5a to generate N(α)-Boc-His-OMe 4a (Saladino, R., et al., 1999). This synthesis 
Scheme 2.1: 2-oxo-histidine is the most likely product of metal-catalysed oxidation of histidine. 
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was reported to have higher yields than MCO - 59 % compared  to 0.1 % (Lewisch, 
S. A. and Levine, R. L., 1995) - and has other advantages such as allowing use of the 
relatively manipulative and protein synthesis friendly Boc protecting groups (see 
Section 2.1.2.) due to the use of non-acidic oxidising conditions and without the 
requirement for ion exchange chromatography for product purification. Therefore, 
this PhD project began by attempting to replicate this reported synthesis of N(α)-
Boc-His-OMe 4a using DMDO. 
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2.1.2. Incorporation of 2-oxo-histidine into the Aβ sequence 
 
For this PhD, once 2-oxo-histidine was synthesised, the initial plan was to 
incorporate this into the Aβ (1-42) sequence at positions 6, 13 and 14. The resulting 
peptide could then be used to study the effects of histidine-only oxidation on the 
structure and fibrillisation behaviour of Aβ. 
Scheme 2.2: Literature syntheses of 2-oxo-histidine. (A) The most common synthesis in the 
literature is an oxidation of N(α)-Bz-His-OH 5b with a Cu2+/Cu+/ascorbate system. However, the 
yields of N(α)-Bz-2-oxo-His-OH 4b  are low i.e. ~0.1 % (Uchida, K. and Kawakishi, S., 1989). (B) 
Saladino et al. report a synthesis of N(α)-Boc-2-oxo-His-OMe 4a using DMDO, with significantly 
higher yields reported i.e. 59 % (Saladino, R., et al., 1999).  
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There are certain considerations that should be made when synthesising 2-oxo-
histidine 4 for use in solid phase synthesis of Aβ(1-42) because Aβ is a “difficult 
sequence” (Tickler, A. K., et al., 2004). Its highly hydrophobic C-terminus increases 
its tendency to aggregate, leading to the fully synthesised peptide being insoluble. 
This aggregation inhibits coupling, deprotection steps and purification during peptide 
synthesis (Lewisch, S. A. and Levine, R. L., 1995). There are certain solutions for 
these problems and these are presented in Figure 2.1, although some modifications 
involving basic conditions may not be suitable for 2-oxo-histidine 4 (see Chapter 1 
Section 1.5.3.) (Bladon, C. M., 1990). In general they aim to prevent hydrophobic 
interactions and acidic conditions near the peptide’s pI. For the same reason, one of 
the most important solutions to consider is the use of Boc groups rather than 
traditional Fmoc groups to protect the N(α) of coupling amino acids, as the basic 
conditions used to deprotect Fmoc groups are likely to degrade 2-oxo-histidine 4. 
However, as orthogonal protection is required of the N(α) and N(τ)/N(π) groups, the 
use of Boc groups as the N(α)-protecting group would require groups on the ring 
nitrogens that are not labile in the presence of TFA e.g. benzyloxymethyl (BOM), 
and these are not compatible with solid-phase synthesis. Therefore, more 
investigation into potential ring nitrogen protecting groups is required. The side-
chain of 2-oxo-histidine 4 would require protecting and this could be done with O-
alkyl groups as these would remove the electrophilic carbonyl group and hence 
increase amino acid stability under the basic conditions of solid phase peptide 
synthesis. 
It was proposed to do a model synthesis with a short histidine-containing 
peptide e.g. thyrotropin releasing hormone (TRH; pGlu-His-Pro-NH2) (Figure 2.2) 
before synthesis of the full Aβ(1-42) peptide is attempted . This would allow 
conditions to be established for oxo-histidine manipulations in solid phase peptide 
synthesis, with a central histidine residue exposed to both amino and carboxyl 
coupling conditions. 
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Figure 2.1: Optimising solid phase peptide synthesis for amyloidogenic peptides. 
The scheme above illustrates the general steps behind solid phase peptide synthesis. Illustrated in red 
are the possible modifications put forward in the literature for improving syntheses of “difficult 
peptides” such as amyloidogenic peptides. In addition, instead of traditional solid phase synthesis, O-
acyl isopeptides which undergo an O-N intramolecular acyl migration to form the correct peptide 
sequence, can be used. (Bailey, P. D., 1992, Barrow, C. and Zagorski, M., 1991, Barrow, C. J., 1999, 
Barrow, C. J., et al., 1992, Blennow, K., et al., 2006, Chan, W. C. and White, P. D., 2004, 
Clippingdale, A. B., et al., 1999, Cohen-Anisfeld, S. T. and Lansbury, P. T., 1993, Colombo, R., et al., 
1984, Fukuda, H., et al., 1999, He, W. and Barrow, C. J., 1999, Hendrix, J. C., et al., 1992, Jobling, 
M., et al., 1999, Kim, Y. S., et al., 2004, Liu, S. T., et al., 1999, Milton, N. G., 1999, Murakami, K., et 
al., 2003, Quibell, M., et al., 1994, 1995, Sampson, W. R., et al., 1999, Sohma, Y., et al., 2005, 
Tickler, A. K. and Wade, J. D., 2001, Wade, J. D., et al., 2003).  
 
Figure 2.2: Thyrotropin Releasing Hormone (TRH). 
Thyrotropin Releasing Hormone (TRH) has the amino acid 
sequence pGlu-His-Pro-NH2). This tripeptide, with histidine in 
the central position would be ideal for testing the suitability of 
2-oxo-histidine 4 and its protecting groups to solid phase 
peptide synthesis.  
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2.1.3. Aims 
 
The histidine residues of Aβ are likely oxidised in AD pathology to 2-oxo-histidine 
4. We propose to synthesise a protected, enantiomerically pure form of 2-oxo-
histidine 4 for incorporation into the Aβ(1-42) peptide via solid phase peptide 
synthesis.  
This chapter will discuss the initial three synthetic strategies used to approach 
2-oxo-histidine 4; all starting from L-histidine. The first two were oxidations using 
either dimethyldioxirane (DMDO) or a metal-catalysed oxidation (MCO) system, in 
particular a Cu
2+
/Cu
+
-ascorbate system. The third strategy was a Bamberger cleavage 
of the imidazole ring with subsequent ring closure to include a carbonyl group at 
C-2.  
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2.2. Results 
 
L-histidine 5 is a good starting material for the synthesis of 2-oxo-histidine 4 for 
several reasons. It is readily available and can be purchased as the pure L-enantiomer, 
thus preventing the need to induce chirality at a later stage. In addition, synthesis 
from L-histidine 4 has the advantage over de novo syntheses, such as those described 
in Chapter 3, of having fewer synthetic steps, as the amino acid functionality is 
already present and the side-chain is almost identical to that of the product.  
 
2.2.1. Synthesis of protected histidine derivatives 
 
The two oxidations of L-histidine, which were originally attempted for this thesis - 
dimethyldioxirane (DMDO)-mediated oxidation and metal-catalysed oxidation 
(MCO) – started from protected forms of L-histidine as starting materials. The 
protecting groups chosen for this required a compromise between being able to 
survive the conditions of oxidation and still being able to be removed to prepare the 
oxidised amino acid for peptide synthesis. The following two sections explain the 
choices of the protecting groups and describe protecting procedures. 
 
Synthesis of N(α)-Boc-His-OMe 5a 
 
The attempted DMDO-mediated oxidations of L-histidine (Section 2.2.2.) used a 
histidine derivative protected at the carboxy-terminus with a methyl ester and at the 
amino terminus with a tert-butyloxycarbonyl (Boc) group. This is denoted 
N(α)-Boc-His-OMe 5a in this thesis.  
Boc groups have the advantage over many other protecting groups in that 
they are easy to remove upon dissolution in trifluoroacetic acid (TFA), mineral acids 
or LiBr in MeCN (Hernandez, J. N., et al., 2003), although a cation scavenger is 
often required (Wuts, P. G. M. and Greene, T. W., 2006). The majority of these 
cleavage methods do not induce racemisation, unlike for other protecting groups, 
which use alkaline hydrolysis (Hernandez, J. N., et al., 2003). Boc groups are also 
less susceptible to nucleophilic attack than protecting groups such as methyl esters 
(Wuts, P. G. M. and Greene, T. W., 2006), thus allowing ester hydrolysis to be 
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performed whilst retaining the Boc group. As mentioned in Figure 2.1, they have 
been shown to increase yields of Aβ synthesis and reduce the likelihood of this 
peptide undergoing a conformational change to the highly aggregating β-sheet form. 
Their disadvantage is their high sensitivity to mineral acids and some organic 
acids, which makes purification methods such as ion-exchange chromatography 
difficult for amino acids thus protected. This sensitivity also makes it more likely 
Boc groups will degrade under acidic oxidising conditions, meaning that they can 
only be used with basic or neutral oxidants such as DMDO.  
A methyl ester was added to the carboxy terminus of L-Histidine 
hydrochloride 5e using thionyl chloride and methanol under reflux, to form 
HisOMe.2HCl 5c before Boc-protection. Methyl esters have the advantage of being 
easily removed by acid/base catalysed hydrolysis. However, this property does make 
them sensitive to hydrolysis in non-neutral aqueous conditions and can lead to 
histidine racemisation, hence protection of the amino nitrogen is required. 
This project compared two methods (Scheme 2.3) for synthesis of 
N(α)-Boc-His-OMe 5a: 
 
1) A one-step synthesis starting from HisOMe·2HCl 5c. 
2) A two-step synthesis; first protecting HisOMe·2HCl 5c to form 
N(α), N(τ)-DiBoc-His-OMe 5d and then deprotecting this to form 
N(α)-Boc-His-OMe 5a. 
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CO2HH3N
Cl
HN
NH
CO2MeH3N
2Cl
SOCl2, MeOH, reflux
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Boc2O (2.1 eq.), Et3N, MeOH, rt
N
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N
NH
CO2MeBocHN
K2CO3, MeOH, reflux
(A) 55 %
(B) 12 %
Boc2O (1 eq.), Et3N, MeOH, rt
72 %
5e
5c
5d 5a
 
The latter was found to be higher yielding, despite the extra synthesis step, at 40 % 
relative to 12 %.  
For the synthesis from HisOMe·2HCl 5c we chose a protection using Boc 
anhydride and the base triethylamine in methanol, similar to that used by Brown et 
al. (Brown, T., et al., 1982). There are alternative methods, as described by Hanford 
et al., which use a base such as pyridine to generate the free base before adding Boc 
anhydride (Hanford, B. O., et al., 1968). However, these methods tend to generate a 
mixture of mono-Boc and di-Boc protected histidine and thus require extra 
purification. 
For the synthesis from N(α), N(τ)-DiBoc-His-OMe 5d the method chosen was 
that of Dancer et al., which uses potassium carbonate in hot methanol to selectively 
remove the N(τ)-Boc group with methanolysis (Dancer, J., et al., 1996). Alternative 
methods for Boc removal tend not to be selective and remove both Boc groups, such 
as the use of dry HCl acidolysis (Gibson, F. S., et al., 1994).  
A successful synthesis of N(α)-Boc-His-OMe 5a from both synthetic methods 
was indicated from 
1
H-NMR data showing the methyl ester as a downfield methyl 
singlet at ca δH 3.70 and showing the presence of the Boc group as a nine proton 
singlet at δH 1.41 and a urethane carbonyl peak at ca 1700 cm
−1 
in the IR spectrum. 
However, due to the difference in yields the method starting from 
N(α), N(τ)-DiBoc-His-OMe 5d was employed for further syntheses. 
 
Scheme 2.3: Synthesis of N(α)-Boc-His-OMe 5a via two synthetic routes.  
 
Chapter 2 
Attempted synthesis of 2-oxo-histidine from L-histidine 
 
 
68 
 
Synthesis of N(α)-Bz-His-OH 5b 
 
Benzoyl protected histidine (N(α)- Bz-His-OH) 5b was used for the attempted 
metal-catalysed oxidations of L-histidine 5. Apart from their relative stability to 
hydrolysis, benzoyl groups have the advantage over Boc groups of being crystalline, 
easing product purification and characterisation. They also provide a chromophore 
which aids analysis of oxidation products by UV absorption. 
 One major disadvantage of benzoyl groups is the difficulty in removing them, 
which often requires quite strongly acidic hydrolysis. However, as 2-oxo-histidine 4 
had been reported as stable to acid environments, this should not present a problem 
for this synthesis (Meister Winter, G. E. and Butler, A., 1996). 
 N(α)-Bz-His-OH 5b was synthesised using the method shown in Scheme 2.4 
using the protecting reagent benzoyl chloride and the base sodium bicarbonate. The 
successful protection was shown by the presence of a five proton multiplet at 
δH 7.68 - 7.79 and a melting point (243 °C ) consistent with that reported in the 
literature (Otani, T. T. and Briley, M. R., 1979). 
N
NH
CO2HBzHN
N
NH
CO2HH3N
Cl
H2O
BzCl, NaHCO3, H2O, rt
5e 5b
5 %
 
 
 
2.2.2. Attempted Dimethyldioxirane (DMDO)-mediated oxidation of N(α)-Boc-His-
OMe 5a 
 
Synthesising dimethyldioxirane (DMDO) 21 
 
Dimethyldioxirane (DMDO) 21 is a mild, selective oxidant derived from acetone 
(Curi, D., et al., 1999). Due to its electrophilic nature it can be used to insert oxygen 
into unactivated C-H bonds at ambient temperatures, without the need for metal ions, 
within short reaction times and with good yields (Simakov, P. A., et al., 1998). It has 
selectivity for side chains of protected amino acids as opposed to α-C-H bonds, 
Scheme 2.4: Synthesis of N(α)-Bz-His-OH 5b.  
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despite the latter having a lower dissociation energy, because the reaction is favoured 
by electron donating substituents on the C-H (Saladino, R., et al., 1999). In general, a 
solvent with high polarity is required to promote the reaction (Shustov, G. V. and 
Rauk, A., 1998). 
One advantage of using DMDO to oxidise protected histidine derivatives is 
that the only reagent is DMDO and the only major side-product is acetone, although 
dangerous peroxy species are possible by-products. However, it is not considered 
particularly harmful to the environment and can be prepared from commercially 
readily-available reagents (Curi, D., et al., 1999). In addition, it can react in neutral 
solvents (Curi, D., et al., 1999). DMDO is relatively mild and thus unlikely to affect 
the protecting groups.  
One downside is that DMDO is unstable, due to fast radical-chain 
decomposition (Bravo, A., et al., 1998), and thus requires synthesis almost 
immediately before the oxidation reaction. Although one-pot syntheses combining 
DMDO synthesis and DMDO-mediated oxidation are reported (Murray, R. W. and 
Singh, M., 1998), we chose a separate synthesis of DMDO using a simple vacuum 
distillation method described by Adam et al. because of the low solubility of oxone 
in acetone, the possibility of remaining oxone degrading DMDO to acetone, 
dioxygen and sulphates (Curi, D., et al., 1999) and the reported higher yield obtained 
using this synthetic method (Adam, W., et al., 1991).  Despite other groups using 
quite elaborate distillation apparatus (Murray, R. W. and Singh, M., 1998), Adam et 
al. have argued against the need for high efficiency condensers and helium 
atmospheres (Adam, W., et al., 1991). Our method differed from Adam et al.’s only 
in the use of a room temperature vacuum distillation as opposed to one at 15 °C. 
 The synthesis of DMDO is quite low yielding, i.e. 5 % (Bravo, A., et al., 
1998) as it suffers from the competing Baeyer-Villiger oxidation, especially at high 
pH (Scheme 2.5) (Curi, D., et al., 1999). Using an iodine/thiosulfate back titration 
the concentration of the final solution of DMDO in acetone obtained in this project 
was determined to be 40 mM, which indicated a 1.7 % yield.  
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Attempted oxidation of L-histidine with DMDO 21 
 
Despite the low yield of DMDO synthesised we expected a moderately high yield of 
the subsequent protected 2-oxo-histidine as described by Saladino et al., who 
reported a 59 % yield of N(α)-Boc-2-oxo-His-OMe 4a from N(α)-Boc-His-OMe 5a 
using DMDO (Saladino, R., et al., 1999). We repeated Saladino et al.’s synthesis on 
a scale of 1.2 mmol of N(α)-Boc-His-OMe 5a as starting material, also at room 
temperature, but for only 12 h as opposed to 3 days, since after this time TLC 
analysis indicated the starting material was no longer present. We also used 10 mol. 
eq. DMDO in acetone as opposed to 2.5 mol. eq. and used acetone exclusively 
whereas Saladino et al. used a small volume of DCM in addition.  However, instead 
of forming N(α)-Boc-2-oxo-His-OMe 4a, we formed a complex mixture of oxidation 
products.  
In general, 2-oxo-histidine 4 formation from L-histidine 5 is indicated from 
NMR data by the loss of the imidazole H-2, or a broadening of the signal here if the 
enol tautomer is stabilised, and with the shift of the imidazole H-4 protons from 
Scheme 2.5: Mechanisms of DMDO 21 synthesis from acetone and potassium 
peroxymonosulfate and the competing Baeyer-Villiger reaction. Acetone and potassium 
peroxymonosulfate will combine to form a Criegee intermediate. This can either undergo 
cyclisation to DMDO 21 (A) or can undergo the Baeyer-Villiger reaction (B). This competing 
reaction explains the low yields obtained during DMDO synthesis.  
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approximately δH 7.2 to approximately δH 6.3 (Lam, A. K. Y., et al., 2010, Meister 
Winter, G. E. and Butler, A., 1996, Uchida, K. and Kawakishi, S., 1989). 
13
C-NMR 
data are available from similar compounds containing the imidazoline-2-one 
structure, e.g. the citronamides (Figure 2.3, 14), with C-2 resonance at δH 154.7 and 
C-4 resonance at δC 107.3 (Carroll, A. R., et al., 2009).  
 
 
 
 
 
 
 
 
 
 
 
 
 
In particular two compounds were isolated following flash chromatography both of 
which incorporated the isopropylidene groups seen in acetone and DMDO at C-2; a 
C-5 oxygen adduct 22 and its formylated intermediate 23c (Scheme 2.6). We 
attempted the oxidation using two different reaction conditions; 12 h at room 
temperature or 27 h at 2 °C. In case the products were not stable at room 
temperature. The former produced only the non-formylated compound 22 whereas 
the combination of colder conditions and longer reaction times produced both 
products.  
 
  
 
 
 
 
Scheme 2.6: DMDO-mediated oxidation of N(α)-Boc-His-OMe 5a yielded two compounds. 
Compound 22 was isolated from both DMDO oxidation attempts on N(α)-Boc-His-OMe (5a) and was 
determined as the structure above. Compound 23c was only isolated from the reaction at 2 °C over 
27 h. The structure is an N-formylated derivative of compound 22.   
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Figure 2.3: Citronamide 14 with a 2-oxo-histidine-type functionality. Carroll et al. isolated two 
citronamides 14 which contained a 2-oxo-histidine-type functionality, shown in red. The 
13
C-NMR 
resonances detected for C-2 was δC 154.7 and for C-4 resonance δC 107.3 (Carroll, A. R., et al., 2009). 
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The structure of the 5-oxo derivative 22 was proposed based on 
1
H-NMR 
(Figure 2.4), 
13
C-NMR (Figure 2.5), DEPT-135, HSQC (Figure 2.6) and COSY data 
and EI-MS data. The amino acid backbone was still present as shown by the presence 
of diastereotopic β-CH2 protons at δH 3.00 and δH 3.07 (Figure 2.4), with the β-C at 
δC 30.8 (Figure 2.5), and a multiplet α-CH resonance at δH 4.71-4.79 (Figure 2.4) and 
an α-C resonance at δC 51.1 (Figure 2.5). The protecting groups remained intact with 
t-Bu CH3 peaks at δH 1.44, δC 28.3, and methyl ester CH3 peaks at δH 3.72 and 
δC 52.4. The H-2 peak of the starting material, ca δH 7.55, is also no longer present 
and instead, the isopropylidene group is indicated by the 
1
H-NMR spectrum (Figure 
2.4), with two peaks at δH 1.45 and δH 1.46 and from the 
13
C-NMR with resonances at 
δC 26.7 and δC 27.0 (Figure 2.5). The 
1
H-NMR spectrum (Figure 2.4) also reveals the 
loss of the imidazole ring protons on the 5-carbon (δH 6.79). There are three carbonyl 
peaks (δC 155.4, 165.0, 171.7), indicating the additional of a carbonyl relative to the 
starting material (Figure 2.5). Finally, a NH peak at δH 7.65 indicates the stabilization 
of the original imidazole tautomerism.  
 
 
 
 
 
Figure 2.4: 
1
H-NMR (400 MHz, CDCl3) spectrum of 2-Boc-amino-3-(2,2,-dimethyl-5-oxo-2,5-
dihydro-1H-imidazol-4-yl)-propionic acid methyl ester 22.  
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Figure 2.6: 
1
H – 13C HSQC (δH(400 MHz, CDCl3), δC(100.65 MHz, CDCl3)) NMR 
spectrum of 2-Boc-amino-3-(2,2,-dimethyl-5-oxo-2,5-dihydro-1H-imidazol-4-yl)-propionic 
acid methyl ester 22.  
 
N
NH
CO2CH3N
H
O
H3C
CH3
O
H3C
H3C
CH3 O
Figure 2.5: 
13
C-NMR (100.65 MHz, CDCl3) spectrum of 2-Boc-amino-3-(2,2,-dimethyl-5-oxo-
2,5-dihydro-1H-imidazol-4-yl)-propionic acid methyl ester 22.  
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The EI-MS data reveals a molecule of mass 314.1713, which is consistent with the 
addition of the isopropylidene group of DMDO and an oxygen atom with the 
subsequent loss of two hydrogen atoms, likely the two ring protons. There is one 
problem with this structure and that is the 
13
C-NMR spectrum (Figure 2.5) is missing 
a carbon environment, in particular the imine C-4 of the ring system in structure 22. 
However, this carbon is present based on the mass spectrometry data for this 
compound and thus is suspected to unseen in the 
13
C-NMR data due to peak overlap. 
Compound 23 was analysed using 
1
H-NMR (Figure 2.7), 
13
C-NMR (Figure 
2.8), DEPT-135, HSQC and COSY (Figure 2.9) data, ESI-MS data and FT-IR and 
from this data several structures were proposed (Scheme 2.7). 
N
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As for 22, peaks can be seen for the amino acid backbone and protecting groups. 
Two methyl groups neighbouring a quaternary carbon are indicated with 
1
H-NMR 
peaks at δH 1.61 and δH 1.62 (Figure 2.7) along with 
13
C-NMR peaks at δC 24.6 and 
δC 24.8 (Figure 2.8) indicative of an isopropylidene group. The EI-MS data indicate a 
molecular weight of 342.1663, which corresponds to a molecular formula of 
C15H23N3O6. This suggested addition of a whole DMDO molecule to 
N(α)-Boc-His-OMe and the loss of two hydrogen atoms with an extra carbon and 
oxygen incorporated into the structure compared to compound 22. 
 The first structure proposed was 23a. This had the correct molecular formula, 
incorporated the isopropylidene groups and showed the clear addition of the DMDO 
molecule as part of a bicyclic system. However, the quaternary carbon of this group 
did not have a corresponding downfield 
13
C-NMR peak (Figure 2.8) for its 
positioning between two oxygens and therefore this carbon was deemed to be 
between two nitrogens as shown in structure 23b and 23c. 
 The second structure proposed was 23b. The chemical shift of the proton at 
δH  9.02 (Figure 2.7) reveals this is in a very electronegative environment. Hence, it 
was initially predicted that this was H-2 in a cyanate environment. However, the 
Scheme 2.7: Possible structures proposed for compound 23.    
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COSY data (Figure 2.9) shows coupling between the α-CH and an NH, hence the α-
NH cannot be bound in a bicyclic ring system.  
Therefore structure 23c was proposed which is a formyl derivative of 
structure 22. This is a proposed product of a side-reaction in the predicted 
mechanism of the synthesis of compound 22 given in Scheme 2.9. The downfield 
proton was now predicted to be a formyl proton. The only data disputing this is the 
lack of an extra carbonyl in the FT-IR data, with the only carbonyls in this structure 
being the Boc urethane (1706 cm
-1
) and the carboxylate ester (1750 cm
-1
).  However, 
this could be due to peak overlap and so structure 23c is the most likely match for the 
characterization data. 
 
 
 
 
 
 
 
 
 
Figure 2.7: 
1
H-NMR (400 MHz, CDCl3) spectrum of 2-Boc-amino-3-(2,2-dimethyl-5-oxo-2,5-
dihydro-1H-imidazol-4-yl)-N(τ)-formyl-propionic acid methyl ester 23.  
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Figure 2.8: 
13
C-NMR (100.65 MHz, CDCl3) spectrum of 2-Boc-amino-3-(2,2-dimethyl-5-oxo-2,5-
dihydro-1H-imidazol-4-yl)-N(τ)-formyl-propionic acid methyl ester 23.  
 
Figure 2.9: 
1
H – 13C HSQC (δH(400 MHz, CDCl3), δC(100.65 MHz, CDCl3)) NMR spectrum of 2-
Boc-amino-3-(2,2-dimethyl-5-oxo-2,5-dihydro-1H-imidazol-4-yl)-N(τ)-formyl-propionic acid 
methyl ester 23.  
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Studying Saladino et al.’s paper more thoroughly reveals that the 13C-NMR data 
presented by the authors does not match the expected N(α)-Boc-2-oxo-His-OMe 4a 
structure. For example, despite the two non-carbonyl carbons (C-4 and C-5) of the 
imidazole ring existing in very similar chemical environments they are denoted as 
having very different chemical shifts in the paper by Saladino et al. i.e. δC 158.15 
and δC 80.39 respectively (Table 2.1). In addition, Saladino et al. propose a 
mechanism that goes via an oxiranyl derivative with subsequent hydrogen shift 
rearrangement (Saladino, R., et al., 1999). However, this mechanism is proposed in 
the rest of the literature to be relevant only to DMDO oxidation of fully saturated 
compounds and thus is unlikely to be applicable to an imidazole ring system which 
contains alkene and imine-type functionalities. In predicting the likely products of 
DMDO on imidazole it is probably more helpful to study its action on similar 
compounds such as benzimidazoles and indoles. 
Interestingly, the 
13
C-NMR data for compound 23c has very similar peak 
chemical shifts to the “protected 2-oxo-histidine” product reported by Saladino et al. 
(Table 2.1), with the exception of the lack of isopropylidene peaks at δc 24.6 and 
δC 24.8 and the quaternary carbon peak at δC 155.2. It may be speculated that this 
relatively weak peak was present but indistinguishable from noise in the data of 
Saladino et al. and that the upfield peaks were mistaken for solvent peaks, and that in 
fact the compound synthesised and proposed to be Boc-protected 2-oxo-histidine 5a 
by Sala-dino et al. is in fact the same as compound 23c. 
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Peaks reported by Saladino et al., 1999 Peaks of compound 23c 
δ (ppm) Structure 
assignment 
δ (ppm) Structure 
assignment 
  24.6 H3CCCH3 
  24.8 H3CCCH3 
28.00 (CH3)3 (Boc) 28.3 (CH3)3 (Boc) 
31.05 β-C 31.4 β-C 
50.70 α-C 51.0 α-C 
52.47 OCH3 52.7 OCH3 
80.39 C(CH3)3 (Boc) 80.3 C 
85.46 C-4 85.5 C 
  155.2 C 
158.15 C-5 158.2 CH 
162.51 COOCH3 162.6 CO 
163.50 C-2 163.5 CO 
171.27 (CH3)3COCO 
(Boc) 
171.3 CO 
Structure proposed by Saladino et al. 
HN
NH
CO2MeN
H
O
O
O28.00 28.00
28.00
80.39 171.27 50.70
31.05
85.46
163.50
158.15
162.51 52.475a  
Structure proposed for compound 23 
 
Table 2.1: Comparison of the 
13
C-NMR peak chemical shifts of Saladino et al.’s oxidised 
histidine product 5a (Saladino, R., et al., 1999) and compound 23c. Proposed assignments are 
given for each structure. 
 
Literature studies on DMDO oxidation would predict preferable addition across the 
alkene bond (between C-4 and C-5 in imidazole) and not the semi-imine bond (N=C-
2 in imidazole). For example tetrahydrobenzimidazoles undergo a pinacol-like 
rearrangement to form a 5-imidazolone derivative (Scheme 2.8(A)) (Lovely, C. J., et 
al., 2004, Sivappa, R., et al., 2007), N-acyl indoles undergo epoxide addition across 
the akylated carbon and the carbon adjacent to the nitrogen leading to indolin-2-ones  
and indolin-3-ones along with methyleneindolines (Adam, W., et al., 1994, Zhang, 
X. and Foote, C. S., 1993) (Scheme 2.8(B)) and in carbethoxypyridines and 
pyrrolidine ene carbamates, DMDO-mediated oxidation leads to epoxide formation 
across the alkene (Scheme 2.8(E)) (Burgess, L. E., et al., 1996). These all replicate 
the oxidation of simple enamines, where DMDO oxidises the olefinic carbons 
equivalent to C-4 and C-5 in imidazole (Adam, W., et al., 1992) (Scheme 2.8(C)). 
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Addition across alkenes rather than imines, to give imidazol-5-one products, is seen 
exclusively in these literature procedures due to the relative stability of the 
carbocation intermediate and this is likely true for the L-histidine derivative used in 
this PhD project. In indole systems, Zhang et al. also found a significant effect of R-
substituent on the alkylated carbon on the yields of these three products. For example 
methyl/ethyl groups on C-3 led to a carbocation forming at the benzylic carbon, 
which led to aromatic ring conjugation and thus the indolin-2-one. i-propyl/t-butyl 
groups on C-2 led to the carbocation at C-2, which led to N-stabilisation and thus the 
indolin-3-one and elimination products (Zhang, X. and Foote, C. S., 1993). 
Translating to L-histidine this has alkylation on C-4 in the form of a methylene group 
so oxygen addition would be expected at C-5.  
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Scheme 2.8: Selectivity of oxygen addition to imidazole-type systems using DMDO. (A) Sivappa 
et al. and Lovely et al. studied tetrahydrobenzimidazoles. These react via a pinacol-like rearrangement 
to form a 5-imidazolone derivative (Lovely, C. J., et al., 2004, Sivappa, R., et al., 2007). (B) Zhang et 
al. and Adam et al. studied N-acyl indoles (Adam, W., et al., 1994, Zhang, X., and Foote, C. S., 1993). 
(C) Adam et al. looked at simple enamines. Products are dependent on R substituents (Adam, W., et 
al., 1992). (D) In a separate study Adam et al. found epoxides formed from enamines could dimerise 
via a zwitteronic intermediate (Adam, W., and Reinhardt, D., 1995). (E) Burgess et al. found 
carbethoxypyridine and pyrrolidine ene carbamates to form epoxides upon addition of DMDO in 
acetone (Burgess, L. E., et al., 1996). 
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Therefore, if we accept that DMDO adds oxygen at C-5, as in compound 22 from our 
synthesis, then the mechanism of this oxidation is likely as shown in Scheme 2.9. 
The weak O-O bond of DMDO is broken as the 4-C=C-5 double bond undergoes 
nucleophilic attack of the electron deficient oxygen of DMDO. The resulting 
zwitterionic species undergoes a hydride transfer from C-5 to C-4 and the formation 
of a ketone at C-4 to stabilise the resulting positive charge. Ring hydrolysis then 
follows at C-2 and finally acetone closes the ring with the addition of isopropylidene 
groups, the last step being similar to that reported by Samsonov et al. on 
cyclohexadiene diamines (Samsonov, V. and Volodarskii, L., 1980). This mechanism 
does go via an oxidation of C-2 but this product is not stable and is oxidised further. 
The mechanism in Scheme 2.9 also predicts formation of the formylated structure 
23c, where without the hydrolysis of the formylated intermediate, acetone reacts to 
form 23c. 
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Scheme 2.9: Proposed mechanism for 
formation of 2-Boc-amino-3-(2,2-dimethyl-
5-oxo-2,5-dihydro-1H-imidazol-4-
yl)propionic acid methyl ester 22 and its 
formylated derivative 23.  
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It is possible that other oxygen adducts are formed from the DMDO oxidation of 
N(α)-Boc-His-OMe 5a, especially in view of the poor yields of 22 and 23 and based 
on the 
1
H-NMR of the crude product which showed numerous minor components 
exhibiting Boc groups, imidazole CH chemical shifts indicating oxygen addition and 
many vinylic peaks. However, these products may not be stable at room temperature 
or even at 0 °C. This was found by Zhang et al. with their work on DMDO-mediated 
oxidation of N-acylindoles, where many products formed at -78 °C, yet only four 
were persistent enough to be characterised at 0 °C (Zhang, X. and Foote, C. S., 
1993). Therefore, it is predicted that more oxygen adducts may have formed from the 
DMDO-mediated oxidation of N(α)-Boc-His-OMe 5a but that they were not possible 
to characterise due to their poor stability at room temperature. 
In conclusion, DMDO-mediated oxidation of N(α)-Boc-His-OMe 5a, despite 
the claims of Saladino et al., is not a feasible synthetic route for generating 
N(α)-Boc-2-oxo-His-OMe 4a from L-histidine 5. Instead, the oxidation generates 
oxygen adducts that add at C-5 in the imidazole ring and which incorporate the 
isopropylidene groups of either acetone or DMDO. 
 
2.2.3. Attempted Cu(II)/ascorbate metal-catalysed oxidation of N(α)-Bz-His-OH 5b. 
 
The majority of 2-oxo-histidine syntheses reported in the literature start with 
N(α)-Bz-histidine 5b and use a metal-catalysed oxidation (MCO) using Cu2+/Cu+ and 
either H2O2 or ascorbate to oxidise histidine via Fenton’s chemistry (Meister Winter, 
G. E. and Butler, A., 1996, Uchida, K. and Kawakishi, S., 1986, 1989). This is also 
believed to be the most physiologically relevant mechanism of histidine oxidation 
(see Chapter 1, Section 1.5.3.).  
A consideration to make when using MCO to oxidise L-histidine is that 
Fenton’s reagents react in a highly pH dependent manner, giving the highest yields at 
neutral to strongly basic pH depending on the environment of histidine, e.g. pH 10.0 
for N(α)-Bz-His-OH (Uchida, K. and Kawakishi, S., 1990) and pH 7.5 for histidine 
in glutamine synthetase (Levine, 1983). In general, it is important that the pH of the 
reaction is greater than pH 6.5, to ensure efficient binding of Cu
2+
 to histidine 
(Casella, L. and Gulloti, M., 1983, Sarell, C. J., et al., 2009). In addition, at pH 7.4, 
ascorbate is a better reductant than at lower pHs, (although it may also be a better 
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antioxidant, see Chapter 1, Section 1.5.3.). The product of MCO on histidine, 
2-oxo-histidine 4, is not stable at greater than pH 8.0 (see Section 2.1.1.) and hence a 
pH of 7.2 was chosen for this synthesis attempt. 
The reaction was carried out at room temperature. Cu
2+
 ions were supplied in 
the form of CuSO4 and the reducing agent used was ascorbic acid (Scheme 2.10).  
N
NH
BzHN
O
OH
HN
NH
BzHN
O
OH
O
Sodium-phosphate pH 7.2 buffer
Cu2SO4 (aq), ascorbate, r.t.
< 7.6 %
5b
4b
 
 
 
We used N(α)-Bz-histidine 5b as the histidine-containing starting material. We found 
some evidence for the formation of N(α)-Bz-2-oxo-histidine 4b with the expected 
upfield shift in the 5-C resonance from δH 6.29 to δH 6.86, as described by Winter 
and Butler (as δH  5.6) and Uchida and Kawakishi as (δH  5.98). In addition, 
reverse-phase-HPLC-MS, run on the sample in negative ion mode, revealed a peak at 
m/z 273.1 (16.5 %) indicative of N(α)-Bz-2-oxo-histidine 4b (M - H+). This 
reverse-phase-HPLC mass spectrometry was performed on an Agilent 1100 Series 
LC-MS with SL Ion Trap MSD and used a similar solvent system to that reported by 
Lewisch and Levine (acetonitrile and water) as successful for isolation for 
2-oxo-histidine (Lewisch, S. A. and Levine, R. L., 1995).  
 The 
1
H-NMR of the crude product showed substantial evidence for ascorbate 
and oxidised ascorbate – monohydroascorbate 24 and dehydroascorbate 25 (Scheme 
2.11) - with a large multiplet at δH 3.48 - 5.05. Therefore, as done by Lewisch and 
Levine (Lewisch, S. A. and Levine, R. L., 1995), a purification by ion exchange 
chromatography was attempted. A cation exchange resin (Dowex, AG 50W-X8 
resin) was acidified with 2 M HCl and the crude oxidation product added in a 50:50 
mixture of distilled water and methanol. The column was eluted with distilled water 
and N(α)-Bz-2-oxo-histidine 4b was expected to elute in the void volume as reported 
by Lewsich and Levine (Lewisch, S. A. and Levine, R. L., 1995). However, the 
isolation of this product from the remaining ascorbic acid and oxidised ascorbic acid 
Scheme 2.10: Metal-catalysed oxidation of N(α)-Bz-His-OH 5b with a Cu2+/ascorbate system 
yields N(α)-Bz-2-oxo-His-OH 4b in low yield.  
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proved difficult and the yield obtained was still low (< 7.6 %). Literature yields 
obtained are reported as being very low, e.g. 0.1 % (Lewisch, S. A. and Levine, R. 
L., 1995), and it was decided that this synthetic method would be abandoned as an 
ineffective route to protected 2-oxo-histidine. 
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2.2.4. Attempted Bamberger cleavage and subsequent ring closure 
 
The third synthetic method attempted was not an oxidation but an acylation and 
cleavage of the imidazole ring between the two nitrogens of the ring, a Bamberger 
reaction, and then a ring closure to include a carbonyl at C2.  
A similar synthetic route has been used to generate Im-H-2 substituted 
derivatives of N(α)-Bz-His-OMe 5b where the substituents have included 
trifluoromethyl (Kimoto, H., et al., 1978), methyl, ethyl, phenyl and benzyl groups 
(Van Der Merwe, P., 1928, Windaus, A. and Langenbeck, W., 1922). These 
syntheses do not produce racemisation of the original L-enantiomer of histidine via 
oxazolone formation if the carboxyl group is protected as its ester (Ashley, J. N. and 
Harington, C. R., 1930, Kimoto, H., et al., 1978).  
 
First step: Acylation and Bamberger cleavage of imidazole ring 
 
The Bamberger reaction was first described by Bamberger in 1893 as a reaction 
capable of opening up the imidazole ring between the two nitrogens to form a 1,2-
diacylamidoethene derivative, by the use of an acylating agent in the presence of an 
aqueous base e.g. Na2CO3 (Heath, H., et al., 1951), K2CO3, NaHCO3
 
(Altman, J. and 
Scheme 2.11: The two products of ascorbic acid oxidation under radical conditions. Any 
oxidative reaction mixtures involving ascorbic acid and Cu
2+  
ions will be expected not to contain 
ascorbic acid  but instead oxidised ascorbic acid i.e., dehydroascorbic acid 25 and monohydroascorbic 
acid 24.  
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Wilchek, M., 1989) and at ambient temperature (Bamberger, E., 1893, Grace, M. E., 
et al., 1980). The mechanism of the reaction is given in Scheme 2.12  with the 
rate-determining step reported by Grace et al. as the formation of 26, the 
hydroxyimidazoline, which can be readily hydrolysed by base catalysis into the 
Bamberger product (Grace, M. E., et al., 1980).  
Warshawsky et al. and Grace et al. optimised this cleavage by reducing the 
concentration of base while increasing the concentration of protected imidazole 
derivative, histamine, and acylating agent (Grace, M. E., et al., 1980, Warshawsky, 
A., et al., 1989). Excess acyl chloride and extended reaction times are required for 
the Bamberger cleavage to overcome the competing hydrolysis of the acylating 
agents (Grace, M. E., et al., 1980), otherwise in most cases only the mono-acylated 
intermediate is isolated (Altman, J., et al., 1984, Patchornik, A., et al., 1957, 
Vliegenthart, J. F. and Dorland, L., 1970). In this PhD project an excess of acylating 
reagents was used to reduce the effects of potential hydrolysis on reaction yield. 
It is not unusual for an N-formyl derivative of the Bamberger product (see 
Table 2.2(B)) to form as well as the full Bamberger product (Table 2.2(A)) (Grace, 
M. E., et al., 1980), and this is detected in our syntheses described below. Some 
literature claims that water alone is enough to effect the final cleavage of this formyl 
group to give the full Bamberger product, as shown in Scheme 2.12 (Loosemore, M. 
J. and Pratt, R. F., 1976), however most groups claim either a base, e.g. 10 % 
NaHCO3  (Altman, J. and Wilchek, M., 1989), or refluxing methanol (Altman, J., et 
al., 1990, Altman, J., et al., 1985) is needed for this deformylation (Grace, M. E., et 
al., 1980). Basic conditions are preferable as refluxing in alcohol may induce 
cis/trans isomerisation in the Bamberger product (Altman, J., et al., 1990). Grace et 
al. also report that to increase the ratio of full product:formyl product the reaction 
can be done at higher temperature or with longer reaction times (Grace, M. E., et al., 
1980).  
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Scheme 2.12: Mechanism for 
Bamberger cleavage of an 
imidazole ring. The Bamberger 
reaction opens up the imidazole 
ring between the two nitrogens by 
the use of an acylating agent 
(RCOCl) in the presence of an 
aqueous base at low temperature. 
The first step is the acylation of 
each nitrogen to form a 
diacylimidazolium ion. The 
addition of water to form a 
tetrahedral intermediate 26, the 
rate determining step as indicated 
by Grace et al., is followed by 
cleavage across C2-N(τ) to form a 
formylated derivative, which has 
been isolated in the case of 
product 28a. Further base 
catalysed (B) hydrolysis cleaves 
this as formic acid leaving the 
Bamberger product 27, 28, 29 
(Grace, M. E., et al., 1980). 
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 Starting material Acylating agent Base Solvent Product Yield  (%) 
A HisOMe·2HCl (5c) BzCl NaHCO3 MeCN No reaction N/A 
B HisOMe·2HCl (5c) BzCl NaHCO3 Toluene:water No reaction N/A 
C HisOMe·2HCl (5c) BzCl NaHCO3 EtOAc:water 
 
Full Bamberger product (A) (27) 31 
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 Starting material Acylating- 
agent 
Base Solvent Product Yield (%) 
D 
 
N(α)-Boc-His-OMe 
(5a) 
BzCl NaHCO3 EtOAc:water Full Bamberger product (A) (28) 20 
Formylated Bamberger product (B) (28a) 3.2 
E HisOMe·2HCl (5c) ZCl NaHCO3 EtOAc:water Mono-acylated product (C) Minor in crude 
F HisOMe·2HCl (5c) ZCl NaHCO3 CHCl3 Mono-acylated product (C) Minor in crude 
G HisOMe·2HCl (5c) MeOCOCl NaHCO3 EtOAc:water Full Bamberger product (A) (29) 31 
H N(α)-Boc-His-OMe 
(5a) 
MeOCOCl NaHCO3 EtOAc:water No reaction N/A 
I HisOMe·2HCl (5c) Boc2O NaOAc MeCN:water Formylated Bamberger product (B) Minor in crude 
Mono-acylated product (C) (5a) Major in crude 
Table 2.2: Summary of the Bamberger reactions attempted on HisOMe.2HCl 5c (i) and N(α)-Boc-His-OMe 5a (ii). The figure illustrates the full Bamberger product (A), its 
formylated intermediate (B), and a non-Bamberger mono-acylated product (C) with mono-acylation on the N(τ) assumed based on similar literature examples (see Section 2.2.1. and 
Brown et al, 1982). R is the acyl group. All reactions were carried out at room temperature.
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Acyl group Substrate References 
Benzoyl (Bz) Benzimidazole (Hofmann, K., 1953) 
His-OMe·2HCl (5c) (Heath, H., et al., 1951) 
Diethyl[2-(4-
imidazoyl)ethyl]malonate 
(Altman, J. and Wilchek, 
M., 1989) 
Ethyl imidazolylpropanoate (Altman, J., et al., 1984) 
tert-butyloxycarbonyl 
(Boc) 
N-tosylhistamine (Altman, J., et al., 1985) 
Imidazole  (Grace, M. E., et al., 
1980) 
Benzyl carbamate (Cbz) Ethyl imidazolylpropanoate (Altman, J., et al., 1984) 
Methyl carbamate Ethyl imidazolylpropanoate  (Altman, J., et al., 1990) 
His-OMe·2HCl (5c) (Glinka, T., et al., 2008) 
Table 2.3: Bamberger reactions in the literature. Bamberger reactions in the literature use a variety 
of acylating reagents and substrates. 
 
Previously work on the Bamberger reaction had been done by the Wyatt group and it 
was found that HisOMe·2HCl 5c could be successfully cleaved across the two ring 
nitrogens using benzoyl chloride to produce the free vinyl diamide 2,4,5-tris-Bz-
amino-pent-4-enoic acid-OMe 27 (Jumnah, R., 1991). This PhD project expanded on 
this synthesis using different acylating reagents as have been reported in the 
literature (Table 2.3). Previous acyl groups used in Bamberger reactions on L-
histidine include benzoyl groups (Altman, J., et al., 1990, Heath, H., et al., 1951, 
Mizusaki, K. and Makisumi, S., 1981), ethoxycarbonyl groups (Loosemore, M. J. 
and Pratt, R. F., 1976, Vliegenthart, J. F. and Dorland, L., 1970), methyl carbamate 
(Glinka, T., et al., 2008) and benzyl carbamate (Patchornik, A., et al., 1957). In 
general, histidine is less reactive than imidazole for the Bamberger cleavage and in 
some cases has been found only to proceed as far as the formyl stage (Grace, M. E., 
et al., 1980). 
 Each of these acyl groups has certain advantages and disadvantages to the 
overall synthesis, besides those discussed on pages 147 - 149. Benzoyl chloride is a 
stronger electrophile than other potential acylating agents such as Boc anhydride and 
hence can be added in lower amounts. However, unlike urethane groups, benzyl 
groups cannot provide a carbonyl for internal cyclisation in the second step of this 
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synthesis. Benzyl chloroformate has the advantage over methyl chloroformate of 
providing crystalline products and being less sensitive to hydrolysis, although if it 
does hydrolyse to form benzyl alcohol this is more difficult to remove than the 
relatively volatile MeOH. We studied a range of acyl groups to try and optimise both 
the yield of the Bamberger product and that of the subsequent cyclisation. 
 In an attempted replication of Jumnah’s method (Jumnah, R., 1991) the 
benzoyl Bamberger product 27 of His-OMe·2HCl 5c was successfully synthesised. 
Initially, a one-phase solvent system of acetonitrile was used, as had been used for 
Bamberger reactions reported by Altman et al. (Altman, J., et al., 1985) (Table 
2.2(A)), in an effort to reduce hydrolysis of the acylating reagent. However, despite 
leaving the reaction for 10 days, thin layer chromatography (TLC) monitoring 
revealed only starting material. Therefore it was decided that two-phase solvent 
systems would be used with an aqueous base. Traditionally benzene-water systems 
have been used (Heath, H., et al., 1951) but we replaced benzene with toluene as a 
similar non-polar solvent but with lower toxicity (Table 2.2(B)). However, with this 
solvent system no Bamberger product was formed with the only new product 
appearing to contain a formyl group. These formylated Bamberger products were 
isolated from reactions with other acylating reagents and are discussed further below. 
 Next an ethyl acetate-water solvent system was used (Table 2.2(C)) and in 
this case there was successful synthesis of the benzoyl Bamberger product 27. The 
1
H-NMR analysis revealed the expected aromatic peaks of the benzoyl groups in the 
correct integral ratios at δH 7.42 - 7.62 (10 H) and δH 7.79 - 7.95 (5 H) and the 
expected lack of a H-2 signal. Mass spectrometry analysis also revealed a molecular 
ion at the expected mass of 470.1 (100%). The yield was only 31 %, which may be 
due to hydrolysis of benzoyl chloride to benzoic acid, but it exceeds yields obtained 
by Jumnah (13 %) (Jumnah, R., 1991)  
There are advantages to the use of orthogonal acylating and α-protecting 
groups; simplification of the analysis of Bamberger products and selective 
deprotection of these two functionalities. Therefore, we attempted the Bamberger 
reaction with benzoyl chloride on N(α)-Boc-His-OMe 5a as a starting material. An 
identical base and solvent system was used to the synthesis from His-OMe·2HCl 5c 
(Table 2.2(D)), although the reaction time was almost tripled as indicated by the 
persistence of starting material on TLC analysis. Despite this extended reaction time 
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and although the Bamberger reaction was successful, the yield of 28 was low at 
20 %. An additional new product was also isolated from the crude product; a 
formylated derivative of the Bamberger product 28a in a 3 % yield. This eluted later 
than the Bamberger product 28 from the flash chromatography column, indicating a 
greater polarity, and the presence of a formyl group was revealed conclusively by a 
1
H-NMR peak at δH 9.17. Coupling (~8 Hz) of the remaining CH (δH 6.65) from the 
original imidazole ring to a benzoylated NH (δH 10.0) revealed that the formyl group 
was on the benzoylated nitrogen next to the quaternary carbon from the original ring. 
In this formylated product 28a the benzoyl groups were still added in the correct 
ratio (i.e. 10 H instead of the 15 H seen for the non-Boc protected starting material). 
This formylated product 28a also formed in a toluene-water solvent system. In 
general, though, the full Bamberger product 28 was formed in greater yield than the 
formylated product 28a without the need for basic conditions or refluxing in 
methanol, as reported by previous studies (see page 87) (Altman, J., et al., 1985). 
In conclusion, benzoyl chloride could be used to successfully generate 
Bamberger products of both His-OMe·2HCl 5c and N(α)-Boc-His-OMe 5a albeit in 
low yields. However, it was predicted that cyclisation on this product would be more 
difficult than one which contained urethane functionality. Therefore, we chose to 
explore different acylating agents.  
Jumnah had previously reported that the use of benzyl chloroformate gave 
higher yields of Bamberger products than benzoyl chloride. In addition, Altman et al. 
had previously commented that for N-tosylhistamine 30, a similar product to 
N-protected histidine, the use of benzyl chloroformate gave the imidazolin-2-one 
derivative 31 without the need for the second cyclisation step (Altman, J., et al., 
1985) (Scheme 2.13). 
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Hence, this acylating reagent was trialled in both a chloroform-water solvent system 
(Table 2.2(F)) and an ethyl acetate-water solvent system (Table 2.2(E)) on 
His-OMe.2HCl 5c. However, with both solvent systems the crude product did not 
show any evidence of a fully cleaved Bamberger product and in both cases mostly 
starting material was recovered. NMR data did indicate some reaction; mono-
acylated histidine for the chloroform two-phase system and formylated product for 
the ethyl acetate two-phase system.  
The next acylating agent tested was methyl chloroformate in an ethyl 
acetate-water solvent system with a sodium bicarbonate base (Table 2.2(G)). This 
successfully generated the Bamberger product 29 over a similar time period and with 
a similar yield (31 %) as the reaction with benzoyl chloride. The expected methyl 
protons of the MeOCO were seen in the correct integral ratios (3.67 (3 H), 3.71 
(3 H), 3.72 (3 H)) and there was a lack of a H-2 proton. A formylated product was 
indicated in the 
1
H-NMR spectrum of the crude product but this was not isolated. 
This acylation was also trialled on N(α)-Boc-His-OMe 5a but only starting material 
was isolated (Table 2.2(H)). 
In a final attempt to find a higher yielding acylating agent, Boc2O was used. 
This can form urethane functionality required for intramolecular cyclisation when 
bound to the imidazole nitrogens. The reaction was carried out in acetonitrile and 
water rather than with ethyl acetate, and the starting material was His-OMe.2HCl 5c. 
Scheme 2.13: Formation of a 2-oxo derivative of histamine 30 via a Bamberger reaction. 
Adapted from Altman et al., 1985 (Altman, J., et al., 1985). 
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The base used was sodium acetate rather than sodium bicarbonate (Table 2.2(I)). 
When the Bamberger reaction was attempted, the main product, indicated by 
1
H-
NMR of the crude product, was the mono-acylated histidine, N(α)-Boc-His-OMe 5a, 
despite the mixture being left to react for 14 days. In addition, a lot of starting 
material was recovered and some evidence of a formylated product.  
In conclusion, three products (Scheme 2.14) were formed under these 
reaction conditions, the full Bamberger cleavage product 27, 28, 29, the formylated 
Bamberger product 28a and the mono-acylated product 5a (see Table 2.2). The only 
two successful acylating reagents for generating Bamberger products were found to 
be benzoyl chloride and methyl chloroformate, which are the two reagents reported 
in the literature to be successful for generating the Bamberger product of His-
OMe·2HCl 5c (Glinka, T., et al., 2008, Heath, H., et al., 1951). Although, there were 
advantages to starting with N(α)-protected histidine 5a, histidine methyl ester 
hydrochloride 5c was found to produce the cleanest reactions. Therefore, for the ring 
closure step the starting material chosen was the tribenzoyl Bamberger product 27. 
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Second step: Ring closure with carbonyl at C2 
 
The second step of this attempted synthesis is a ring closure with addition of 
carbonyl at C-2 in the imidazole ring. There are two main approaches for this ring 
closure: 
 
Scheme 2.14 Summary of major products formed by the Bamberger reaction. Three 
derivative of the full Bamberger product were successfully synthesised 27 (benzoyl), 28 (Boc) and 
29 (methyl carbamate) in addition to a formylated derivative with Boc groups 28a. 
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1) Internal source of carbonyl group (Scheme 2.15(A)) – if the N-bound acyl 
group forms a urethane then the carbonyl within this group can be 
incorporated at C2 to close the ring and form an imidazolin-2-one derivative. 
Therefore, this cyclisation could occur if the acyl groups used were Cbz, 
methoxycarbonyl or Boc, but not if they were Bz. Use of a non-nucleophilic 
base, e.g. t-butoxide, might be sufficient to effect the cyclisation. Literature 
examples include Altman et al. (Altman, J., et al., 1985). 
2) External source of carbonyl group (Scheme 2.15(B)) – in the cases where 
urethane functionality is not already part of the Bamberger product, a 
carbonyl-containing reagent, such as diethyl carbonate, is likely to be 
required with either a strong acid/base catalyst or high temperatures. There 
are several examples in the literature (Ashley, J. N. and Harington, C. R., 
1930, Van Der Merwe, P., 1928, Windaus, A. and Langenbeck, W., 1922).  
 
However, the only successful Bamberger product containing urethane functionality 
was the methyl carbamate derivative 29 and was only produced in quite low yield. 
Thus all cyclisation attempts were using an external source of carbonyl group on the 
benzoyl derivative 2,4,5-tris-Bz-amino-pent-4-enoic acid-methyl ester 27. 
Ring closure of imidazoyl Bamberger products has been done successfully in 
the literature with incorporation of methyl, ethyl, phenyl and benzyl at C-2 with the 
use of carboxylic anhydrides at high temperatures (Ashley, J. N. and Harington, C. 
R., 1930, Van Der Merwe, P., 1928, Windaus, A. and Langenbeck, W., 1922). In 
addition, trifluoroacetic anhydride  at reflux will generate 2-trifluoromethyl-histidine 
from the imidazoyl Bamberger product (Kimoto, H., et al., 1978). In general, the 
reagents used to ring close the Bamberger products are carbonyl-containing 
electrophilic reagents (Scheme 2.16). 
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Scheme 2.15: Mechanisms of ring closure of the Bamberger product. (A) External source of 
carbonyl group – A base is used to deprotonate one of the acylated nitrogens in the Bamberger 
product 27, 28, 29. This then attacks at the carbonyl of the other ring nitrogen’s acyl group bridging 
across the nitrogens to form an imidazolin-2-one derivative (a). Alternatively the mechanism can go 
via an isocyanate intermediate (b). 
(B) Internal source of carbonyl group – an acylated nitrogen of the Bamberger product attacks the 
carbonyl of the reagent with the loss of an alcohol. A further attack from the other acylated nitrogen 
bridges the carbonyl across the two nitrogens.  
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Scheme 2.16: Ring closure of Bamberger products 
using a carboxylic anhydride.  
Kimoto et al. proposed this mechanism for the ring 
closure of a Bamberger product 27 using a carboxylic 
anhydride (Kimoto, H., et al., 1978). 
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It was envisaged that triphosgene could be used as an electrophilic reagent for the 
formation of 2-oxo-histidine derivatives from Bamberger products. This is a solid 
trimer of the toxic gaseous phosgene. It has three carbons in the same oxidation state 
which can be incorporated as the carbonyl and thus is only required in 0.33 mole 
equivalence. This reagent has been used successfully to ring close 
o-aminobenzamides to form quinazolinediones (Cortez, R., et al., 1991) and α-amino 
alcohols to produce oxazolidinones (Pridgen, L. N., et al., 1989).  
The initial attempted cyclisation with triphosgene was conducted at 0 °C 
under an inert atmosphere (Scheme 2.17(a)). Triphosgene (0.3 mole equivalents) was 
added to 2,4,5-tris-Bz-amino-pent-4-enoic acid-methyl ester 27 suspended in 
anhydrous THF. 2 Molar equivalents of sodium hydride were added to increase the 
nucleophilicity of the nitrogens in the Bamberger product 27. The occurrence of a 
reaction was indicated by the mixture changing from colourless to yellow and 
formation of a white precipitate.  Despite evidence of the Bamberger product salt 
intermediate forming, overall the reaction yielded only starting material. 
 
 
 
 
 
 
 
It was suspected that the nucleophilicity of the acylated nitrogens was still 
compromised by extensive delocalisation of the 4-C=C-5 double bond electrons. 
However, there was reluctance to add more base in case of racemisation of the amino 
acid backbone chiral centre. In addition, the formation of a white precipitate 
suggested that the intermediate sodium salt had formed successfully. Therefore, to 
try and increase the reactivity of the triphosgene reagent the reaction was repeated at 
70 °C. The reaction was left for 6 hours until a tan-brown emulsion formed. 
However, as before, 
1
H-NMR of the crude product indicated only starting material. 
 A second cyclisation agent was then examined; diethyl carbonate (Scheme 
2.17(b)). Initially an acid catalyst was then used because this could protonate the 
diethyl carbonate reagent providing a better electrophile for attacking the acylated 
Scheme 2.17: Attempted cyclisation of 2,4,5-tris-Bz-amino-pent-4-enoic acid-methyl ester 27.  
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nitrogens of the Bamberger product 27. The acid catalyst used was p-toluene sulfonic 
acid and it was added at 1 mole equivalent relative to the Bamberger product 27. The 
reaction product was expected to be in equilibrium with the starting material and 
hence, to try and promote the forward reaction diethyl carbonate was added in excess 
and the mixture was heated to 140 °C for 22 h. However, 
1
H-NMR of the crude 
product showed a lack of α-CH or β-CH2 peaks indicating that the amino acid 
functionality had not survived the reaction. 
Hence, a base catalyst was trialled for the same reasons as discussed above; 
to increase the nucleophilicity of the acylated nitrogens within the Bamberger 
product starting material 27. Potassium carbonate was used as the base at 1 mole 
equivalent to the starting material. Again the reaction was heated to 140 °C for 22 h 
and once again the 
1
H-NMR showed no evidence of amino acid functionality.  
Therefore, the reaction was repeated but with only a 1 h 20 min reaction time. 
This time the amino acid components survived the reaction conditions but, as for the 
attempted cyclisation with triphosgene, only starting material was recovered. 
Therefore, it was concluded that the conditions required for cyclisation of the 
Bamberger product 27 were too severe for the stability of the amino acid 
functionality present in the Bamberger product 27. 
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2.3. Discussion 
 
In conclusion, the three synthetic methods attempted to synthesise protected 
2-oxo-histidine from L-histidine have been unsuccessful. However, there are both 
1
H-NMR and mass spectrometric data which indicate the presence of a low yield of 
N(α)-benzoyl protected 2-oxo-histidine 4b from a Cu2+/Cu+/ascorbate 
metal-catalysed oxidation.  
 The initial attempted oxidation of L-histidine was conducted on 
N(α)-Boc-His-OMe 5a and yielded two novel compounds 22 and 23, both containing 
isopropylidene groups. This was based on a literature procedure for synthesising 
N(α)-Boc-2-oxo-His-OMe 4a described by Saladino et al., however, upon further 
analysis of their 
13
C-NMR data for N(α)-Boc-2-oxo-His-OMe 4a it was deemed an 
unfeasible strategy for generating 2-oxo-histidine (Saladino, R., et al., 1999). In 
addition, literature on DMDO-mediated oxidation of compounds similar to imidazole 
indicate that oxygen addition at C-4/C-5 in the imidazole ring, as seen with product 
22, was more likely than at the C-2 position (Adam, W., et al., 1992, Sivappa, R., et 
al., 2007, Zhang, X. and Foote, C. S., 1993). 
 The second potential synthetic strategy for generating 2-oxo-histidine in the 
literature is the use of a metal-catalysed oxidation system, in particular 
Cu
2+
/Cu
+
/ascorbate (Hovorka, S. W., et al., 2002, Schoneich, C., 2000, Uchida, K., 
2003, Uchida, K. and Kawakishi, S., 1986). With this system we generated 
N(α)-Bz-2-oxo-His-OMe 4b but in very small yields and also within an environment 
of high concentrations of ascorbate and oxidised ascorbate. Despite several attempted 
purifications with ion exchange chromatography and reverse-phase HPLC, this 
2-oxo-histidine could not be successfully extracted and, due to the poor yield, this 
MCO system was abandoned as a potential synthetic strategy for generating 
2-oxo-histidine.  
 The third synthetic strategy attempted was an acylation and cleavage of the 
imidazole ring followed by ring closure to include a carbonyl at C-2. The initial step 
showed some success with use of the acyl groups, benzoyl and methyoxycarbonyl, in 
an EtOAc-water solvent system and using the base NaHCO3. However, cyclisation 
attempts with triphosgene yielded only starting material, while cyclisation attempts 
with diethyl carbonate, either degraded the amino acid functionality of the histidine 
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or yielded starting material. 
 Hence, it was decided that a different synthetic strategy from that starting 
from L-histidine should be undertaken. Therefore, syntheses starting with the known 
compound imidazolin-2-one 36 were studied. This is discussed further in Chapter 3.  
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3.1. Introduction 
 
Chapter 2 discussed attempted synthesis of 2-oxo-histidine 4 from L-histidine 5, 
however, these attempts were unsuccessful in providing 2-oxo-histidine in 
synthetically useful quantities. Therefore, it was proposed to start a synthesis from 
the imidazolin-2-one 36 ring system, a carboxylic derivative 49 of which can be 
formed by the known synthesis from urea 17 and (+)-tartaric acid 36 (Duschinsky, R. 
and Dolan, L. A., 1946, Hilbert, G. E., 1932) (Scheme 3.1).  
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3.1.1. A retrosynthetic analysis of 2-oxo-histidine identifies derivatives of the 
imidazolin-2-one ring system 36 as a starting point. 
 
From a retrosynthetic analysis, 2-oxo-histidine 4 there are several potential synthetic 
routes (Scheme 3.2). Simple cleavage of either the C-α, C-β bond (Scheme 3.2(A)) 
or C-γ, C-β bond (Scheme 3.2(B)) indicates syntheses from either a glycine enolate 
equivalent or serine derivative respectively, and these are discussed further in 
Section 3.2.2.  
However, the most successful synthesis discussed in this thesis used an 
alternative approach by first considering an α, β-dehydro derivative of 
2-oxo-histidine. Further retrosynthetic analysis on this intermediate predicted the 
required coupling of an imidazolin-2-one-derived cation synthon and a glycine anion 
synthon. The synthetic equivalents used for this project were a protected form of the 
aldehyde, 4-formylimidazolin-2-one 38, and a protected form of the phosphonate, 
phosphonoglycine trimethyl ester 39 (Scheme 3.2(C)).  
In terms of forming the aldehyde 38 there are several related synthetic 
strategies reported in the literature. Nakajima et al. report on a coupling of 
imidazolin-2-one 36 to ethyl formate using a Grignard reagent (Nakajima, M., 1958). 
Scheme 3.1: Synthesis of the carboxylic derivative 49 of imidazolin-2-one 36 from urea 17 and 
(+)-tartaric acid 36. (Duschinsky, R. and Dolan, L. A., 1946, Hilbert, G. E., 1932) 
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The Vilsmeier-Haack reaction has also been used recently to formylate imidazolin-2-
one 36 (Ma, Z., et al., 2011). This synthesis is explored further in Section 3.2.2. A 
second synthetic approach is that described by Dransfield et al. in their syntheses of 
several dienes (Dransfield, P. J., et al., 2006). This synthesis protected the ring 
nitrogens of 4-carboxyimidazolin-2-one, esterified the carboxylic acid group to an 
ester, reduced this to an alcohol and then oxidised this up to the aldehyde. This 
literature procedure is the basis of the synthesis described in Section 3.2.1. 
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3.1.2. Synthesising the imidazolin-2-one ring system 36 from urea 17 and tartaric 
acid 37 
 
Imidazolin-2-one 36 (Scheme 3.3) is a well-characterised ring system that has been 
studied extensively in the literature.  
Scheme 3.2: A retrosynthetic analysis of 2-oxo-histidine 4.  
(A)  Cleavage of the C-α, C-β bond predicts synthons who synthetic equivalents could be a glycine 
enolate equivalent and an activated imidazoline species. 
(B) Another set of synthons could be generated by cleaving the C-4, C-β bond, which would be 
equivalent to a serine derivative and a halogenated imidazoline derivative. 
(C) By forming the chiral centre of 2-oxo-histidine 4 by asymmetric reduction, retrosynthetic 
analysis of the dehydro starting material predicts the use of a Wittig style coupling between an 
imidazolene aldehyde 37 and a phosphonate 38. 
R is an alkyl group. 
PG is a protecting group.  
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In 1892 Marckwald claimed to have devised a synthesis of imidazolin-2-one 36 from 
an amino acetal 47 (Scheme 3.4(A)) (Marckwald, W., 1892). However, this synthesis 
was prone to polymerisation of the ureidoacetal intermediate 48 instead of 
cyclisation to the imidazolin-2-one species 36 (Aiman, C. E. and Daugs, E. D., 1994, 
Duschinsky, R. and Dolan, L. A., 1946). Despite some improvements to the method, 
e.g. use of an alcoholic solvent (Aiman, C. E. and Daugs, E. D., 1994), it was still far 
from an ideal synthesis of imidazolin-2-one.  
Thus is 1932, Hilbert et al. proposed an alternative two-step synthesis 
(Hilbert, G. E., 1932). The first step is a  condensation of urea 17 and tartaric acid 37 
in concentrated sulfuric acid to form 4-carboxyimidazolin-2-one 49 (Scheme 3.4(B)). 
The pure carboxylic acid 49 can be precipitated by pouring the reaction mixture onto 
ice  and has been used subsequently by several groups to generate this carboxylic 
acid 49 as an end product (Dransfield, P. J., et al., 2006, Otter, B. A., et al., 1968). 
The second step of this imidazolin-2-one synthesis is a decarboxylation of the 
carboxylic acid 49. This can be carried out in several ways, although the most 
common method is refluxing in aqueous base (Baxter, R. L., et al., 1992, Zav'yalov, 
S. I., et al., 1972) (Scheme 3.4(B)), which avoids the high temperatures (230 – 240 
°C) of other decarboxylation methods such as sublimation (Scheme 3.4(C)) (Hilbert, 
G. E., 1932, Nakajima, M., 1958). Another potential synthesis is that described by 
Fenton and Wilks which uses a condensation of maleic acid 50 with urea 17 (Scheme 
3.4(D)) (Fenton, H. J. H. and Reginald, W. A. W., 1909), however there is little 
characteristic data to back up this synthesis. Therefore, this PhD uses the two-step 
synthesis starting from urea 17 and tartaric acid 37 described by Hilbert et al. 
(Hilbert, G. E., 1932) (Scheme 3.4(A)). 
Scheme 3.3: Tautomeric forms of imidazolin-2-one 36.  
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3.1.3. Imidazolinones as important biological molecules 
 
Chapter 1 discussed the importance of histidine residues in sequences for biological 
processes, specifically for the Aβ peptide, and postulated how these roles could be 
affected by histidine oxidation. However, imidazolinone derivatives have other 
biological activities as well (Diness, F. and Meldal, M., 2009). Imidazolinones are 
implicated in receptor antagonists (Burgey, C. S., et al., 2006, Carling, R. W., et al., 
1999, Reitz, D. B., et al., 1993), phosphodiesterase (PDE) inhibitors (Andrés, J. I., et 
al., 2002), β-adrenergic receptor agonists (Naylor, E. M., et al., 1999), GABA 
receptor ligands (Desimone, R. W. and Blum, C. A., 2000), natural antibiotics 
(Fiedler, H.-P., et al., 1982) and bacterial antifungal compounds. Thus novel 
synthetic methods increasing the functionality and synthetic potential of this group 
Scheme 3.4: Two-step synthesis of imidazolin-2-one from urea 45 and (+)−tartaric acid 
46. 
(A) Markwald’s Method: The reaction of an aminoacetal 47 with a cyanate to form 
ureidoacetal 48. This is followed by an acid-catalysed condensation to form imidazolin-2-one 
36 (Duschinsky, R., and Dolan, L. A., 1946). 
(B) This synthesis is composed of two steps (Hilbert’s Method); condensation of urea 17 and 
(+)-tartaric acid 37 to form 4-carboxyimidazolin-2-one 49 (Hilbert, G. E., 1932, Hagenmaier, 
H., et al., 1979) and decarboxylation of 4carboxyimidazolin-2-one 49 to form imidazolin-2-
one 36 (Zav’yalov, S. I., et al., 1972, Baxter, R. L., 1992) 
(C) Sublimation of 4-carboxyimidazolin-2-one 49 at 120 °C (Hilbert, G. E., 1932). 
(D) The condensation of maleic acid 50 and urea 17 (Fenton, H. J. H., and Wilks, W. A. W., 
1909).  
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may have uses beyond simply constructing oxidised histidine. In addition, 
imidazolinones can act as either nucleophiles or electrophiles and are substrates for 
copper-catalysed cross-coupling to aryl groups (Diness, F. and Meldal, M., 2009), 
which may indicate how 2-oxo-histidine will react in oxidised proteins such as Aβ. 
 
3.1.4. Aims 
 
The aim of this chapter is to use the imidazolin-2-one 36 ring system to generate 
enantiomerically pure 2-oxo-histidine 4 with suitable protecting groups for solid 
phase peptide synthesis of the Aβ peptide.  
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3.2. Results 
 
3.2.1. Synthesis from 4-carboxyimidazolin-2-one 49 
 
As discussed in Section 3.1.1. the object of this synthesis was to couple the aldehyde 
4-formylimidazolin-2-one 38 and the phosphonate, phosphonoglycine trimethyl ester 
39 (Scheme 3.1) in a Horner-Wadsworth-Emmons (HWE) reaction to form a 
protected dehydro-derivative of 2-oxo-histidine 40, which could then be reduced to 
form protected 2-oxo-histidine 4. Suitable protection of the nitrogens was required, 
so initially para-methoxybenzyl (PMB) groups were used to protect the ring 
nitrogens, while benzyloxycarbonyl (Cbz) groups were used to protect the amino 
nitrogen. 
 
para-methoxybenzyl (PMB) as a nitrogen protecting group 
 
PMB groups (also known as MPM groups) are reported as being suitable protecting 
groups for imidazole rings (Kamijo, T., et al., 1983). In terms of imidazolin-2-one 
ring systems, previous ring-nitrogen protections have used PMB as the second 
nitrogen-protecting group after mono-benzylations of the ring. PMB groups have 
been shown to be stable to reactions similar to those described below (Dransfield, P. 
J., et al., 2006). However, the use of di-PMB protection on imidazolin-2-one ring 
systems has not been used to date.  
PMB groups were considered to be advantageous because they are reported to 
be removable by a simple cerium(IV) diammonium nitrate (CAN)-mediated 
oxidation (Bartoli, G., et al., 2003, Smith, A. B., et al., 1992, Yamaura, M., et al., 
1985), which was not expected to have an effect on the imidazolin-2-one 36 ring 
system given its oxidised structure. 
PMB groups are typically added using a 4-methoxybenzyl halide and the base 
NaH in DMF. They are stable to a range of reaction conditions including hot aqueous 
alkali, aqueous acid, mild oxidants such as potassium permanganate, cold Lewis 
acids, several nucleophilic reagents e.g. CN
− 
and ArO
−
 and mild catalytic 
hydrogenolysis (Buckle, D. R. and Rockell, C. J. M., 1982). 
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 Obtaining protected 1,3-bis(PMB)-4-formylimidazolin-2-one 38a 
 
This multi-step synthesis started with urea 17 and (+)-tartaric acid 37 and resulted in 
the synthesis of 1,3-bis(PMB)-4-formylimidazolin-2-one 38a (Scheme 3.5). The 
initial product, 4-carboxyimidazolin-2-one 49, has the correct heterocyclic ring for 
2-oxo-histidine 4. The synthesis of protected 4-formylimidazolin-2-one 38 from 
4-carboxyimidazolin-2-one 49 is well documented by Dransfield et al. (Dransfield, 
P. J., et al., 2006), although with use of a different set of protecting groups. 
 
 
 
 
The carboxylic acid, 4-carboxyimidazoline-2-one 49 was synthesised from urea 17 
and (+)-tartaric acid 37 heated in concentrated sulfuric acid. The presence of a single 
CH environment (δH) in both the 
1
H-NMR (δH 7.13) and the 
13
C-NMR spectra (δC 
115.0) indicated the ring system had formed and both IR and 
13
C-NMR evidence was 
obtained for the presence of two carbonyls. This indicated that this product was 
likely 4-carboxyimidazolin-2-one 49.  
This carboxylic acid 49 was then converted into the protected imidazoline 
aldehyde 38a via four steps, which were based on those described by Dransfield et 
al. and Dilley et al. (Dilley, A. S. and Romo, D., 2001, Dransfield, P. J., et al., 2006). 
Scheme 3.5: Synthesis of 1,3-bis(PMB)-4-formylimidazolin-2-one 38a. The red star indicates an 
attempted one step reduction of methyl ester 52a to aldehyde 38a.  
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Firstly, 49 was esterified using thionyl chloride and methanol to yield 
4-methoxycarbonylimidazolin-2-one 52. Alternative syntheses, which use heating in 
concentrated sulfuric acid with the corresponding alcohol, are reported in the 
literature but with poor yields (50 – 55 %) (Hilbert, G. E., 1932, Otter, B. A., et al., 
1968). Esterified product 52 gave IR data with a new carbonyl band at 1728 cm
−1
 
typical of an α,β-unsaturated ester and 1H-NMR data revealed the addition of a new 
OMe group with the correct 3H integral at δH 3.70, which compared favorably to the 
OMe peak reported for 49 by Otter et al. (δH 3.74) (Otter, B. A., et al., 1968). The 
syntheses also achieved a higher yield (80 %) than the alternative syntheses 
mentioned above.   
The PMB protective groups were added next, to the nitrogens of the 
imidazole using 4-methoxybenzyl chloride and sodium hydride base, in strictly 
anhydrous conditions to prevent ester hydrolysis to the original carboxylic acid 49. 
The work-up also used acidic aqueous phases to try to neutralize any remaining 
sodium hydroxide, and thus prevent base-catalysed hydrolysis. The crude product 
required some column chromatography in ethyl acetate and petrol and 
recrystallisation from ether and n-hexane but this yielded crystalline 
1,3-bis(PMB)-4-methoxycarbonylimidazolin-2-one 52a with NMR data showing 
new aryl ring environments (δH 6.91 - 6.78, 7.19 and 7.32, δC 113.4 (2 CH), 114.0 
(CH), 114.4 (CH), 120.1 (CH), 127.2 (CH), 129.5 (CH), 129.6 (CH), 130.2 (2 C), 
153.4 (C), 158.9 (C)), OMe protons (δH 3.76 and 3.79) and benzyl CH2 environments 
(δH 4.76 and 5.16, δC 45.1 and 47.2). Two additional CH3 groups were also detected 
in the DEPT-135 data (δC 55.2 and 55.3) indicative of the OMe of the PMB groups. 
The expected mass of 383.1602 (M + H
+
) was also confirmed by high resolution 
mass spectrometry. 
Reduction of the methyl ester group in this compound 52a using 
diisobutylaluminium hydride (DIBAl-H) with recrystallisation gave the alcohol 53a 
in comparable yields to the Bn/BOM protected analogue synthesised by Dransfield et 
al. (92 % relative to Dransfield et al.’s 87 %) (Dransfield, P. J., et al., 2006). Initially 
Rochelle salt (potassium sodium tartrate) was used in the work-up, as this chelates 
aluminium released from DIBAl-H to prevent it forming hydroxide gels. These gels 
can disrupt partitioning of the crude product between DCM and water. However, 
subsequent work-ups simply used more MeOH to break-up these gels and produced 
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comparable yields, so the use of Rochelle salt was removed from the work-up. The 
IR showed one fewer carbonyl band than the starting material and an alcohol O-H 
band at 3270 cm
−1
. NMR showed evidence of a new CH2 (δC 108.9) as a doublet (δH 
4.20), with splitting attributed to the neighbouring alcohol group, and loss of peaks 
associated with the third OMe group in the ester starting material 52a. In addition, 
the mass spec. data gave the correct corresponding mass for the alcohol structure 
(M + H
+
; 355.1654).  
The alcohol 53a was then oxidised to 
1,3-bis(PMB)-4-formylimidazolin-2-one 38 using manganese dioxide. Mass 
spectrometry of the aldehyde showed a mass of 353 as expected. Both 
1
H-NMR and 
13
C-NMR showed peaks indicative of an aldehyde (δH 9.12 and δC 178.6) and loss of 
peaks from the starting material, which corresponded to the C-5 alcohol adduct. The 
IR data showed a new aldehyde carbonyl at 1703 cm
−1
. This aldehyde 38a was 
immediately frozen until needed, as it is reported to autooxidise back to the 
carboxylic acid 49 if left at room temperature in aerobic conditions (Hagenmaier, H., 
et al., 1979). 
An attempt was made to reduce the protected methyl ester 52a to aldehyde 
38a in one step (as shown in Scheme 3.5 by the red star *) rather than two steps via 
the alcohol 53a. This has not been reported in the literature in relation to 
imidazolin-2-one derivatives but it has been reported on alkyl esters converted to 
alkyl aldehydes (Mears, R. J., et al., 2006, Qin, H.-L. and Panek, J. S., 2008), and 
Thenappan and Burton state that distinguishing between an alcohol product and an 
aldehyde product is as simple as using 3 mole equivalents of DIBAl-H instead of 
stoichiometric quantities, with the latter only generating 3 % alcohol (Thenappan, A. 
and Burton, D. J., 1990). Therefore, the mole equivalence of DIBAl-H used in the 
reduction of ester 52a was reduced from three to one. However, 
1
H-NMR of the 
crude product showed no formyl peak and only the protected alcohol 53a was 
recovered, so the synthesis was left unmodified. 
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Obtaining a dehydro derivative of N(α)-Cbz, N(π),N(τ)-bis(PMB)-oxo-His-OMe 40a 
via a Horner Wadsworth-Emmons (HWE) reaction 
 
The Horner-Wadsworth-Emmons (HWE) reaction is a modified Wittig reaction 
(Horner, L., et al., 1958, Horner, L., et al., 1959, Wadsworth, W. S. and Emmons, 
W. D., 1961, Wadsworth, W. S. J. and Emmons, W. D., 1973). This reaction couples 
an aldehyde or ketone to a phosphonate, as opposed to the usual triphenyl 
phosphonium ylide used in the Wittig Reaction. A strong base, such as NaH, is used 
to deprotonate the phosphonate, giving an anionic species that is a better nucleophile 
that traditional phosphonium ylids.  
Many groups have reported the HWE reaction to generate dehydroamino 
acids from phosphorylglycine esters and aldehydes (Armstrong, R. W., et al., 1992, 
Baldwin, J. E., et al., 1993, Ciattini, P. G., et al., 1988, Daumas, M., et al., 1989, 
Debenham, S. D., et al., 1997, Hammadi, A., et al., 1992, Marino, S. T., et al., 2004, 
Ratcliffe, R. W. and Christensen, B. G., 1973, Schmidt, U., et al., 1992, Shin, C.-G., 
et al., 1987), which can be enantioselectively hydrogenated using a chiral 
rhodium-phosphine catalyst (Marino, S. T., et al., 2004, Schmidt, U., et al., 1982, 
Schmidt, U., et al., 1984). It also avoids the potentially acidic conditions and high 
temperatures, which can induce racemisation, of the alternative dehydroamino acid 
forming Erlenmeyer-Plöchl amino acid synthesis (Marino, S. T., et al., 2004). 
Schmidt et al. note the importance of protecting the ring nitrogens when 
synthesising histidine via a HWE reaction (Schmidt, U., et al., 1984), and thus our 
precursor aldehyde 38 is ring nitrogen protected. This protected aldehyde 38a has 
been coupled using the HWE reaction in a couple of literature reports(Dilley, A. S. 
and Romo, D., 2001, Dransfield, P. J., et al., 2006), however, this was to a vinyl 
chloride and vinyl acetate  and not to prepare amino acid derivatives. Nevertheless, 
these literature reports show that this imidazolin-2-one derivative is stable under the 
conditions of HWE reactions, e.g. strong base, unlike 2-oxo-histidine (see Chapter 1, 
Section 1.5.3.), and can give high yields, e.g. 89 % (Dransfield, P. J., et al., 2006). 
There are several syntheses of the phosphoryl glycine derivatives required for 
the HWE in the literature and these are summarised by Ferris et al. (Ferris, L., et al., 
1996). It is now most commonly generated by a Michaelis-Arbusov reaction of an α-
alkoxyl glycine ester and a trialkyl phosphite (Schmidt, U., et al., 1982, Schmidt, U., 
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et al., 1984), as a high yielding, inexpensive synthetic route (Shankar, R. and Scott, 
A. I., 1993), and thus this is the synthetic route that this project took. Initially the 
triethyl ester 39a was to be used and this was synthesised by modification of the 
procedures described by Williams et al. who use benzyl carbamate 55 and glyoxylic 
acid monohydrate 56 to form the analogous trimethyl ester (Scheme 3.6) (Williams, 
R. M., et al., 1990).  
The addition of the diethoxyphosphinyl group was based on the procedure 
described by Coleman and Carpenter (Coleman, R. S. and Carpenter, A. J., 1993), 
which used a one-pot synthesis without isolation, in which the intermediate halide 
was used in a Michaelis-Arbuzov reaction with triethyl phosphite. This formed ethyl 
N-(benzyloxycarbonyl)-α-diethoxyphosphinylglycinate (Scheme 3.6) as phosphonate 
39a.  
Cbz
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O
O
OH
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H
O
Cbz
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84 % yield
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N
H
O
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OEt
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H
O
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O
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PO
OEt
OEt
92 % yield
55 56 57 58
39a
 
 
However, the trimethyl ester can be purchased commercially and has the advantage 
over the triethyl ester of being more crystalline and being more easily hydrolysed 
upon deprotection (Schmidt, U., et al., 1984). It is also more commonly used in the 
literature than the triethyl ester with a 95-fold greater number of publications citing 
the trimethyl ester on the Beilstein database than the trimethyl ester. Hence, this 
phosphonate 39b was chosen for the HWE reaction.  
The N-terminus protection used for the phosphonate 39b, and hence the 
overall dehydroamino acid after coupling, was the carboxybenzyl (Cbz) group. This, 
along with the acetyl (Ac) group have been used successfully in the literature during 
synthesis of the phosphonate and under the conditions of HWE (Coleman, R. S. and 
Carpenter, A. J., 1993, Williams, R. M., et al., 1990). In general, the Cbz group has 
the advantage over the Ac group of being removed under milder conditions - 
hydrogenation with a palladium catalyst - rather than the strongly acidic hydrolysis 
Scheme 3.6: Preparation of ethyl N-(Cbz)-α-ethoxyglycinate 39a. 
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conditions required to remove the Ac group. Hydrogenation as a deprotecting route 
would also have the advantage that, within the same reaction, Boc anhydride can be 
added to reprotect the amino function with a Boc group (Sakaitani, M., et al., 1988), 
to give the desired N(α) protection required for Aβ synthesis (see Chapter 2, Section 
2.1.2.). However, for the reasonably acid stable 2-oxo-histidine (see Chapter 1, 
Section 1.5.3.), with a ring system that may undergo hydrogenation, the acetyl 
protecting group may be more suitable that Cbz. 
Several literature reports used 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) as 
the base for the HWE reaction instead of sodium hydride because it gave higher 
yields and stereoselectivity (Schmidt, U., et al., 1992, Vaswani, R. G. and 
Chamberlin, A. R., 2008, Wang, W., et al., 2002). This project also used this base for 
the additional reasons that it is a liquid, and hence easy to dispense, and it is soluble 
in organic solvents. Literature reports have also found DCM to be a higher yielding 
solvent than THF and thus this project used this solvent (Vaswani, R. G. and 
Chamberlin, A. R., 2008).  
Aldehyde 38a was successfully coupled to phosphonate 39b in a HWE 
reaction and generated an α,β-unsaturated precursor 40 to protected 2-oxo-histidine 
(Scheme 3.7). Characterisation of the product from the HWE reaction showed the 
expected olefinic proton at δH 6.49, with a downfield quaternary carbon (α-C) peak 
in the 
13
C-NMR characteristic of an alkene (δC 119.5). In addition, peaks associated 
with both the Cbz and PMB groups were seen in the correct ratio indicating 
successful coupling of the aldehyde and the phosphonate to form a de-hydro 
derivative of 2-oxo-histidine. 
(PMB)N N(PMB)
O
O
+
HN
Cbz OMe
P
MeO
O
OMe
O
DBU, anhydrous DCM, rt
N(PMB)
(PMB)N
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Cbz OMe
O
38a
39b
40a 
 
Scheme 3.7: Horner-
Wadsworth-Emmons 
reaction to generate the  
N(α)-Cbz, N(τ),N(π)-
PMB-dehydro-amino 
acid derivative 40a.  
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The characterisation data does not distinguish the configuration (E or Z) of the 
dehydro derivative 40a. Use of 1D-NOE would be limited due to the lack of protons 
on the double bond with which to couple. However, based on literature reports on 
similar compounds, the likely predominant form is the Z isomer and this is how the 
dehydro derivative is represented in this PhD thesis. Schmidt et al. found the dehydro 
derivative of histidine, formed by a HWE reaction between the acetyl form of 
phosphonate 39c and a non-oxidised analogue of the imidazoline aldehyde 38a, to 
have a > 20 ratio of Z/E. It should be noted that Coleman and Carpenter have 
reported this diastereomeric selectivity to be highly base specific (Coleman, R. S. 
and Carpenter, A. J., 1993), and that Schmidt et al. use a different base to the one 
used in this PhD, i.e. potassium t-butoxide as opposed to DBU. However, subsequent 
papers by Schmidt et al. and Wang et al. used DBU as the base for their HWE 
reactions to form didehydroamino acid esters and also found a Z-selectivity 
(Schmidt, U., et al., 1992, Wang, W., et al., 2002), indicating that this is the likely 
isomer of 40a formed.  
 
Attempted asymmetric hydrogenation 
 
The aim of this multi-step synthesis was to generate 2-oxo-histidine in the 
enantiomerically pure L-histidine form 4. Starting from the dehydro-derivative 40a 
required the introduction of a correctly configured chiral centre at the α-carbon. 
Therefore, initially a chiral catalyst was chosen to attempt α,β hydrogenation of the 
dehydro derivative 40a.  
In general, rhodium catalysts lead to hydrogenations with higher 
enantioselectivity than are seen if other metals, such as iridium, are used (Burk, M. 
J., et al., 1993). Enantioselective rhodium catalysts were developed from the achiral 
rhodium-phosphine, Wilkinson’s catalyst (chlorotris(triphenylphosphine)rhodium(I)) 
(Knowles, W. S., 2002). The use of phosphine ligands allows use of higher 
hydrogenation pressures to ensure faster reactivity, without losses in selectivity 
(Nagel, U. and Albrecht, J., 1998). Burk et al. then developed DuPHOS-based 
rhodium(I) catalysts (1,2-bis ((2S, 5S) with the DuPHOS ligands being electron rich 
bisphospholane ligands; 1,2-bis(phospholano)benzene (Nagel, U. and Albrecht, J., 
1998). These catalysts have the advantage of having high efficiency (1/2500 ratio 
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catalyst/substrate), being commercially available, reacting quickly, producing high 
enantiomeric excess (> 99 %) and not being affected by changes in temperature or 
pressures below 50 atm, over which point there are slight reductions in selectivity 
(Knowles, W. S., 2002, Nagel, U. and Albrecht, J., 1998). They also hydrogenate 
both the Z- and E-isomer of the dehydroamino derivative to give the same absolute 
configuration (Knowles, W. S., 2002, Marino, S. T., et al., 2004), which is not 
always the case for all chiral catalysts.  Several groups have successfully used Burk’s 
DuPHOS catalyst to enantioselectively hydrogenate α-enamides with aromatic 
substituents with a high enantioselectivity (Marino, S. T., et al., 2004, Wang, W., et 
al., 2002).  A search of the literature on rhodium catalysts suitable to hydrogenate 
dehydroamino acids shows DuPHOS catalysts to have the highest enantiomeric 
excesses.  
These catalysts work by generating two diastereomic catalyst-substrate 
complexes, with the minor diastereomer having much greater reactivity than the 
major diastereomer and thus generating the predominant product enantiomer 
(Scheme 3.8) (Halpern, J., 1982, Nagel, U. and Albrecht, J., 1998). These two 
catalyst-substrate diastereomers reacts via two catalytic cycles; the minor manifold 
pathway and the major manifold pathway (Scheme 3.8). The cyclooctadiene (COD) 
ligand of the catalyst is first hydrogenated and this loses affinity for the rhodium 
metal so it is displaced by two solvent molecules to form a bis-solvent-catalyst 
complex. The substrate then displaces these solvent molecules and chelates the 
rhodium metal side on via both its olefinic group and its amido oxygen. This 
complex can exist in two diastereomeric forms, the minor form reacting with 
hydrogen substantially faster than the major form to form a dihydro complex. This is 
the first irreversible step in the hydrogenation and hence the geometry of the dihydro 
complex, rather than the geometry of the substrate, determines the enantioselectivity 
of the hydrogenation (Nagel, U. and Albrecht, J., 1998), explaining why the E- and 
Z-isomers of the dehydro derivative are equally well hydrogenated. 
 Burk et al. compared a range of catalysts to generate α,γ-unsaturated 
dehydroamino acid derivatives and found the Et-DuPHOS-Rh(I) 59 to have the 
highest enantioselectivity (> 99 %) and, possibly more importantly, to have the 
highest regioselectivity; reducing the C-α=C-β double bond over the C-γ=C-δ double 
bond, which is as desired in our dehydro derivative of 2-oxo-histidine 40a (Burk, M. 
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J., et al., 1998a). The absolute configuration generated by Et-DuPHOS-Rh(I) 
catalysts is the same configuration as the catalyst (Burk, M. J., et al., 1993), therefore 
to generate protected L-2-oxo-histidine, equivalent to (S)-2-oxo-histidine, a (S,S)-Et-
DuPHOS-Rh(I) would be required. 
 
Scheme 3.8: The two catalytic cycles for hydrogenation by soluble rhodium complexes. The COD 
ligand of the catalyst is first hydrogenated and thus loses affinity for the rhodium metal so is displaced 
by two solvent molecules to form a bis-solvent-catalyst complex. The substrate then displaces these 
solvent molecules and chelates the rhodium metal side-on via both its olefinic group and its amido 
oxygen. The catalyst-substrate complex forms two diastereomers which react via two catalytic cycles; 
the minor manifold pathway and the major manifold pathway. The minor form reacts with hydrogen 
substantially faster than the major form to form a dihydro complex. This is the first irreversible step in 
the hydrogenation and hence the geometry of the dihydro complex, rather then the geometry of the 
substrate, determines the enantioselectivity of the hydrogenation (Nagel, U., and Albrecht, J., 1998).  
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In this project, hydrogenation of the dehydro derivative 40a was attempted using the 
chiral rhodium catalyst; 
1,2-bis[(2S, 5S)-2,5-dimethyl phosphono]benzene(cyclooctadiene)rhodium(I)tetraflu
oroborate abbreviated to (S, S)-Et-DuPHOS-Rh(I) 59. The catalyst was added at a 
1:40 ratio with the substrate, the dehydro derivative 40a.The hydrogenation was 
carried out in methanol, which had previously been reported to allow the greatest 
enantiomeric selectivity and regioselectivity when using Et-DuPHOS-Rh(I) catalysts 
over a range of solvents (Burk, M. J., et al., 1998a, Fabrello, A., et al., 2010). The 
flask was evacuated before the catalyst was added to reduce oxidation of the catalyst 
(Scheme 3.9). The hydrogenation was initially carried out under atmospheric 
conditions (i.e. approx. 1 – 2 bar) but only starting material was recovered. The 
hydrogenation was then attempted again in an autoclave under approximately 10 bar 
of hydrogen but, again, only starting material was recovered.  
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Non-enantioselective hydrogenation 
 
To check if general hydrogenation of the dehydro derivative 40a was possible an 
achiral catalyst, platinum oxide (PtO2, Adam’s catalyst), was used. The same 
hydrogenation conditions were used as for the chiral catalyst 59 but at a 1:3 molar 
ratio of catalyst to substrate. This did successfully yield a protected derivative of 
2-oxo-histidine 4d (Scheme 3.10) with the expected β-CH2 pair of 
Scheme 3.9: Attempted enantioselective hydrogenation of the N(α)-Cbz dehydro derivative 
40a. This used the catalyst (S, S)-Et-DuPHOS-Rh(I) 59.  
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doublets-of-doublets at δH 2.67 and δH 2.72 (δC 28.1 and 44.2) and a doublet for the 
α-CH at δH 4.41 (δC 114.1) (Figure 3.1 and Figure 3.2). However, this is will be a 
racemic product and hence not suitable for peptide synthesis of Aβ.  
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Figure 3.1: 
1
H-NMR (400 MHz; CDCl3)
 
spectrum of 
N(α)-Cbz, N(π), N(τ)-Bis(PMB)-2-oxo-His-OMe 4d.  
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Figure 3.2: 
13
C-NMR (100.65 MHz; CDCl3) spectrum of 
N(α)-Cbz, N(π), N(τ)-Bis(PMB)-2-oxo-His-OMe 4d.  
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Two additional compounds were isolated from the crude product of the 
hydrogenation; a C-4,C-5 dihydro, α,β-dehydro derivative of 2-oxo-histidine 60 and 
a C-4,C-5 dihydro 2-oxo-histidine derivative 61, as a 45:55 mixture of two 
diastereomers (Scheme 3.10). This shows that the 4-C=C-5 double bond of imidazole 
is reduced more readily than the corresponding double bond in non-oxidised histidine 
derivatives, which have a greater aromatic character. 
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The C-4,C-5 dihydro, α,β-dehydro derivative of 2-oxo-histidine 60 showed the 
remaining olefinic proton at the β-carbon (δH 6.13, δC 130.2, Figure 3.3 and Figure 
3.4) indicating this bond had not been hydrogenated. In addition, the C-5 proton 
signal was now presenting as an AB system of two doublets at δH 2.90 and δH 3.38 
(δC 46.3) indicating 60 now had diastereotopic CH2 environments (Figure 3.3). The 
new chiral centre was identified as C-4, which presented as a doublet of doublets of 
doublets at δH 4.06 (δC 51.1) coupled to both the β-CH and the H2C-5 (Figure 3.5). 
The C-4,C-5 dihydro 2-oxo-histidine derivative 61 presented the expected α,β 
reduction with a pair of diastereotopic doublets of doublets at δH 1.59 and δH 2.20 (δC 
53.5, Figure 3.6 and Figure 3.7) coupled to both the new chiral centre at the α-CH 
(δH 4.12 – 4.20, δC 128.1) and the new chiral centre at C-4 (δH 3.23 - 3.34, δC 114.0, 
Figure 3.8). As with product 60, this product presented with the diastereotopic H-5 
(δH 2.74 and 3.14, δC 47.9) protons and the new chiral centre at C-4.  
Scheme 3.10: Hydrogenation of the N(α)-Cbz, N(τ),N(π)-bis(PMB)-dehydro-derivative of 
2-oxo-histidine 40a with a platinum catalyst. 
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Figure 3.3: 
1
H-NMR (400 MHz; CDCl3) spectrum of 
N(α)-Cbz, N(π), N(τ)-Bis(PMB)-α,β-dehydro-4,5-dihydro-2-oxo-His-OMe 60.  
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Figure 3.4: 
13
C-NMR (100.65 MHz; CDCl3) spectrum of 
N(α)-Cbz, N(π), N(τ)-Bis(PMB-α,β-dehydro-4,5-dihydro-2-oxo-His-OMe 60.  
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Figure 3.6: 
1
H-NMR (400 MHz; CDCl3) spectrum of 
N(α)-Cbz, N(π), N(τ)-Bis(PMB)-4,5-dihydro-2-oxo-His-OMe 61.  
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Figure 3.5: 
1
H – 1H COSY (400 MHz; CDCl3) NMR spectrum of 
N(α)-Cbz-N(π),-N(τ)-Bis(PMB)-α,β-dehydro-4,5-dihydro-2-oxo-His-OMe 60.  
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Figure 3.7: 
13
C-NMR (100.65 MHz; CDCl3) spectrum of 
N(α)-Cbz,  N(π), N(τ)-Bis(PMB)-4,5-dihydro-2-oxo-His-OMe 61.  
 
N
N
O
H
N
H
OCH3
O
H
H3CO
OCH3
O
O
Figure 3.8: 
1
H – 1H COSY (400 MHz; CDCl3) NMR spectrum of 
N(α)-Cbz, N(π), N(τ)-Bis(PMB)-4,5-dihydro-2-oxo-His-OMe 61.  
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Of the three hydrogenation products generated in this reaction the most high yielding 
(41 %) is the derivative 61 with both the 4-C=C-5 and α-C=β-C double bonds 
reduced. Of the two mono-reduced products the most common product is α-C=β-C 
dihydro derivative (2-oxo-his) 4d with a 38 % yield compared to the 21 % yield of 
the 4-C=C-5 dihydro derivative 60 indicating that the imidazole ring is less reactive 
to hydrogenation than the α-C=β-C double bond.  
 
Use of the N(α)-Acetyl group 
 
It was at this time that a paper was found describing the necessity of an amide group 
as the amino-protective groups in these hydrogenations, in order to allow 
co-ordination of the rhodium cation of the catalyst complex via the amide oxygen 
(Burk, M. J., et al., 1998b). Burk et al. found this true for α,γ-dienamide esters, 
which have a similar pattern of unsaturation as 2-oxo-histidine (Burk, M. J., et al., 
1998a). Carbamates such as N-Cbz were found not to chelate the rhodium metal. In 
addition, the universal enantiomeric selectivity across both Z-isomers and E-isomers 
is slightly less for N(α)-Cbz protected enamides than N(α)-Ac protected enamides 
(i.e. 92 % ee compared to > 99 % ee) (Burk, M. J., et al., 1993) and other studies 
have found N-Ac protected dehydro derivatives to give a better enantiomeric excess 
than N-Cbz dehydro derivatives (Kreuzfeld, H.-J., et al., 1993). In addition, an Ac 
protecting group may, as discussed above, allow a different selection of rhodium 
chiral catalysts, which were not suitable for N-Cbz protected dehydro derivative, to 
be trialled on the N-Ac-dehydro derivative. 
Therefore, the enantioselective hydrogenation using the (S, 
S)-Et-DuPHOS-Rh(I) catalyst 59 was trialled on the Ac-dehydro derivative 40b 
(Scheme 3.13). This required the synthesis of the dehydro-derivative of 
2-oxo-histidine to be redesigned to incorporate an acetyl protecting group at the 
amino terminus rather than a Cbz group. It was decided that this protecting group 
would be introduced onto the phosphonate before the HWE coupling.  
Schmidt et al. note that the N-Cbz group can easily be cleaved and replaced 
with an N-acetyl group without adding any more complications to the subsequent 
HWE reaction (Schmidt, U., et al., 1984). Indeed, several N-protecting groups can be 
used such as N-Boc, N-chloroacetyl and N-formyl, but not N-trifluoroacetyl 
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(Schmidt, U., et al., 1984). However, Schmidt et al. used a two-step method 
(Schmidt, U., et al., 1984) for generating the Ac-phosphonate 39c from the 
Cbz-phosphonate 39b which seemed unnecessary based on the similarity in reagents 
used in both steps and the fact that the isolated intermediate was likely to be 
unstable. Therefore, the method used in this project was based on that described by 
Hoshina et al. which used a one-pot synthesis of the Ac-phosphonate 39c from the 
Cbz-phosphonate 39b via a hydrogenation with a Pd/C catalyst in conjunction with 
an acetylation by acetic anhydride (Scheme 3.11) (Hoshina, Y., et al., 2007). This 
synthesis also uses acetic acid as the solvent instead of either a two component 
methanol-DCM solvent system or methanol, used in other syntheses (Schmidt, U., et 
al., 1984, Vaswani, R. G. and Chamberlin, A. R., 2008), to try and prevent methyl 
acetate forming as a by-product. The Ac-phosphonate 39c was successfully 
synthesised, as shown by a similar melting point to those reported in the literature 
(Mazurkiewicz, R. and Kuznik, A., 2006, Schmidt, U., et al., 1984), the loss of the 
Cbz-group-associated benzyl protons from the 
1
H-NMR and the addition of an acetyl 
CH3 at δH 2.06, as reported by Hoshina et al. (δH 2.09). The 
31
P-NMR also showed a 
pure compound with only one peak (δP 20.0).  
 
 
 
 
 
The Ac-phosphonate 39c was successfully coupled to the PMB-protected aldehyde 
38a using the HWE condensation used on the original Cbz-phosphonate (Scheme 
3.12). The Ac and PMB associated protons signals presented in the correct ratios and 
the olefinic environments associated with the α,β double bond were seen at δH 6.28 
and δC 116.4. However, on attempted hydrogenation of the Ac-dehydro derivative 
40b with the (S, S)-Et-DuPHOS-Rh(I) catalyst 59, only starting material was 
obtained (Scheme 3.13).  
 
Scheme 3.11: Synthesis of ethyl N-(Ac)-α-dimethoxyphosphinylglycinate (39b).  
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The catalyst (S, S)-Et-DuPHOS-Rh(I) 59 is reported in the literature as being highly 
air sensitive (Burk, M. J., et al., 1999, Guernik, S., et al., 2001), especially when in 
solution. Hence, an analysis of the structure and function of this catalyst 59 was then 
done. A 
1
H-NMR spectrum of the catalyst run in CDCl3 showed mostly upfield 
methyl and olefinic protons, not expected of the catalyst’s ligands. A test of 
functionality was then done by analysing the effect of the catalyst on a typical model 
hydrogenation of methyl-2-acetamido-acrylate 62 to 2-acetamidopropionic acid 
methyl ester 63 (Scheme 3.11) (Burgemeister, K., et al., 2007, Cobley, C. J., et al., 
2003). Only starting material 62 was obtained. Therefore, use of this chiral catalyst 
was abandoned. There may be more potential for an enantioselective hydrogenation 
of protected N(α)-Cbz-2-oxo-his with use of (S,S)-Pr-DuPHOS-Rh(I) catalyst 59, 
which has been successfully been shown to hydrogenate N(α)-Cbz-alanine (Burk, M. 
J., et al., 1993) or the non-air sensitive ferrocenyldiphosphine rhodium catalyst 
Scheme 3.13: Attempted enantioselective hydrogenation of the N(α)-Ac dehydro derivative 
40b. This used the catalyst (S, S)-Et-DuPHOS-Rh(I) 59.  
 
Scheme 3.12: Horner-Wadsworth-Emmons reaction to generate the  
N(α)-Ac, N(τ),N(π)-PMB -dehydro-amino acid derivative 40b.  
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(Kang, J., et al., 1998). However, this required further time and resources than were 
available for this PhD project. 
N
H
O
O
O
N
H
O
O
O
P
Rh
P
CH3CH2
CH2CH3
CH2CH3
H3CH2C
H2, MeOH, rt
62 63
59
 
 
 
As a non-asymmetric hydrogenation was now the only route to protected 2-oxo-
histidine from the dehydro-derivative 40 it was now an imperative to find a method 
of separating the enantiomers of 2-oxo-histidine generated by such a hydrogenation. 
One proposed method was the use of enzymes which would selectively deprotect a 
single enantiomer of the oxidised amino acid at the amino terminus, thus allowing 
easy separation of the deprotected enantiomer from the protected enantiomer using 
column chromatography. One such enzyme is Hog renal acylase (aka Acylase 1 from 
porcine kidney) (Bretschneider, T., et al., 1988). This will only cleave acetyl groups 
from the amino terminus of L-configured amino acids and thus allows separation of 
racemic mixtures of protected 2-oxo-histidine by solvent extraction.  
Therefore, with this method in mind, a non-asymmetric hydrogenation of the 
Ac-dehydro derivative 40b was attempted using Adam’s catalyst (Scheme 3.15), 
with similar hydrogenation conditions as had been previously done on the Cbz-
dehydro derivative 40a. However hydrogenation of the Ac-dehydro-derivative 
(7, R = Ac) with PtO2 led to reduction of the PMB benzyl groups, with a multitude of 
upfield hydrocarbon peaks in the 
1
H-NMR of the crude product. It appeared that the 
N(α)-Cbz protection was affording some protection of the N(τ),N(π)-PMB groups 
from hydrogenation, which was not afforded by the N(α)-Ac protection. Therefore, it 
was decided to abandon syntheses using N(α)-Ac protection. 
Scheme 3.14: Model reduction of methyl-2-acetamido-acrylate 62.  
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Attempted deprotection of N(α)-Cbz, N(π),N(τ)-bis(PMB)-oxo-his OMe 4d 
 
As discussed above, PMB protecting groups for the ring nitrogens were considered 
advantageous over groups such as BOM because the literature reported that they 
could be removed by oxidation with cerium(IV) diammonium nitrate (CAN) (Bull, S. 
D., et al., 2001, Johansson, R. and Samuelsson, B., 1984, Smith, A. B., et al., 1992, 
Yamaura, M., et al., 1985), instead of the usual hydrogenation required to deprotect 
other protecting groups such as BOM groups. This reduces the chance of the C-4,C-5 
double bond of the imidazolin-2-one ring system being reduced as was seen in the 
formation of products 60 and 61.  
 Therefore, a deprotection using CAN was attempted on the protected 
2-oxo-histidine derivative 4d (Scheme 3.16(A)). This was performed in acetonitrile, 
as this is a solvent unlikely to be oxidised. Both 4-methoxybenzaldehyde 64 in 96 % 
yield and traces of PMB alcohol 65 (identified by TLC) were recovered, implying 
CAN deprotects by both oxidative and hydrolytic mechanisms. This second 
mechanism has been implied in the literature by the recent finding that CAN can 
have Lewis acid like behaviour (Scheme 3.17) (Caruso, T., et al., 2006).  
 But the only amino acid derivative recovered was over oxidised so that the 
ring now contained two nitrone groups 66. This structure is supported by imine 
bands in the IR at 1613 cm
−1
 and 
1
H-NMR at δH 8.64 (Figure 3.9). The mass 
spectrometry data - 564.2335 (M + H
+
), 581.2599 (M + NH4
+
), 586.2149 (M + Na
+
) - 
predicted the mass of the product to be approximately 563.23. The product was also 
found to dimerise under electrospray ionisation (ESI) conditions giving an M + NH4
+
 
ion at 1144.4890. All three protecting groups were indicated as intact by 
1
H-NMR. 
Scheme 3.15:  Attempted hydrogenation of the  
N(α)-Ac, N(τ),N(π)-bis(PMB )-dehydro-derivative of 2-oxo-histidine 40b with a platinum catalyst. 
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This is a novel compound, but it was little use as a deprotection product of 2-oxo-
histidine. The yield obtained was less than 4 % for this over-oxidised amino acid, but 
no other product with an intact imidazolin-2-one ring was detected by 
1
H-NMR. This 
indicates that, although deprotection was successful, the remaining amino acid 
derivative was destroyed by the oxidative conditions. However, using less CAN is 
unlikely to cause deprotection, as Yamaura et al. have reported poor deprotection 
yields at low CAN concentrations (Yamaura, M., et al., 1985). In addition, CAN has 
been shown to promote intramolecular cyclisation between ketones in imidazolinone 
ring systems and neighbouring alkyl chains (Zancanella, M. A. and Romo, D., 2008) 
and so may not be appropriate for deprotection of imidazolin-2-one ring systems. 
 
N
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Figure 3.9: 
1
H-NMR (400 MHz; CDCl3) spectrum of 
2-carboxybenzylamino-4,5-bis-(PMB-imino)pentanoic-acid methyl ester N(4), N(5)-dioxide 65.  
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Scheme 3.16:  Attempted 
deprotection of PMB 
groups from imidazolin-
2-one ring nitrogens using 
cerium (IV) ammonium 
nitrate (CAN). (A) 
Attempted deprotection of 
protected 2-oxo-histidine 
derivative 4d. (i) 3 h with 8 
mol. eq. CAN. (ii) 30 min 
with 4 mol. eq. CAN. (B) 
Attempted deprotection of 
protected methyl ester 
derivative 52a  
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Scheme 3.17: CAN removes PMB 
groups by both hydrolytic and 
oxidative mechanisms. (A) Hydrolytic 
mechanisms generate PMB-aldehyde 64. 
(B) Oxidative mechanisms generate 
PMB-alcohol 65. Both have been 
recovered from CAN-mediated 
deprotections of N(α)-Cbz, N(π), N(τ)-
Bis(PMB)-2-oxo-His-OMe 4d.  
 
Chapter 3 
Synthesis of 2-oxo-histidine from urea 
 
 
131 
 
CAN-mediated deprotection was then attempted on a simpler model system, the 
PMB-methyl ester 52a (Scheme 3.16(B)), but, despite 4-methoxybenzaldehyde 64 
being isolated, the deprotected methyl ester could not be extracted into an organic 
solvent so as to separate it from cerium ions. This made NMR based characterisation 
impossible due both to domination of the spectra with ammonium ion peaks and to 
peak broadening due to paramagnetic Ce
3+
. Therefore, CAN-mediated oxidation was 
abandoned as a deprotection method.  
PMB groups are also reported in the literature to be removable by strongly 
acidic conditions (Yamaura, M., et al., 1985). Therefore, the second method of 
deprotection tested was an acid-based deprotection. Initially TFA was trialled. Room 
temperature reactions (4 h incubation) on the PMB-methyl ester 52a (Scheme 
3.18(A)), based on procedures used by Chida et al. (Chida, N., et al., 1993), led to 
simply starting material being recovered. Reactions under reflux, based on 
procedures used by Brooke et al. (Brooke, G. M., et al., 1997) (96 h incubation) 
(Scheme 3.18(B)) led to deprotection but only of one PMB group leaving the 
mono-PMB-methyl ester 67. 
1
H-NMR showed the new free NH with a broad peak at 
δH 10.90 and the integrals of the PMB associated protons were reduced by half 
compared to the original di-PMB protected product 52a. The specific regiochemistry 
of this compound was determined using a 1D-NOE experiment (Figure 3.10). The 
ring proton was irradiated at δH 7.47 and an enhanced peak was observed at δH 4.68  
i.e. CH2 of the PMB group. This indicated that the remaining PMB group was 
positioned next to the ring proton as opposed to next to the methyl ester group 
(Figure 3.10).  
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Scheme 3.18:  Attempted deprotection of PMB groups from imidaozlin-2-one ring nitrogens using 
acid hydrolysis. 
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Figure 3.10: 1D NOE (400 MHz, DMSO) spectrum of 1-PMB-4-methoxycarbonylimidazolin-2-one 67. 
This indicates, after deprotection with TFA, the remaining PMB group of methyl ester 67 is positioned next to 
the ring. The ring proton was irradiated at δH 7.47 ppm and an enhanced peak was observed at δH 4.68 ppm i.e. 
CH2 of the PMB group.  
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Some literature examples of TFA-mediated deprotections indicate the importance of 
using a nucleophilic scavenger such as anisole (Boger, D. L., et al., 2000, Forbes, I. 
T., et al., 1992, Wood, J. L., et al., 1995) in the reactions to remove the electrophilic 
PMB-deprotection product. Although there are few nucleophilic sites in the 
unprotected 2-oxo-histidine derivative, the deprotections on the PMB-methyl ester 
52a were repeated for completeness, using TFA and one of two easily available 
nucleophile scavengers; thiophenol (Scheme 3.18(C)) (Tam, J. P., et al., 1985) or 
dimethyl sulphide (Scheme 3.18(D)) (Lundt, B. F., et al., 1978). With use of the 
former scavenger mono-PMB-methyl ester 67 was obtained along with unreacted 
thiophenol, whereas for the latter the PMB groups remained.  
Another acid used for attempted deprotections on PMB-methyl ester 52a was 
hydrobromic acid at room temperature for 20 h but only starting material was 
recovered (Scheme 3.18(E)). To see whether hydrobromic acid would have any 
effects on the Cbz and OMe protecting groups an attempted deprotection of the fully 
protected 2-oxo-his 4d with hydrobromic acid at room temperature for 24 h was 
attempted but it was not possible to purify the product with ion exchange 
chromatography as the product would neither bind to anion (IRA400 OH resin) or 
cation (DOWEX 50W-X8) exchange columns (Scheme 3.18(F)). This may be due to 
2-oxo-histidine being less basic than histidine and therefore less likely to bind to 
these columns. The crude product indicated both formyl peaks (δH 8.2), PMB peaks 
(δH 6.7-7.0) and amino acid peaks (e.g. δH 2.9-3.1 for βCH2). 
Finally, a quite extreme deprotection of the fully protected 2-oxo-his 4d using 
a 24 h reflux with 6M HCl (Scheme 3.18(G)) produced an initially promising 
1
H-NMR of the crude reaction mixture with a halving in the integrals of PMB-related 
peaks indicating mono-deprotection, and loss of the Cbz-aromatic peaks at δH ~7.3 . 
However, as for the hydrobromic acid based deprotection, purification of this using 
ion exchange chromatography proved impossible.  
Due to the difficulty in removing the second PMB-group from our protected 
molecules we decided to attempt synthesis using different protecting groups; 
benzyloxymethyl (BOM) and dimethoxybenzyl (DMB). The literature also gives 
examples of other groups, such as 2-(trimethylsilyl)ethoxycarbonyl (Teoc) (Lanman, 
B. A., et al., 2007) or benzyl (Bn) (Wang, S., et al., 2006), being used to protect 
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imidazolin-2-one, but these protecting groups are more difficult to manipulate or can 
cause intramolecular cyclisation upon deprotection. 
 
Benzyloxymethyl (BOM) as a nitrogen protecting group 
 
BOM groups are stable to TFA, basic conditions and aqueous carboxylic acids 
(Brown, T., et al., 1982). Brown et al. concluded this was the best protecting group 
with which to protect imidazole nitrogens and could be carried through to solid phase 
peptide synthesis and still be stable (Brown, T., et al., 1982). They were one of the 
orthogonal protecting groups initially discussed in the Dransfield et al. paper from 
which the synthesis discussed above is based (Dransfield, P. J., et al., 2006). 
However, this project initially did not use the BOM group as a potential ring nitrogen 
protecting group because of the requirement for hydrogenation in order to remove 
these groups at deprotection, which may target the 4-C=C-5 bond of the ring system 
in 2-oxo-histidine.  
  
Attempted alterations to synthesis of 2-oxo-histidine 4 with use of the 
BOM-protecting group 
 
The synthetic route to the dehydro derivative 40c is summarised in Scheme 3.19 and 
follows a similar synthetic route to that with the PMB intermediates. One difference 
was the production of two products upon protection of the methyl ester 52, the 
expected methyl ester 52b and an ester substitution to a BOM ester 68 at the C-4 
position. This is likely due to impurities in the benzyl chloromethyl ether, such as 
benzyl chloride, acting as a friedel craft-type alkylating agent. The extent of this 
transesterification was considerable, with higher yields obtained for the BOM ester 
68 than the methyl ester 52b. There may have been some evidence for this with the 
PMB protection of 52 with extra peaks seen in the crude product NMR in a 2:1 ratio 
with the expected product 52a. However, such an ester substituted product was not 
isolated and was not the major product, unlike with the BOM protection. In general, 
the protection of the methyl ester with BOM-Cl was lower yielding (6 %) than the 
protection with PMB-Cl (21 %). This is probably due to the poor purity of 
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commercial benzyl chloromethyl ether (60 % quoted by Sigma Aldrich) in 
comparison to 4-methoxybenzyl chloride (98 % quoted by Sigma Aldrich).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This substituted ester could still be used for the DIBAl-H reduction as the side 
product alcohol could be isolated by column chromatography or, in the case of PMB 
alcohol, by recrystallisation. The alcohol 53b was successfully oxidised to the 
aldehyde 38b using MnO2.  The characterisation data for the BOM-aldehyde 38b 
compared favourably with those reported by Ma et al. with all peaks within 0.03 ppm 
of those reported, with the aldehyde peak at δH 9.34 in particular measured as being 
between the peak recorded by Ma et al. (δH 9.33) (Ma, Z., et al., 2011) and that 
recorded by Dransfield et al. (δH 9.36) (Dransfield, P. J., et al., 2006), noting that the 
latter was recorded in a different solvent. 
Synthesis of the dehydro derivative with BOM protecting groups was lower 
yielding than that with PMB protecting groups with an overall yield of  0.13 % 
(BOM) compared to 0.95 % (PMB). However, it could be done successfully 
indicating BOM could be a viable alternative to the PMB group for protecting the 
ring nitrogens.  
 
 
Scheme 3.19: Synthesis of the N(α)-Cbz, N(τ), N(π)-bis(BOM)–dehydro derivative of 
2-oxo-histidine 39c.  
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Dimethoxybenzyl (DMB) as a nitrogen protecting group 
 
The use of DMB as a nitrogen protecting group, along with trimethylsilylethyl (Tse) 
groups, in an imidazoline-2-one system exposed to strong acids and mild oxidising 
agents, has been demonstrated previously by several groups (Dransfield, P. J., et al., 
2006, Dransfield, P. J., et al., 2005, Wang, S., et al., 2006, Zancanella, M. A. and 
Romo, D., 2008). The group can be easily removed using potassium persulfate 
(Huffman, W. F., et al., 1977, Qian, X., et al., 2002), p-toluenesulfonic acid (Chern, 
C. Y., et al., 2003), DDQ (Grunder-Klotz, E. and Ehrhardt, J.-D., 1991, Mori, S., et 
al., 1988), or TFA-mediated hydrolysis with or without cation scavengers (Deshong, 
P., et al., 1985, Schlessinger, R. H., et al., 1985, Shimshock, S. J., et al., 1991, 
Wood, J. L., et al., 1995, Wood, J. L., et al., 1997, Wood, J. L., et al., 1996), which 
will also remove the Cbz groups (Lundt, B. F., et al., 1978). They are also easily 
deprotected from electron-rich systems (Watson, D. J., et al., 2001), of which the 
imidazolin-2-one ring system is an example, making them ideal nitrogen protecting 
groups for this project. 
This PhD looked at the isomeric 2,4- and 3,4-dimethoxybenzyl groups, with 
the 2,4 form predicted to be easier to remove due to the stability of the carbocation 
formed. This has the advantage over PMB as a protecting group that the extra 
electron-donating methoxy group stabilises the carbocation produced as an 
intermediate in the deprotection process.  
The chlorides 69 and 70 required to add these groups were synthesised 
according to literature methods from the corresponding alcohols (Howell, S. J., et al., 
2001, Nicoletti, T. M., et al., 1990, Smyth, M. S., et al., 1993). However, upon 
attempted protection of the methyl ester 52 with these chlorides (Scheme 3.20(A); 
for 2,4-DMB-Cl 69, and Scheme 3.20 (B); for 3,4-DMB-Cl (70)), using a NaH/DMF 
method similar to literature procedures (Leigh, C. D. and Bertozzi, C. R., 2008, 
Paterson, I., et al., 2009), a complex mixture of products, as shown by TLC, was 
produced. 
1
H-NMR showed numerous methoxy environments indicating that this 
was not an efficient protecting strategy for the methyl ester. The 2,4-DMB-Cl 69 also 
polymerised rapidly to form a purple crystalline solid upon exposure to air. 
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3.2.2. Alternative syntheses from urea 17 attempted 
 
There are alternative synthetic routes to 2-oxo-histidine which may seem more 
elegant than those described above. Indeed with the seven steps required to go from 
urea and tartaric acid to protected 2-oxo-histidine, overall yields are below 1 %. 
Therefore, other simpler syntheses based on the imidazolin-2-one ring system were 
attempted.  
 
 Alcohol activation of hydroxymethylimidazolin-2-one 53 with subsequent 
substitution with a glycine enolate 
 
An alternative proposed synthesis from 4-hydroxymethylimidazolin-2-one 53 to 
2-oxo-histidine requires the alcohol to be activated by the introduction of a good 
leaving group. This leaving group can then be substituted with a glycine enolate 
equivalent e.g. diethyl acetamidomalonate 71 (see Section 3.1.1.) (Burgoyne, D. L., 
et al., 1991, Jones, R. G. and Mclaughlin, K. C., 1949, Kuwano, R. and Kondo, Y., 
2004, Steinhuebel, D., et al., 2006). Ester hydrolysis and decarboxylation then leaves 
the protected amino acid 4. This has an advantage over the previously described 
Scheme 3.20: Attempted protection of methyl ester 52 with dimethoxybenzyl groups.  
(A) Attempted protection with 2,4-dimethoxybenzyl chloride 69. (B) Attempted protection with 
3,4-dimethoxybenzyl chloride 70.  
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synthesis in that the glycine enolate 71 is at the same oxidation level as the desired 
2-oxo-histidine product and thus avoids the use of a α-C=β-C reduction step with the 
associated risk of reduction of the C-4=C-5 double bond in the imidazole ring. In 
addition, diethyl acetamidomalonate 71 is inexpensive and readily available 
(Steinhuebel, D., et al., 2006).  
There are several good leaving groups that can be incorporated at the C-4,C-5 
carbon of the imidazolin-2-one ring system instead of the alcohol (Scheme 3.21). 
These include tosyl and mesyl groups (Burgoyne, D. L., et al., 1991), alkyl 
carbonates (Kuwano, R. and Kondo, Y., 2004, Steinhuebel, D., et al., 2006, Yeung, 
K.-S., et al., 2001), alkyl halides (Anilkumar, G., et al., 2002, Bayle-Lacoste, M., et 
al., 1990, Choi, Y., et al., 2003, Jones, R. G. and Mclaughlin, K. C., 1949, 
Krogsgaard-Larsen, P., et al., 1984, Lisowski, V., et al., 2001) and alkyl acetates 
(Yokogi, M. and Kuwano, R., 2007). Alkyl halides were avoided because they can be 
quite low yielding (Jones, R. G. and Mclaughlin, K. C., 1949), can undergo 
reversible reactions and can be difficult to synthesise. Out of the alcohol activation 
procedures presented in Scheme 3.21, the following were studied in this project; 
tosylation/mesylation and carbonate formation. 
Tosylation has been successfully employed by Burgoyne et al. to generate a 
dibenzyloxybenzyl substituted glycine (Scheme 3.21(B)) (Burgoyne, D. L., et al., 
1991). For this project, both a tosylation and mesylation were attempted on alcohol 
53. The procedure used was very similar to that used by Burgoyne et al. (Burgoyne, 
D. L., et al., 1991), although the solvent used was either anhydrous DCM or 
anhydrous diethyl ether rather than benzene. For the tosylation (Scheme 3.22) both 
sodium hydride and pyridine were trialed as bases. Pyridine was initially avoided due 
to the likelihood it would be react with the tosylated ring system 72 to form a 
pyridinium salt. However, 
1
H-NMR of the crude product after NaH was used as the 
base showed no peak shift indicative of the sodium salt forming. Therefore, pyridine 
was used as the base for the tosylation. For the mesylation, triethylamine was used as 
the base. In both cases the reaction was performed under a nitrogen atmosphere. 
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Scheme 3.21: Literature examples of activated alcohols coupled to glycine enolates. 
(A) 1-substituted imidazole chlorides (Jones, R. G., and McLaughlin, K. C., 1949). 
(B) Dibenzyloxybenzyl tosylates (Burgoyne, D. L., et al., 1991). 
(C) Vinyl amine ethyl carbonates (Steinhuebel, D. L., et al., 2006). 
(D) Benzyl methyl carbonates (Kuwano, R., and Kondo, Y., 2004). 
(E) Bromo-benzyl bromides (Bayle-Lacoste, M., et al., 1990). 
(F) Tetrahydrocycloheptaisoxazolone bromides (Krogsgaard-Larsen,  P., et al., 1984). 
(G) Benzyl acetates (Yokogi, M., and Kuwano, R., 2007).  
(H) Alkyl acetates (Yokogi, M. and Kuwano, R., 2007).  
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However, the use of either TsCl or MsCl did not result in the conversion of the 
alcohol into a tosyl or mesyl ester respectively but instead yielded 
5-methyl-imidazolin-2,4-dione 74 (Scheme 3.23), an isomer of the alcohol 53 in 
25 % yield. The remaining crude was starting material. In the IR spectrum of the 
fraction containing purified product 74a no alcohol bands, present in 53 at 
~ 3200 cm
−1
, were seen. Instead two carbonyls were present as bands at 1768 cm
−1
 
and 1704 cm
−1
. The 
13
C-NMR spectrum (Figure 3.12) showed two carbonyl peaks at 
δC 173.4 and δC 156.1. In addition the 
1
H-NMR spectrum (Figure 3.11) shows a new 
methyl group (doublet at δH 1.30) coupled to a ring proton (quartet at δH 3.70) 
indicating a methyl group (δC 15.1) attached to an imidazoline ring carbon next to a 
ring CH (δC 54.7). The C-5 CH singlet peak seen in the starting material at 
approximately δH 6.04 was absent from the spectrum of the imidazolin-2,4-dione 24. 
The 
1
H-NMR data (Figure 3.11) also showed an AB system (δH 4.47 and δH 4.59) 
indicative of the aryl CH2 protons being in diastereotopic environments induced by 
the formation of a new chiral centre at C-4 in the imidazole ring.  
 
Scheme 3.22: Proposed alternative synthesis of 2-oxo-histidine via an alkylation of a glycine 
enolate equivalent. This synthesis takes the alcohol 53 and activates it to either a tosyl or mesyl 
group 72. This can then undergo a coupling to a glycine enolate equivalent e.g. diethyl 
acetamidomalonate 71 to form diester 73. Deprotection and decarboxylation can then give 
2-oxo-histidine 4.  
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Scheme 3.23: Isomerisation of protected 4-methylhydroxylimidazolin-2-one 53 induced by TsCl 
and MsCl. This occurs with both TsCl and MsCl as a reagent and for 4-methylhydroxylimidazolin-2-
one protected with either PMB 74a or BOM 74b groups.  
 
Figure 3.11: 
1
H-NMR (400 MHz, CDCl3) spectrum of 1,3-bis(PMB)-5-methylimidazolidine-2,4-dione 
74a.  
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One potential mechanism for this isomerisation is given in Scheme 3.24. 
Interestingly, this isomerisation occurs for both the PMB-protected alcohol 53a and 
the BOM-protected alcohol 53b.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12: 
13
C-NMR (100.65 MHz, CDCl3) spectrum of 
1,3-bis(PMB)-5-methylimidazolin-2,4-dione 74a.   
 
Scheme 3.24: Proposed 
mechanism for the 
isomerisation of alcohols 
53 by sulfonyl chlorides.  
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Another activation of the protected alcohol, this 
time exclusively with ring nitrogen BOM 
protection 53b, was the conversion to the 
methyl carbonate 75. It was envisaged that this 
could then be coupled to the glycine enolate 
equivalent discussed above, diethyl 
acetamidomalonate 71 (Scheme 3.24). Similar 
methods have been used for coupling allylic 
carbonates to diethyl acetamidomalonate 
(Steinhuebel, D., et al., 2006) (Scheme 
3.20(C)) and coupling of benzyl ethyl 
carbonates to a selection of glycine enolate 
equivalents (Kuwano, R. and Kondo, Y., 2004) 
(Scheme 3.20(D)).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3.25: Activation of  
1,3-bis(BOM)-4-hydroxymethyl-imidazolin-2-one 
53 as a methyl carbonate 75. Two synthetic 
methods to make the carbonate 40 were compared: 
(A) Using NaH as the base. (B) Using pyridine as 
the base.  
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Two methods were compared for the synthesis of the methyl carbonate 75 from the 
alcohol 53b (Scheme 3.25). One used NaH as a base in anhydrous THF and 
generated the methyl carbonate 75 in very poor yields (3 %, Scheme 3.25(A)). A 
better method used pyridine as the base in anhydrous DCM and generated the methyl 
carbonate 75 in 36 % yield (Scheme 3.25(B)). In both cases the characterisation 
confirmed the formation of the methyl carbonate with an expected high resolution 
MS peak at 413.1704 (M + H
+
) and NMR peaks for the new methyl ether group (δH 
3.69, δC 55.0). The product was found not to be stable to chromatography on 
standard flash silica gel and so columns were pre-treated with triethylamine before 
chromatography was performed on the carbonate. In addition, organic layers were 
washed with pH 7.4 phosphate buffer rather than HCl.  
The coupling of the carbonate 75 to diethyl acetamidomalonate 71 was then 
attempted (Scheme 3.25) using firstly NaH in DMF to form the sodium salt of the 
malonate and then adding BINAP with the Pd(allyl)Cl2 catalyst and diethyl 
acetamidomalonate for the coupling. These conditions were similar to the conditions 
used by Steinhuebel et al. but using the more readily available BINAP ligand rather 
than dppe (Steinhuebel, D., et al., 2006). However, the coupling step did not generate 
the expected histidine derivative 4f. Instead, carbon-carbon bond formation occurred 
on the unsubstituted ring carbon to form an isomer 77 of the expected product 
(Scheme 3.26). The mass spectrometric data showed the expected mass of 554.2494 
(M + H
+
) for the carboxylated protected histidine derivative 4f. However, the 
1
H-NMR data showed the loss of the ring proton at δH 6.29 and addition of an extra 
methyl CH3 peak at δH 1.78. The remaining peaks were derived from diethyl 
acetamidomalonate; δH 2.05 for the acetyl CH3, δH 4.01 – 4.03 and δH 1.21 for the 
ethyl ester peaks, δH 7.89 (br) for the amide NH peak, indicating that the malonate 
had bound to the imidazolin-2-one ring system, just not at the expected carbon. 
Therefore the isomer 77 was assigned as the structure of the product.  
 
 
 
 
 
Scheme 3.26: Formation of unwanted isomer 77 from Pd-catalysed coupling of carbonate 75 with 
diethyl carbonate 71.  
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The mechanism proposed for 
this coupling is given in Scheme 
3.27 and is based on the general 
mechanism for 
palladium(0)-catalyzed allylic 
alkylations,  specifying diethyl 
acetamidomalonate 71 with 
strong base as a stabilized 
carbanion, and the carbonate 75 
as the allylic substrate. It is 
proposed that the malonate 70 
adds to the allylic cation system 
at the C-5 position (Scheme 
3.27(b)), as opposed to the C-4 
position (Scheme 3.27(a)) which 
would lead to the carboxylated 
histidine derivative 4f due to the 
stabilisation of the positive 
charge in the π-allylpalladium 
intermediate 78 at C-5 (Scheme 
3.27(b)) by the neighbouring τ-
nitrogen. This isomer 77, 
although a novel compound, 
does not aid in the synthesis of 
protected 2-oxo-histidine. 
 
 
  
 
  
Scheme 3.27: Proposed mechanism for formation of the carbonate-derived isomer 77. The 
malonate 71 can add at either a or b in the π-allylpalladium intermediate 78 but addition at b is stabilised 
by the neighbouring τ-nitrogen. 
 
Chapter 3 
Synthesis of 2-oxo-histidine from urea 
 
 
147 
 
A Vilsmeier-Haack reaction to obtain 1,3-bis(PMB)-4 formylimidazolin-2-one 38a  
 
A two-step synthesis of 4-formylimidazolin-2-one 38, for use in the HWE reaction, 
was considered. This started with a decarboxylation of 4-carboxyimidazoline-2-one 
49 to yield imidazolin-2-one 36, as described in Section 3.1.2. and then proceeded 
via a modified Vilsmeier-Haack reaction (Scheme 3.28).  
HN
NH
O
HO2C
K2CO3, reflux
HN
NH
O
HN
NH
O
DMF, POCl3, 100 C°
O
49
36 38
 
 
 
This modified Vilsmeier-Haack reaction used dimethylformamide (DMF) and 
phosphoryl chloride, which combine to generate the electrophilic species, a dimethyl 
chloromethyleniminium ion, that can formylate electron-rich aromatics and olefinic 
carbons at high temperatures and so should introduce a formyl group at C-4 of 
imidazolin-2-one. The reaction mixture was heated to 100 °C for 1.5 h. Ice was 
added and the mixture left to warm to room temperature. A very fine precipitate 
formed which required centrifugation to separate it from the filtrate. A 
1
H-NMR 
spectrum of the crude product in DMSO-d6 showed evidence of an aldehyde product 
(δH 9.77) in a 4:1 ratio with a product displaying a more downfield proton (δH 10.1). 
The only comparable unprotected 4-formylimidazolin-2-one 38 structure in the 
literature is that of an extraction from bacterial anti-fungal sugar (Hagenmaier, H., et 
al., 1979). This product was analysed using a 
1
H-NMR in D2O and showed a formyl 
peak at δH 9.20, therefore the peak at δH 9.77 in the crude product may indicate the 
formation of 4-formylimidazolin-2-one 38 by this modified Vilsmeier-Haack 
reaction.  
Although the 
1
H-NMR of the crude product showed no evidence of DMF 
contamination, without peaks around δH 2.8 – 2.9, evidence for phosphoryl chloride 
contamination was seen, with substantial large splitting (12.7 Hz) of the C-5 proton 
peaks characteristic of phosphorus splitting.  This crude product had limited 
solubility in both organic solvents and water and this hindered purification attempts, 
which included recrystallisation from water and column chromatography in both 
Scheme 3.28: Attempted use of the Vilsmeier-Haack reaction to synthesise 
4-formylimidazolin-2-one 38.  
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methanol and ethyl acetate-based solvent systems. Eventually this synthetic approach 
was abandoned, however it was decided that further syntheses should use 
imidazoline derivatives with protection on the nitrogens of the ring to improve 
solubility.     
Since experiments finished for this PhD project a paper has been published 
by Ma et al. which describes a one-pot Vilsmeier-Haack reaction to generate BOM-
protected 4-formylimidazolin-2-one (Ma, Z., et al., 2011). 
 
Halogenation of imidazolin-2-one 36 and Negishi cross-coupling to an activated 
serine derivative 79 
 
Finally another approach to synthesise 2-oxo-histidine from imidazolin-2-one 36 was 
proposed. This involved halogenation of imidazolin-2-one 36 and subsequent 
Negishi cross-coupling to a serine derivatized organozinc reagent 79 (Scheme 3.29). 
The serine derivative is activated by first substituting the alcohol with iodide and 
then co-coordinating this iodide to zinc to form the activated derivative 79, 
synthetically equivalent to a β-alanine anion (see Section 3.1.1.). An advantage of 
this approach is that the innate chirality in the serine derivative would avoid the need 
to induce stereoselectivity at a later stage by performing an asymmetric step. This 
approach has been used to successfully synthesise novel amino acids with aromatic 
side chains using both aryl iodides and aromatic bromides (Scheme 3.30) (Jackson, 
R. F. W., et al., 1992, Oswald, C. L., et al., 2008). The approach tolerates numerous 
functionalities in the aryl groups, including heteroarenes such as pyridyl and 
pyrimidyl side chains (Jackson, R. F. W., et al., 1992, Oswald, C. L., et al., 2008, 
Tabanella, S., et al., 2003, Walker, M. A., et al., 1997). In addition, reactivity may be 
enhanced by co-ordination to trace metals (Oswald, C. L., et al., 2008), which is a 
likely behavior of the imidazolin-2-one ring. 
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It was decided that bromination would be conducted before ring nitrogen protection 
because the electron-rich PMB groups are sensitive to bromination. Bromination was 
attempted on imidazolin-2-one 38 with just over 1 mol. eq. of bromine in either 
acetic acid or TFA to reduce the likelihood of the dibromo product forming. The 
reaction was undertaken under strongly acidic conditions with concentrated sulfuric 
acid added to the acetic acid solvent system to encourage bromination of the 
semi-aromatic 4-C=C-5 double bond. Bromine was seen to be consumed from the 
solution with the loss of red colouration to the reaction mixture with time. However, 
the product could not be isolated from the starting material by recrystallisation, had 
limited solubility in organic solvents and the 
1
H-NMR of the crude product showed a 
complex mixture of products most of which did not appear to be the mono-
brominated imidazolin-2-one 81.  
ZnI
NH(Boc)
MeO2C
(A) ArBr
Ar
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Scheme 3.30:  Previous Negishi cross-coupling of activated serine derivatives and aromatic or 
oxo-compounds to give novel amino acids. 
(A) Negishi cross-coupling of zinc iodide-serine derivative 81 with aryl bromides using palladium 
catalysts (Oswald, C. L., et al., 2008).  
(B) Negishi cross-coupling of zinc iodide-serine derivative  81 with aryl iodides using palladium 
catalysts (Jackson, R. F. W., et al., 1992).  
 
Scheme 3.29: Attempted synthesis of 2-oxo-histidine by a Negishi cross-coupling of imidazolin-2-
one bromide 80 and an activated serine derivative 79.  The C-4/5 of imidazoline-2-one 36 is 
activated as a bromide, which is then coupled via a Negishi cross-coupling to an activated serine 
derivative 79 to generate an enantiomerically pure form of 2-oxo-histidine 4. Use of an 
imidazolin-2-one bromide 80 requires bromination followed by ring-nitrogen protection.  
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3.3. Discussion 
 
 A racemic form of protected 2-oxo-histidine has successfully been synthesised;   
N(α)-Cbz, N(π),N(τ)-Bis(PMB)-2-oxo-His-OMe 4d. Future work will need to 
develop an enantioselective synthesis of this compound and determine the most 
suitable protective groups for Fmoc synthesis. This novel amino acid can then be 
used to synthesise peptides containing oxidized histidine residues in order to study 
the effects of histidine oxidation on the physiological behaviour of these peptides. 
Initially a short peptide synthesis such as that for Thyrotropin Releasing Hormone 
(TRH) (see Chapter 2, Section 2.1.2.) could be used to determine the oxidised 
residue’s versatility to peptide synthesis conditions before incorporation into the 
Aβ(1-42) sequence at positions 6, 13 and 14 (Figure 3.13). The rate of fibril 
formation of this peptide can then be measured using a Th-T assay. 
 
 
 
Since these studies have been done a total synthesis of racemic 2-oxo-histidine has 
been claimed by Lam et al. (Lam, A. K. Y., et al., 2010). This synthesis is shown in 
Scheme 3.31 and is based on a synthesis of racemic 2-thiooxo-histidine 82 reported 
by Furuta et al. (Furuta, T., et al., 1992). A similar synthesis of the 
(L)-2-thioxo-histidine 82 using a Bamberger cleavage has recently been described in 
a patent by Trampota (Scheme 3.32) (Trampota, M., 2009). This involved forming a 
Bamberger product of L-histidine with benzoyl chloride in the presence of base 
which was then hydrolysed to form an (L)-ketobenzamide 83a. This was then 
subjected to deprotection via acid-catalysed hydrolysis and subsequently reacted with 
potassium thiocyanate to obtain the (L)-thioxohistidine 82. A similar synthesis is 
under investigation in the Wyatt group (Scheme 3.33)  (Oyedele, T. A. O., 2011) and 
optimum conditions are being sought for formation of (L)-2-oxo-histidine by reaction 
of an (L)-ketoaminoacid with potassium cyanate.  
DAEFRH-oxDSGYEVH-oxH-oxQKLVFFAEDVGSNKGAIIGLMVGGVVIA 
Figure 3.13: The location of oxidised histidines in solid-phase peptide synthesised Aβ(1-42)-His-ox.  
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Scheme 3.32: Synthesis of protected (L)-
2-thioxo-histidine 81 using a Bamberger 
cleavage (Trampota, M., 2009). 
 
Scheme 3.33: Attempted adaptation of Lam et al’s synthesis of 2-oxo-histidine conducted by Oyedele 
and Wyatt (Oyedele, T, A. O., 2011). 
 
Scheme 3.31: Lam et al’s synthesis of 2-oxo-
histidine 4. Taken from Lam et al., 2010 (Lam, A. 
K. Y., et al., 2010). 
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An analysis of ring nitrogen protecting groups showed that both PMB and BOM 
groups can be used successfully to the dehydro-derivative stage of synthesis although 
the latter groups give lower synthetic yields. The PMB group proved difficult to 
deprotect leaving polar compounds, which were difficult to isolate. In addition, these 
groups may not be suitable for solid phase peptide synthesis and thus alternative 
groups such as t-butoxymethyl groups could be used on the imidazolin-2-one ring 
system. As discussed in Chapter 2, Section 2.1.2. the amino terminus of 
2-oxo-histidine requires either Boc or Fmoc protection rather than the Cbz protection 
used in this thesis. In general, further analysis of appropriate protecting groups is 
needed. 
In conclusion this thesis presents a multi-step synthesis to a protected form of 
2-oxo-histidine 4d for further progress towards synthesising peptides containing 
oxidised histidine, which can be used to analyse the effects of histidine oxidation on 
peptide structure and functionality.  
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4.1. Introduction 
 
Chapter 1 concluded that Aβ is likely exposed to metal-catalysed oxidation of 
histidine and methionine residues in vivo due to Cu
2+
 ions being highly concentrated 
in plaques and known to bind Aβ via the three histidines and N-terminus with high 
affinity (Dong, J., et al., 2003, Sarell, C. J., et al., 2009, Syme, C. D., et al., 2004). 
This copper ion, Cu
2+
, is redox active and will generate hydrogen peroxide and 
hydroxyl radicals via metal catalysed oxidation (MCO) (Nadal, R. C., et al., 2008, 
Stadtman, E. R. and Berlett, B. S., 1991). Chapters 2 and 3 discussed synthetic 
attempts towards 2-oxo-histidine for incorporation into the Aβ sequence. Although 
this peptide synthesis of Aβ-His-Ox was never realised during the timescale of this 
PhD, whole peptide studies were done under oxidising conditions, in order to analyse 
the effect of oxidation on the rate of Aβ fibrillisation; the hallmark of AD pathology 
according to the Amyloid Cascade Hypothesis. This is the topic of this chapter.  
The two types of oxidation investigated were: 
 
1) Hydrogen Peroxide (H2O2) alone, which causes methionine oxidation to 
methionine sulfoxide (2e
−
 oxidation). In Aβ this would be at residue 
Met35. 
2) Metal catalysed oxidation via either H2O2 and Cu
2+
 ions or ascorbate and 
Cu
2+
 ions, which causes both methionine (1e
−
 oxidation) and histidine 
oxidation most likely to the 2-oxo-histidine form (see Chapter 1, page 
51). In Aβ this would be at residues His6, His13, His14 and Met 35. Note 
ascorbate may reduce oxidised methionine (Schoneich, C., 2002). In this 
project this oxidation is conducted under aerobic conditions.  
 
These processes have been described in detail in Chapter 1, Section 1.10.5. The two 
MCO systems are reported to generate different forms of histidine due to different 
complexes forming with Aβ (Ueda, J. I., et al., 1995); Cu2+/ascorbate giving 
2-oxo-histidine and the Fenton’s reagents, Cu2+/H2O2, giving ring-ruptured and 
α, β-oxygen adducts (Cooper, 1985, Khossravi, M. and Borchardt, D. R., 1998, 
Uchida, K. and Kawakishi, S., 1990, 1993).  In general, however, it can be considered 
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that Cu
2+
/Cu
+
-catalysed oxidation efficiently converts histidine into an oxidised form 
in the Aβ sequence. 
 
4.1.1. Previous studies into the effects of oxidation on fibril growth 
 
The only previous study that has been conducted on the effects of MCO on Aβ 
aggregation is that by Dyrks et al. (Dyrks, T., et al., 1992). This study used both the 
Aβ(1-42) peptide and the Aβ(1-42)+Met, which is equivalent to the Aβ sequence 
with an additional N-terminal methionine residue. Dyrks et al. used two methods to 
oxidise Aβ; a H2O2 based method devised by Solar et al., which used an 
oxygen-binding protein to ensure a high oxygen concentration for efficient oxidation 
(Solar, I., et al., 1990), and a second metal-catalysed oxidation (MCO) method as 
described by Halliwell and Gutteridge, which used iron as the redox active metal 
(Halliwell, B. and Gutteridge, J. M. C., 1984). Analysis on SDS-PAGE gels of 
peptides derived from these oxidations found both to produce higher-size bands 
relative to controls, indicative of faster aggregation under oxidation. Dyrks et al. also 
found that the use of radical scavengers, such as ascorbate and trolox, prevented Aβ 
aggregation and concluded that not only did radical-based oxidation of Aβ accelerate 
fibril growth; it was a prerequisite for it. However, this early study did not measure 
amyloid fibrils specifically but only aggregate size because SDS-PAGE does not 
distinguish between the formation of amorphous aggregates and the formation of 
fibrils.  
Apart from the Dyrks et al. study, all literature on the effects of oxidation on 
Aβ fibril kinetics involves oxidation of methionine alone. These studies contain 
contradictory results although more recent studies seem to have reached a consensus 
that methionine oxidation leads to decreased Aβ fibrillisation rates.  
The first three studies after Dyrks et al. were those by Snyder et al., 
Seilheimer et al.  and Lorenzo et al., which either found an increased rate of 
fibrillisation (Snyder, S. W., et al., 1994) or no change in fibrillisation (Lorenzo, A., 
et al., 1993, Seilheimer, B., et al., 1997) after oxidation of Met35 to methionine 
sulfoxide. However, like Dyrks et al., these studies used analyses that simply 
measured overall aggregation, rather than fibrillisation specifically; absorbance 
change indicative of turbidity change, analytical ultracentrifugation and HPLC-MS. 
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In addition, these studies used high concentrations of Aβ peptide, 
i.e. 45 μM - 100 μM, which can increase the chances of amorphous aggregates 
forming instead of fibrillar aggregates (Sarell, C. J., et al., 2010). So, for both these 
reasons, Seilheimer et al., Snyder et al. and Lorenzo et al. appear to have been 
measuring the effects of methionine oxidation on the rate of amorphous aggregate 
formation, not fibril formation. It is also likely that methionine oxidation in the Aβ 
sequence increases the formation of amorphous aggregates at the expense of fibrils 
and the reasons for this are hypothesised in Section 4.4.1.  
A later study by Varadarajan et al. also found no effect of Met35 oxidation on 
Aβ fibrillisation kinetics (Varadarajan, S., et al., 2001). However, it is likely that the 
samples were left too long, i.e. at least 24 h, before the analysis of fibre morphology 
by electron microscopy (EM) was conducted, thus allowing both oxidised and 
unoxidised samples to reach the plateau phase of fibrillisation. In addition, upon 
closer inspection of the electron micrographs, the morphologies do appear dissimilar 
between oxidised and unoxidised samples with unoxidised peptides appearing 
sparser and shorter, as would be expected if shorter, oligomeric neurotoxic species 
were forming. 
All other studies on the effects of methionine oxidation on Aβ fibrillisation 
kinetics have found a decrease in fibrillisation rate and this is the general consensus 
currently in the literature (Hou, L., et al., 2002, Hou, L., et al., 2004, Johansson, A.-
S., et al., 2007, Maiti, P., et al., 2010, Palmblad, M., et al., 2002, Watson, A. A., et 
al., 1998). However, there are still some criticisms of these studies. For example, 
Watson et al. claim to have used an Aβ(1-40) concentration of 1.2 mM at pH 6.5 
(Watson, A. A., et al., 1998). This is outside of the solubilisation range of Aβ(1-40). 
The solubilisation techniques used by Palmblad et al. and Watson et al. may also be 
likely to cause amorphous aggregation. Their solubilisation techniques involve direct 
dissolving of Aβ into the experimental media; pH 3 acetic acid and dilute hydrogen 
peroxide, respectively. Snyder et al. commented that this solubilisation technique 
leads to ‘non-homogeneous solvation’; an initially high local aggregation-promoting 
Aβ concentration. For this PhD study, all peptides were solubilised at 5 °C at 
strongly alkaline pH to prevent aggregation via this process. 
The pHs used in these studies are also of concern. Palmblad uses the extreme 
pH 3 for their studies by conducting them in acetic acid and not surprisingly found a 
complete prevention of fibrillisation (Palmblad, M., et al., 2002). In addition, the use 
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of co-solvents such as acetic acid may promote α-helical formation, an intermediate 
secondary structure en route to the β-sheet form required for fibrillisation (Hou, L., et 
al., 2002). At a lesser extreme is Watson et al.’s study, which is conducted at both 
pH 4 and 6.5 (Watson, A. A., et al., 1998), however, this is bringing Aβ(1-40) closer 
to its isoelectric point (pI) of ~5.3 than is physiologically relevant. This is likely 
affecting kinetics, as discussed further in 4.4.2. For this PhD project, no co-solvents 
were used and experiments were conducted at pH 7.4, as this is the most 
physiologically relevant pH and prevents amorphous aggregation associated with 
being close to the Aβ(1-40) peptide’s pI. 
 The molar ratio of H2O2 to Aβ varies widely between studies, typically 
200 mol. eq. to 40,000 mol. eq. (800 μM to 2 M) (Table 4.1) (Hou, L., et al., 2002, 
Johansson, A.-S., et al., 2007, Palmblad, M., et al., 2002, Watson, A. A., et al., 
1998). The concentration of H2O2 in bodily fluids ranges from 0.05 μM to 117 μM 
(Banerjee, D., et al., 2002, Lászó, G., 2006). These levels are probably higher in the 
oxidative stress environment of AD, and the increase in overall peroxide levels 
between normal and AD age-matched controls has been estimated at 1.3–fold 
(Squitti, R., et al., 2006). Therefore, with CSF Aβ concentration at ~75 nM (Mclean, 
C. A., et al., 1999) there is a 2000-fold greater concentration of H2O2 in CSF than 
Aβ, therefore this molar ratio would be more suitable for modelling the effects of 
H2O2 on Aβ fibrillisation in vivo. As discussed in Section 4.3.1. a range of H2O2 
concentrations were analysed as part of this PhD, which attempted to cover amounts 
of H2O2 present in healthy and AD brain. 
 
First Author Concentration 
of H2O2 used 
Concentration 
of Aβ used 
Ratio 
H2O2:Aβ 
References 
Hou 2 M 50 μM 40,000-fold Hou et al., 
2002 
Hou et al., 
2004 
10 mM 200-fold 
Watson 0.9 M 1.2 mM 750-fold Watson et al., 
1998 
Palmblad 800 μM 2 μM 400-fold Palmblad et 
al., 2002 4 μM 200-fold 
Johansson 800 mM 10 μM 80,000-fold Johansson et 
al., 2007 100 μM 8,000-fold 
Table 4.1: Varying ratios of H2O2 to Aβ in literature studies on Aβ fibrillisation. A summary of 
H2O2 and Aβ concentrations used by studies in the literature on Aβ fibrillisation oxidation by H2O2 
only. 
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The analysis methods used in these literature studies also deserve some criticism. 
Again, methods that do not discriminate amorphous aggregates and amyloid fibrils 
were used, such as size-exclusion chromatography (SEC) (Johansson, A.-S., et al., 
2007) and fourier transform ion cyclotron resonance mass spectrometry (FTICR-MS) 
(Palmblad, M., et al., 2002). However, these methods can give an indication of the 
size of oligomeric species forming, as discussed in Section 4.1.2. Other methods are 
indirect measures of fibrillisation, in that they detect β-sheet formation, a precursor 
to fibril formation, rather than fibrillisation itself. Examples of these methods are 
UV-CD (Hou, L., et al., 2002, Maiti, P., et al., 2010, Watson, A. A., et al., 1998) and 
NMR (Hou, L., et al., 2004). The ideal methods for detecting fibrillisation are 
Th-T-binding assays (Hou, L., et al., 2002) and electron microscopy (Maiti, P., et al., 
2010), and the former was used in this project’s investigation into the effects of 
varying oxidation techniques on Aβ fibrillisation kinetics.  
 In general the most authoritative papers on the effects of methionine 
oxidation on Aβ fibrillisation may be regarded as Hou et al., Johansson et al. and 
Maiti et al. (Hou, L., et al., 2002, Johansson, A.-S., et al., 2007, Maiti, P., et al., 
2010). In all three of these studies, H2O2-mediated oxidation of Aβ increased the 
time for fibres to form in vitro. This behaviour seems to run counter to the 
observation that amyloid plaques contain a high proportion of Met35-Ox Aβ (Dong, 
J., et al., 2003). 
 
4.1.2. Previous studies into the effects of oxidation on oligomeric state 
 
If oxidation inhibits fibrillisation, it may be interesting to determine at which point 
fibrillisation is arrested i.e. is it at the monomer-dimer stage or does oxidation 
promote formation of oligomeric species in competition with fibres. These 
oligomeric species could be more neurotoxic than the fibrillar form e.g. the 
pentameric Aβ* (Aβ56 kDa) species (see Chapter 1, Section 1.6.1.). This has indeed 
been indicated for an indirect effect of oxidative stress on Aβ i.e. the action of 
oxidised metabolites on Aβ in the studies by Bieschke et al. (Bieschke, J., et al., 
2005). 
The only study for the effects of MCO on Aβ oligomeric state is Dyrks et al., 
who found only a high molecular weight smear on their SDS-PAGE gels after 
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oxidation of Aβ(1-42). They concluded that MCO of Aβ led to larger oligomeric 
species forming than for Apo. This study also found that oxidation led to aggregates 
which were more resistant to degradation, possibly explaining the role of oxidative 
stress in accelerating AD pathology.  
Previous studies on the effects of oxidation by H2O2 alone are summarised in 
Table 4.2. All studies apart from Dyrks et al. found smaller Aβ species formed under 
H2O2 oxidation. The actual size of these smaller species is yet to be determined. The 
four remaining studies use varying techniques to measure oligomeric size from 
morphology analysis, AFM and EM, to the more quantitative, molecular 
size-determining SEC and MS. In the case of Palmblad et al.’s study the fourier 
transform ion cyclotron resonance-MS (FTICR-MS) technique has a particular 
advantage in that it is highly sensitive and thus can be used with relatively low, 
physiologically relevant, Aβ concentrations (Palmblad, M., et al., 2002). Johansson 
et al. and Palmblad et al. agree that monomers or dimers are the most likely forms of 
Met35 oxidised Aβ(1-40) and Aβ(1-42), although they disagree on the specific size 
of the unoxidised species. This may be due to the different conditions and incubation 
times used for each study.  
Hou et al. and Bitan et al. disagree slightly on what form the oxidised species 
takes, with the former stating it is globular amyloid-based oligomeric form while the 
latter states it is a non-amyloid amorphous aggregated form. This discrepancy may 
simply be because amorphous aggregates and globular oligomeric species are 
difficult to distinguish using AFM. Bitan et al.’s theory that Met35 oxidation causes 
the usual paranuclei forming Aβ(1-42) peptide to revert to the non-paranuclei 
forming Aβ(1-40) aggregation pathway is an attractive hypothesis (Bitan, G., et al., 
2003). However, without a method of species size determination which also 
incorporates an amyloid-specific binding dye such as Congo red or Th-T, this 
discrepancy cannot be resolved. Nevertheless this PhD study will aim to resolve the 
size of oligomeric species formed under both Cu
2+
/Cu
+
-catalysed oxidation and 
oxidation by H2O2 alone, both under aerobic conditions, using SEC. 
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Table 4.2: Summary of previous studies on the effects of hydrogen peroxide only oxidation of Aβ on its oligomeric state. 
Reference First 
author  
Aβ 
fragment  
Oligomeric species found before 
oxidation  
Oligomeric species found after 
oxidation  
Technique used  
Dyrks et al., 
1992 
Dyrks 
 
Aβ(1-42) Monomers Tetramers and octamers (50%) & 
larger aggregates (50%) 
SDS-PAGE 
Hou et al., 
2002 
Hou 
 
Aβ(1-42) 
 
Protofibrils (3.6 ± 0.6 nm ᴓ, 21 ± 4 nm 
periodicity) and filaments (0.65 ± 0.07 
nm ᴓ, no periodicity) 
Globular, oligomeric species 
(0.7-3.3 nm ᴓ) 
AFM 
Palmblad et 
al., 2002 
Palmblad 
 
Aβ(1-40) 
 
Monomers and dimers & trimers & 
tetramers 
Monomeric and dimeric only 
until 100 h 
SEC & FTICR-MS 
Johansson et 
al., 2007 
Johansson 
 
Aβ(1-42) 
 
Trimers and tetramers Mostly monomers & dimers 
 
SEC 
Bitan et al., 
2003 
Bitan Aβ(1-42) Quasi-Globular Paranuclei Revert back to non-paranuclei, 
amorphous aggregates as found 
for Aβ(1-40) 
Photoinduced Cross-linking 
Unmodified Proteins (PICUP) 
& EM 
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4.1.3. Aims 
 
Although there are numerous lines of evidence to link oxidative stress with AD, there 
have been relatively few studies on the effect of Cu
2+
/Cu
+
-catalysed oxidation on Aβ 
fibrillogenicity. In contrast, the effect of H2O2-promoted oxidation of Aβ on fibril 
growth kinetics has been studied by a number of groups, however these studies have 
not always been in agreement. With this in mind, in this chapter we investigate how 
oxidation by H2O2 alone and Cu
2+
/Cu
+
-catalysed oxidation of Aβ influences fibre 
and oligomer formation.  
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4.2. Experimental methods and background theory 
 
The majority of chemicals were purchased from Sigma Aldrich at the highest purity 
available. Deuterium oxide was purchased from GOSS Scientific Instruments Ltd. 
Water used was of ultra high quality (UHQ) with ρ > 10-18 Ω-1 cm-1. 
 
4.2.1. Origin of Aβ peptide stocks 
 
Aβ peptides and peptide fragments were synthesised using solid-phase Fmoc 
chemistry (ABC; Imperial College London and Zinisser Analytic). The peptides 
synthesised were Aβ(1-40) and Aβ(1-28). The C-termini and N-termini of the full 
peptides were left native as carboxyl and amino groups respectively. The peptide 
fragments were synthesised with a native amino terminus and an ethyl ester at the 
carboxyl terminus. After removal from the resin and deprotection, peptides were 
purified via RP-HPLC. Mass spectrometry was used to characterise these peptides 
and 
1
H-NMR confirmed the peptides were not oxidised at the Met35 residue. 
Peptides were freeze dried for transportation and found to contain 20 % moisture by 
weight. 
 These lyophilized peptides were solubilised at 0.7 mg ml
-1
 Aβ in pH 10.5 
UHQ water. This has been shown to be the best method for solubilising Aβ in order 
to avoid aggregation and precipitation and produce fibres typical of amyloids 
(Fezoui, Y., et al., 2000). Aβ stocks contains salts of TFA the removal of acid labile 
groups and the cleavage of completed peptide sequences from solid supports during 
synthesis (Teplow, D. B., 2006). This means that upon solubilising to neutral pH, the 
initial Aβ microenvironment is an acidic milieu with pHs of 3-4, which then 
bypasses pH 5.3 on the way to neutral pH. This pH corresponds to the isoelectric 
point (pI) of Aβ and hence exposes the peptide to an environment where aggregation 
and precipitation is strongly promoted (Barrow, C. J., et al., 1992, Fezoui, Y., et al., 
2000, Teplow, D. B., 2006, Wood, S. J., et al., 1996). Fezoui et al. have shown that 
by using the strongly alkaline (pH~10.5) pre-treatment of Aβ, stocks of the peptide 
are seed (pre-existing aggregate) free and this allows repeatable data to be recorded 
using the peptide stocks without batch-to-batch variability (Fezoui, Y., et al., 2000). 
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The solution of Aβ in UHQ water was incubated at 5 °C for 72 h with gentle 
agitation on a rocker before being separated into aliquots and stored at −80 °C until 
required. The concentration of Aβ was determined using its Tyr10 absorption at 
280 nm (ε280 = 1280 M
-1 
cm
-1
). Seed-free preparations could be determined by 
checking for a substantial lag-phase using a growth assay, although samples are 
expected to contain low MW species such as dimers and trimers. 
   
4.2.2. Oxidation method 
 
Oxidation was achieved using either H2O2 alone or via MCO, the latter using a 
H2O2/Cu
2+
/Cu
+ 
system or an ascorbate/Cu
2+
/Cu
+
 system. Both of these were 
conducted under aerobic conditions. Cu
2+
 was added to the samples in the form of 
copper(II) chloride at a substoichiometric ratio of 0.1 mol. eq. to Aβ (typically 1 μM 
CuCl2 to 10 μM Aβ). H2O2 and ascorbate levels were at 10 mol. eq. (typically 
100 μM H2O2 or 100 μM ascorbate to 10 μM Aβ).  
Temperature was controlled throughout analysis of samples due to its 
significant effects on Aβ fibrillisation (Barrow, C. J., et al., 1992). The pH was also 
controlled using a HEPES/NaCl buffer. HEPES was chosen because of its low 
binding affinity for Cu
2+
 ions (Sokolowska, M. and Bal, W., 2005) and its lack of 
interference with Aβ fibrillisation (Qin, Z., 2010). For the well plate assays the buffer 
was 50 mM HEPES/160 mM NaCl, with the concentration of NaCl being the 
physiological concentration of saline (1.6 p.c.) as defined by Lazarus-Barlow 
(Lazarus-Barlow, W. S., 1896). For SEC analysis the buffer was 
50 mM HEPES/150 mM NaCl. For UV-CD analysis the buffer was 
0.25 mM HEPES/0.8 mM NaCl so that the salt concentration did not cause 
absorbance outside of the dynamic range of the CD machine. UHQ water (ρ = 10−18 
Ω−1cm−1) was used to make up these buffers. 
 Samples were made up in a specific order with addition of H2O2 or ascorbate 
after addition of Th-T to reduce potential oxidative decomposition of the dye. The 
pH was adjusted after addition of H2O2 to a pH of 7.4 with small additions of 10 mM 
HCl or 10 mM NaOH. Aβ(1-40) was added last to each sample, which was then 
immediately analysed. The concentration of Aβ(1-40) varied for each analysis, 
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although molar ratios of reagents were kept consistent. This is discussed further in 
Section 4.3.1. 
Aβ fibrillisation was monitored using a Th-T binding well-plate assay 
(Section 4.2.3.) and UV-circular dichroism (UV-CD) (Section 4.2.4.). Size-exclusion 
chromatography (SEC) (Section 4.2.5.) was used to analyse the size of Aβ(1-40) 
species formed.  
 
4.2.3. Thioflavin-T binding well-plate assay 
 
Thioflavin-T (Th-T) as an amyloid fibril detecting dye 
 
Thioflavin-T (Th-T) binds predominantly to crossed β-sheet structures in amyloid 
fibres (Figure 4.1) and is commonly used for detecting amyloid fibrils (Levine, H., 
1995, Uversky, V. N., et al., 2001). When bound to fibrils, Th-T fluoresces strongly 
with an emission at 482 nm and an excitation maximum at 450 nm (Naiki, H., et al., 
1989). Unbound Th-T is virtually non-fluorescent at these wavelengths. Thus the 
intensity of the fluorescence gives a quantitative measure of fibril growth. 
 Several models have been proposed to explain the exclusivity of fluorescence 
when bound to amyloid fibres but not monomeric species. These include the 
Monomeric Model (Krebs, M. R. H., et al., 2005), the Excimer Model (Groenning, 
M., et al., 2007), the Micelle Model (Khurana, R., et al., 2005) and the Lateral 
Stacking Model (Wu, C., et al., 2008). The Lateral Stacking Model may explain 
Th-T binding best and incorporates mechanisms proposed from all three of the other 
models. This model states that Th-T binds to monomers via aromatic ring-ring 
interactions and hydrophobic interactions in the grooves of β-sheets. As monomers 
come together to form an oligomeric species, bound Th-T molecules are then 
laterally stacked (Wu, C., et al., 2008), which leads to a fluorescence enhancement 
via the mechanisms described in other papers; Th-T dimerisation leading to excimer 
formation (Groenning, M., et al., 2007) and steric interactions between Th-T 
molecules and fibril side chains (Krebs, M. R. H., et al., 2005) (Figure 4.1).  
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Figure 4.1: Thioflavin-T (Th-T) structure and fluorescence when bound to amyloid fibrils. 
The structure shown is of Thioflavin-T (Th-T). It is a dye which fluoresces only when bound to 
fibres containing a crossed β-sheet structure, i.e. amyloid fibres. The lateral stacking of the Th-T 
molecules (Wu, C., et al., 2008) is believed to cause steric interactions with the side chains of the 
Aβ residues (Krebs et al., M. R. H., 2005) and excimer formation (Groenning, M., et al., 2007) 
leading to enhanced Th-T fluorescence at 482 nm. The appearance of this in both an in situ 
histological slide of amyloid fibrils (Williams, A. D., et al., 2004) and an in vitro fibril solution is 
shown. The image of an amyloid fibre was taken from Dobson et al., 1999 (Dobson, C. M., 1999). 
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Th-T was added at a molar ratio of 2.0 to Aβ(1-40) concentration, as fibril Aβ is 
saturated at these levels. The Th-T stock was dissolved in UHQ water at a 
concentration of 2 mM and kept foil wrapped at 5 °C to prevent light-induced 
decomposition. 
This dye was used for the fibrillisation studies in this PhD project because it 
binds to Aβ(1-40) at the relevant pH 7.4 due to its positively charged state at this pH, 
with a suitable binding affinity ( Kd = 2 μM) and is not NaCl sensitive (Levine, H., 
1993). 
 
Well-plate methodology 
 
A BMG-Galaxy fluoro-star fluorescence (96) well plate reader was used to measure 
Th-T fluorescence because it allows temperature and agitation to be controlled and 
can perform automated measurements at specific time points. A typical well plate 
reader apparatus is shown schematically in Figure 4.2. 
Samples were placed in a sterile, flat bottomed 96 well plate (Becton 
Dickinson) using a 300 μl sample volume. Only the central 60 wells were used 
because the outer wells are prone to undergo evaporation during the study. The plates 
were sealed with Starseal polyolefin film sealing tape (Starlabs) to minimise 
evaporation. 
Temperature was controlled using an in-machine incubator set at 30 °C. Fibril 
growth kinetics are very sensitive to peptide concentration, which was tightly 
controlled by making up a single stock of each condition and then separating this into 
each set of wells as repeats. Reagents, such as CuCl2
 
solution and H2O2, were added 
at an approximate volume of 5 µl per 1800 µl of stock sample to reduce diluting 
effects.  
Wavelengths used were 440 nm for excitation and 490 nm for emission 
detection. Typically measurements of fluorescence intensity (AFU) were taken every 
1 h directly after a 3 mm width orbital agitation for 1 min. Within each measurement, 
100 flashes (readings) were taken and averaged.  
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Measurement gain was optimised after an initial preliminary study at each Aβ(1-40) 
concentration. To do this, once the fibril growth curves obtained from this 
preliminary study showed maximum fibril growth i.e. has reached the plateau 
(equilibrium) phase, several measurements were taken over a range of gains and the 
results of three wells plotted against intensity of fluorescence. An example is given 
in Figure 4.3. The optimal gain in this case would be 49 %, as this gives the greatest 
differential in fluorescence intensity between the wells without being close to the 
machine’s saturation level, 65,000 AFU. The optimal gain for each Aβ concentration 
was found and applied in future analyses. These gains ranged from 49 - 55%. 
Data were averaged across traces, as indicated in the captions to data figures. 
The data were also zeroed to the initial fluorescence reading typically over the first 
30 h to allow for both noise at the beginning of a well plate run due to condensation 
Figure 4.2: Well-plate reader apparatus. A basic schematic of the well-plate reader apparatus.  
A xenon flash lamp produces a high intensity light beam. An excitation filter wheel can be set to 
split the light so that a single excitation wavelength exits the filter. This is fed via fibre optic tubes 
to a specific well plate sample well. The fluorescence produced by the sample is then emitted 
back to an emission filter wheel, which resolves the beam so only the fluorescence at the desired 
wavelength is transmitted via further fibre optic fibres to the photomultiplier detector. This gives 
an output for fluorescence intensity for that well.  
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and plate warming and also for a substantial part of the lag phase of each growth 
curve before the elongation phase began. 
 
    
 
 
 
Fibril growth curve analysis 
 
The output from the well-plate reader is a fibril growth curve, as described in 
Chapter 1 and shown in Figure 1.6, where Th-T fluorescence intensity can be seen as 
a direct indicator of fibril formation. The curve describes three phases; an initial lag 
phase, an elongation phase and a plateau phase.  The lag phase is also known as a 
nucleation phase in reference to the time taken for monomeric Aβ to become a 
nucleating species. The elongation phase refers to the time taken for the addition of 
monomeric Aβ to nucleating species and thus the formation of fibres. The plateau 
phase refers to equilibrium where there is no net increase in the number of amyloid 
fibres.  
Figure 4.3: Optimising the gain for well plate analysis. Once the plateau phase had been reached 
for a preliminary Th-T binding well plate assay of 5 μM Aβ(1-40),this plate was used to find the 
optimal gain for this concentration of Aβ to use for future fibrillation analyses. Several 
measurements were made over a range of gains (10 – 60 %) and the Th-T fluorescence of three 
wells was plotted. For the example above the optimal gain is 49 %. This gives the greatest 
differential between wells but is not too close to the saturation of the instrument at 65,000 AFU.  
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The fibril growth curves obtained in this study were fitted to two equations in order 
to obtain parameters by which to compare and characterise growth curves. The curve 
fitting software used was Origin Lab’s Origin 8.5.0 SR0. If the fitting would not 
converge under suitable initial parameters or if the expected sigmoidal growth curve 
shape was not achieved with a data set, these data were discarded as unsuitable for 
analysis. In addition, upon obtaining parameters from this curve fitting, any 
parameters which lay outside 1.5*interquartile range of the data set were excluded 
from the analysis as outliers.  
The first equation used to fit growth curves (Figure 4.4) is described by 
Uversky et al., 2001 (Equation 1) (Uversky, V. N., et al., 2001). It gives values for: 
 
t50 - (annotated x0 by Uversky et al.) half-maximal fibril growth in h.   
tlag = t50 - 2τ; lag phase in h.  
kapp = 1/τ; apparent fibril growth rate in h
−1
.   
 
           
        
   
     
 
 (Eq. 1) 
The other parameters in Eq. 2 are: 
Y – concentration of fibres. 
t – (annotated x by Uversky et al.) time. 
 
The term        refers to the lag phase of the curve, while the term        
refers to the plateau phase. Both these expressions allow for a slope in these two 
phases. Uversky et al. note that Equation 1 does not relate to underlying molecular 
mechanisms of fibrillisation but instead simply provides a model for comparing how 
different growth conditions affect fibril growth kinetics. They used this equation 
successfully to analyse the effect of pH change on α-synuclein fibrillisation 
(Uversky, V. N., et al., 2001). 
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The second equation used to fit growth curves (Figure 4.5) is that described by 
Morris et al. (Equation 2) (Morris, A. M., et al., 2008) and gives values for: 
 
kn – (annotated k1 by Morris et al.) nucleation rate; the rate at which monomeric Aβ 
species become nucleating in h
−1
. 
ke - (annotated k2 by Morris et al.) elongation rate; the rate at which monomeric Aβ 
adds onto the nucleating species in h
−1
. 
[B]t - the maximal fluorescence in AFU corresponding to the maximal concentration 
of Aβ fibres. 
 
          
  
  
     
  
  
      
               
 (Eq. 2) 
The other parameters in Eq. 2 are: 
[A]t - the concentration of Aβ monomer at time t. 
[A]0 = [B]t - [A]t; the total Aβ concentration.  
t = time. 
 
These parameters can be applied to Figure 1.6 as shown in Figure 4.5. The equation 
was based on the Finke-Watzky (F-W) 2-step mechanism of aggregation (Figure 
Figure 4.4: Application of parameters from the curve fitting equation described by Uversky 
et al. to the fibre growth curve shown in Figure 1.7. Parameters from the growth curve fitting 
equation described by Uversky et al. are fitted to the sigmoidal growth curve associated with Aβ 
fibrillation. t50 is the time to half maximal growth of fibrils and hence refers to halfway through the 
elongation phase. tlag is the time of the lag phase. 2τ is the difference between these two values and 
½ of this value gives the apparent fibre growth rate, kapp (Uverksy, V.N., et al., 2001). 
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4.6), for transition metal nanocluster formation (Watzky, M. A. and Finke, R. G., 
1997), which can just as easily be applied to fibril growth. Morris et al. showed that 
this mechanism could accurately describe 14 sets of literature data on neurological 
protein aggregation with an R
2 ≥ 0.98 (Morris, A. M., et al., 2008), including several 
data sets involving Aβ aggregation (Bieschke, J., et al., 2005, Dong, J., et al., 2006, 
Vestergaard, M., et al., 2005, Zirah, S., et al., 2006). The mechanism described an 
initial slow continuous nucleation step (AB) with rate constant kn followed by a 
rapid, autocatalytic growth step (A+B2B) with rate constant ke similar to the two 
step Nucleation-Dependent-Polymerisation (NDP) mechanism described in 
Chapter 1 (Jarrett, J. T. and Lansbury, P. T., 1993). A was defined as ‘unfolded, or 
misfolded, ready-to-aggregate protein’ where B is the ‘growing surface area of the 
aggregating protein’ and included both oligomeric and fibrillar species (Morris, A. 
M., et al., 2008). 
 
 
 
 
 
Figure 4.5: Application of parameters from the curve fitting equation described by Morris 
et al. to the fibre growth curve shown in Figure 1.7. Parameters from the growth curve fitting 
equation described by Morris et al. are fitted to the sigmoidal growth curve associated with Aβ 
fibrillation. kn is the rate of nucleation and hence is related to the lag phase of the curve. ke the 
elongation rate and hence is related to the elongation phase of the curve. [B]t is the concentration 
of oligomeric Aβ at time t and when extracted from curve fitting data indicates the maximal fibril 
concentration (Morris, A. M., et al., 2008). 
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This description of fibril growth had the advantage over the previously most cited 
mechanism, the ‘Subsequent Monomer Addition Mechanism for Aggregation of 
Proteins’(Eisenverg, H., 1971) (abbreviated here to SMAMAP), in that it provides 
easy curves for fitting and it clearly illustrates the two initial phases of nucleation 
and elongation (Morris, A. M., et al., 2008). Other mechanisms of protein 
aggregation have involved modifications of the SMAMAP model so that it 
incorporates elongation via species of various sizes (‘Random association 
mechanism’) (Thusius, D., et al., 1975), assumes that the rate constant of dimer 
formation is unique but all subsequent additions have the same rate constant 
(Wegner, A. and Engel, J., 1975) and finally involves a monomer activation state to a 
nucleating species (Frieden, C. and Goddette, D. W., 1983). These were all 
precursors to Morris et al.’s model based on the F-W 2-step mechanism. Even more 
complicated, unwieldy mechanisms have been devised that describe polymerisation 
as either beginning with heterogeneous nucleation – polymers growing onto existing 
polymers - or homogeneous nucleation – polymers growing from seeds (Ferrone, F. 
A., et al., 1980). In addition, Lansbury devised the ‘passive autocatalysis 
mechanism’ which indicated three rates as important, essentially the nucleation rate, 
the elongation rate and the dissociation rate (Come, J. H., et al., 1993). Finally, Saito 
et al. devised a 3-step mechanism which included, before the nucleation step, a 
monomer-micelle step (Kamihira, M., et al., 2000, Lomakin, A., et al., 1997). 
However, Morris et al. showed that this could be reduced to the F-W 2-step 
mechanism without losing any accuracy (Morris, A. M., et al., 2008).  
 There are some limits to Equation 2. The model does not take account of the 
effect of species size on kn and ke and it assumes the concentration of monomer is 
constant during the nucleation phase. The latter assumption means the equation 
Figure 4.6 Finke-Watzky (F-W) 2-step mechanism 
for nucleation and growth phenomenon. This was 
used as a model for the fibre growth curve equation 
devised by Morris et al., 2008,  Equation 2.  
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needs an ample lag phase to get an accurate nucleation rate and this must be 
considered when analysing the data described in this chapter.  
 
Statistical tests of significance 
 
Tests of significant difference between two data sets were performed using unpaired, 
two-tailed, t-tests. Initially an F-test was performed to determine whether the data 
sets had equal variance using the formula Equation 3. 
 
  
  
 
  
  (Eq. 3) 
where ni is the sample size of the ith data set and Si
2
 is an unbiased estimator of  the 
variance of the ith data set given in Equation 4. 
 
   
 
   
     X  
 
 
   
 (Eq. 4) 
F-test 95% probability critical value tables were obtained from the StatSoft 
Electronic Statistics Textbook (Statsoft). There were n−1 degrees of freedom. 
In the cases of equal variance a homoscedastic Student’s t-test was used to 
test for significant differences between the means of the two data sets using the 
formula in Equation 5. 
 
   
X   X  
          
 
  
 
 
  
 
(Eq. 5) 
where X i is the mean of the ith data set, ni  is the sample size of ith data set and 
      is the pooled standard deviation as given in Equation 6. 
 
         
         
            
 
        
 (Eq. 6) 
The degrees of freedom were given by         . 
In the cases of unequal variance a heteroscedastic Welch’s t-test was used to 
test for significant differences between the means of the two data sets using the 
formula in Equation 7. 
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(Eq. 7) 
where X i is the mean of the ith data set, ni is the sample size of ith data set and si
2
 is 
an unbiased estimate of the variance of the ith data set as described above. The 
degrees of freedom were given by the Welch-Satterthwaite equation (Equation 8). 
 
     
   
        
     
 
   
                 
              
 (Eq. 8) 
t-test 95% probability critical value tables were obtained from the StatSoft Electronic 
Statistics Textbook (Statsoft). 
 
4.2.4. UV-Circular Dichroism (UV-CD) analysis 
 
A theoretical background to UV-Circular Dichroism (UV-CD) 
 
UV-Circular Dichroism (UV-CD) is a spectroscopic measurement of the differential 
absorbance of left and right circularly polarised light by a sample. Samples such as 
proteins, which are optically active, have non-zero values for this differential 
absorbance.  
 The instrument used to measure this, a CD spectrometer, has a set-up as 
shown in Figure 4.7. This instrument generates a monochromatic, linearly polarised 
light source which is then given a periodic variation in polarisation from left- to 
right-circularly polarised light which is passed through the sample before being 
detected. Any differences in the absorbance between each polarisation of light are 
then recorded and from this a measure of ellipticity calculated. 
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Proteins have an optical activity, and thus a differential absorbance of left and right 
circularly polarised light. The amide bond within the polypeptide backbones of 
proteins acts as a chromophore with two electronic absorptions; one at approximately 
190 nm due to a π - π* transition and one at approximately 210 nm due to a n – π* 
transition. These transitions, and hence the extent of the absorptions, become 
optically active due to the chirality of the α-carbon adjacent to the amide group and 
hence the orientations of its substituents. This orientation is heavily influenced by the 
secondary structure of the protein and hence UV-CD spectra can be used to as an 
indicator of this conformational level of a protein. The distinct spectra produced by 
certain conformations are shown in Figure 4.8. 
Figure 4.7: UV-CD spectrometer apparatus. A high intensity xenon lamp generates a light 
source which is both made monochromatic and polarised linearly by  a monochromator. This 
light then passes through a polarization modulator where it is given a periodic variation in 
polarization ranging from left to right circular directions. This is then passed through the sample 
and a photomultiplier and detector records the differential absorbance of each light polarisation 
by the sample. (Adapted from Drake, A. F., 1994)  
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UV-Circular Dichroism (UV-CD) methodology 
 
CD measurements were made on a Chirascan CD Spectrometer (Applied 
Photophysics). During measurements temperature was controlled using a Peltier 
Temperature Controller at 37 °C. Between measurements the sample was kept at 
37 °C in an incubator with a 100 rpm rotation. The latter was to provide gentle 
agitation to the samples, another factor which can promote fibril formation. 
 Measurements were made at 95 minutes, 200 h, 305 h, 390.5 h, 561 h, 
632.5 h, 680.5 h and 730.5 h. For each measurement, three repeats were recorded, 
which were later averaged. Sampling points were taken every 0.5 nm, with 3 seconds 
for each point. Spectra were obtained from 190 – 270 nm. Three background 
readings of the buffer were taken before measurements of the samples commenced 
and the average of these was subtracted from the averaged data sets for each 
measurement. Data were also zeroed at 260 nm and smoothed using the Applied 
Photophysics’ Chirascan Viewer program. 
Figure 4.8: Characteristic UV-CD spectra of protein secondary structures. α-helical proteins 
display UV-CD spectra (red) typically with two negative bands at 222 nm and 208 nm and a 
positive band at 192 nm. β-sheet proteins give UV-CD spectra (green) with a weak negative band 
at 217 nm and a positive band at 195 nm. Random coil structures give a negative band at 198 nm 
and a weak positive band at 218 nm. 
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Although the CD spectrometer measures light absorption, for historical reasons the 
units for data obtained from the CD machine is the ellipticity of linear polarised light 
passing through the sample and thus is given as an angle in millidegrees (θ). This can 
be converted into a measure of sample absorbance using an adaptation of Beer’s 
Law. The output is a measure of molar ellipticity (Δε) with units M−1cm−1 using 
Equation 9.  
 
    
 
           
 
(Eq. 9) 
where c is the concentration in M and l is the path length in cm. The sample cell used 
had a 1 mm path length.  
 
4.2.5. Size-exclusion chromatography (SEC) analysis 
 
Background theory to size-exclusion chromatography (SEC) 
 
Size-exclusion chromatography (SEC) is a form of chromatography which separates 
components of a solution predominantly according to their size rather than by their 
enthalpic interactions with the stationary phase. It has the advantage of being quick, 
convenient and involves separation with very narrow bands. It is often used as a 
method for finding the approximate molecular weight (Mr) and hydrodynamic radius 
(Rh) of macromolecules, although the specific property that molecules are separated 
by using size-exclusion chromatography is molecular hydrodynamic volume (Mori, 
S. and Barth, H. G., 1999). The technique involves passing the macromolecules in 
solution (the mobile phase) through a column of an inert gel medium stationary 
phase with pores of a nominal size, e.g. polyacrylamide or dextran, under a low 
pressure (Mori, S. and Barth, H. G., 1999). A basic schematic diagram of the size-
exclusion apparatus is shown in Figure 4.9.  
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The elution time of each macromolecule depends on the volume of column the 
macromolecule travels through. This means the smaller the molecule, the more pore 
volume the molecule will penetrate and the more time it will take for the 
macromolecule to fully elute the column. In reality the theory behind particle 
separation is not this simple as there will be some variation in pore and particle size 
for each defined size. Therefore, elution curves are actually Gaussian distributions. 
The eluant from the column is analysed constantly using detection such as UV 
absorbance (Figure 4.10). The elution volume (Ve) decreases approximately linearly 
with the log of the molecular weight. Thus using macromolecules of known 
molecular weight, a relationship between elution volumes and molecular weight can 
be determined via a calibration curve and this can be used to convert the elution 
volumes of sample proteins to their molecular weight (Figure 4.10). This is discussed 
in detail below. 
The Void Volume (V0) of the column is the volume of mobile phase that 
passes through the column containing particles too large to interact at all with the 
Figure 4.9: Size-exclusion chromatography apparatus. A basic schematic diagram of a size-
exclusion chromatography apparatus. A pump causes flow of solvent (mobile phase) through the 
column via an injection valve which can allow diversion of the mobile phase via a sample. The 
column then separates molecules in the sample solution by their size. Smaller molecules (red) 
penetrate more of the pores in the column stationary phase and hence take longer to elute from the 
column than large molecules (brown). Only two molecule sizes are shown for simplicity’s sake. The 
eluate from the column is then analysed using UV detection which produces a trace of UV 
absorbance against elution volume/time.  
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stationary phase. The Column Volume (Vc) is the maximum volume of mobile phase 
that passes through the column before molecules too small to be separated by the 
column start to elute as a final single band.  
The behaviour of molecules on size-exclusion columns can be described by 
Equation 10.  
 
where Vi is the pore volume accessible to the molecules and  KSEC is a 
thermodynamic parameter defined as the ratio of column pore volume (ci) to 
interstitial column volume (c0) (Equation 11). It is often referred to as the SEC 
distribution coefficient. 
 
      
  
  
  (Eq. 11) 
For size-exclusion to reliably separate molecules based on their molecular size then 
the criteria 0 < KSEC > 1 must be satisfied. If KSEC = 0, the molecules will elute in the 
void volume. If KSEC = 1, the molecules will elute after the column volume and if 
KSEC > 1 then the molecules are likely interacting with the stationary phase in an 
enthalpic manner and are not eluting based on molecular size alone. Electrostatic 
charges, for example, may also be influencing elution volume in this case (Mori, S. 
and Barth, H. G., 1999). These factors must be taken into consideration when 
designing a SEC experiment. Depending on the size of molecules, different packing 
material is used with different pore size. For example for studying the oligomeric 
size of Aβ(1-40) around the expected Aβ*56 size, Superdex 75 was used, which 
measures molecular weights from 3,000 – 70,000 Da. 
 
 
                (Eq.10) 
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 General SEC methodology 
 
Analytical size-exclusion chromatography was carried out using a Superdex-75 
10/300 GL column (3,000 < Mr > 70,000) with a UV detector set at 280 nm in order 
to detect UV active compounds eluting from the column. This was housed within an 
Figure 4.10: Typical SEC calibration curve for a protein sample. SEC is a relative rather than 
absolute method for measuring molecular weight and therefore requires a calibration curve. The 
lower trace shows a typical output from a SEC processing unit with elution volume plotted against 
UV intensity and peaks showing proteins exiting the column. The upper trace shows a typical 
calibration curve determined by running proteins of known molecular weight down the column. 
Molecular weights of sample proteins can be read off this based on their elution volumes. V0 
represents the void volume of the column. It is not until the end of this volume that reliable 
molecular weights can be determined and this point is marked as M0, the exclusion limit of the 
column. Vc represents the column volume, which is the maximum volume of the column from 
which reliable molecular weights can be determined. It is marked as Mt, the total permeation limit 
of the column. Adapted from Mori and Barth 1999 (Mori, S., and Barth, H. G.. 1999). 
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ӒKTA FPLC unit. The UV data were processed using Unicorn Software. The 
concentration of Aβ(1-40) used was 10 μM with an injection volume of 500 μl. 
The column conditions were isocratic. For all experiments at pH 7.4 a 
50 mM HEPES/150mM NaCl buffer was used as described above. For experiments 
at pH 10.5 samples were run in alkaline saline solution ([NaCl] = 150 mM) only, 
with careful adjustment of pH using small amounts of 10 mM NaOH and 10 mM 
HCl. In all cases UHQ water (ρ > 18 MΩ cm) was used. All buffers were filtered and 
degassed before use. 
For sets of readings taken at increasing time intervals a stock sample was kept 
incubated in a water bath set at 30 °C and 500 μl aliquots were taken at 2 hour 
intervals. As for the well-plate and UV-CD analyses, Aβ(1-40) was used instead of 
Aβ(1-42).This is even more important for SEC because of the latter’s tendency to 
form insoluble aggregates over 24 h which can cause irreversible changes to the 
column packing material (Kuo, Y.-M., et al., 1998).  
The void volume of the column was determined by measuring the elution 
volume of blue dextran (Mr 2 MDa) and was found to be 8.57 ml at pH 7.4 and 
7.99 ml at pH 10.5. This volume is indicated with grey shading in the figures 
discussed in Section 4.3. The column volume was determined by running acetone 
(Mr = 58.1 Da) down the column and was found to be 19.5 ml. This is where the 
trace terminates in these figures, because, as explained in above, outside of these 
regions, molecules eluting the column are not been separated by molecular weight 
alone. 
Before and after each measurement the column was cleaned with 1.5 column 
volumes of 2 M NaOH, to dissociate any remaining Aβ(1-40) aggregates and allow 
thorough cleaning of the column, and then 2 column volumes of distilled water to 
restore pH. The column was stored in either 0.2 % azide or distilled water, depending 
on the period of storage. The injection loop was also syringed through with NaOH 
and water. Between different mobile phases the column pumps were washed and the 
column was re-equilibrated using 1.5 column volumes of the relevant cleaning agent 
or experimental buffer to ensure the column was a uniform environment before the 
sample was run down it. 
For each measurement 1.2 – 1.5 column volumes of elution buffer was run 
down the column following sample injection. The flow rate used was 0.5 ml min
−1
 to 
prevent the column pressure limit (1.8 MPa) being exceeded.  
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Determining molecular weight from SEC elution volume 
 
In order to determine the molecular weight of Aβ(1-40) species exiting the column it 
was necessary to calibrate the column. This involved running proteins of known 
molecular weight down the column. These proteins were all globular, compact 
proteins and included bovine serum albumin (BSA), Mr = 66.4 kDa and lysozyme, 
Mr= 14.6 kDa. At this salt concentration (150 mM NaCl) BSA forms both dimers and 
monomers. For pH 7.4 the dimeric form of BSA (Mr = 132 kDa) gave a band within 
the void volume and thus could not be used for calibration. Although at pH 10.5 this 
dimer did show a band within the reliable part of the column, the column 
specifications state that no proteins greater than 70,000 Da can be measured on the 
column so this could not be used for calibration purposes. 
 An attempt was made to use Agrobacterium phytochrome (Agp1) 
(Mr = 34683.37 Da) and the prion protein fragment, PrP(57-90) (Mr = 3370.45 Da) as 
calibrating proteins. The behaviour of each on the SEC column is shown in Figure 
4.11(A) and Figure 4.11(B) respectively. Both proteins showed poor resolution on 
the SEC column, with PrP(57-90) showing significant degradation and Agp1 
showing excessive aggregation and possibly some degradation. Therefore, only 
lysozyme and BSA were used to construct the calibration curve. 
Calibrating proteins were run in the same buffers as were the samples, and 
thus two separate calibrations were performed for pH 7.4 and pH 10.5. Each protein 
(5 mg ml
-1
) was run down the column in conjunction and the resulting chromatogram 
is shown in Figure 4.11. For pH 7.4 (Figure 4.11(A)) two repeats were run of the 
calibrating proteins and the average elution columns used in calibration calculations. 
The elution volumes were very similar indicating a high reproducibility of this 
method. For pH 10.5 (Figure 4.11(B)) only one run of calibrating proteins was done. 
 Elution volumes were then converted into a retention factor, KAV, using 
Equation 12. 
 
    
     
     
 
(Eq. 12) 
where Ve is the elution volume of the calibrating protein. V0 is the void volume of the 
column and Vc is the total column volume as measured with acetone. 
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KAV was then plotted against log(Mr) of the calibrating proteins to produce a straight 
line graph with equation       . This equation can be used to convert the KAV of 
sample proteins using Equation 13 to the log of their molecular weight. 
 
 
         
      
 
 
(Eq. 13) 
 
A simple inverse log function then gives the molecular weight (Mr). 
However, unstructured proteins have considerably larger hydrodynamic radii 
than folded proteins of equivalent molecular weight. Danielsson et al. gave the 
formula in Equation 14 to relate hydrodynamic radius (Rh) and molecular weight 
(Mr) for unstructured proteins (Danielsson, J., et al., 2002).  
 
Talmard et al. found that Rh of Aβ species calculated from this formula matched Rh 
determined using pulse field gradient (PFG) NMR whereas SEC gave an even larger 
value for Rh (Talmard, C., et al., 2007). The SEC is calibrated with globular proteins 
whereas Aβ species are unstructured.  This would lead to calibrating proteins of a 
similar molecular weight to Aβ exiting the column later, making Aβ appear larger 
than it is, specifically so that a monomeric Aβ species would appear hexameric 
(Talmard, C., et al., 2007). In addition, papers such as Teplow, 2006, have indicated 
that low molecular weight Aβ will elute from a size exclusion column at 5-15 kDa 
and that monomer may appear as heptamer (Teplow, D. B., 2006). 
There were some cases when application of this formula was not appropriate. 
For example Aβ complex with Zn2+ ions leads to a more structured peptide which 
increases lag time on the column. However, in general, it can be stated that 
monomeric Aβ may appear anywhere from pentameric to heptameric on a column 
calibrated with globular proteins. 
 
           
    (Eq. 14) 
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Figure 4.11: Chromatogram of BSA and lysozyme used for calibration of SEC. UV traces 
of eluting products from a size exclusion after injection of 5 mg
-1
 ml each of bovine serum 
albumin (BSA) and lysozyme. (A) Proteins run in pH 7.4 50 mM HEPES/150 mM NaCl 
buffer. Two repeats were done. (B) Proteins run in pH 10.5 150 mM NaCl UHQ H2O.  
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4.3. Results 
 
4.3.1. Fibril growth rates of oxidised and unoxidised Aβ(1-40) 
 
Initially the effects of oxidation on the fibrillisation kinetics of Aβ were studied, 
including both the nucleation and elongation rates of fibril formation. The first 
section of the results will discuss these studies. 
 
Determining the optimal concentration of Aβ(1-40) for fibril growth assays 
 
Initially, well-plate assays were run on Aβ(1-40) alone, in order to establish the 
optimal concentration of peptide to obtain growth curves over a time period which 
would allow detection of both increased and decreased rates of fibril growth under 
various oxidising conditions. The assay used was a Th-T fluorescence binding assay 
at two different Aβ(1-40) concentrations, 10 µM and 20 µM. The data are shown in 
Figure 4.12(A). The fibril growth curves were then fitted to the two equations 
described in Section 4.2.3. and the values obtained were then averaged across five 
traces (10 µM Aβ(1-40)) or six traces (20 µM Aβ(1-40)) to give various kinetic 
parameters with standard errors given in parentheses (Table 4.3 and Table 4.4). 
Doubling the concentration of Aβ(1-40) nearly doubled the apparent fibril 
growth rate (kapp) from 0.064 ± 0.008 h
−1
 with 10 µM Aβ(1-40) to a kapp  of 
0.11 ± 0.01 h
−1
 for 20 µM Aβ(1-40) (Table 4.3). The time taken to half maximal 
growth of the Aβ(1-40) fibres was tripled for 10 µM Aβ(1-40) with a t50 of 
231 ± 11 h compared to just 75 ± 3 h for 20 µM Aβ(1-40) (Table 4.3, 
Figure 4.12(B)) and statistical testing (t-test) showed this change to be significant (p 
< 0.05) (Table 4.5). The apparent discrepancy between these two indicators of fibril 
growth rate, kapp and t50, can be explained by the vastly different nucleation rates for 
these two concentrations with a nucleation rate of just 5×10
−7 
± 3 ×10
−7
 h
−1
 for 10 
µM Aβ(1-40) versus the significantly faster 10×10−5 ±  3×10−5 for 20 µM Aβ(1-40) 
(p < 0.05) (Table 4.4, Figure 4.12(C)). The t50 is highly dependent on nucleation rate 
and thus the apparent numerical differences in the extent of the effect of 
concentration of Aβ(1-40) on fibril growth can be explained. This is also illustrated 
by the greater difference in lag phase between the two concentrations – a four-fold 
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difference between 200 ± 2 h for 10 µM Aβ(1-40) and 56 ± 2 h for 20µM Aβ(1-40) 
(Table 4.3) – which is a significant component of the time to half maximal growth.  
To varying degrees, these quantitative measurements all indicate the same 
conclusion, that a doubling in Aβ(1-40) concentration causes a significant (p < 0.05)  
increase in the rate of fibril growth and thus must be taken into consideration when 
designing assays to determine the effects of peptide oxidation on fibril growth. 
  It is interesting to note that although doubling the concentration of Aβ(1-40) 
significantly increased the nucleation rate it did not profoundly affect the elongation 
rate, which was in fact only marginally faster at the lower peptide concentration; 
3.6×10
−6
 ± 0.3×10
−6
 h
−1
 for  10 µM Aβ(1-40) and 2.9×10−6 ± 0.2×10−6 h−1 for 20 µM 
Aβ(1-40) (Table 4.4, Figure 4.12(D)). These data suggest that under these conditions 
nucleation, as defined by Equation 2, is considerably more influenced by 
concentration than is elongation. 
As expected maximal Th-T fluorescence intensity is approximately half when 
the concentration of Aβ(1-40) is halved; 15,900 ± 270 AFU for 10 µM Aβ(1-40) 
compared to 29,300 ± 290 AFU for 20 µM Aβ(1-40)  (Table 4.4). This demonstrates 
that the Th-T fluorescence binding assay gives meaningful quantitative 
measurements of fibril formation.  
 From these data it was decided that the best Aβ(1-40) concentration to use for 
the oxidation assays was 10µM Aβ(1-40) as this would allow an adequate range of 
tlag values around the control Apo tlag of 200 ± 8 h, should oxidation either increase 
or decrease fibril growth rates. In addition, previous publications had indicated that 
at Aβ concentrations greater than 10µM Aβ, amorphous aggregates form and thus 
amyloid fibres could not be detected under certain conditions, e.g. in the presence of 
Cu
2+
 ions (Sarell, C. J., et al., 2010). This indicated that higher concentrations of 
Aβ(1-40) may not be favourable for amyloid fibre formation and may instead favour 
amorphous aggregation.  
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Figure 4.12: Effect of Aβ(1-40) concentration on fibril growth. (a) Fibril growth curves of Aβ(1-40) at 
10 µM (blue) and 20 µM (green) with 2 mol. eq. Th-T at 30 °C, pH 7.4 (50 mM HEPES, 160 mM NaCl Buffer). 
Th-T fluorescence values are zeroed at 30 h . Six traces are shown for each concentration. (b) Summary plot 
showing the mean time to half maximal growth (t50) for each concentration of Aβ(1-40) used; 10 µM (blue) and 
20 µM (green) Aβ(1-40). Error bars are for standard error of 5 traces (10 µM) and 6 traces (20 µM). Halving the 
concentration of Aβ(1-40) significantly decreases the fibril growth rate. Significant changes are indicated with a 
red star. c) Summary plot showing the nucleation rate (kn) for each concentration of Aβ(1-40) used; 10 µM 
(blue)and 20 µM (green) Aβ(140). Error bars are for standard error of 4 traces (10 µM) and 6 traces (20 µM). 
Halving the concentration of Aβ(1-40) significantly decreases nucleation rate, so much so that the two sets of 
data cannot be plotted on the same chart. Significant changes are indicated with a red star .d) Summary plot 
showing the elongation rate (ke) for each concentration of Aβ(1-40) used; 10 µM (blue) and 20 µM (green) 
Aβ(1-40). Error bars are for standard error of the mean of 5 traces (10 µM) and 6 traces (20 µM). Halving the 
concentration of Aβ(1-40) has no significant effect on elongation rate.  
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Table 4.3: t50, tlag and kapp values for varying concentrations of Aβ(1-40). 
Calculated using the equation specified by Uversky et al., 2001 (Uversky, V., et al., 2002) by fitting 
the curves shown in Figure 4.12(A). In parentheses are the standard errors for each measurement. 
 
Table 4.4: kn, ke and [B]t values for varying concentrations of Aβ(1-40). 
Calculated using the equation specified by Morris et al., 2008 (Morris, A. M., et al., 2008) by fitting 
the curves shown in Figure 4.12(A). In parentheses are the standard errors for each measurement. 
 
Table 4.5: Tests of significant difference on t50 from Figure 4.12(A).  
Calculated using the equations specified in Section 4.2.3. Degrees of freedom for each test are given 
in brackets. 
 
The effects of H2O2 oxidation on Aβ(1-40) fibril growth rates 
 
In Figure 4.13 the kinetics of fibril growth under various oxidising conditions are 
compared using well plate-Th-T binding assay on 10 μM Aβ(1-40). Comparison of 
unoxidised Aβ(1-40) (Figure 4.13(A)) with H2O2-oxidised Aβ(1-40) (Figure 4.13(B)) 
indicates that the rate at which fibres are formed is significantly increased with H2O2 
oxidation (p < 0.05) (Table 4.8). In particular, the time to half maximal fluorescence 
(t50) is reduced from 221 ± 7 h for un-oxidised Aβ to 104 ± 4 h for the H2O2 oxidised 
Aβ(1-40) (Table 4.6). The difference in t50s was shown to be significant according to 
an unpaired t-test (p < 0.05) (Figure 4.13(D)). 
Aβ(1-40) 
concentration 
(µM)  
Mean t50 (h)  Mean tlag (h)  Mean kapp (h
-1
) 
10  231.4 (11.2)  
n = 5 
200.0 (8.4)  
n = 5 
0.064 (0.0081) 
n = 5 
20  74.9 (3.2)  
n = 6 
56.4 (2.1)  
n = 6 
0.11 (0.013) 
n = 6 
Aβ(1-40) 
concentration 
(µM)  
Mean kn (x10
-7
))  Mean ke (x10
-7
) Mean [B]t  (AFU) 
10  1.71 (0.75) 
n = 4  
 36.2 (3.3)  
n= 5 
15900 (269.0) 
n = 3 
20  976.0 (270.0)  
n = 6 
29.0 (2.0) 
n = 6  
29300 (288.0) 
n = 4 
Statistic 
 
Value  
 
Critical value  
 
Conclusion 
 
F-statistic 10.291  
 
5.1922 (4, 5)  
 
Unequal variances 
- Welch's t-test 
 
t-statistic  13.408 2.1318 (4.7966) Means 
significantly differ 
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Comparison of the elongation and nucleation rates suggests that it is the lag phase 
(nucleation rate) that is most influenced by H2O2 oxidation. H2O2 oxidation reduces 
the lag phase from 192 ± 4.5 h to 73 ± 3.7 h. The nucleation rate 
(1.5×10
−4 
± 0.5×10
−4
 h
−1
) is increased 950-fold compared to un-oxidised 
(1.6×10
−7 
± 0.7×10
−7
 h
−1
) while the elongation rate (4.3×10
−6 
± 0.3×10
−6
 h
−1
) is only 
increased 1.2-fold compared to Apo (3.6×10
−6 
± 0.3×10
−6
 h
−1
) (Table 4.7). This 
indicates that although oxidising Aβ significantly increases the rate at which the 
peptide nucleates it has little effect on the rate at which the nucleating species then 
elongates. It is also notable that the total amount of fibres generated at equilibrium is 
comparable. 
 
Oxidising 
condition 
Mean t50 (h)  Mean tlag (h)  Mean kapp (h
-1
) 
Apo  
 
221.2 (7.3)  
n = 5 
192.0 (4.5)  
n = 5 
0.075 (0.0094) 
n = 3 
Cu
2+
 
 
52.1 (3.5) 
n = 5  
49.7 (6.6)  
n = 5 
0.276 (0.032) 
n = 5 
H2O2 
 
104.8 (4.3)  
n = 4 
72.8 (3.7)  
n = 4 
0.0606 (0.0023) 
n = 2 
Cu
2+
 and H2O2  131.7 (45.8)  
n = 2 
95.5 (17.6)  
n = 2 
0.031 (N/A) 
n = 1 
Table 4.6: t50, tlag and kapp values for 10 µM Aβ(1-40) under oxidising conditions. 
Calculated using the equation specified by Uversky et al., 2001(Uversky, V., et al., 2002) by fitting 
the curves shown in Figure 4.13(A). In parentheses are the standard errors for each measurement. 
 
Aβ(1-40) 
concentration 
(µM)  
Mean kn (x10
-7
))  Mean ke (x10
-7
) Mean [B]t  (AFU) 
Apo  1.60 (0.67)  
n = 4 
 36.4 (3.3) 
n = 5 
15700 (110.1) 
n = 3 
Cu
2+
 730.0 (337.0)   
n = 6 
133.0 (21.5)  
n = 6 
10400 (680.6) 
n = 5 
H2O2   1530 (513.0) 
n = 5 
42.8 (3.0)  
n = 4  
13500 (1560.0) 
n = 5 
Cu
2+
 and H2O2   4680 (3020)   
n = 2 
26.4 (6.86) 
n = 2 
10300 (517.3) 
n = 2 
Table 4.7: kn, ke and [B]t values for 10 µM Aβ(1-40) under oxidising conditions. 
Calculated using the equation specified by Morris et al. (Morris, A. M., et al., 2008) by fitting the 
curves shown in Figure 4.13(A). In parentheses are the standard errors for each measurement. 
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Figure 4.13: Cu
2+
 and hydrogen peroxide based oxidation of 10 µM Aβ(1-40) accelerates 
fibril growth. (a) All six growth curves for Apo (10µM Aβ(1-40)). Th-T fluorescence values 
are zeroed at 30 h. (b) All six growth curves for addition of H2O2 (100 µM). Th-T fluorescence 
values are zeroed at 30 h. (c) Fibril growth curves of 10 µM Aβ(1-40) with 20 µM Th-T at 
303K, pH 7.4 (50 mM HEPES, 160 mM NaCl buffer). Th-T fluorescence values are zeroed at 
30 h and are averaged across six traces (red, green, blue), five traces (pink) or two traces 
(purple). Conditions used were Apo (red), 1 µM CuCl2 (pink), 100 µM H2O2 (green), 1 µM 
CuCl2 and 100 µM H2O2 (purple), 1 µM CuCl2 and 100 µM ascorbate (blue).  pH was 
rechecked after addition of H2O2 and readjusted to be pH 7.4. (d) Summary plot showing the 
mean time to half maximal growth (t50) for each oxidising condition as referenced for Figure 
5.11(C). Error bars are for standard error of the mean of 5 traces (both Apo and H2O2) , 6 traces 
(CuCl2) and 2 traces (CuCl2 and H2O2). All three conditions increase fibril growth rate 
compared to Apo. Significant differences are indicated by a red star.  
 
  Apo      Cu
2+
        H2O2      Cu
2+
+H2O2 
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Oxidising 
condition  
F-
statistic  
F-
critical  
Variance 
Conclusion  
t-
statistic 
t-critical Mean 
conclusion 
Apo vs. 
Cu
2+
  
 
4.5627  6.3882(4, 
4)  
Equal 
variances 
(Student's 
t-test)  
18.583  1.9432 
(95 %, 
6)  
Means 
significantly 
differ 
Apo vs. 
H2O2  
3.7040  9.1172 
(4, 3)  
Equal 
variances 
(Student's 
t-test) 
11.155   1.8946 
(95 %, 
7) 
Means 
significantly 
differ  
 
Apo vs. 
Cu
2+
 and 
H2O2  
15.432  7.7086 
(1, 4)  
 Unequal 
variances 
(Welch's t-
test)  
1.9308   
 
6.3138 
(95 %, 
1)  
Means do 
not 
significantly 
differ 
Table 4.8: Tests of significant difference on t50 from Figure 4.13(A). 
Calculated using the equations specified in Section 4.2.3. Degrees of freedom for each test are given 
in brackets. 
 
The effects of Cu
2+
/Cu
+
-catalysed oxidation on Aβ(1-40) fibril growth rates 
 
The effect of fibril growth rates when Aβ(1-40) is oxidised using Cu2+/Cu+-catalysed 
oxidation has also been studied with both a H2O2 and Cu
2+ 
incubation and a Cu
2+
 and 
ascorbate incubation. The behaviour relative to H2O2 driven oxidation is quite 
different. It is notable that some of the well plate samples did not generate any fibril 
growth while for others the final maximal Th-T fluorescence was reduced relative to 
unoxidised Aβ(1-40). In particular, Cu2+ and ascorbate incubated Aβ(1-40) resulted 
in no detectable Th-T fluorescence even after more than 250 h (Figure 4.13(C)), 
while for Cu
2+
 and H2O2 only two wells generated fibres out of the 6 wells set up. It 
should be noted that with only two fibre growth curves available reliable kinetic data 
cannot be determined for the Cu
2+
 and H2O2 preparations.  
 The lack of fibre detection suggests that Cu
2+
/Cu
+
-catalysed oxidation under 
these conditions inhibits fibre growth perhaps by generating non Th-T-binding 
amorphous aggregates. Alternatively, the oxidising conditions may be degrading the 
Th-T dye. However, it will be shown later in this chapter that the latter is not the 
case.  
 As a control the effect of Cu
2+
 ions only, which will not oxidise Aβ 
appreciably, was also studied and it was found that just 0.1 mol equivalents of 
Cu
2+ 
ions led to a four-fold decrease in t50 values from 221 ± 7 h for Apo Aβ(1-40) to 
just 52 ± 4 h for 1 µM CuCl2 (Table 4.6). These results, regarding the ability of Cu
2+
 
to bind to Aβ and thus accelerate fibre formation, parallel findings recently published 
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by Sarell et al. (Sarell, C. J., et al., 2010), and thus provide validity to the assays run 
in this project. 
 
Fibril growth at high concentration of oxidised Aβ(1-40) 
 
The Th-T dye may be sensitive to free radical oxidation and so interfere with the 
detection of fibres. It was therefore proposed that the assay should be re-run at a 
higher concentration of Aβ(1-40) i.e. 20 µM to enable faster fibril growth and hence 
hopefully allow fibril growth curve formation before Th-T degradation. In addition, 
the data shown in Figure 4.12 indicate that 20 µM might be a better concentration of 
Aβ(1-40) to use than 10 µM because of improved signal-to-noise for fibre detection 
values. 
The assay was re-run at 20 µM Aβ(1-40) and the resulting data are shown in 
Figure 4.14, including a complete fibril growth curve for the Cu
2+
 and ascorbate 
condition. Perhaps the most striking difference in the fibril growth curves obtained 
under the various oxidising conditions is the marked reduction in the maximal Th-T 
fluorescence generated for the Cu
2+
/Cu
+
-catalysed oxidation from ~25,000 AFU for 
unoxidised Aβ down to ~4,000 AFU for the Cu2+/Cu+-catalysed Aβ. This may be due 
to either the Th-T degradation discussed above or to the production of insoluble 
amorphous aggregates, which do not cause Th-T fluorescence. 
Figure 4.14(A) displays the results of a well-plate Th-T assay on 20 μM 
Aβ(1-40) under the same oxidising conditions as Figure 4.13. The traces displayed 
are averages of up to six data sets. The data were fitted to the two curve equations 
described by Uversky et al. and Morris et al. to give the parameters seen in Tables 
4.9 and 4.10 respectively. The t50s deduced from fitting Uversky et al.,’s equation are 
plotted in Figure 4.14(B) and their significance is analysed using unpaired t-test 
methodology as shown in Table 4.11. 
As for the 10 μM Aβ(1-40) data, t50 values for 20 μM Aβ(1-40) (Table 4.9) 
show that fibril growth was generally faster with the addition of either Cu
2+
 alone 
(50 ± 1 h) or hydrogen peroxide (68 ± 4 h) compared to unoxidised Aβ(1-40) 
(75 ± 3 h). Only the effect of Cu
2+
 was deemed a significant (p < 0.05) increase by 
statistical t-test values given in Table 4.11.  
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Cu
2+
 and H2O2 incubation lead to an increase in the time to generate fibres, with a t50 
of 100 ± 14 h, compared to unoxidised Aβ(1-40), with a t50 of 75 ± 3 h. 
The other Cu
2+
/Cu
+
-catalysed condition, with ascorbate, appears to significantly 
increase the time for half maximal growth of Aβ fibres, with a t50 of 128 h. However, 
although 6 repeats were run for this condition, only one sample generated a Th-T 
fluorescence signal and even this was with a greatly reduced intensity of 
~4,000 AFU compared to unoxidised Aβ (~25,000 AFU). With only one fibril trace 
generated it is not possible to make reliable inferences as to the significance of this 
observation.  
 In conclusion, Figures 4.13 and 4.14 show some variation in the behaviour of 
fibril growth kinetics of Aβ(1-40) under the conditions applied. However, in general, 
oxidation of Aβ(1-40) by H2O2 tends to accelerate the rate of fibre formation. In 
contrast Cu
2+
/Cu
+
-catalysed oxidation tends to result in reduced fibre formation. For 
a limited number of traces there are some fibres generated but the maximal intensity 
of Th-T fluorescence is significantly reduced.  
 
 
 
 
 
 
 
 
 
Figure 4.14: Cu
2+
 and hydrogen peroxide based oxidation of 20 µM Aβ(1-40) accelerates fibril 
growth.  (a) Fibril growth curves of 20 µM Aβ(1-40) with 40 µM Th-T at 303K, pH 7.4 (50 mM HEPES, 
160 mM NaCl buffer). Th-T fluorescence values are zeroed at 30 h and are averaged across six traces 
(red, pink, green), two traces (purple) or one trace (blue). Conditions used are Apo (red), 2 µM CuCl2 
(pink), 200 µM H2O2 (green), 2 µM CuCl2 and 200 µM H2O2 (purple), 2 µM CuCl2 and 200 µM 
ascorbate (blue). (b) Summary plot showing the mean time to half maximal growth (t50) for each 
oxidising conditions as referenced for Figure 5.12(A). Error bars are for standard error of the mean of 6 
traces (Apo, CuCl2 only and H2O2 only) 2 traces (CuCl2 and H2O2) and 1 trace (CuCl2 and ascorbate). pH 
was re-checked after addition of H2O2 and readjusted to be pH 7.4. Contrary to the data shown in Figure 
5.11(C) the Cu
2+
-catalyzed oxidation condition appears to significantly decelerate fibril growth relative to 
Apo. H2O2 alone may increase fibril growth slightly although statistical tests show this difference is not 
significant. 
 
Apo         Cu
2+
      H2O2   Cu
2+
+H2O2  Cu
2+
+Asc 
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Oxidising 
condition 
Mean t50 (h)  Mean tlag (h)  Mean kapp (h
-1
) 
Apo  
 
74.7 (3.2) 
n = 6  
57.3 (2.0) 
n = 6  
 0.12 (0.016) 
n = 6 
Cu
2+
 
 
49.1 (1.1) 
n = 6  
34.8 (2.5)  
n = 6 
0.15 (0.019) 
n = 6 
H2O2 
 
67.8 (3.8)  
n = 6 
28.1 (6.6)   
n = 6 
0.057 (0.0020) 
n = 4 
Cu
2+
 and H2O2  99.8 (14.2)  
n = 2 
82.0 (19.1)   
n = 2 
0.12 (0.034) 
n = 2 
Cu
2+
 and ascorbate  127.6 (N/A) 
n = 1 
102.6 (N/A)   
n = 1 
0.080 (N/A) 
n = 1 
Table 4.9: t50, tlag and kapp values for 20 µM Aβ(1-40) under oxidising conditions. 
Calculated using the equation specified by Uversky et al., 2001(Uversky, V., et al., 2002) by fitting 
the curves shown in Figure 4.14(A). In parentheses are the standard errors for each measurement. 
 
Table 4.10: ke and 
[B]t values for 20 
µM Aβ(1-40) under 
oxidising conditions. 
Calculated using the 
equation specified by 
Morris et al., 2008 
(Morris, A. M., et al., 
2008) by fitting the 
curves shown in 
Figure 4.14(A). In 
parentheses are the 
standard errors for 
each measurement. 
The kn has been 
removed due to 
unusual curve fitting. 
Table 4.11: Tests of significant difference on t50 from Figure 4.14(A). 
Calculated using the equations specified in Section 4.2.3. Degrees of freedom for each test are given 
in brackets. 
 
 
Aβ(1-40) 
concentration 
(µM)  
Mean ke (x10
-7
) Mean [B]t  (AFU) 
Apo  35.9 (3.2)  
n = 6 
28000 (26.5) 
n = 4 
Cu
2+
 34.9 (2.70)  
n = 6 
28100 (30.9) 
n = 5 
H2O2   25.9 (0.63)  
n = 4 
23100 (79.7) 
n = 6 
Cu
2+
 and H2O2   110.0 (23.1)  
n = 2 
6080 (681.7) 
n = 2 
Cu
2+
 and ascorbate   148.0 (N/A)  
n = 1 
4210 (N/A) 
n = 1 
Oxidising 
condition  
F-
statistic  
F-critical  Variance 
Conclusion  
t-statistic t-critical Mean 
conclusion 
Apo vs. 
Cu
2+
  
 
8.3852      5.0503 
(5, 5) 
Unequal 
variances 
(Welch's t- 
test) 
7.5256 1.9432 
(95 %, 6) 
Means 
significantly 
differ 
Apo vs. 
H2O2  
1.4249  5.0503 
(5, 5)   
 
Equal 
variances 
(Student's 
t-test) 
1.3786 1.8125 
(95 %, 
10) 
Means do 
not 
significantly 
differ 
Apo vs. 
Cu
2+
 and 
H2O2  
6.4735  
 
6.6079 
(1, 5)  
Equal 
variances 
(Student's 
t-test)  
2.8208  1.9432 
(95 %, 6) 
Means 
significantly 
differ 
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Dependence of Aβ fibrillisation on H2O2 concentration 
 
To investigate further whether different concentrations of H2O2 would exert different 
effects on Aβ fibrillisation rates, the Th-T binding assay on 10 µM Aβ(1-40) was 
conducted at six different H2O2 concentrations. Figure 4.15 shows the Th-T 
fluorescence fibril growth data using a range of H2O2 concentrations (0, 10, 50, 100, 
200 and 1,000 μM). The traces displayed are averages as indicated in the Figure’s 
caption. The fibril growth curves were fitted to the two equations described by 
Uversky et al. and Morris et al. to give the lag phase, rates of nucleation and 
elongation and maximal fluorescence as displayed in Tables 4.12 and 4.13 
respectively. The t50 data deduced from fitting were analysed for significance and 
this produced the values given in Table 4.14. 
 Slight variations in the t50s were observed over the range of H2O2 
concentrations used (Figure 4.15(B); however, none of these differences were 
significant (Table 4.14). Values of tlag for the various H2O2 concentrations were also 
quite similar to that of unoxidised Aβ(1-40) (Table 4.12). 
 The maximal intensity of the Th-T signal, at equilibrium, was reduced and 
the numbers of growths curves obtained decreased with increasing amounts of H2O2. 
This may indicate that Aβ oxidised by H2O2 is forming amorphous aggregates 
instead of fibrils that activate Th-T. This is a significant effect of H2O2 on Aβ(1-40) 
fibril growth.  
However, there is one other possibility to explain these results; that oxidation 
of Th-T is also taking place and this could be affecting the Th-T fluorescence signal.  
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Hydrogen 
peroxide 
concentration 
(µM) 
Mean t50 (h)  Mean tlag (h)  Mean kapp (h
-1
) 
Apo   115.0 (7.2)  
n = 8 
95.4 (6.1)  
n = 7  
0.15 (0.016) 
n = 7 
10  114.0 (2.9)  
n = 7 
101.5 (0.76)  
n = 6 
0.14 (0.011) 
n = 9 
50  109.2 (4.4)  
n = 9 
92.0 (3.2) 
n = 9  
0.14 (0.011) 
n = 8 
100  104.8 (3.8)  
n = 4 
68.2 (6.1)  
n = 4 
0.051 (0.012) 
n = 5 
200  139.2 (18.3) 
n = 3 
115.9 (25.4)  
n = 3 
0.11 (0.036) 
n = 3 
1000  109.6 (N/A)   
n = 1 
103.0 (N/A)   
n = 1 
0.30 (N/A) 
n = 1 
Table 4.12: t50, tlag and kapp values for 10 µM Aβ1-40) with varying concentrations of hydrogen 
peroxide. Calculated using the equation specified by Uversky et al., 2001(Uversky, V., et al., 2002) 
by fitting the curves shown in Figure 4.15(A). In parentheses are the standard errors for each 
measurement. The 100 µM data was recorded on a separate occasion to the rest of the data shown. No 
fibril growth curves were obtained for the 2 mM H2O2 condition. 
 
 
Figure 4.15: The effect of varying hydrogen peroxide concentration on Aβ(1-40) fibril growth. (a) Fibril growth 
curves of 10 µM Aβ(1-40) with 20 µM Th-T at 303K, and varying concentrations of H2O2 , pH 7.4 (50 mM HEPES, 160 
mM NaCl Buffer). H2O2 concentrations used were Apo (red), 10 µM (orange), 50 µM (light green), 100 µM 
(dark green), 200 µM (dark blue), 1 mM (light blue), 2 mM (purple). The 100 µM data was recorded on a separate 
occasion to the rest of the data shown and hence is illustrated with crosses (x) as opposed to circles (o). pH was 
rechecked after addition of H2O2 and readjusted to be pH 7.4. Th-T fluorescence values are either one trace (light blue) 
or are averaged across three traces (dark blue), six traces (dark green), eight traces (red) or nine traces (orange, light 
green, purple).(b) Summary plot showing the mean time to half maximal growth (t50) for each hydrogen peroxide 
concentration as referenced for Figure 5.14(A). Error bars are for standard error of the mean of 9 traces (10 µM, 50 µM), 
8 traces (Apo), 5 traces (100 µM), 3 traces (200 µM) and 1 trace (1 mM). None of the hydrogen peroxide concentrations 
appears to cause a significant change in fibril growth rate compared to Apo. 
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Hydrogen 
peroxide 
concentration 
(µM) 
Mean kn (x10
-7
))  Mean ke (x10
-7
) Mean [B]t  (AFU) 
Apo   42.5 (20.9)   
n = 6 
27.9 (5.0)   
n = 8 
29500 (2440) 
n = 8 
10  11.9 (4.7)   
n = 8 
68.9 (4.0)  
n = 8  
14700 (118.6) 
n = 8 
50  141.3 (33.9)  
n = 8 
38.7 (4.4) 
n = 9 
18900 (305.0) 
n = 7 
100  1230 (405.1)   
n = 5 
44.7 (3.3)  
n = 5  
12900 (1510) 
n = 5 
200  574.0 (526.0)  
n = 3 
40.1 (5.2)   
n = 3 
14200 (1300) 
n = 3 
1000  154.9 (N/A)  
n = 1 
27.1 (N/A)  
n = 1 
16500 (N/A) 
n = 1 
Table 4.13: kn, ke and [B]t values for 10 µM Aβ1-40) with varying concentrations of hydrogen 
peroxide. Calculated using the equation specified by Morris et al., 2008 (Morris, A. M., et al., 2008) 
by fitting the curves shown in Figure 4.15(A). In parentheses are the standard errors for each 
measurement. The 100 µM data was recorded on a separate occasion to the rest of the data shown. No 
fibril growth curves were obtained for the 2 mM H2O2 condition. 
 
 
Hydrogen 
peroxide 
concentration 
(µM) 
F-
statistic  
F-
critical  
Variance 
Conclusion  
t-
statistic 
t-
critical 
Mean 
conclusion 
Apo vs. 10  1.2013   3.8660 
(6, 7)  
Equal 
variances 
(Student's 
t-test)  
0.091295  1.7709 
(95 %, 
13)  
Means do 
not 
significantly 
differ 
 
Apo vs. 50  2.3489  3.5005 
(7, 8)  
 
Equal 
variances 
(Student's 
t-test)  
1.4360  1.7531 
(95 %, 
15)  
Means do 
not 
significantly 
differ 
Apo vs. 100  7.2828  8.8867 
(7, 3)   
Equal 
variances 
(Student's 
t-test)  
 0.95309  1.8125 
(95 %, 
10) 
 
Means do 
not 
significantly 
differ 
Apo vs. 200  
 
2.4409  
  
4.7374 
(2, 7)  
Equal 
variances 
(Student's 
t-test)   
1.5321   1.8331 
(95 %, 
9)   
Means do 
not 
significantly 
differ 
Table 4.14: Tests of significant difference on t50 from Figure 4.15(A). Calculated using the 
equations specified in Section 4.2.3. Degrees of freedom for each test are given in brackets. 
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Cu
2+
/Cu
+
-catalysed oxidation does not interfere with Th-T detection. 
           
Some batches of Aβ(1-40) used in these assays, despite vigorous solubilisation and 
disaggregation procedures, still behaved as seeded in the assays, i.e. they produced 
no lag phase. This is a common occurrence as indicated in the literature (Dobeli, H., 
et al., 1995). An example from this PhD study is shown in Figure 4.16. These data 
sets were not useful for extracting meaningful kinetic parameters. However, they do 
illustrate that growth curves can be successfully obtained for all five conditions for 
up to six repeats, even for the radical-based oxidative conditions.  
An appreciable Th-T fluorescence intensity can be obtained for both the H2O2 
and Cu
2+
/Cu
+
-catalysed oxidation and the oxidation by H2O2 alone, with only a slight 
decrease for the ascorbate and Cu
2+
/Cu
+
-catalysed oxidation condition. As these 
samples are seeded this promotes fibrillisation over amorphous aggregation (see 
Chapter 1, Section 1.5.3.). Therefore, in previous, non-seeded samples, the drop in 
Th-T intensity can be attributed to amorphous aggregates forming, not Th-T 
degradation under oxidising conditions. 
To confirm the results found so far using the Th-T binding assay for the 
effects of oxidation on Aβ(1-40) fibrillisation results, a second technique was used. 
This procedure, which does not use an in-sample dye that is thus exposed to reaction 
conditions, was circular dichroism (CD) (Section 4.3.2.). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16: Aβ(1-40) with Cu2+ and ascorbate can show fibril growth curves for seeded 
samples. Fibril growth curves of seeded 20 µM Aβ(1-40) with 40 µM Th-T at 303K, pH 7.4 
(50 mM HEPES, 160 mM NaCl buffer). Th-T fluorescence values are zeroed at 30 h and are 
averaged across six traces. Conditions used are Apo (red), 2 µM CuCl2 (pink), 200 µM H2O2 
(green), 2 µM CuCl2 and 200 µM H2O2 (purple), 2 µM CuCl2 and 200 µM ascorbate (blue). pH 
was re-checked after addition of H2O2 and readjusted to be pH 7.4  
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Delay in Th-T binding mature fibres 
 
Figure 4.17 shows the change in Th-T fluorescence with time of two separate wells 
that were both filled with 5 µM Aβ(1-40) but with Th-T added at either the 
beginning of the study, or at 174.5 h, when the first well had shown maximal fibril 
growth. This shows that Th-T takes over 30 h to bind mature Aβ fibres rather than 
undergoing an instantaneous binding event. An alternative explanation is that Th-T is 
needed to facilitate growth; however, it is generally accepted that this is not the case 
(Nicotera, T. M., 2007). Therefore, it is likely that Th-T added to mature fibres will 
exhibit a delay in fluorescence of greater than 30 h before maximal fluorescence is 
detected. Interestingly Th-T added to concentrated (50 μM) Aβ as monomer can 
show the formation of maximal Th-T fluorescence in considerably less than 30 h 
(Sarell, C. J., et al., 2010). Thus the fluorescence signal shown in Figure 4.17 reflects 
the time taken for Th-T to diffuse into all parts of the mature fibres’ core. 
 
 
 
 
 
4.3.2. β-sheet formation with oxidation of Aβ 
 
Circular dichroism (CD) is a spectroscopic technique which does not require any 
fluorophore or chemical additive, thus problems associated with competitive 
oxidation of the additive are avoided. Hence, the effects of Aβ(1-40) oxidation on 
Figure 4.17: Th-T takes over 30 h to bind mature Aβ fibres. Fibril growth curves of 5 µM 
Aβ(1-40) at 303K, pH 7.4 (50 mM HEPES, 160 mM NaCl Buffer). 10 µM Th-T was either 
added at 0 h (grey trace) or at 174.5 h (orange trace). Th-T fluorescence values are zeroed at 
30 h. Data are from two individual wells.  
 
Chapter 4 
The influence of oxidation on Aβ fibril growth 
200 
 
fibril growth rate were studied using CD to detect fibrillisation. This method 
measures changes in the amount of β-sheet over time. As conformational switching 
from a random coil to β-sheet is a requirement for fibrillisation, this change can be 
used as an indication of fibrillisation rates. 
 Across all oxidising conditions and Apo, the only spectrum to show any 
change was that for the Apo condition (Figure 4.18). Here, a slight shift from mostly 
random coil to partially β-sheet was seen. This can be visualised in Figure 4.18(B) 
where the decrease in the 198 nm band characteristic of random coil and the increase 
in the 217 nm band characteristic of β-sheet is plotted. However, a full shift from 
random coil to β-sheet could not be recorded before the peptide precipitated, hence 
the general decrease in signal seen in Figure 4.18(A). This is also indicated by the 
general drift of the maximum trough from 198 nm to 202 nm and the lack of an 
isosbestic point, suggesting not all of the peptide recorded for the initial random coil 
structures was soluble during the later measurements.  
Very low NaCl concentration and low Aβ peptide concentrations were 
needed to obtain measurements using UV-CD (see Section 4.3.2.). These low 
concentrations meant the peptide took a lot longer to fibrillise. Because of this none 
of the oxidising conditions studied produced data that showed changes in secondary 
structure over 730 h. After 700 h there was a general loss of CD signal, which 
indicated peptide was precipitating out of solution (data not shown). Because no 
change was seen at all in secondary structure under oxidising conditions it can be 
assumed that oxidation causes a slowing in fibrillisation but this decrease cannot be 
quantified.  
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4.3.3. The oligomeric state of oxidised Aβ(1-40) as detected by SEC 
 
We were interested in studying if oxidation of Aβ influenced the formation of 
oligomeric species of Aβ(1-40). 
 
 
 
Figure 4.18: Aβ fibril growth involves a beta sheet transition but also aggregate precipitation. 
(a) UV-CD spectra of the secondary structure of 5 µM Aβ(1-40), 310K, pH 7.4 (0.25 mM HEPES, 
8 mM NaCl buffer). 8 readings were taken at 95 min (red), 200 h (orange) 308 h (dark green), 
390.5 h (light green), 561 h (dark blue), 632.5 h (light blue), 680.5 h (lilac), 730.5 h (pink). An 
in-spectrometer incubator at 310K was used for each reading. Between readings the sample was 
stored at 310 K and shaken at 100 rpm. (b) A plot of the change in molar ellipticity at 198 nm 
(orange - indicative of random coil) and 217 nm (red - indicative of β-sheet) with time. 
 
(A) 
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pH 7.4 studies 
 
Freshly prepared Aβ(1-40) was generated from a solubilised stock of Aβ and 
analysed using size-exclusion chromatography (SEC). Figure 4.19 (Table 4.15) 
shows a size-exclusion chromatograph where 10 µM Aβ(1-40) has been injected at 
volume 0 ml.  
This chromatogram is dominated by a band with an elution volume of 14.1 
ml. The calibration curve suggests these elution volumes correspond to a Mr of 
26,500 Da. At first we were surprised that a fresh Aβ(1-40) preparation would elute 
with an apparent molecular weight close to a hexameric Aβ(1-40) oligomer, instead 
of the molecular weight of Aβ(1-40) monomer, which is 4,327 Da. However, with 
the correction devised by Talmard et al. (seepage 185) this band would correspond to 
monomeric Aβ(1-40). This correction is based on the fact that a column calibrated 
with folded, globular proteins will lead to an unfolded protein, such as Aβ(1-40), 
eluting from the SEC more rapidly than its mass would suggest. It has been shown 
previously that unfolded monomeric Aβ will elute a SEC column with an apparent 
molecular weight of 26 kDa  (Talmard, C., et al., 2007). 
 Aβ(1-40) was then incubated for 17 h under various oxidising conditions and 
size-exclusion chromatograms were obtained (Figure 4.20, Table 4.16). For 
Cu
2+
 ions, H2O2 and the combination of these two reagents the single elution band 
was produced indicative of a hexameric Aβ(1-40) species (on average an elution 
volume of 14.1 ml indicating a molecular weight of 26,500 Da before correction). 
However, the second radical-based oxidation with ascorbate and Cu
2+
 ions produced 
an additional band with an elution volume of 17.4 ml; a low molecular weight 
species (i.e. < 1,000 Da). Ascorbate was known to be observable on the UV trace and 
it was suspected that as this band was at a similar elution volume to the small 
molecule acetone (Mr 58 Da) this may correspond to the elution of other small 
molecules, due to ascorbate or products of ascorbate oxidation; dehydroascorbate (Mr 
174 Da) or monodehydroascorbate (Mr 176 Da) (Figure 2.11). Hence, a control run 
of ascorbate, after a 17 h incubation at 30 °C and pH 7.4 with Cu
2+
 ions, was done on 
the size-exclusion column. Figure 4.21 (Table 4.17) shows the result of this control 
alongside the trace for the incubation of these two reagents with Aβ(1-40). As 
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expected the extra non-monomeric-Aβ(1-40) species band in this latter trace appears 
at a similar elution volume to the control band for ascorbate i.e. at 16.9 ml. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.19: Size exclusion chromatogram of 
fresh Aβ(1-40) shows one predominant 
oligomeric species. A UV trace of eluting products 
from a size exclusion column is shown after 
injection of fresh 10 µM Aβ(1-40) at volume 0 ml 
with 50 mM HEPES, 150 mM NaCl pH 7.4 buffer. 
Three data sets are shown, two of which are from 
the same stock (red and orange traces) and the third 
from a stock made up on a separate occasion 
(green). The major peak shown represents 
monomer. The void volume was determined using 
blue dextran. For elution volumes at the peaks see 
Table 5.16.  
 
 
Figure 4.20: Size exclusion chromatogram of 
Aβ(1-40) under different oxidising conditions 
after a 17 h incubation at 30 °C. Five UV traces of 
eluting products from a size exclusion column are 
shown after separate injections of 10 µM Aβ(1-40) 
at volume 0 ml with 50 mM HEPES, 150 mM NaCl 
pH 7.4 buffer and varying oxidising conditions; Apo 
(red), 1 µM Cu
2+
 (orange), 100 µM H2O2 (dark 
green), 1 µM Cu
2+
 and 100 µM H2O2 (light green), 
100 µM ascorbate and 1 µM Cu
2+
 (blue). Each 
sample was incubated for 17 h at 30 °C before 
injection. The void volume was determined using 
blue dextran. Data are zeroed at 12 ml. For elution 
volumes at the peaks see Table 5.17. 
 
 
Figure 4.21: Size exclusion chromatogram of 
ascorbate and Cu
2+
 /Cu
+
 control. Two UV traces 
of eluting products from a size exclusion column are 
shown. Two samples of 100 µM ascorbate and 
1 µM Cu
2+
 were incubated for 17 h at 303K, one 
with 10 µM Aβ and one without. These were 
injected separately at volume 0 ml with 
50 mM HEPES, 150 mM NaCl pH 7.4 buffer. The 
void volume was determined using blue dextran. 
Data are zeroed at 12 ml. For elution volumes at the 
peaks see Table 5.18.  
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Table 4.15: The elution volumes for peaks in Figure 4.19. Molecular weights are calculated using 
an equation derived from a calibration curve based on data in Figure 4.11(A). 
 
Table 4.16: The elution volumes for peaks in Figure 4.20. Molecular weights are calculated using 
an equation derived from a calibration curve based on data in Figure 4.11(A). 
 
Table 4.17: The elution volumes for peaks in Figure 4.21. Molecular weights are calculated using 
an equation derived from a calibration curve based on data in Figure 4.11(A). 
 
Therefore, in general, after a 17 h incubation with each condition, Aβ(1-40) seems to 
show no more variation in oligomeric species than unoxidised Aβ. Further studies 
were carried out to see whether species size varied over the 17 h incubation. The 
results of three different conditions are shown in Figure 4.22 (Table 4.18). 
A sample of 10µM Aβ(1-40) was incubated at 30 °C, pH 7.4 and aliquots 
were taken and injected onto the size-exclusion column at approximately 2 h 
intervals as indicated. Figure 4.22(A) shows the results of this procedure on 
Aβ(1-40) alone. Initially (17 min reading) some minor high and low molecular bands 
appear at 8.82 ml (Mr 79,000 Da), 12.6 ml (Mr 36,300 Da) and 17.2 ml (Mr 14,000 
Da). If Aβ was still exhibiting characteristics of an unstructured peptide, these would 
correspond to approximately trimer, 1.4-mer and a fragment respectively. However, 
if it was becoming more globular as it formed aggregates, which is more likely, these 
bands may indicate the appearance of higher order oligomers. 
These extra three bands disappear by 2.5 h although the low molecular weight 
band reappears for the 4.5 h alongside another with an elution volume of 19.12 ml 
(Mr 9400 Da), which corresponds to a low molecular weight species. Throughout all 
Trace Elution volume at peak (ml) Molecular weight 
(Da) 
Aβ(1-40) Stock 1 (red) 14.14 26400 
Aβ(1-40) Stock 1 (orange) 14.04 27000 
Aβ(1-40) Stock 2 (green) 9.42, 14.15 70000, 26400 
Trace Elution volume at peak 
(ml) 
Molecular weight 
(Da) 
Apo (red) 14.12 26500 
Cu
2+
 (orange) 14.22 26000 
H2O2 (dark green) 14.16 26300 
Cu
2+
 and H2O2 (light green) 14.02 27100 
Cu
2+
 and Ascorbate (blue) 14.18, 17.40 26200, 13500 
Trace Elution volume at 
peak (ml) 
Molecular weight 
(Da) 
Cu
2+
 and Ascorbate only (red) 16.93 14800 
Cu
2+
 and Ascorbate and Aβ(1-40) 
(orange) 
14.18, 17.40 26200, 13500 
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the readings a band at approx. 14.0 ml (Mr 27,000 Da) was recorded which reveals 
that the hexameric species was present over the whole 13 h under these conditions. 
The addition of H2O2 (Figure 4.22(B)) also produced a monomeric species 
with an average elution volume (Ve) of 14.1 ml (Mr 26,700 Da) throughout all of the 
readings. Even after 13 h incubation there is no evidence of the formation of 
oligomeric species. Larger Aβ(1-40) oligomers eluting in the void volume are not 
apparent. Also the intensity of the hexameric band is maintained during incubation 
indicating that the only Aβ(1-40) species produced is hexameric.  
Finally a radical based oxidation of Aβ(1-40) was conducted using Cu2+ ions 
and ascorbate as shown in Figure 4.22(C). The two bands for monomeric Aβ(1-40) 
and oxidised ascorbate were seen at on average 14.20 ml (Mr 26100 Da) and 
17.20 ml (Mr 14,000 Da)  respectively. Some higher molecular weight bands were 
observed at approximately 4.5 h with bands at 9.87 ml (Mr 64,000 Da) and 11.36 ml 
(Mr 47,000 Da). These extra bands were not observed for longer incubation times. In 
general, the only significant band seen throughout these time-dependent readings is 
the monomeric Aβ(1-40) band under both unoxidised and oxidised conditions.  
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Figure 4.22: Periodic size exclusion runs of Aβ(1-40) with and without oxidising conditions 
over a ~13 h period. (a) A sample of 10 µM Aβ(1-40) was incubated at 30 °C. Aliquots were 
taken at different time points and injected onto a size exclusion column at volume 0 ml. Eluting 
products were detected using UV as shown. 50 mM HEPES, 150 mM NaCl pH 7.4 buffer was 
used and the void volume was determined using blue dextran. Readings were taken at 17 min 
(red), 2 h 29 min (orange), 4 h 36 min (dark green), 6 h 56 min (light green), 9 h 2 min 
(dark blue), 11 h 9 min (light blue), 13 h 14 min (pink). (b) As for (a) but with a sample of 10 µM 
Aβ(1-40) and 100 µM H2O2. Readings were taken at 5 min (red), 2 h 6 min (orange), 4 h 21 min 
(dark green), 6 h 30 min (light green), 8 h 35 min (dark blue), 10 h 41 min (light blue), 12 h 46 
min (pink). (c) As for (a) but with a sample of 10 µM Aβ(1-40), 1 µM CuCl2 and 100 µM 
ascorbate. Readings were taken at 3 min (red), 2 h 11 min (orange), 4 h 23 min (dark green), 6 h 
30 min (light green), 8 h 37 min (dark blue), 10 h 52 min (light blue), 13 h 2 min (pink). For 
elution volumes at the peaks see Table 5.19.  
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Trace Elution volume at peak 
(ml) 
Molecular weight (Da) 
Apo 8.82, 12.60, 17.20, 19.12, 
13.90, 14.00, 14.10 
79300, 36300, 14000,  
9440, 27800, 27200, 
26600 
H2O2 14.00, 14.10, 14.20, 17.46, 
19.23 
27200, 26600, 26100, 
13300, 9230 
Cu
2+
 and Ascorbate 9.87, 11.36, 14.10, 14.20, 
14.30, 17.10, 17.20 
63800, 46900, 26600, 
26100, 25600, 14300, 
14000 
Table 4.18: The elution volumes for peaks in Figure 4.22 Molecular weights are calculated using 
an equation derived from a calibration curve based on data in Figure 4.11(A). 
 
pH10.5 studies 
 
A final investigation was done to confirm the interpretation that unfolded Aβ 
monomer eluted from the SEC column with an apparent molecular weight of 26 kDa. 
pH 10.5 is highly solubilising for Aβ and will favour monomer. Therefore, a 20 µM 
sample of Aβ(1-40) was injected onto the column at volume 0 ml on Figure 4.23 and 
the column was eluted with 160 mM NaCl in pH 10.5 UHQ H2O. A single major 
band was observed at an elution volume of 13.46 ml along with a very minor band at 
19.40 ml (Figure 4.23, Table 4.19). Using a new calibration curve, based on proteins 
run at this pH, these bands corresponded to 28,800 Da and 8,900 Da respectively, 
which using Talmard et al.,’s corrections corresponds to monomeric and a low 
molecular weight fragment (~ 1,000 Da) respectively. Therefore, as at high pH the 
only Aβ(1-40) species is monomer, the major peak at pH 7.4 is also likely to be 
monomeric because the derived molecular weights are of a similar magnitude. 
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Table 4.19: The elution volumes for peaks in Figure 4.23. Molecular weights are calculated using 
an equation derived from a calibration curve based on data in Figure 4.11(B). 
  
Trace Elution volume at peak 
(ml) 
Molecular weight (Da) 
pH 10.5 Aβ(1-40) 13.46, 19.40 28800, 8900 
Figure 4.23: Size exclusion chromatogram of Aβ(1-40) at pH 10.5. A UV trace of eluting 
products from a size exclusion column are shown. 20 µM Aβ was injected at volume 0 ml 
with 160 mM NaCl in pH 10.5 UHQ H2O. The void volume was determined using blue 
dextran. For elution volumes at the peaks see Table 5.20.  
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4.4. Discussion 
 
4.4.1. The effect of H2O2-only oxidation Aβ(1-40) fibrillisation 
 
It is clear from the fibril growth experiments that oxidation by H2O2 alone either 
accelerates fibre formation, especially of the nucleation phase, or has no significant 
effect. Although various experimental trials of H2O2 oxidised Aβ have been studied 
in this project, in no cases is there a reduction in the rate of fibre formation. This is in 
stark contrast to previous literature reports (Hou, L., et al., 2002, Hou, L., et al., 
2004, Johansson, A.-S., et al., 2007, Maiti, P., et al., 2010, Palmblad, M., et al., 
2002, Watson, A. A., et al., 1998). 
 Several of these reports used different procedures to those used in this 
project. For example, Hou et al. and Watson et al. used higher concentrations of Aβ, 
50 μM and 1.2 mM respectively (Hou, L., et al., 2002, Watson, A. A., et al., 1998). 
Such high concentrations of Aβ are likely to lead to amorphous aggregation. 
Palmblad et al. and Watson et al. also used a solubilisation technique which is likely 
to subject Aβ to initially high concentrations and thus is also likely to favour 
amorphous aggregation (Palmblad, M., et al., 2002, Watson, A. A., et al., 1998). 
This amorphous aggregation may occur at the expense of fibrillisation explaining the 
decreases seen in fibrillisation rates reported in these studies. 
Palmblad  et al. and Watson et al. also used different pHs to this study which 
may explain the differing results (Palmblad, M., et al., 2002, Watson, A. A., et al., 
1998). A final difference between previous studies and this study is the concentration 
of H2O2 used. For example Hou et al. used 10 mM and Watson et al. used 0.9 M, 
which are both greater than the 1 mM maximum H2O2 concentration this project 
could achieve fibril growth at. Therefore, these observations of experimental 
technique may go some way to explaining the different findings of this project and 
previous studies. 
 In addition, in order to explain the findings of this project at the molecular 
level, it is necessary to consider how the biophysical properties of the peptide (see 
Chapter 1, Section 1.5.3.), are altered by oxidation. These include hydrophobicity, 
hydrogen-bonding capacity, and protonation state, and thus the total charge on Aβ. 
Oxidation of Aβ(1-40) by H2O2 alone occurs specifically at methionine. In most 
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cases, and in Aβ isolated from senile plaques (Dong, J., et al., 2003), methionine is 
oxidised to methionine sulfoxide (Nadal, R. C., et al., 2008, Schoneich, C., 2005), 
although the sulfone is also noted in the literature (Maiti, P., et al., 2010).  
Methionine sulfoxide is a stronger hydrogen bond acceptor than the original 
methionine due to the addition of oxygen (Watson, A. A., et al., 1998), and thus the 
oxidation of Met35 to methionine sulfoxide will lead to this residue contributing 
more to Aβ(1-40) hydrogen bonding (Hung, A., et al., 2008). Previous papers, which 
have found a decrease in Aβ fibrillisation after H2O2 oxidation, have implied that this 
conversion to methionine sulfoxide may disrupt the specific hydrogen bonding 
between β-sheets which leads to a β-hairpin structure. This would then promote 
amorphous aggregation leading to decreases in observed fibrillisation rates (Hung et 
al.., 2008). However, the degree of specificity of hydrogen bonding required for Aβ 
fibre formation is debatable. For example Wetzel et al. report that there is no specific 
relationship between the number of hydrogen bonds in an Aβ fibre and that fibre’s 
stability (Jarrett, J. T., et al., 1993, Williams, A. D., et al., 2004). Therefore, 
methionine oxidation may strengthen overall hydrogen bonding of the Aβ(1-40) 
peptide and thus promote the formation of β-sheets, leading to increased nucleation 
and thus fibrillisation rates. In addition, methionine oxidation in other peptides has 
been shown to induce conformational changes from α-helix to β-strand (Nishino, S. 
and Nishida, Y., 2001, Schenck, H. L., et al., 1996), which is the precursor to 
fibrillisation. This is one of the effects of H2O2 oxidation seen in this thesis.  
The second effect seen with H2O2 oxidation is a lack of change in fibril 
growth rates. Previous studies that reported a decrease in Aβ(1-40) fibrillisation rates 
with oxidation by H2O2 alone used very high concentrations of H2O2, 200 mol. eq. to 
40,000 mol. eq., and it may be the case, as discussed in Chapter 1, Section 1.10.5, 
that this oxidises other residues such as glutamine, threonine and tyrosine. Hence it 
may be the case that decreasing fibrillisation rates seen in previous literature reports 
were due to oxidation of amino acids other than methionine. In the experiments 
reported in this thesis, which use a much lower H2O2 concentration, it is more likely 
that only methionine is oxidised. Therefore, as fewer amino acids are affected, there 
is less change in hydrogen bonding capability of the Aβ(1-40) peptide and this may 
explain the lack of change seen in some oxidation by H2O2 alone experiments.  
Methionine sulfoxide has a reduced hydrophobicity relative to methionine. In 
addition, molecular dynamics studies have predicted that oxidation of methionine 
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alters the residue’s orientation so it contributes more to the Aβ surface polarity 
(Triguero, L., et al., 2008a) and hence is more exposed to an aqueous environment. 
There is some controversy over how the change in surface polarity with methionine 
oxidation would affect Aβ fibrillisation rates.  Methionine sulfoxide is a larger and 
more polar residue than methionine (Kim, Y. H., et al., 2001) and thus this increases 
the surface polarity (Triguero, L., et al., 2008b). This would be expected to reduce 
β-sheet self-association into fibres and thus reduce Aβ fibrillisation rates (Bitan, G., 
et al., 2003, Hou, L., et al., 2002). However, some groups argue that surface polarity 
change does not explain altered Aβ fibrillisation rates after methionine oxidation. 
When Maiti et al. performed molecular dynamic calculations on Aβ-Met-Ox they 
found little change in fibrillisation rate relative to unoxidised peptide despite 
oxidised methionine having a dipole of approximately 5.24 Debye relative to just 1.6 
Debye for unoxidised methionine (Maiti, P., et al., 2010).  
It should be noted that these oxidising conditions may also promote more 
cross-linking, which may further promote amorphous aggregate formation relative to 
amyloid formation (Butterfield, D. A. and Stadtman, E. R., 1997). The decreased 
maximal fluorescence intensity and decreased number of fibre growth curves 
obtained when H2O2 only was used in this PhD backs up the prediction that 
amorphous aggregates are formed under this condition. 
In conclusion, oxidation by H2O2 alone is expected to reduce surface 
hydrophobicity of Aβ, promoting peptide folding and fibrillisation, increase 
hydrogen bonding capacity of the Met35 residue, which may either contribute more 
to Aβ β-sheet formation or have little effect, and increase the residue’s polarity, 
although this is unlikely to alter overall peptide fibrillisation rates. It is not surprising 
therefore that we observe either an increase in fibrillisation rates or no significant 
effects when Aβ(1-40) is oxidised by H2O2 alone.  
 
4.4.2. The effect of Cu
2+
/Cu
+
-catalysed oxidation on Aβ(1-40) fibrillisation 
 
Metal catalysed oxidation (MCO), in this case Cu
2+
/Cu
+
-catalysed oxidation, 
produced an apparent decrease in fibrillisation rates of Aβ(1-40) and often a 
complete inhibition of fibril formation. This occurred for both a H2O2/Cu
2+
 system 
and an ascorbate/Cu
2+
 system; although only the former was shown to be a 
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significant effect (p < 0.05). In order to explain the effects of Cu
2+
/Cu
+
-catalysed 
oxidation on fibrillisation rate the effects of histidine oxidation, as well as 
methionine oxidation, on Aβ must be considered. The likely cause of these decreased 
fibrillisation rates is an increased propensity of Aβ(1-40) to form amorphous 
aggregates instead of amyloid fibres after Cu
2+
Cu
+
-catalysed oxidation.  
The conversion of histidine to 2-oxo-histidine alters its pKa. The pKa 
associated with peptide-bound histidine are given in Figure 4.24 (A). The pKa for 
2-oxo-histidine (Figure 4.24 (B)) have not been experimentally determined, although 
it contains an electron withdrawing urea instead of a simple imidazole and thus the 
pKa is expected to be a lot lower than that of histidine. At neutral pH therefore 
unoxidised Aβ(1-40) will be approximately 17 % protonated compared to His-Ox 
Aβ(1-40), which will effectively be neutrally charged. This difference in electrostatic 
nature of the oxidised peptide is likely to disrupt the specific cross-β structure of the 
amyloid fibre associated with unoxidised Aβ leading to amorphous aggregation.  
HN
NH
HN
N6.7
HN
NH
HN
NH
Histidine
2-oxo-histidine
OOH
(A)
(B)
<6.7
 
 
 
 
It addition, 2-oxo-histidine does have a greater hydrogen-bond capacity than native 
histidine and therefore it is likely that oxidised histidine interferes with the specific 
hydrogen bonding of the Aβ peptide, and thus formation of β-sheets. Again, this will 
lead to amorphous aggregates forming instead of fibrils and this would give an 
apparent decrease in fibril formation, as indicated by the results of this PhD project. 
This explanation is backed up by the finding that maximal Th-T fluorescence 
decreases under Cu
2+
/Cu
+
-catalysed oxidising conditions, indicating that non Th-T 
binding amorphous aggregates are forming in this case instead of amyloid fibres. In 
Figure 4.24: Protonation of histidine and 2-oxo-histidine.  Peptide-bound histidine had one pKa 
associated with it; the pKa of the imidazole N(τ) which is 6.7 (A). Due to the electron-withdrawing 
of the urethane in 2-oxo-histidine, the pKa is significantly lower than 6.7 (B). 
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conclusion, the effect of Cu
2+
/Cu
+
-catalysed oxidation on Aβ(1-40) is to promote 
amorphous aggregation formation over amyloid fibrillisation.  
There were some concerns that the presence of H2O2 and, in particular, 
radical based oxidants might interfere with Th-T bound fibril detection by degrading 
the Th-T.  This may explain why Hou et al. chose to delay initiation of methionine 
oxidation at varying intervals to allow some progress in Aβ growth to the elongation 
phase before Th-T was exposed to the oxidising agents (Hou, L., et al., 2002). In 
some previous studies procedures to remove oxidants before addition of Th-T have 
been employed. However the seeded experiment run in this project indicated that Th-
T is resistant to degradation under oxidising conditions (Heegaard, P. M. H., et al., 
2004, Jayaraman, S., et al., 2007, Kim, N. H. and Kang, J. H., 2003). The 
explanation above indicates that decreased Th-T fluorescence intensity is expected 
under Cu
2+
/Cu
+
-catalysed oxidation conditions because Aβ(1-40)-HisOx forms 
amorphous aggregates, which do not bind Th-T, rather than amyloid fibres, which 
do. 
 
Attempted use of UV-CD to study Aβ(1-40) fibrillisation rates 
 
UV-CD was also used to analyse the effects of oxidation on Aβ(1-40) fibrillisation 
because this technique did not involve any growth indicators internal to the sample. 
However, due to the low peptide and salt concentrations, needed to prevent 
absorbance exceeding the machine’s dynamic range, the samples did not show fibril 
growth before precipitation of amorphous aggregates occurred (Snyder, S. W., et al., 
1994), apart from a slight shift to the β-sheet form of the Apo peptide. The oxidised 
samples took even longer to form β-sheets. 
 Therefore, the Th-T binding well-plate assay data was used exclusively to 
determine the effects of oxidation of Aβ(1-40) fibrillisation rates.  
 
4.4.3. Oxidation and Aβ oligomers 
 
SEC studies found that across two pHs, 7.4 and 10.5, unoxidised, fresh Aβ(1-40) 
exists in a monomeric form. Both oxidation by H2O2 alone and Cu
2+
/Cu
+
-catalysed 
oxidation were found not to generate detectable small oligomeric species of 
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Aβ(1-40). Only monomeric Aβ(1-40) was detected throughout a 17 h incubation with 
either of these conditions. 
 It should be noted that the range of the SEC column is only 3 – 70 kDa. 
Oligomers and fibres could be considerably larger, however, there is no evidence that 
larger species eluted in the void volume. Indeed, the intensity of the main Aβ 
(monomer) band remains constant throughout the incubation, suggesting appreciable 
amounts of oligomers/fibres were not formed under these conditions over 17 hour 
incubations.  
 
4.4.4. Conclusion 
 
In contrast to the literature this PhD study has found oxidation of Aβ(1-40) using 
H2O2 alone either increases or has little effect on fibrillisation rates. Any effect it 
appears to have is in increasing the nucleation phase rather than the elongation phase. 
These effects are likely mediated by the increased hydrogen-bond capacity and 
decreased hydrophobicity of methionine sulfoxide, which promote β-sheet formation 
and folding to bury the methionine sulfoxide residue respectively.  
These effects are highly biologically relevant as H2O2 concentrations increase 
1.3–fold in AD (Squitti, R., et al., 2006) and not surprisingly Met35 of Aβ extracted 
from plaques has been found to have a high sulfoxide content (Dong, J., et al., 2003). 
Therefore, if oxidation by H2O2 alone of Aβ is occurring in vivo it may be a 
significant factor in contributing to increased fibrillisation of the peptide in AD 
pathology. It is notable that H2O2 oxidation did not cause formation of the highly 
toxic oligomeric form of the peptide, Aβ*, which would have eluted on the SEC at 
56 kDa. Instead it seems that any extra fibrillisation is continuing to higher molecular 
weight forms of the peptide. 
In addition, Aβ plaques have been found to be the site of high concentrations 
of redox active metals (Huang, X., et al., 1999). These bind Aβ with a high affinity 
(Sarell, C. J., et al., 2009) and hence it is highly likely that Aβ is exposed to 
Cu
2+
/Cu
+
-catalysed oxidation as opposed to oxidation by H2O2 alone in the AD 
brain. The in vitro studies described above suggest that this oxidation leads to a 
propensity of Aβ(1-40) to form amorphous aggregates as opposed to the amyloid 
fibres which are associated with Aβ-induced toxicity. The mechanism by which 
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copper catalysed oxidation might promote amorphous aggregation of Aβ is not clear. 
However, the oxidised histidine ring system will become a stronger hydrogen-bond 
acceptor and consequently will be capable of forming hydrogen bonds with amides 
from the main chain, disrupting hydrogen-bond networks along the backbone 
required for the cross-beta structure in amyloid fibres. In addition, the charge of the 
peptide will be closer to neutral for Aβ containing 2-oxo-histidine as opposed to the 
unoxidised peptide, due to the much lower pKa of this oxidised residue compared to 
its native form. Consequently amorphous self-association will be favoured over 
amyloid formation. However, these experiments are performed at micromolar levels 
of Aβ and physiologically Aβ levels are considerably lower, around the nM mark. At 
this considerably lower concentration of Aβ fibrils may form over amorphous 
aggregates.  
In conclusion, oxidation by H2O2 alone leads to an increase in Aβ 
fibrillisation. In the environment of the AD brain, where disrupted metal homeostasis 
has led to increased concentrations of redox active metals (Bush, A. I., 2003), Aβ is 
more exposed to Cu
2+
/Cu
+
-catalysed oxidation, which may delay the toxicity-related 
fibrillisation that the peptide undergoes as described by the Amyloid Cascade 
Hypothesis. 
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Protein oxidation is a physiological process associated with age-related diseases 
(Adams, J. D. J., 1991, Coyle, J. T. and Puttfarcken, P., 1993). These diseases include 
Alzheimer’s Disease (Markesbery, W. R., 1997), with oxidation of the Amyloid beta 
(Aβ) peptide reported to occur (Dong, J., et al., 2003, Head, E., et al., 2001, Shearer, J. 
and Szalai, V. A., 2008). This is a peptide whose fibrillisation is a seminal event in the 
aetiology of the disease as described by the Amyloid Cascade Hypothesis (Hardy, J. A. 
and Higgins, G. A., 1992) (Figure 5.1).  
 Chapter 4 of this thesis presents evidence that oxidation of the Aβ peptide can 
alter these disease-related fibrillisation rates. Previous literature has focused on the 
effects of H2O2-only mediated oxidation, on Aβ fibrillisation kinetics. This oxidation 
method exclusively oxidises Met35 in the Aβ sequence (Hou, L., et al., 2004). These 
studies report that this oxidation causes a decrease in fibrillisation rates (Hou, L., et al., 
2002, Hou, L., et al., 2004, Johansson, A.-S., et al., 2007, Maiti, P., et al., 2010, 
Palmblad, M., et al., 2002, Watson, A. A., et al., 1998). Firstly, in contrast to the 
literature, this thesis presents evidence that H2O2-only mediated oxidation of Aβ(1-40) 
actually either increases or has little effect on fibrillisation rates (Figure 5.1). In the 
environment of the AD brain, where H2O2 concentrations increases 1.3-fold (Squitti, R., 
et al., 2006), this may therefore represent a trigger of increased Aβ fibrillisation in the 
disease. 
 Secondly, in the environment of the AD brain, where metal homeostasis is 
severely disrupted and redox-active metal ions such as Cu
2+
 and Fe
3+
 can reach 
concentrations of 340 µM – 400 µM and 1 mM respectively (Bush, A. I., 2003, Dong, 
J., et al., 2003, Lovell, M. A., et al., 1998), the more physiologically probable oxidation 
that the Aβ peptide is exposed to is metal catalysed oxidation (MCO), in particular 
Cu
2+
/Cu
+
-catalysed oxidation. Indeed, Aβ binds Cu2+ ions with a high affinity (Sarell, 
C. J., et al., 2009) and hence Aβ is likely exposed to this highly site-specific oxidation 
mechanism. The only previous study on the effects of this oxidation mechanism on Aβ 
is that by Dyrks et al. who found an increase in fibrillisation rates with MCO of Aβ 
(Dyrks, T., et al., 1992). However, this study used SDS-PAGE to measure Aβ 
aggregation rates, which does not distinguish between the disease-causing amyloid 
fibres of Aβ (Seilheimer, B., et al., 1997) and the relatively non-toxic amorphous 
aggregates of the peptide (Howlett, D. R., et al., 1995, Lorenzo, A. and Yankner, B. A., 
1994).  
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Figure 5.1: Summary of the role of oxidation in the Amyloid Cascade Hypothesis. Aβ(1-40) exposed to 
H2O2 mediated oxidation (green) exhibits faster on-pathway fibrillisation, which has been linked via the Aβ 
oligomer to neurodegeneration. Aβ(1-40) exposed to Cu2+/Cu+-catalysed oxidation (red) is diverted onto the 
non-toxic off-pathway amorphous aggregation pathway. The fibrillisation rate of native Aβ is shown in blue.  
 
Chapter 5 
Conclusion 
 
 
219 
 
This thesis presents the first study into the effects of MCO on Aβ fibrillisation using a 
technique that can detect the specific cross-β structure of the Aβ peptide; Th-T binding 
fluorescence well-plate assays. This study found that Aβ fibrillisation rates are 
decreased after Cu
2+
/Cu
+
-oxidation indicating that MCO of the Aβ peptide is likely 
promoting folding to the non-toxic amorphous form of the peptide rather than the toxic 
amyloid fibrillar form (Figure 5.1). Therefore, increasing oxidative stress in AD 
pathology may actually reduce toxicity of the Aβ peptide, although it is still likely to 
promote the disease state via other mechanisms such as DNA and RNA oxidation and 
further loss of metal homeostasis (Atwood, C. S., et al., 1999, Mecocci, P., et al., 1994, 
Nunomura, A., et al., 1999). 
MCO of the Aβ peptide targets both methionine and histidine residues (Inoue, 
K., et al., 2006, Nadal, R. C., et al., 2008, Schiewe, A. J., et al., 2004, Schoneich, C. 
and Williams, T. D., 2002). Oxidation of methionine, to methionine sulfoxide, differs 
from oxidation of histidine to its most common physiological form, 2-oxo-histidine 4 
(Schoneich, C. and Williams, T. D., 2002, Traore, D. A. K., et al., 2009), as the former 
is reversible. The methionine sulfoxide reductases can convert methionine sulfoxide 
back into the native methionine form (Schoneich, C., 2005) and this is a likely 
mechanism by which Aβ can act as a scavenger of toxic reactive oxygen species (ROS) 
(Nadal, R. C., et al., 2008). However, histidine oxidation of the Aβ peptide represents 
irreversible damage to the peptide. Therefore, to study how Aβ fibrillisation kinetics 
alter with increasing oxidative stress it is necessary to study the effects of histidine-only 
oxidation on the peptide. The whole-peptide oxidation methods used in Chapter 4 
cannot be applied to this study because histidine cannot be oxidised exclusively without 
oxidising other residues. Thus, this PhD project proposed to synthesise protected, 
enantiomerically pure, oxidised histidine and then incorporate this into the sequence for 
Aβ(1-42) (Figure 5.2) for further analysis of the effect of histidine specific oxidation on 
Aβ(1-42) structure and fibrillisation. 
 
 
 
 
Chapter 2 describes initial attempts to synthesise 2-oxo-histidine from L-histidine 
(Scheme 5.1). Synthesis from L-histidine has the advantages of the starting material 
being available as the pure L-enantiomer, thus preventing the need to induce chirality at 
DAEFRH-oxDSGYEVH-oxH-oxQKLVFFAEDVGSNKGAIIGLMVGGVVIA 
Figure 5.2: The location of oxidised histidines in solid-phase peptide synthesised Aβ(1-42)-His-ox.  
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a later stage, and the synthesis including few steps. The first attempted synthesis used a 
DMDO-mediated oxidation of mono-Boc protected L-histidine methyl ester 5a, which 
was reported in the literature to generate mono-Boc protected 2-oxo-L-histidine methyl 
ester 4a via a single oxygen transfer (Saladino, R., et al., 1999). However, this thesis 
reports that the products of this oxidation in fact incorporate whole DMDO molecules 
into their structure with isopropylidene groups as shown in structures 22 and 23, the 
latter being the formyl intermediate of the former (Scheme 5.1(A)). A second synthesis 
attempted to replicate literature synthesis of mono-Bz protected 2-oxo-L-histidine 4b 
(Meister Winter, G. E. and Butler, A., 1996, Uchida, K. and Kawakishi, S., 1986, 1989), 
however, as described in the literature (Lewisch, S. A. and Levine, R. L., 1995), yields 
were low and purification from the side products of oxidised ascorbate was challenging 
(Scheme 5.1(B)). A final attempted synthesis from L-histidine 5 used a two step 
synthesis, starting with a Bamberger cleavage of the imidazole ring (Scheme 5.1(C(i))) 
followed by a second step to close the ring with the addition of a carbonyl at C-2 
(Scheme 5.1(C(ii))). The benzoyl derivative of mono-Boc protected L-histidine methyl 
ester 28 was successfully synthesised as were two derivatives of the Bamberger product 
of L-histidine methyl ester; a methyl carbamate derivative 29 and a benzoyl derivative 
27. Ring closure was attempted on the diamidoethane 27 using triphosgene and diethyl 
carbonate but the former reagent led to only starting material being recovered and the 
latter to destruction of the amino acid functionality.  
Chapter 3 presented a synthesis of protected 2-oxo-histidine, starting from urea 
17 and tartaric acid 37. These were coupled together to form the known ring system 
4-carboxyimidazolin-2-one 49. This product was further derivatized to form 
4-formylimidazolin-2-one 38a, which was subsequently coupled to a phosphonate 39b 
using a Horner-Wadsworth-Emmons reaction to generate a dehydro-derivative of 
protected L-histidine 40a. Platinum-catalysed hydrogenation was then used to generate a 
protected form of 2-oxo-histidine (Scheme 5.2). However, at the end of this 
experimental work this product still required further work to ensure its suitability to 
solid-phase peptide synthesis; resolution of this racemate to an enantiomerically pure 
form, and re-protection using groups suitable to peptide synthesis. 
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Scheme 5.1: Summary of attempted syntheses of 2-oxo-histidine 4 from L-histidine. 
(A) DMDO-mediated oxidation of N(α)-Boc-His-OMe 5a.(B) Cu2+/Cu+-catalysed oxidation of 
N(α)-Bz-His-OH 5b. (C) (i) Bamberger cleavage of either N(α)-Boc-His-OMe 5a or  
His-OMe.2HCl 5c. (ii) Attempted ring closure of the benzoyl Bamberger product of L-histidine 27.  
 
 
Scheme 5.2: Summary of synthesis of 2-oxo-histidine 4 from urea 17 and tartaric acid 37. Urea 17 and 
tartaric acid 37 were coupled together to form 4-carboxyimidazolin-2-one 49. This was further derivatized to 
form 4-formylimidazolin-2-one 38a, which was coupled to phosphonate 39b using a Horner-Wadsworth-
Emmons reaction to generate a dehydro-derivative of protected 2-oxo-L-histidine 40a. Platinum-catalysed 
hydrogenation was then used to generate N(α)-Cbz, N(π),N(τ)-Bis(PMB)-2-oxo-His-OMe 4d.  
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Since thesis writing has begun, the Wyatt lab has generated 2-oxo-L-histidine using an 
adaptation of a synthesis of the racemate reported by Lam et al. (Lam, A. K. Y., et al., 
2010). This adaptation is shown in Scheme 5.3 and includes the use of the Bamberger 
cleavage to generate the initial diamine pentanoic acid 83b, thus avoiding several 
synthesis steps and ensuring only L-enantiomers are formed. Protection strategies are 
currently being investigated for this novel amino acid. Before its use in synthesising the 
Aβ peptide, this 2-oxo-histidine should be tested for its suitability to solid phase peptide 
synthesis by incorporating it into a short peptide sequence such as that for the tripeptide 
Thyrotropin Releasing Hormone (TRH) (Figure 5.3). This represents one of several 
future projects that can be extended from these syntheses of 2-oxo-histidine. 
In conclusion, this thesis has shown that oxidation of Aβ has a profound influence on its 
fibrillisation and that incorporation of a stable oxidised histidine into Aβ is a realisable 
goal. 
 
 
 
  
 
  
 
Scheme 5.3: Synthesis of 2-oxo-histidine 4 from L-histidine 5b.  
 
Figure 5.3: Thyrotropin Releasing Hormone (TRH).  
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6.1. General procedures 
 
31
P-NMR readings and some 
1
H-NMR readings were performed on a Jeol 
JNMEX270 Spectrometer (
1
H frequency 270 MHz, 
31
P frequency 109.33 MHz). 
13
C-NMR, DEPT-135, COSY, HSQC readings and the remaining 
1
H-NMR 
readings were performed on either a Bruker AV400 Spectrometer or a Bruker 
AMX400 Spectrometer (both 
1
H frequency 400 MHz, 
13
C frequency 100.65 MHz). 
All measurements are done at room temperature. 
31
P-NMR and 
13
C-NMR were run 
as proton decoupled. In each case spectra are reported as; δ (in ppm), the number of 
nuclei in a particular chemical environment (determined by integration), the 
multiplicity (s = singlet, d = doublet, dd = doublet of doublet, t= triplet, q = quartet, 
m = multiplet), coupling constants if appropriate and assignment.  
 
High-resolution mass spectrometry was performed at the EPSRC National Mass 
Spectrometry Service Centre using several ionisation techniques; positive 
electrospray (ESI), positive nano-electropray (NSI) and electron impact ionisation 
(EI). Reverse-phase-HPLC mass spectrometry was performed on an Agilent 1100 
Series LC-MS with SL Ion Trap MSD. 
 
ATR-IR was performed on a Bruker Tensor 37 spectrometer with a PIKE MIRacle 
ATR accessory. KBr-IR was performed on an FTIR-8300 spectrometer with 
samples dispersed in potassium bromide pellets. 
 
Melting points were recorded using either a Reichert hot stage microscope 
apparatus or using capillary tubes in a Gallenkamp melting point instrument. 
Measurements are uncorrected and reported in degrees celsius (°C). 
 
Thin layer chromatography (TLC) was performed on Merck silica gel 60F254 plates. 
Flash chromatography was conducted on either BDH silica gel (particle size 33-77 
μm) or Zeoprep silica (particle size 40-63 μm). 
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1M, pH 7.2 sodium phosphate buffer was made up of 28 ml of sodium 
dihydrogenphosphate (2M, 13.8 g in 50 ml) and 72 ml of disodium hydrogen 
phosphate (2 M, 28.4 g in 100 ml) in 100 ml ultra-high-quality (UHQ) water. UHQ 
water was purified using a Millipore Simpak 2 system and has >18 M.cm 
resistivity. 
 
Activated manganese(IV) oxide (~85%, 5μm) was obtained from Sigma Aldrich. 
Tosyl chloride was purified by dissolution in with DCM, addition of petrol, 
filtration to remove insoluble impurities and evaporation of the filtrate. MeOH was 
distilled over magnesium and iodine. DMF, Et2O and DCM were purified using a 
Solvent Purification System; M Braun MB SPS-800. THF was either dried using 
aforementioned solvent purification system or distilled under nitrogen with sodium 
metal and benzophenone. All other reagents were of reagent grade or better and 
used without further purification. 
 
6.2. Experimental data 
 
This thesis refers to the atoms of histidine as notated in Figure 6.1(A). However, 
the literature may label the atoms of histidine as denoted in Figure 6.1(B) as, 
historically, histidine atoms have been labelled differently depending on whether 
the context was organic chemistry (Figure 6.1 (A)) or biochemistry 
(Figure 6.1 (B)).  
N
NH
H2N
OH
O
N
NH
H2N
OH
O
(A) (B)
2 








4
5


 
 
 
 
 
 
Figure 6.1: Labelling histidine 5. In both cases, the nitrogen atoms are labelled based on their 
proximity to the side chain; pros (near) with π and tele (far) with τ. Older papers may denote these 
as 1 or 3 with the order of this depending on whether the papers were by organic chemists or 
biochemists. In both cases the amino acid backbone is labelled using greek letters. (A) Labelling of 
histidine as defined by IUPAC. The carbon atom next to the τ-nitrogen is labelled 5 and the carbon 
between the two nitrogens is labelled 2. (B) Labelling of histidine more typical of that in 
biochemistry papers. In this case the ring carbons are labelled as a continuation of the backbone 
carbons with Greek letters. The carbon closest to the π-nitrogen is labelled γ whereas the carbon 
between the two nitrogens is called the ε-carbon. 
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His-OMe·2HCl 5c 
 
 
 
 
 
Based on the method described by Dancer et al. (Dancer, J., et al., 1996), 
L-histidine hydrochloride 5e (25.0 g, 0.13 mol) was suspended in methanol (250 
ml). Thionyl chloride (20 ml, 0.28 mol) was added dropwise over 15 min. The 
mixture was refluxed for 6 h or until no solid remained. The mixture was 
concentrated in vacuo and ether was added to precipitate out the product. This was 
filtered off, washed with Et2O and dried in vacuo over sodium hydroxide pellets to 
yield His-OMe·2HCl 5c (14.5 g, 46 %) as a white powder; mp 204 - 205 °C dec 
(Lit. 205 – 206 °C dec (Hanford, B. O., et al., 1968), Lit. 200 – 201 °C (Davis, N. 
C., 1956)); [α]D + 17.9 (c 1.0 in methanol) (Lit. [α]D + 10.8 c 1.0 in water (Gerhard, 
G. and Schunack, W., 1980)); νmax(KBr)/cm
−1
 3000 (NH), 1763 (CO). 
 
N(α), N(τ)-DiBoc-His-OMe 5d 
 
 
 
 
 
N(α), N(τ)-DiBoc-His-OMe 5d was synthesised from His-OMe·2HCl (1) (9.68 g, 
40 mmol) and Boc2O (18.3 g, 84 mmol) using the method described by Brown et 
al. (Brown, T., et al., 1982) and was obtained as a white solid (10.7 g, 72 %); 
mp 107 - 108 °C (Lit. 105 - 107 °C (Xu, J. and Yadan, J. C., 1995)); [α]D + 28.8 
(c 1.0 in DCM) (Lit. [α]D + 23.3 c 1.0 in DCM (Xu, J. and Yadan, J. C., 1995)); 
νmax(ATR)/cm
−1
 3244 (NH),1739 (CO), 1702 (2 CO); δH(270 MHz; CDCl3) 1.41 (9 
H, s, CH3 (Boc)), 1.57 (9H, s, CH3 (Boc)), 2.99 (1 H, dd J 14.3 Hz and 4.9 Hz, β-
CHH), 3.03 (1 H, dd, J 14.3  Hz and 4.9 Hz, β-CHH), 3.70 (3 H, s, OCH3), 4.50 - 
4.59 (1 H, m, α-CH), 5.69 (1 H, d, J 6.3 Hz, br, α-NH), 7.11 (1 H, s, Im 5-H), 7.96 
HN
NH
H3N
O
OH
2Cl
N
NBoc
BocHN
O
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(1 H, d, J 1.2 Hz, Im 2-H); δC(400 MHz; CDCl3) 27.9 (3 CH3), 28.3 (3 CH3), 30.3 
(CH2), 52.3 (OCH3), 53.2 (CH), 79.8 (C), 85.6 (CH), 136.9 (C), 138.7 (CH), 146.9 
(CO), 155.5 (CO), 172.3 (CO).  
 
N(α)-Boc-His-OMe 5a 
 
 
 
 
Two methods were used: 
 
(A) Based on the method described by Dancer et al. (Dancer, J., et al., 1996), 
N(α), N(τ)-DiBoc-His-OMe 5d (1.00 g, 2.7 mmol) was suspended in anhydrous 
methanol (10 ml). Potassium carbonate (37 mg, 0.27 mmol) was added and the 
mixture was refluxed for 2 h. The mixture was then concentrated in vacuo. The 
resulting oil was partitioned between water and dichloromethane. The organic 
phase was dried over MgSO4 to yield N(α)-Boc-His-OMe 5a (400 mg, 55 %) as a 
viscous brown-yellow oil; [α]D  + 11.7 (c 1.0 in chloroform) (Lit. [α]D − 11.7 c 1.0 
in methanol (Hanford, B. O., et al., 1968)); νmax(KBr)/cm
−1 
3369 (NH), 1740 (CO), 
1701 (CO); δH(270 MHz; CDCl3) 1.41 (9 H, s, CH3 (Boc)), 2.98 – 3.17 (2 H, m, 
β-CH2), 3.70 (3 H, s, OCH3), 4.47 - 4.58 (1 H, m, α-CH), 5.71 - 5.84 (1 H, m, 
α-NH), 6.78 (1 H, s, Im 5-H), 7.52 (1 H, s, Im 2-H). δC (400 MHz; CDCl3) 28.3 (3 
CH3), 29.8 (CH2), 52.3 (OCH3), 53.6 (CH), 80.0 (C), 116.2 (CH), 134.0 (CH), 
135.2 (C), 155.61 (CO), 172.6 (CO). 
 
(B) Based on the method described by Brown et al. (Brown, T., et al., 1982), 
His-OMe·2HCl (5c) (12.3 g, 0.051 mol) was suspended in methanol (50 ml) and 
Boc2O (11.3 g, 0.052 mol) was added. The mixture was cooled to 0 °C (ice/salt 
bath). Triethylamine (14 ml, 0.10 moles) was added dropwise and the reaction was 
left stirring overnight at room temperature. The mixture was then concentrated in 
vacuo and extracted into ethyl acetate (50 ml). The organic extract was washed 
with citric acid (5 x 25 ml), neutralized with NaHCO3 and extracted into ethyl 
N
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acetate before dying over MgSO4 to yield N(α)-Boc-His-OMe 5a (1.58 g, 12 %) as 
a white glassy solid; mp 140.8 – 142.6 °C (Lit. 126.0 – 128.0 °C (Perfetti, R. B., et 
al., 1976)); νmax(KBr)/cm
−1 
3308 (NH), 3120 (NH), 1748 (CO), 1699 (CO); δH(270 
MHz; CDCl3) 1.41 (9 H, s, CH3 (Boc)), 3.01 – 3.13 (2 H, m, β-CH2), 3.69 (3 H, s, 
OCH3), 4.48 – 4.57 (1 H, m, α-CH), 5.58 – 5.69 (1 H, m, α-NH), 6.80 (1 H, s, Im 
5-H), 7.56 (1 H, s, Im 2-H). 
 
Dimethyldioxirane (DMDO) 21 solution in acetone 
 
 
 
Dimethyldioxirane 21 solution in acetone was prepared using the vacuum 
distillation method described by Adam et al. (Adam, W., et al., 1991). Sodium 
hydrogencarbonate (29.0 g, 0.35 mol) was dissolved in a mixture of water (127 ml) 
and acetone (96 ml) within the distillation flask and cooled to 0 °C (ice-salt bath). 
Oxone (60.0 g, 98 mmoles) was added in 5 portions over 15 min. The apparatus 
was evacuated to ca 15 mmHg using a water aspirator. The distillation flask was 
then gradually warmed to room temperature and the distillation started. Distillation 
was continued until the reactants stopped effervescing. The distillate (30 ml) was a 
solution of DMDO in acetone. The DMDO concentration of this was determined, 
by an iodine/thiosulfate back titration, to be 40 mM (1.7 % yield). The solution was 
stored over 4 Å molecular sieves at −20 °C for short periods. 
 
Oxidation of N(α)-Boc-His-OMe 5a by DMDO in acetone 
  
Based on the method used by Saladino et al. (Saladino, R., et al., 1999) to 
synthesise N(α)-Boc-2-oxo-His-OMe 4a, N(α)-Boc-His-OMe 5a (329 mg, 
1.2 mmol) was added to DMDO in acetone (40 mM, 30 ml, 1.2 mmol) and left to 
react under one of two possible reaction conditions; 12 h at r.t. (A) or 27 h at 2 °C 
(B). The mixtures were then concentrated and dried in vacuo over phosphorus 
pentoxide to yield a yellow, glassy solid. This was purified by flash 
O
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chromatography using EtOAc-petrol (50:50 to 75:25) followed by further 
chromatography using EtOAc-DCM (10:90) to yield two colourless oils: 
 
 
 
 
 
 
i) 2-Boc-amino-3-(2,2-dimethyl-5-oxo-2,5-dihydro-1H-imidazol-4-yl)propionic 
acid methyl ester 22 (7.4 mg, 2.0 %) (Rf 0.30 in 65 % EtOAc-DCM).  Produced 
under conditions (A) and (B). δH(400 MHz; CDCl3) 1.44 (9 H, s, CH3 (Boc)), 1.45 
(3 H, s, 2-CCH3), 1.46 (3 H, s, 2-CCH3), 3.00 (2 H, dd, 10.8 Hz and 2.7 Hz, β-CH), 
3.07 (2 H, dd, 10.8 Hz and 5.4 Hz, β-CH), 3.72 (3 H, s, OCH3), 4.71 – 4.79 (1 H, 
m, α-CH), 5.77 (1 H, br, d, J 5.5 Hz, α-NH), 7.65 (1 H, s, br, τ-NH); 
δC(100.65 MHz; CDCl3) 26.7 (H3CCCH3), 26.8 (H3CCCH3), 28.3 (3 CH3 (Boc)), 
30.8 (β-CH2), 51.1 (α-CH), 52.4 (OCH3), 80.0 (C), 81.9 (C), 155.4 (CO), 165.0 
(CO), 171.7 (CO). Assignments based on 1D spectra, DEPT-135, COSY and 
HSQC analysis; m/z (ESI) found: 314.1713 (M + H
+
) (C14H24N3O5 requires 
314.1710).  
 
 
 
 
 
ii) 2-Boc-amino-3-(2,2-dimethyl-5-oxo-2,5-dihydro-1H-imidazol-4-yl)-N(τ)-formyl 
-propionic acid methyl ester (1 mg, 0.25 %) (Rf 0.40 in 65 % EtOAc-DCM).  
Produced under condition (B). νmax(KBr)/cm
−1 
3369 (NH), 1750 (CO), 1706 (CO); 
δH(400 MHz; CDCl3) 1.43 (9 H, s, CH3 (Boc)), 1.61 (3 H, s, H3CCCH3), 1.62 (3 H, 
s, H3CCCH3), 2.98 (1 H, dd, J 10.4 Hz and 4.7 Hz, β-CHH), 3.04 (1 H, dd, J 10.5 
Hz and 3.4 Hz, β-CHH), 3.71 (3 H, s, OCH3), 4.70 – 4.79 (1 H, m, α-CH), 5.47 
(1 H, d, J 7.9 Hz, NH), 9.02 (1 H, s, CHO); δC(100.65 MHz; CDCl3) 24.6 
(H3CCCH3), 24.8 (H3CCCH3), 28.3 (3 CH3 (Boc)), 31.4 (β-CH2), 51.0 (α-CH), 
N
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52.7 (OCH3), 80.3 (C), 85.5 (C), 155.2 (C), 158.2 (HC), 162.6 (C), 163.5 (C), 
171.3 (C). Assignments based on 1D spectra, DEPT-135, COSY and HSQC 
analysis; m/z (ESI) found: 342.1663 (M + H
+
) (C15H24N3O6 requires 342.1660).  
 
N(α)-Bz-His-OH 5b 
 
 
 
 
 
 
L-Histidine hydrochloride monohydrate 5e (21.0 g, 0.10 mol) was dissolved in 
water (200 ml) and cooled to 0 °C. Benzoyl chloride (11.6 ml, 0.10 mol) and 
sodium bicarbonate (16.8 g, 0.20 mol) were added dropwise, concurrently. The 
mixture was then stirred at room temperature for 9 h. The solution was then 
acidified to pH 3.0 using HCl and the product precipitated. This was then air dried 
followed by re-crystallisation from methanol. A low melting point (< 190 °C) 
indicated the presence of impurities and so the product was then recrystallised from 
boiling ethanol, then methanol and diethyl ether to yield N(α)-Bz-His-OH (5b) 
(1.26 g, 5.0 %) as a yellow crystalline solid; mp 243 °C dec (Lit. 243 °C (Otani, T. 
T. and Briley, M. R., 1979)); νmax(ATR)/cm
−1
 3437 (NH), 3296 (NH), 1655 (CO), 
1630 (CO); δH(270 MHz; CDCl3) 3.00 – 3.09 (2 H, m, β-CH2), 5.56- 5.64 (1 H, m, 
α-CH), 6.86 (1 H, s, Im 5-H), 7.44 – 7.57 (3 H, m, CH (Bz), 7.59 (1 H, s, Im 2-H), 
7.79 – 7.68 (2 H, m, CH (Bz)), 8.73 (1 H, d, J 8.2 Hz, α-NH); δC(100.65 MHz; 
CDCl3) 28.4 (CH2), 52.8 (CH), 116.4 (CH), 127.2 (2 CH), 128.3 (2 CH), 131.3 (C), 
133.9 (C), 134.0 (C), 134.8 (C), 166.1 (CO), 173.0 (CO). 
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N(α)-Bz-2-oxo-His-OH 4b (within crude products) 
 
 
 
 
 
 
N(α)-Bz-His-OH 5b (200 mg, 0.73 mmol) was dissolved in sodium phosphate pH 
7.2 buffer (0.75 ml, pH 7.2) and ultra-high quality (UHQ) water (14.25 ml) to make 
a 50 mM solution of protected histidine. This solution was incubated for 26 h at r.t. 
with rapid mixing and the addition of aqueous ascorbic acid (17 ml, 50 mM) and 
aqueous copper(II) sulfate (15 ml, 0.5 mM). The pH of the solution was maintained 
by checking every 30 minutes for the first 6 h, adding small amounts of 1M NaOH 
and 2M HCl as necessary. A further 10 ml UHQ water was added at 21 h. Over the 
26 h incubation the solution changed from colourless to brown. At 26 h the solution 
was concentrated in vacuo to leave a yellow oil which was dried over phosphorus 
pentoxide. 
1
H-NMR showed evidence of peaks derived from ascorbate and thus 
further purification was attempted using a 8.0 ml Dowex AG 50W-X8, 60-140 
mesh H
+
 form ion exchange resin. The material exited the column within the first 
ten fractions with a water based eluant. In addition, reverse phase analytical HPLC 
was performed on an Agilent Series 1100 machine on a Lichrosphere RP select B 
column run with acetonitrile and water. However, the product was still deemed 
impure by 
1
H-NMR. All analyses are of the crude material;
 δH(270 MHz; DMSO) 
2.89 – 3.17 (2 H, m, β-CH2), 2.89 – 3.17 (1 H, m, α-CH), 3.48- 5.05 (>100 H, m, 
ascorbate and oxidized ascorbate), 6.29 (1 H, s, Im 5-H), 7.28-7.83 (5 H, m, CH 
(Bz)); m/z (RP-HPLC-MS, negative ion) found: 273.1 (16.5 %, N(α)-Bz-2-oxo-
histidine 4b – 2H+).  
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2,4,5-Tris(benzamido)pent-4-enoic acid methyl ester 27 
 
 
 
 
 
His-OMe·2HCl 5c (1.00 g, 4.13 mmol) was suspended in a mixture of ethyl acetate 
(26 ml) and water (17 ml) and cooled to 0 °C. Benzoyl chloride (4.8 ml, 
41.3 mmol) was added followed by aqueous sodium bicarbonate (6.5 g in 19.6 ml), 
each in three portions over a 45 min interval. The solution was then warmed to r.t. 
and left for 6.5 h. The product was then partitioned between water and ethyl acetate 
(2 x 15 ml). The combined organic extracts were dried over MgSO4. The EtOAc 
extract was concentrated in vacuo. The compound was then triturated with diethyl 
ether and the resulting residue recrystallised from methanol to yield 
2,4,5-Tris(benzamido)pent-4-enoic acid-methyl ester 27 (603 mg, 31 %) as a white 
powder; mp 212.0 – 213.1 °C (Lit. 213 - 215 °C (Trampota, M., 2009)); 
νmax(ATR)/cm
−1
 3315 (NH), 1743 (CO), 1674 (CO), 1640 (CO)1623 (CO); 
δH(270 MHz; CDCl3) 2.85 (1 H, dd, J 14.2 Hz and 10.1 Hz, β-CHH), 3.20 (1 H, dd, 
J 14.2 Hz and 4.7 Hz, CHH), 3.63 (3 H, s, OCH3), 4.71 (1 H, m, HNCHCO), 6.70 
(1 H, d, J 9.4 Hz, HNHC=C), 7.42- 7.62 (9 H, m, CH (Bz)), 7.79 – 7.95 (6 H, m, 
CH (Bz)), 8.75 (1 H, d, J 8.2 Hz, HNCHCO), 9.54 (1 H, s,), 9.80 (1 H, d, J 9.4 Hz, 
C=CHNH); δC (100.65  MHz, CDCl3) 38.6 (β-CH2), 51.5 (α-CH), 53.2 (OCH3), 
114.6 (C-4), 116.1 (HC-5), 127.2 (2 CH), 127.4 (2 CH), 127.7 (2 CH), 128.7 
(4 CH), 128.8 (2 CH), 132.0 (2 CH), 132.25 (CH), 132.31 (C), 132.9 (C), 133.4 
(C), 166.1 (2 CO), 167.8 (CO), 172.2 (CO); m/z (RP-HPLC-MS, -ve ion) found: 
470.1 (100 %, M - H
+
) (C27H26N3O5 requires 470.17).  
 
Bamberger reaction on N(α)-Boc-His-OMe 5a using BzCl 
 
N(α)-Boc-His-OMe 5a (500 mg, 1.9 mmol) was suspended in a mixture of ethyl 
acetate (26 ml) and water (17 ml) and cooled to 0 °C. Benzoyl chloride (2.2 ml, 
15.7 mmol) was added followed by aqueous sodium hydrogencarbonate (6.5 g) in 
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water (19.6 ml), each in three portions over a 45 min interval. The solution was 
then warmed to r.t. and left for 19.5 h. The product was then partitioned between 
water and ethyl acetate (2 x 15 ml) and extracted twice into the organic layer. This 
organic layer was dried over MgSO4. This was concentrated in vacuo and then 
purified twice by flash chromatography, both using EtOAc-petrol (10:90 to 30:70 
and 20:80 to 30:70) to yield two colourless oils: 
 
 
 
 
 
i) 4,5-Bis-benzamido-2-tert-butoxycarbonylamino-pent-4-enoic acid methyl ester 
28 (180 mg, 20 %) (Rf 0.17 in 40 % EtOAc-DCM); νmax(ATR)/cm
−1
 3264 (NH), 
1748 (CO), 1684 (CO), 1654 (CO), 1634 (CO); δH(400 MHz; CDCl3); 1.43 (9 H, s, 
CH3 (Boc)), 2.63 (1 H, dd, J 14.8 Hz and 5.7 Hz, CHH), 2.85 (1 H, dd, J 14.8 Hz 
and 5.7 Hz, CHH), 3.73 (3 H, s, OCH3), 4.46 – 4.58 (1 H, m, HNCHCO), 5.46 (1 
H, d, J 7.4 Hz, HNCHCO), 7.36 – 7.67 (7 H, m, CH (Bz) and C=CHNH), 7.87 -
 8.10 (4 H, m, CH (Bz)); δC(400 MHz; CDCl3) 28.2 (CH3), 38.6 (CH2), 52.6 
(OCH3), 52.9 (CH), 80.9 (C), 114.8 (CH), 115.9 (C), 127.4 (2 CH), 127.6 (2 CH), 
128.6 (2 CH), 128.7 (2 CH), 131.9 (CH), 132.2 (CH), 133.49 (C), 133.54 (C), 
155.8 (CO), 164.0 (CO), 166.0 (CO), 172.2 (CO); m/z (ESI) found: 468.2126 (M + 
H
+
) (C25H29N3O6 requires 468.2129). 
 
 
 
 
 
 
 
ii)5-Benzamido-4-(N-benzoyl, N-formylamino)-2-tert-(butoxycarbonylamino)pent-
4-enoic acid methyl ester 28a (30 mg, 3.2 %, Rf 0.30 in  40 % EtOAc-petrol); 
δH(400 MHz; CDCl3); 1.40 (3 H, s, CH3 (Boc)), 1.51 (6H, s, CH3 (Boc)), 2.85 (1 H, 
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dd, J 12.3 Hz and 7.4 Hz, CHH), 3.01 (1 H, dd, J 12.3 Hz and 6.4 Hz, CHH), 3.74 
(3 H, s, CO2CH3 (OMe)), 4.35 – 4.45 (1 H, m, HNCHCO), 6.65 (1 H, d, J 8.0 Hz, 
C=CHNH), 7.35 – 7.69 (10 H, m, CH (Bz)), 8.42 (1 H, s, br, HNCHCO), 9.17 
(1 H, s, HNCHO), 10.0 (1H, d, J 8.0 Hz, C=CHNH). 
 
2,4,5-Tris(methoxycarbonylamino)pent-4-enoic acid methyl ester 29  
 
 
 
 
 
 
His-OMe·2HCl 5c (500 mg, 2.1 mmol) was suspended in ethyl acetate (26 ml) and 
water (17 ml) and cooled to 0 °C (ice-salt bath). Methyl chloroformate (3.2 ml, 
41.4 mmol) was added followed by aqueous sodium bicarbonate (6.5 g in 19.6 ml), 
each in three portions over 45 min. The solution was then warmed to r.t. and left 
for 6.5 h.  The product was then partitioned between water and ethyl acetate 
(2 x 15 ml). The combined ethyl acetate extracts were dried over MgSO4, 
concentrated in vacuo, dried over phosphorus pentoxide and purified by flash 
chromatography using Et2O-DCM (10:90 to 50:50) to yield 
2,4,5-tris(methoxycarbonylamino)pent-4-enoic acid methyl ester 29 (220 mg, 31 
%) (Rf 0.21 in 50:50 Et2O-DCM) as a colourless oil; δH(400 MHz; CDCl3) 2.44 
(1 H, dd, J  14.1 Hz and 7.9 Hz, CHH), 2.68 (1 H, dd, J 14.6 Hz and 4.4 Hz, CHH), 
3.58 (3 H, s, OCH3 (OMe)), 3.67 (3 H, s, OCH3 (MeOCO)), 3.71 (3 H, s, CO2CH3 
(MeOCO)), 3.72 (3 H, s, CO2CH3 (MeOCO)), 4.37 – 4.48 (1 H, m, HNCHCO), 
5.67 (1 H, d, J 8.2 Hz, HNCHCO), 6.21 (1 H, d, J 8.7 Hz, HC=CNH), 6.62 (1 H, s, 
C=CHNH), 7.39 - 7.50 (1 H, m, C=CHNH). 
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4-carboxyimidazolin-2-one 49 
 
 
 
 
Using the procedure described by Baxter et al. (Baxter, R. L., et al., 1992), urea 17 
(65 g, 1.08 moles) and tartaric acid 37 (210 g, 1.40 moles) were ground together 
and added in small portions to stirring concentrated sulfuric acid (500 ml).  The 
mixture was heated to 80 °C for 1h. The mixture was then cooled to 10 °C, poured 
over crushed ice (5 kg) and left to stand until a precipitate formed. This precipitate 
was filtered off, washed with water and dried over KOH pellets to yield 
4-carboxyimidazolin-2-one 49 (34.1 g, 25 %) as a grey solid; mp 221 - 223 °C 
(Lit. 226 - 230 °C (Baxter, R. L., et al., 1992), 1992. Lit. 232 – 235 °C (Zav'yalov, 
S. I., et al., 2004); νmax(ATR)/cm
−1
 2972 (NH), 2820 (NH), 1741 (CO), 1647 (CO); 
δH (270 MHz, DMSO) 7.13 (1H, s, CH), 10.43 (1H, s, br, NH), 10.55 (1H, s, br, 
NH); δC (100.65 MHz, DMSO) 115.0 (CH), 118.2 (C), 154.4 (CO), 160.9 (CO). 
 
Imidazolin-2-one 36 
 
 
 
Using the procedure described by Baxter et al. (Baxter, R. L., et al., 1992), 
4-carboxyimidazolin-2-one 49 (16.7 g, 0.13 mol) was dissolved in aqueous 
potassium carbonate (17.9 g, 0.13 mol) and refluxed for 4 h. Charcoal (6.2 g) was 
added to the reaction mixture and this was refluxed for 30 min. The hot solution 
was filtered and concentrated in vacuo. The product was washed with ether (25 ml) 
and acetone (19 ml) to yield imidazolin-2-one 36 (8.6 g, 79 %) as a white solid; 
mp 216 – 220 °C (Lit. 238 – 240 °C (Baxter, R. L., et al., 1992)); νmax(ATR)/cm
−1
 
3024 (NH), 1631 (CO); δH (270 MHz; CDCl3) 6.24 (2 H, s, CH), 9.79 (2 H, s, br, 
NH); δC (100.65 MHz; CDCl3) 108.9 (2 CH), 155.4 (CO). 
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 4-Methoxycarbonylimidazolin-2-one 52 
 
 
 
 
 
Using the procedure briefly described by Dransfield et al. (Dransfield, P. J., et al., 
2006), 4-carboxyimidazolin-2-one 49 (3 g, 23.4 mmol) was suspended in MeOH 
(60 ml). Thionyl chloride (6 ml, 82.6 mmol) was added slowly and the mixture was 
refluxed for 4 h. The mixture was concentrated in vacuo and dried over phosphorus 
pentoxide. The residue was recrystallised from MeOH to yield  
4-methoxycarbonylimidazolin-2-one 52 (2.66 g, 80 %) as a grey powder; mp 
284 - 286 °C dec (Lit. 280 °C (Stanovnik, B., et al., 1979));  νmax(ATR)/cm
−1
 3144 
(NH), 3013 (NH), 1728 (CO), 1670 (CO); δH (270 MHz; DMSO) 3.70 (s, 3H, 
OCH3),  7.26 (s, 1H, CH), 10.60 (s, br, 1H, NH), 10.68 (s, br, 1H, NH); 
δC(400 MHz; DMSO) 51.7 (CH3), 113.5 (CH), 118.6 (C), 153.9 (CO), 159.5 (CO). 
 
1,3-Bis(PMB)-4-methoxycarbonylimidazolin-2-one 52a 
 
 
 
 
 
Sodium hydride (60% dispersion in mineral oil, 942 mg, 19.0 mmol) was washed 
with petroleum  ether. The washed NaH was suspended in anhydrous DMF (28.5 
ml). 4-Methoxycarbonylimidazolin-2-one 52 (1.12 g, 7.85 mmol) was added. The 
mixture was stirred under nitrogen for 30 min, by which time a viscous gel had 
formed. 4-Methoxybenzyl chloride (3.69 g, 19.0 mmol) was added slowly to the 
mixture and this was left stirring at r.t. under nitrogen for 20 h until the mixture had 
become a non-viscous liquid again. The mixture was diluted with Et2O (200 ml), 
then washed twice with brine, dried with magnesium sulfate and concentrated in 
vacuo to yield a brown oil. This was purified by flash chromatography using 
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EtOAc-petrol (30:70 to 40:60) to yield a yellow oil (Rf 0.14 in 20% EtOAc in 
petrol). This was recrystallised from a mixture Et2O and n-hexane to yield 
1,3-bis(PMB)-4-methoxycarbonylimidazolin-2-one 52a as fine white crystals 
(718 mg, 21%); mp 98.7 – 99.0 °C; IR (ATR) νmax(ATR)/cm
−1 
 1724 (CO), 1676 
(CO); δH (270 MHz, CDCl3) 3.70 (3 H, s, OCH3), 3.76 (3 H, s, OCH3), 3.79 (3 H, s, 
OCH3), 4.76 (2H, s, CH2  (PMB)), 5.16 (2H, s, CH2 (PMB)), 6.91-6.78 (4 H, m, 
ArH), 6.89 (1 H, s, CH), 7.19 (2 H, d, J 8.7 Hz, ArH), 7.32 (2 H, d, J  8.6 Hz, 
ArH); δC (100.65  MHz, CDCl3) 45.1 (CH2 (PMB)), 47.2 (CH2 (PMB)), 51.4 
(OCH3), 55.2 (OCH3), 55.3 (OCH3), 113.4 (CH (Ar)), 114.0 (2 CH (Ar)), 114.4 
(CH (Ar)), 120.1 (CH (Ar)), 127.2 (CH (Ar)), 129.5 (CH (Ar)), 129.6 (2 CH (Ar)), 
130.2 (C)), 153.4 (C (Ar)), 158.9 (C (Ar)), 159.6 (CO), 159.7 (CO); m.p 98.7 - 99.0 
°C; m/z (ESI) found: 383.1602 (M + H
+
) (C21H23N2O5 requires 383.1601).  
 
1,3-Bis(PMB)-4(hydroxymethyl)imidazolin-2-one 53a  
 
 
 
 
 
1,3-bis(PMB)-4-methoxycarbonylimidazolin-2-one 52a (1.00 g, 2.61 mmol) was 
suspended in anhydrous DCM (19 ml) and cooled to − 78 °C (EtOAc/ice bath) 
under a nitrogen atmosphere. DIBAL-H (7.8 ml, 7.84 mmol in heptane) was added 
to the mixture and it was stirred at − 78 °C for 3 h 15 min. MeOH (4.8 ml) was 
added to quench the reaction. The mixture was allowed to warm to room 
temperature and then diluted with 2M HCl. The product was partitioned between 
DCM and water. The aqueous phase was extracted and three further times with 
DCM. The combined organic extracts were washed twice with brine. The organic 
phase was dried with sodium sulfate and concentrated in vacuo to yield 
1,3-bis(PMB)-4-hydroxyimidazolin-2-one as a yellow oil. This was recrystallised 
from EtOAc and n-hexane to yield 
1,3-bis(PMB)-4-(hydroxymethyl)imidazolin-2-one 53a (850 mg, 92 %) as white 
crystals; m.p. 142.0 - 143.5 °C, νmax(ATR)/cm
−1
 3270 (OH), 2930 (CH2), 1656 
(PMB)N
N(PMB)
O
OH
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(CO); δH (270 MHz, CDCl3) 3.76 (3 H, s, OCH3), 3.78 (3 H, s, OCH3), 4.20 (2 H, 
d, J 5.9 Hz, HOCH2), 4.71 (2 H, s, CH2), 4.90 (2 H, s, CH2), 6.04 (1 H, s, CH), 
6.78-6.90 (4 H, m, ArH (PMB)), 7.15-7.28 (4 H, m, ArH (PMB)); δC (100.65 MHz, 
CDCl3) 44.5 (CH2), 46.7 (CH2), 55.4 (2 OCH3), 108.9 (CH2), 114.2 (CH), 114.3 
(CH), 122.4 (CH), 128.8 (CH), 128.9 (CH), 129.6 (2 C), 129.9 (C), 153.8 (C) , 
159.1 (C), 159.3 (CO); m/z (ESI) found: 355.1654 (C20H23N2O4 (M + H
+
)  requires 
355.1652).  
 
1,3-Bis(PMB)- 4-formylimidazolin-2-one 38a 
 
 
 
 
 
1,3-bis(PMB)-4(hydroxymethyl)imidazolin-2-one 53a (920 mg, 2.60 mmol) was 
dissolved in anhydrous DCM (101 ml) under a nitrogen atmosphere. Activated 
manganese(IV) oxide (2.34 g, 26.9 mmol) was added. The mixture was stirred for 
36 h and then filtered through celite with DCM washes. The filtrate was then 
concentrated in vacuo to yield a brown oil. The crude mixture was purified by flash 
chromatography using EtOAc-petrol (40:60) to yield 
1,3-bis(PMB)-4-formylimidazolin-2-one 38a (670 mg, 73 %) as a yellow oil 
(Rf 0.47 in 60% EtOAc:petrol); IR (ATR) νmax(ATR)/cm
−1 
 1703 (CO), 1653 (CO);  
δH (270 MHz, CDCl3) 3.75 (3 H, s, OCH3), 3.78 (3 H, s, OCH3), 4.78 (2 H, s, CH2), 
5.15 (2H, s, CH2), 6.94-6.77 (4 H, m, ArH), 6.89 (1 H, s, CH), 7.32 (2 H, d, 
J 8.6 Hz, ArH), 7.38 (2 H, d J 8.9 Hz, ArH), 9.12 (1H, s, CHO); δC (100.65 MHz, 
CDCl3) 45.5 (CH2), 47.5 (CH2), 55.3 (CH3), 55.4 (CH3), 113.9 (CH), 114.6 (2 CH), 
123.1 (2 CH), 127.4 (2 CH), 129.9 (2 CH), 130.0 (C), 153.3 (C), 159.2 (2 C), 159.9 
(2 C), 176.8 (CO); m/z (ESI) found: 353.1499 (M + H
+
) (C20H21N2O4 requires 
353.1496). 
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N(α)-Cbz, N(π),N(τ)-Bis(PMB), α,β-dehydro-4,5-dihydro-2-oxo-His-OMe 40a 
 
 
 
 
 
 
1,3-Bis(PMB)-4-formylimidazolin-2-one 38a (580 mg, 1.65 mmol) and 
(±)-benzyloxycarbonyl-α-phosphonoglycine trimethyl ester 39b (707 mg, 
2.13 mmol) were suspended in anhydrous DCM (25 ml) under a nitrogen 
atmosphere. 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU) (0.32 ml, 2.13 mmol) was 
added slowly to the reaction mixture. This was left stirring for 4.5 h. The mixture 
was concentrated in vacuo to a give a yellow oil. Flash chromatography with 
EtOAc-DCM (20:80 to 100:0) yielded 
N(α)-Cbz, N(π),N(τ)-bis(PMB)-α,β-dehydro-oxo-His-OMe 40a (840 mg, 91 %) as 
a yellow powdery solid (Rf 0.17 in 20% EtOAc-DCM); mp. 53.0 - 54.5°C; 
νmax(ATR)/cm
−1 
3252 (NH), 1725 (CO), 1682 (CO), 1632 (CO); δH (270 MHz, 
CDCl3) 3.71 (3 H, s, OCH3), 3.76 (3 H, s, OCH3), 3.78 (3 H, s, OCH3), 4.70 (2 H, 
s, CH2 (PMB)), 4.88 (2 H, s, CH2 (PMB)), 5.04 (s, 2H, CH2 (Cbz)), 5.93 (1 H, s, br, 
NH), 6.49 (1 H, s, br, Im 5-H), 6.83 (4 H, d, J 7.9 Hz, ArH), 7.40-7.06 (9 H, m, 
ArH); δC (100.65 MHz, DMSO) 44.3 (CH2 (PMB)), 47.1 (CH2 (PMB)), 52.9 
(OCH3), 55.3 (2 OCH3), 67.6 (CH2 (Cbz)), 114.3 (2 CH (Ar)), 114.3 (2 CH (Ar)), 
116.3 (HC-5), 117.6 (C (Ar)), 119.5 (β-CH), 121.0 (α-C), 128.2 (C (Ar)), 128.3 (2 
CH (Ar)), 128.4 (2 CH (Ar)), 128.6 (2 CH (Ar)), 128.6 (2 CH (Ar)), 128.9 
(C (Ar)), 129.4 (CH (Ar)), 152.6 (C (Ar)), 153.9 (C (Ar)), 159.2 (C (Ar)), 159.4 
(CO), 165.0 (CO). Assignments based on 1D spectra, DEPT-135, COSY and 
HSQC analysis; m/z (EI) found: 558.2228 (M + H
+
) (C31H32N3O7 requires 
558.2235). 
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Hydrogenation of 
N(α)-Cbz, N(π),N(τ)-Bis(PMB), α,β-dehydro-4,5-dihydro-2-oxo-His-OMe 40a 
 
The dehydro-derivative 40a (340 mg, 0.609 mmol) and Adam’s catalyst (PtO2) 
(42.5 mg, 0.241 mmol) were suspended in methanol (42.5 ml) in a two-necked 
flask and stirred. The flask was evacuated via a three way tap and then connected to 
a hydrogen balloon (1 atm) for 4.5 h at r.t.. The mixture was then filtered through 
celite and concentrated in vacuo to yield a brown oil. This was purified by flash 
chromatography using EtOAc-DCM (10:90 to 30:70) to yield three colourless oils: 
 
 
 
 
 
 
i) N(α)-Cbz, N(π), N(τ)-Bis(PMB)-2-oxo-His-OMe 4d (140 mg, 38 %) (Rf 0.18 in 
1:4 EtOAc-DCM);  mp 110.5 – 111.5 °C; νmax(ATR)/cm
−1
 3179 (NH), 1739 (CO), 
1713 (CO), 1655 (CO); δH(400 MHz; CDCl3) 2.58 (1 H, dd, J 15.5 Hz and 6.3 Hz, 
β-CHH), 2.69 (1 H, dd, J 15.5 Hz and 5.2 Hz, β-CHH),  3.51 (3 H, s, OCH3), 3.67 
(3 H, s, OCH3), 3.68 (3 H, s, OCH3), 4.27-4.38 (1 H, m, α-CH), 4.59-4.62 (3 H, m, 
1.5 CH2 (PMB)), 4.77 (1H, d, J 16.0 Hz, CHH (PMB)), 4.98 (2 H, s, CH2 (Cbz)), 
5.26-5.34 (1 H, m, α-NH), 5.79 (1 H, s, Im 5-H), 6.73 (2 H, d, J 8.7 Hz, 2 ArH 
(PMB)), 6.76 (2 H, d, J 8.7 Hz, 2 ArH  (PMB)), 7.04 (2 H, d, J 8.3 Hz, 2 ArH 
(PMB)), 7.08 (2 H, d, J 8.3 Hz, 2 ArH (PMB)), 7.22-7.28 (5 H, m, 5 ArH (Cbz)); 
δC(100.65 MHz; CDCl3) 28.1 (β-CH2), 44.2 (CH2 (PMB)), 46.6 (CH2 (PMB)), 52.4 
(α-CH), 52.9 (OCH3), 55.25 (OCH3), 55.27 (OCH3),  67.2 (CH2 (Cbz)), 108.2 
(HC-5), 114.1 (2 CH (Ar)), 117.8 (C-4), 128.1 (2 CH (Ar)), 128.3 (2 CH (Ar)), 
128.4 (2 CH (Ar)), 128.6 (2 CH (Ar)), 129.1 (C (Ar)), 129.3 (2 CH (Ar)), 129.5 
(C (Ar)), 136.1 (C (Ar)), 153.6 (C (Ar)), 155.6 (C (Ar)), 159.0 (CO), 159.2 (CO), 
171.5 (CO). Assignments based on 1D spectra, DEPT-135, COSY and HSQC 
analysis; m/z (ESI) found: 560.2383 (M + H
+
) (C31H34N3O7 requires 560.2391). 
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ii) N(α)-Cbz, N(π), N(τ)-Bis(PMB)-α,β-dehydro-4,5-dihydro-2-oxo-His-OMe 60 
(100 mg, 21 %) (Rf 0.74 in 20 % EtOAc-DCM); mp 100 -104 °C; νmax(ATR)/cm
−1
 
3208 (NH), 1740 (CO), 1716 (CO), 1664 (CO); δH(400 MHz; CDCl3) 2.86 – 2.93 
(1 H, m, Im 5-HH), 3.33 – 3.44 (1 H, m, Im 5-HH), 3.67 (3 H, s, OCH3), 3.67 (3 H, 
s, OCH3), 3.72 (3 H, s, OCH3), 3.93 (1 H, d, J 14.8 Hz, CHH (PMB)), 4.06 (1 H, 
ddd, J  9.6 Hz, 6.8 Hz and 6.8 Hz, Im 4-H), 4.19 (1 H, d, J  14.8 Hz, CHH (PMB)), 
4.33 (1 H, d, J  14.4 Hz, CHH (PMB)), 4.44 (1 H, d, J  14.8 Hz, CHH (PMB)), 4.99 
(2 H, s, CH2 (Cbz)), 6.13 (1 H, d, J 9.6 Hz, β-CH), 6.27 (1 H, s br, α-NH), 6.72 
(2 H, d, J 6.8 Hz, 2 ArH (PMB)), 6.78 (2 H, d, J 8.8 Hz, 2 ArH (PMB)), 7.05 (2 H, 
d, J 8.4 Hz, 2 ArH (PMB)), 7.12 (2 H, d, J 8.4 Hz, 2 ArH (PMB)), 7.20-7.31 (5 H, 
m, 5 ArH (Cbz)); δC(100.65 MHz; CDCl3, TMS) 46.3 (H2C-5), 46.8 (CH2 (PMB)), 
47.6  (CH2(PMB)), 51.1 (HC-4), 52.8 (OCH3), 55.2 (OCH3), 55.3(OCH3), 67.7 
(CH2(Cbz)), 113.8 (2 CH (Ar)), 114.0 (2CH (Ar)), 128.1 (2 CH (Ar)), 128.5 (2 CH 
(Ar)), 128.6 (2 CH (Ar)), 129.0 (2 C (Ar)), 129.3 (2 C (Ar)), 129.7 (2 CH (Ar)), 
130.0 (2 CH (Ar)), 130.2 (β-CH), 135.5 (C (Ar)), 154.3 (CO), 159.0 (2 C (Ar)), 
160.2(CO), 164.3 (CO). Assignments based on 1D spectra, DEPT-135, COSY and 
HSQC analysis; m/z (ESI) found: 560.2392 (M + H
+
) (C31H34N3O7 requires 
560.2391).  
N(PMB)
(PMB)N
O
H
(Cbz)HN
OMe
O
H
 
iii) N(α)-Cbz, N(π), N(τ)-Bis(PMB)-4,5-dihydro-2-oxo-His-OMe 61 (150 mg, 
41 %, Rf 0.54 in 20 % EtOAc-DCM); 45:55 mixture of two diastereomers; 
mp 100.0 - 104.0 °C; νmax(ATR)/cm
−1 
3150 (NH), 1738 (CO), 1714 (CO), 1690 
N(PMB)
(PMB)N
O
(Cbz)HN
OMe
O
 
Chapter 6 
Experimental (for chapters 2 and 3) 
 
 
 
242 
 
(CO); δH(400 MHz; CDCl3); 1.59 (1 H, ddd, J 13.6  Hz, 7.6 Hz, 2.8 Hz, β-CHH), 
2.20 (1 H, ddd, J 13.6 Hz, 6.8 Hz, 2.4 Hz, β-CHH), 2.74 (1 H, dd, J 8.4 Hz, 8.4 Hz, 
Im 5-HH), 3.14 (1H, dd, J 8.4 Hz and 8.4 Hz, Im 5-HH), 3.23-3.34 (1H, m, 
Im 4-H), 3.69 (3 H, s, OCH3), 3.72 (3 H, s, OCH3), 3.73 (3 H, s, OCH3), 3.85 (1 H, 
d, J  9.2 Hz, CHH (PMB)), 3.89 (1 H, d, J 9.2  Hz, CHH (PMB)), 4.12-4.20 (1 H, 
m, α-CH), 4.65 (2H, s, CH2 (PMB)), 5.00 (2 H, s, CH2 (Cbz)), 6.73 – 6.83 (4H, m, 
4 ArH (PMB)), 7.07 – 7.15 (4H, m, 4 ArH (PMB)), 7.24 - 7.31 (5 H, m, 5 ArH 
(Cbz)); δC(100.65 MHz; CDCl3); 45.2 (CH2 (PMB)), 45.4 (CH2 (PMB)), 47.5 
(H2C-5),  49.8 (HC-4), 51.3 (α-CH), 52.6 (OCH3), 52.8 (OCH3), 53.5 (β-CH2), 55.3 
(OCH3),  67.2 (CH2 (Cbz)) 114.0 (CH (Ar)), 128.1 (2 CH (Ar)), 128.2 (2 CH (Ar)), 
128.4 (2 CH (Ar)), 128.6 (2 CH (Ar)), 129.0 (4 C (Ar)), 129.5 (2 CH (Ar)), 129.6 
(2 CH (Ar)), 159.0 (C (Ar)), 160.5 (CO), 171.2 (CO), 172.1 (CO). Assignments 
based on 1D spectra, DEPT-135, COSY and HSQC analysis; m/z (ESI) found: 
562.2547 (M + H
+
) (C31H36N3O7 requires 562.2548). 
 
Attempted mesylation/tosylation of 1,3-Bis(PMB)-4-
(hydroxymethyl)imidazolin-2-one 53a: formation of 1, 3-bis(PMB)-5-
methylimidazolidin-2,4-dione 74a 
 
 
 
 
 
This dione was produced by two similar methods which both aimed to activate the 
alcohol of 1,3-bis(PMB)-4-(hydroxymethyl)imidazolin-2-one 53a: 
 
(A) 1,3-Bis(PMB)-4-(hydroxymethyl)imidazolin-2-one 53a (110 mg, 0.268 mmol) 
was dissolved in anhydrous DCM (2 ml) and placed under a nitrogen atmosphere. 
The mixture was cooled to 0 °C and triethylamine (87.7 μl, 0.630 mmol) was 
added. Mesyl chloride (40.3 μl, 0.521 mmol) was added and the mixture was left 
for 120 h. The product was then partitioned between DCM and 2M HCl and 
extracted into the organic layer. The aqueous layer was washed twice with DCM 
(PMB)N
N(PMB)
O
O
Me
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and these washings were added to the final organic layer. The combined organic 
extracts were dried with MgSO4 and concentrated in vacuo to yield a brown oil. 
This was purified using flash chromatography with EtOAc-petrol (30:70 to 50:50) 
to yield 1,3-bis(PMB)-5-methylimidazolidin-2,4-dione 74a (24 mg, 25 %) as a 
yellow oil (Rf 0.31 in 3:1 EtOAc-petrol); δH (400 MHz, CDCl3) 1.30 (3 H, d, 
J 7 Hz, CH3CH), 3.70 (1 H, q, J 8.7 Hz, CH3H), 3.77 (6 H, s, 2 OCH3), 4.47 (2 H, 
d, J 14.3 Hz, CHH (PMB)), 4.59 (2 H, d, J 14.3 Hz, CHH (PMB)), 6.83 (4 H, d, 
J 8.6 Hz, ArH), 7.15 (2 H, d, J 8.6 Hz, ArH), 7.34 (2 H, d, J 8.6 Hz, ArH); m/z 
(ESI) found: 355.1656 (M + H
+
) (C20H23N2O4 requires 355.1652). 
 
(B) Sodium hydride (60% dispersion in mineral oil; 17.6 mg, 0.732 mmol) was 
washed with petroleum spirit. The washed NaH was suspended in anhydrous Et2O 
(14 ml) under a nitrogen atmosphere and 1,3-bis(PMB)-4-
(hydroxymethyl)imidazolin-2-one 53a (150 mg, 0.365 mmol) was added. Tosyl 
chloride (83.7 mg, 0.439 mmol), which was purified first by washing with DCM 
and petrol and removing any precipitates of toluenesulfonic acid, was added and 
the mixture was left for 36 h. 
1
H-NMR showed only starting material so more tosyl 
chloride (83.7 mg, 0.439 mmol) and a different base, pyridine (34.7 mg, 0.439 
mmol) was added and the mixture was left stirring at r.t. for 24 h. The product was 
then partitioned between DCM and 2M HCl and extracted into the organic layer. 
The aqueous layer was washed twice with DCM and these washings were added to 
the final organic layer. This organic layer was dried with MgSO4 and concentrated 
in vacuo to yield a brown oil. This was purified using flash chromatography with 
EtOAc-petrol (20:80 to 40:60) to yield 
1,3-bis(PMB)-5-methylimidazolidin-2,4-dione (74a) (70 mg, 54 %) as a yellow oil 
(Rf 0.12 in 40:60 EtOAc-petrol); IR (ATR) νmax(ATR)/cm
−1 
 2936 (NH), 2838 
(NH), 1768 (CO), 1704 (CO); δH (400 MHz, CDCl3) 1.24 (3 H, d, J 9.4 Hz, 
CH3CH), 3.66 (1 H, q, J 9.4 Hz, CH3CH), 3.70 (6 H, s, 2 OCH3), 3.99 (2 H, d, 
J 10.1 Hz, CHH (PMB)), 4.49 (2 H, d, J 9.4 Hz, CHH (PMB)), 4.56 (2 H, d, 
J 9.5 Hz, CHH (PMB)), 4.81 (2 H, d, J 10.3 Hz, CHH (PMB)), 6.75 – 6.78 (4 H, m, 
ArH), 7.08 (2 H, d, J 8.6 Hz, ArH), 7.27 (2 H, d, J 8.6 Hz, ArH); δC (100.65 MHz, 
CDCl3)  15.1 (CH3CH), 42.0 (CH2 (PMB)), 44.0 (CH2 (PMB)), 54.7 (CHCH3), 
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55.26 (OCH3), 55.30 (OCH3), 114.0 (2 CH (Ar)), 114.3 (2 CH (Ar)), 128.5 
(C (Ar)), 129.5 (2 CH (Ar)), 129.7 (C (Ar)), 130.1 (2 CH (Ar)), 156.1 (CO), 159.3 
(C (Ar)), 159.4 (C (Ar)), 173.4 (CO). Assignments based on 1D spectra, 
DEPT-135, COSY and HSQC analysis. 
 
N-(Benzyloxycarbonyl)-α-hydroxyglycine 57 
 
 
 
The title compound was synthesised from benzyl carbamate 55 (6.4 g, 42.3 mmol) 
and glyoxylic acid monohydrate 56 (4.3 g, 46.7 mmol) using the procedure 
described by Williams et al. (Williams, R. M., et al., 1990) and obtained as a white 
powder (7.97 g,  84 %); mp 194.3 °C dec. (Lit. 196 – 198 °C dec. (Zoller, U. and 
Ben-Ishai, D., 1975)); νmax(ATR)/cm
−1
 3328 (NH), 1724 (CO), 1699 (CO); 
δH(270 MHz, CDCl3) 3.40 (1 H, s br, OH), 5.05 (2 H, s, CH2), 5.22 (1 H, d, 
J 8.9 Hz, CH), 7.43-7.28 (5 H, m, ArH), 8.12 (1 H, d br, J 8.6 Hz, NH). 
 
Ethyl N-(benzyloxycarbonyl)-α-ethoxyglycinate 58 
 
 
 
 
Using the method described by Williams et al..(Williams, R. M., et al., 1990) to 
synthesise ethyl N-(benzyloxycarbonyl)-α-methoxyglycinate but using ethanol (100 
ml) in place of methanol, with N-(benzyloxycarbonyl)-α-hydroxyglycine 57 (6.00 
g, 26.6 mmol) and concentrated sulfuric acid (1 ml), 
ethyl N-benzyloxycarbonyl-α-ethoxyglycinate 58 (7.43 g, 86 %) was obtained as a 
white powder; mp 69 - 70 °C (Lit. 71 – 72 °C (Kawai, M., et al., 1996)); δH 
(270 MHz, CDCl3) 1.21 (3 H, t, J 6.9 Hz, HCOCH2CH3), 1.29 (3 H, t, J 7.2 Hz, 
OCOCH2CH3), 3.60-3.80 (2 H, m, HCOCH2CH3), 4.22 (2 H, q, J 7.2 Hz, 
OCOCH2CH3), 5.12 (2 H, s, ArCH2), 5.38 (1 H, d, J 9.4 Hz, CH), 5.94 (1 H, d, 
J 9.4 Hz, NH), 7.40-7.26 (5 H, m, ArH). 
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 Ethyl N-(benzyloxycarbonyl)-α-diethoxyphosphinylglycinate 39a  
 
 
 
 
The title compound was prepared by analogy with the method described by 
Coleman and Carpenter (Coleman, R. S. and Carpenter, A. J., 1993) for making 
methyl N-(benzyloxycarbonyl)-α-dimethoxyphosphinylglycinate, but using ethyl 
esters. Thus reaction of phosphorus trichloride (1.97 ml, 5.79 mmol) and 
N-(benzyloxycarbonyl)-α-ethoxyglycinate 58 (2.00 g, 5.79 mmol) followed by 
addition of triethyl phosphite (1.46 ml, 5.79 mmol) gave ethyl 
N-(benzyloxycarbonyl)-α-diethoxyphosphinylglycinate 39a (2.27 g, 92 %) as a 
colourless oil; δH (270 MHz, CDCl3) 1.01-1.04 (9 H, m, 3 OCH2CH3), 4.01-4.18 
(4 H, m, 2 POCH2CH3),  4.24 (2 H, q, J  7.2 Hz, COCH2CH3), 4.85 (1 H, d, 
J 9.4 Hz, PCH), 5.06 (1 H, d, J 12.1 Hz, ArCHH), 5.13 (1 H, d, J 12.1 Hz, ArCHH) 
5.64 (1 H, d,  J 9.4 Hz, NH), 7.33-7.25 (5 H, m, ArH); δP (109.3 MHz, CDCl3) 16.5 
(PO(OEt)2), 7.9 (O=PH.(OEt)2 impurity, 17.6% peak intensity of δ 16.5 peak). 
 
Methyl N-(acetyl)-α-dimethyoxyphosphinylglycinate 39c 
 
 
 
 
(±)-Benzyloxycarbonyl-α-phosphonoglycine trimethyl ester 39b (2.00 g, 6.04 
mmol), acetic anhydride (2.85 ml, 30.2 mmol) and 10 % palladium on carbon 
catalyst (100 mg) were suspended in acetic acid (17.3 ml). The flask was evacuated 
and then placed under hydrogen (1 atm) for 17 h. The mixture was then filtered 
through celite and concentrated in vacuo to yield a brown oil. This was 
recrystallised from EtOAc and hexane to yield 
methyl N-(acetyl)-α-dimethoxyphosphinylglycinate 39c (1.13 g, 78 %) as a white 
powder; mp 85 – 86 °C (Lit. 88 – 89 °C (Schmidt, U., et al., 1984), Lit. 88.0 -
(Cbz)HN
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P
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 88.5 °C (Mazurkiewicz, R. and Kuznik, A., 2006);; δH(270 MHz; CDCl3) 2.06 
(3 H, s, CH3 (Ac)), 3.78 (3 H, d, J 5.4 Hz, POCH3), 3.81 (3 H, s, OCOCH3), 3.82 
(3 H, d, J 5.4 Hz, POCH3) 5.22 (1 H, dd, J 22.2 Hz, 8.9 Hz, HNCHCO), 6.45 (1 H, 
d, J 8.9 Hz, NH); δP (109.3 MHz, CDCl3) 20.0 (PO(OEt)2). 
 
N(α)-Ac, N(π),N(τ)-Bis(PMB), α,β-dehydro-oxo-His-OMe 40b  
 
 
 
 
 
 
1,3-Bis(PMB)-4-formylimidazolin-2-one 38a (240 mg, 0.681 mmol)  and 
ethyl N-(acetyl)-α-dimethy(oxyphosphinyl)glycinate 39c (243 mg, 1.02 mmol) 
were suspended in anhydrous DCM (12.0 ml) under a nitrogen atmosphere. 
1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU) (115 mg, 1.02 mmol) was added 
slowly to the reaction mixture. This was left stirring for 20 h. The mixture was 
concentrated in vacuo to yield a yellow oil. This was purified using flash 
chromatography with EtOAc-DCM (40:60 to 70:30) to yield 
N(α)-Ac, N(π),N(τ)-Bis(PMB), α,β-dehydro-oxo-His-OMe 40b (190 mg, 60 %) as 
a white powder (Rf 0.19 in 40:60 EtOAc-DCM); mp 198 – 201 °C; νmax(ATR)/cm
−1 
3253 (NH), 1701 (CO), 1655 (CO),  1644 (CO); δH(400 MHz, CDCl3) 1.92 (3 H, s 
br, CH3CO), 3.67 (3 H, s, OCH3), 3.70 (3 H, s, OCH3), 3.72 (3 H, s, OCH3), 4.70 
(2 H, s, CH2 (PMB)), 4.81 (2 H, s, CH2 (PMB)), 6.28 (1 H, s br, β-CH), 6.77 (2 H, 
d, J 8.8 Hz, 2 ArH (PMB)), 6.80 (2 H, d, J 8.8 Hz, 2 ArH (PMB)), 6.90 (1 H, s br, 
α-NH), 7.05 (1 H, s br, Im 5-H), 7.12 (2 H, d, J 8.8 Hz, 2 ArH (PMB)), 7.13 (2 H, 
d, J 8.8 Hz, 2 ArH (PMB)); δC(100.65 MHz; CDCl3); 44.3 (CH2 (PMB)), 47.2 
(CH2 (PMB)), 52.6 (OCH3), 55.28 (OCH3), 55.34 (OCH3), 114.2 (CH (Ar)), 114.3 
(CH (Ar)), 116.4 (β-CH), 117.5 (C (Ar)), 119.3 (HC-5), 120.8 (α-C), 127.9 
(C (Ar)), 128.6 (CH (Ar)), 128.9 (C (Ar)), 129.7 (CH (Ar)), 152.6 (CO), 159.2 
(C (Ar)), 159.5 (C (Ar)), 165.1 (CO), 168.0 (CO). Assignments based on 1D 
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spectra, DEPT-135, COSY and HSQC analysis; m/z (EI) found: 465.1890 (M
 
+ H
+
) 
(C25H27N3O6 requires 465.1894). 
 
Attempted deprotection of 1,3-bis(PMB)-4-methoxycarbonylimidazole 52a 
using TFA 
 
 
 
 
 
 
1,3-Bis(PMB)-4-methoxycarbonylimidazolin-2-one 52a (60 mg, 0.157 mmol) was 
dissolved in a mixture of trifluoroacetic acid (1.9 ml) and thiophenol (32.1 μl, 
0.314 mmol). This was refluxed under nitrogen for 51 h. Et2O (~ 5 ml) was added 
gradually. The resultant white precipitate was filtered off and dried to give 
1-PMB-4-methoxycarbonylimidazolin-2-one 70 (24.6 mg, 60%) a white solid; 
mp 172
 
- 173 °C; νmax(ATR)/cm
−1 
1717 (NH), 1676 (CO); δH(400 MHz, DMSO) 
3.71 (3 H, s, OCH3 (PMB)), 3.74 (3 H, s, CO2CH3 (OMe)), 4.68 (2 H, s, CH2 
(PMB)), 6.91 (1 H, d, J 8.8 Hz, ArH (PMB)),  7.25 (1 H, d, J 8.8 Hz, ArH (PMB)),  
7.48 (1 H, s, HNCCH), 10.90 (1 H, s br, NH); δC(100.65 MHz; DMSO) 45.5 (CH2 
(PMB)), 51.3 (CH3 (PMB)), 55.1 (CH3 (OMe)), 112.1 (C (Ar)), 114.0 (CH (Ar)), 
120.9 (HC-5), 129.2 (CH (Ar)), 152.7 (C (Ar)), 158.7 (C (Ar)), 159.3 (C (Ar)); 
1D-NOE (400 MHz, DMSO), irradiated at δ 7.47 (HNCCH), NOE observed at 
δ 4.68 (1.33%, CH2 (PMB)); m/z (ESI) found: 263.1031 (M + H
+
) (C13H15N2O4 
requires 263.1032). 
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Attempted deprotection of 1,3-Bis(PMB)-4-methoxycarbonylimidazolin-2-one 
52a using CAN 
 
 
 
 
1,3-Bis(PMB)-4-methoxycarbonylimidazolin-2-one 52a (200 mg, 0.523 mmol) 
was dissolved in a mixture of acetonitrile (12.7 ml) and water (3.91 ml). 
Cerium(IV) diammonium nitrate (2.29 g, 4.18 mmol) was added and the solution 
was stirred for 3 h at room temperature. The product was concentrated in vacuo. 
The resulting oil was then partitioned between EtOAc and water and extracted into 
the organic layer. This was then concentrated in vacuo and dried in vacuo over 
phosphorus pentoxide to yield 4-methoxybenzaldehyde 64 (200 mg, 99 %) as a 
colourless oil; δH(270 MHz, CDCl3) 3.90 (3 H, s, OCH3), 6.99 (2 H, d, J 8.9 Hz, 
ArH), 7.83 (2 H, d, J 8.9 Hz, ArH), 9.84 (1 H, s, CHO), which matches literature 
data (Moorthy, J. N., et al., 2010). 
 
Attempted deprotection of N(α)-Cbz, N(τ),N(π)-Bis(PMB)-2-oxo-His-OMe 4d 
using 8 mol. eq. CAN 
 
 
 
 
N(α)-Cbz, N(τ),N(π)-Bis(PMB)-2-oxo-His-OMe 4d (60 mg, 0.107 mmol) was 
dissolved in a mixture of acetonitrile (2.6 ml) and water ( 0.8 ml). Cerium(IV) 
diammonium nitrate (469.3 mg, 0.856 mmol) was added and the solution was 
stirred for 3 h at room temperature. The mixture was then poured into water (4 ml) 
and EtOAc (4 ml) and then extracted into the organic layer. This organic layer was 
washed with saturated aqueous sodium hydrogen carbonate and water. It was then 
dried over MgSO4. This was concentrated in vacuo to yield 
4-methoxybenzaldehyde 64 (14 mg, 96 %) as a brown oil;; δH(270 MHz, CDCl3) 
H
O
MeO
H
O
MeO
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3.87 (3 H, s, OCH3), 6.98 (2 H, d, J 8.7 Hz, ArH), 7.81 (2 H, d, J 8.7 Hz, ArH), 
9.85 (1 H, s, CHO), which matches literature data (Moorthy, J. N., et al., 2010).  
 
Attempted deprotection of N(α)-Cbz, N(τ),N(π)-Bis(PMB)-2-oxo-His-OMe 4d 
using 4 mol. eq. CAN 
 
 
 
 
 
 
N(α)-Cbz, N(τ),N(π)-Bis(PMB)-2-oxo-His-OMe 4d (60 mg, 0.107 mmol) was 
dissolved in a mixture of acetonitrile (2.6 ml) and water (790 μl). Cerium(IV) 
diammonium nitrate (235 mg, 0.428 mmol) was added and the solution was stirred 
for 30 min at room temperature. The mixture was then concentrated in vacuo and 
washed through a silica plug with acetonitrile. The eluate was diluted with DCM, 
washed with water to remove cerium ions and then was purified by flash 
chromatography, first using EtOAc-DCM (5:95 to 10:90) and then using 
methanol-CHCl3 (2:98 to 5:95). This yielded 
2-carboxybenzylamino-4,5-bis-(PMB-imino)pentanoic-acid methyl ester N(4), 
N(5)-dioxide 66 (2 mg, 3.3 %) as a colourless oil (Rf 0.11 in 2 % methanol-CHCl3); 
νmax(ATR)/cm
−1
 1766 (C=O), 1704 (C=O), 1613 (C=N);  δH(400 MHz; CDCl3) 
2.76 (1 H, d, J 16.4 Hz, N=CCHH), 3.00 (1 H, dm, J 16.4 Hz, N=CCHH),  3.66 
(3 H, s, OCH3), 3.69 (3 H, s, OCH3), 3.71 (3 H, s, OCH3), 4.51-4.57 (1 H, m, 
HCCH2), 4.59 (2 H, s, CH2 (PMB)), 4.67 (2 H, s, CH2 (PMB)), 5.04 (2 H, s, CH2 
(Cbz)), 5.74 (1 H, d, J 7.2 Hz, NH), 6.67 (2 H, d, J 8.4 Hz, 2 ArH (PMB)), 6.72 
(2 H, d, J 8.4 Hz, 2 ArH (PMB)), 6.92 (2H, d, J 7.6 Hz, 2 ArH (PMB)), 7.12 (2H, 
d, J 7.6 Hz, 2 ArH (PMB)), 7.25 – 7.32 (5 H, m, 5 ArH (Cbz)), 8.64 (1H, s, 
HC=N); m/z (ESI) found: 564.2335 (M + H
+
) (C30H34N3O8 requires 564.2340), 
581.2599 (M + NH4
+
) (C30H37N4O8 requires 581.2611), 586.2149 (M + Na
+
) 
(C30H33N3O8Na requires 586.2165). 
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                 2,4-dimethoxybenzyl chloride 69 
 
 
 
 
The title compound was synthesised using the procedure described by Nicoletti et 
al. (Nicoletti, T. M., et al., 1990). 2,4-dimethoxybenzyl alcohol (1.00 g, 5.95 
mmol), anhydrous thionyl chloride (910 μl, 12.6 mmol) and anhydrous pyridine (1 
ml) were reacted in anhydrous DCM (6.5 ml) and yielded 2,4-dimethoxybenzyl 
chloride 69 (820 mg, 74 %) as a yellow oil;
 δH(270 MHz, CDCl3) 3.80 (3 H, s, 
OCH3), 3.85 (3 H, s, OCH3), 4.62 (2 H, s, CH2), 6.45 (1 H, d, J 5.4 Hz, ArH), 6.46 
(1 H, d, J 8.1 Hz, ArH), 7.24 (1 H, d, J 8.9 Hz, ArH) which matched the literature 
data (Nicoletti, T. M., et al., 1990). 
 
3,4-dimethoxybenzyl chloride 70  
 
 
 
The title compound was synthesised using the procedure described by Howell et al. 
(Howell, S. J., et al., 2001). 3,4-dimethoxybenzyl alcohol (1.00 g, 5.95 mmol), 
triethylamine (0.93 ml, 6.66 mmol) and thionyl chloride (0.66 ml, 9.09 mmol) were 
reacted in DCM (12.1 ml) and yielded 3,4-dimethoxybenzyl chloride 70 (510 mg, 
46 %) as an off-white powder; δH(270 MHz, CDCl3) 3.87 (3 H, s, OCH3), 3.89 
(3 H, s, OCH3), 4.56 (2 H, s, CH2), 6.81 (1 H, d, J 7.9 Hz, ArH), 6.91 (1 H, s, ArH), 
6.92 (1 H, d, J 7.9 Hz, ArH), which matched the literature data (Howell, S. J., et 
al., 2001). 
 
Protection of 4-methoxycarbonylimidazolin-2-one 52 with benzyl chloromethyl 
ether 
 
Based on the literature preparation by Dransfield et al. (Dransfield, P. J., et al., 
2006), sodium hydride (60 % dispersion in mineral oil, 507 mg, 21.1 mmol) was 
OMe
Cl
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Cl
OMe
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washed with petroleum spirit. The washed NaH was suspended in anhydrous DMF 
(26 ml). 4-Methoxycarbonylimidazolin-2-one 52 (1.00 g, 7.04 mmol) was added. 
The mixture was stirred under nitrogen for 30 min by which time a viscous gel had 
formed. Benzyl chloromethyl ether (2.9 ml, 21.1 mmol) was added slowly to the 
mixture and this was left stirring at r.t. under nitrogen for 18 h until the mixture has 
become a non-viscous liquid again. The mixture was diluted with Et2O (30 ml), 
then washed twice with brine, dried with magnesium sulfate and concentrated in 
vacuo to yield a brown oil. This was purified by flash chromatography using 
EtOAc-petrol (30:70) to yield two products: 
(BOM)N
N(BOM)
O
O(Bn)
O
 
i) 1,3-Bis(BOM)-4-benzyloxycarbonylimidazolin-2-one 68 (586 mg, 17 %) as a 
colourless oil (Rf 0.45 in 40 % EtOAc-petrol); δH(400MHz; CDCl3) 4.57 (2 H, s, 
CH2 (BOM)), 4.63 (2 H, s, CH2 (BOM)), 4.74 (2 H, s, CH2 (BOM)), 5.13 (2 H, s, 
CH2 (BOM)), 5.52 (4 H, s, 2 CH2OBn), 7.09 (1 H, s, HNCCH), 7.23 – 7.41 (15 H, 
m, ArH (BOM)); δC(100.65 MHz; CDCl3); 71.2 (CH2), 71.3 (CH2), 71.4 (CH2), 
72.3 (CH2), 72.8 (CH2), 88.7 (CH2), 114.0 (CH), 121.1 (CH), 127.68 (2 CH), 
127.72 (2 CH), 127.88 (4 CH), 127.91 (CH), 128.06 (4 CH),  128.13 (CH), 128.3 
(C), 136.8 (C), 137.0 (C), 137.8 (C), 153.7 (C), 158.3 (C). 
(BOM)N
N(BOM)
O
OMe
O
 
ii) 1,3-Bis(BOM)-4-methoxycarbonylimidazolin-2-one 52b (484 mg, 12.4 %) as a 
colourless oil. (Rf 0.10 in 40 % EtOAc-petrol); δH(400MHz; CDCl3) δH(400MHz; 
CDCl3) 3.75 (3 H, s, OCH3), 4.51 (2 H, s, CH2 (BOM)), 4.59 (2 H, s, CH2 (BOM)), 
5.06 (2 H, s, CH2 (BOM)), 5.48 (2 H, s, 2 CH2 (BOM)), 7.13 (1 H, s, HNCCH), 
7.15 – 7.32 (10 H, m, ArH (BOM)). 
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1,3-Bis(BOM)-4-hydroxymethylimidazolin-2-one 53b 
 
 
 
 
 
1,3-Bis(BOM)-4-methoxycarbonylimidazolin-2-one 52b (1.6 g, 3.61 mmol) was 
suspended in anhydrous DCM (12.6 ml) and cooled to − 78 °C (EtOAc/ice bath) 
under a nitrogen atmosphere. DIBAL-H (31.0 ml, 31.2 mmol) was added to the 
mixture and it was stirred at − 78 °C for 7 h. MeOH (11.7 ml) was added to quench 
the reaction and the mixture was allowed to warm to room temperature. The 
mixture was diluted with 2M HCl and the product was extracted into DCM. The 
organic layer was washed twice more with brine. The organic layer was dried with 
magnesium sulfate and concentrated in vacuo to yield a yellow oil. This was 
purified using flash chromatography with EtOAc-petrol (40:60 to 70:30) to yield 
1,3-bis(PMB)-4-hydroxyimidazolin-2-one 53b (980 mg, 77 %) as a colourless oil 
(Rf 0.12 in 1:1 EtOAc-petrol); δH (400MHz; CDCl3)  4.43 (2 H, s, CH2), 4.52 (2 H, 
s, CH2), 4.55 (2 H, s, CH2), 5.02 (2 H, s, CH2), 5.26 (2 H, s, CH2), 6.29 (1 H, s, 
HNCCH), 7.20 – 7.38 (10 H, m, ArH (BOM)). 
 
1,3-Bis(BOM)-4-formylimidazolin-2-one 38b 
 
 
 
 
The title compound was synthesised using the procedure described by Dransfield 
et al. using 1,3-bis(BOM)-4-hydroxymethylimidazolin-2-one 53b (545 mg, 
1.54 mmol) and manganese dioxide (1.07 g, 12.3 mmol) in DCM (22 ml) to 
produce a yellow oil. This was purified using flash chromatography with 
EtOAc-petrol (40:60 to 50:50) to yield 1,3-bis(BOM)-4-formylimidazolin-2-one 
38b (302 mg, 56 %) as a colourless oil (Rf 0.18 in 50 % EtOAc-petrol); δH 
(400 MHz, CDCl3) 4.61 (2 H, s, CH2), 4.68 (2 H, s, CH2), 5.19 (2 H, s, CH2), 5.54 
(BOM)N
N(BOM)
O
OH
(BOM)N
N(BOM)
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(2 H, s, CH2), 7.15 (1 H, s, HNCCH), 7.25 – 7.41 (10 H, m, ArH (BOM)), 9.34 
(1 H, s, CHO). 
 
N(α)-Cbz, N(π),N(τ)-Bis(BOM), α,β-dehydro-4,5-dihydro-2-oxo-His-OMe 40c 
 
 
 
 
 
 
1,3-Bis(BOM)-4-formylimidazolin-2-one 38b (232 mg, 0.66 mmol) and 
(±)-benzyloxycarbonyl-α-phosphonoglycine 39b trimethyl ester (327 mg, 
0.99 mmol) were suspended in anhydrous DCM (11.7 ml) under a nitrogen 
atmosphere. 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU) (0.148 ml, 0.99 mmol) 
was added slowly to the reaction mixture. This was left stirring for 16.5 h. The 
mixture was concentrated in vacuo to a brown-yellow oil. This was purified using 
flash chromatography with EtOAc-DCM (10:90 to 30:70) to yield 
N(α)-Cbz, N(π),N(τ)-Bis(BOM), α,β-dehydro-4,5-dihydro-2-oxo-His–OMe 40c 
(110.2 mg, 29 %) as a colourless oil (Rf 0.55 in 60 % EtOAc-DCM); 
νmax(ATR)/cm
−1
 2953 (CH), 1716 (CO), 1704 (CO), 1655 (CO); δH(400 MHz; 
CDCl3)  3.68 (3 H, s, OCH3), 4.44 (2 H, s, CH2 (Cbz)), 4.47 (2 H, s, CH2 (BOM)), 
4.96 (2 H, s, CH2 (BOM)), 5.06 (2 H, s, CH2 (BOM)), 5.14 (2 H, s, CH2 (BOM)), 
6.36 (1 H, s br, α-NH), 6.67 (1 H, s br, β-CH),  7.14 (1 H, s, Im 5-H), 7.20-7.40 
(15 H, m, 3 Ph); δC(100.65 MHz; CDCl3); 52.7 (CH3), 67.7 (CH2), 70.5 (CH2), 70.7 
(CH2), 71.1 (CH2), 72.7 (CH2), 116.1 (CH), 118.3 (C), 118.5 (CH), 119.3 (CH), 
123.9 (C), 127.7 (C), 127.9 (CH), 127.9 (C), 128.0 (CH), 128.3 (CO), 128.4 (C), 
128.5 (C), 128.6 (CO), 135.9 (C), 137.0 (C), 137.2 (C), 152.9 (C), 153.7 (C), 165.0 
(C). Assignments based on 1D spectra, DEPT-135, COSY and HSQC analysis; m/z 
(ESI) found: 558.2229 (M + NH4
+
) (C31H33N3O7 requires 558.2235). 
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Attempted mesylation/tosylation of 
1,3-Bis(BOM)-4-(hydroxymethyl)imidazolin-2-one 52b: formation of 1, 3-
bis(PMB)-5-methylimidazolidin-2,4-dione 74b 
 
 
 
 
1,3-Bis(BOM)-4-hydroxymethylimidazolin-2-one 53b (100 mg, 0.282 mmol) was 
dissolved in anhydrous DCM (1.8 ml) and placed under a nitrogen atmosphere. The 
mixture was cooled to 0 °C using an ice bath and triethylamine (94.4 μl, 0.677 
mmol) was added. Mesyl chloride (43.7 μl, 0.564 mmol) was added and the 
mixture was left for 7 h. The product was then partitioned between DCM and 2M 
HCl. The aqueous layer was then washed twice with DCM and the combined 
organic layers were dried with MgSO4 and concentrated in vacuo to yield a brown 
oil. This was purified by flash chromatography using EtOAc-petrol (30:70 to 
50:50) to yield 1,3-bis(BOM)-5-methylimidazolidin-2,4-dione 74b (50 mg, 38%) 
as a yellow oil (Rf 0.43 in 40% EtOAc-petrol): IR (ATR) νmax(ATR)/cm
−1 
 2937 
(NH), 2877 (NH), 1780 (CO), 1716 (CO); δH (400 MHz, CDCl3) 1.31 (3 H, d, 
J 7.2 Hz, CH3CH), 4.46 (1 H, q, J 7.2 Hz, CH3CH), 4.58 (2 H, s, CH2(BOM)), 4.68 
(1 H, d, J 11.2 Hz, CHH(BOM)), 4.95 (2 H, s, CH2 (BOM)), 4.97 (1 H, d, 
J 11.2 Hz, CHH(BOM)), 5.22 (2 H, s, CH2(BOM)), 7.22 - 7.30 (10 H, m, 2 Ph); 
δC(100.65 MHz, CDCl3); 15.2 (CH3CH), 54.6 (CHCH3), 68.2 (CH2 (BOM)), 70.8 
(CH2 (BOM)), 71.0 (CH2 (BOM)), 72.0 (CH2 (BOM)), 127.5 (2 CH (Ar)), 127.82 
(2 CH (Ar)), 127.84 (CHCH3), 128.1 (2 CH (Ar)), 128.4 (CH (Ar)), 128.6 
(CH (Ar)), 137.21 (C (Ar)), 137.6 (C (Ar)), 155.8 (CO), 173.3 (CO). Assignments 
based on 1D spectra, DEPT-135, COSY and HSQC analysis; m/z (ESI) found: 
372.1916 (M + NH4
+
) (C20H26N3O4 requires 372.1918). 
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1,3-Bis(BOM)-2-oxo-imidazolin-4-methyl methyl carbonate 75 
 
 
 
 
 
 
Two methods were used: 
 
(A) 1,3-Bis(BOM)-4-hydroxymethylimidazolin-2-one 53b (100 mg, 0.28 mmol) 
was dissolved in anhydrous DCM (0.7 ml). This was cooled to 0 °C. Pyridine (26.4 
μl, 0.33 mmol) was added followed by methyl chloroformate (24.0 μl, 0.31 mmol). 
The mixture was allowed to warm to r.t. and then kept at r.t. for 5.5 h. Water 
(0.4 ml) was added and the product was extracted into ethyl acetate (0.7 ml). The 
organic layer was then washed with pH 7.4 phosphate buffer (2 x 0.7ml) and brine 
(2 x 0.7 ml), dried with MgSO4 and concentrated in vacuo to yield a yellow oil. 
This was purified using flash chromatography with the column prepared with Et3N 
and then run with EtOAc-petrol (30:70 to 80:20) to yield 
1,3-bis(BOM)-2-oxo-imidazolin-4-methyl methyl carbonate 75 (41.6 mg, 36.0 %, 
Rf  0.19 in 50 % EtOAc-petrol); δH (400 MHz, CDCl3) 3.69 (3 H, s, OCH3), 4.48 
(2 H, s, CH2 (BOM)), 4.49 (2 H, s, CH2 (BOM)), 4.94 (2 H, s, CH2 (BOM)), 5.02 
(2 H, s, CH2 (BOM)), 5.17 (NCCH2), 6.42 (1 H, s, NCH), 7.17-7.28 (10 H, m, 
2 Ph); δC(100.65 MHz; CDCl3); 55.0 (OCH3), 59.2 (CH2 (BOM)), 70.8 (NCCH2), 
70.9 (CH2 (BOM)), 70.9 (CH2 (BOM)), 78.0 (CH2 (BOM)), 112.7 (CH (Ar)), 117.8 
(C (Ar)), 127.8 (CH (Ar)), 127.8 (CH (Ar)), 127.9 (CH (Ar)), 128.0 (CH (Ar)), 
128.3 (2 CH (Ar)), 128.4 (2 CH (Ar)), 128.5 (2 CH (Ar)), 137.1 (C (Ar)), 137.3 (C 
(Ar)), 137.7 (C (Ar)), 138.0 (C (Ar)), 153.8 (C (Ar)), 155.3 (C (Ar)). Assignments 
based on 1D spectra, DEPT-135, COSY and HSQC analysis.  
 
(B) Sodium hydride (60 % dispersion in mineral oil, 13.1 mg, 0.55 mmol) was 
washed with petroleum spirit. The washed NaH was suspended in anhydrous THF 
(1 ml), then cooled to 0 °C. 1,3-Bis(BOM)-4-hydroxymethylimidazolin-2-one 53b 
(BOM)N
N(BOM)
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(100 mg, 0.28 mmol) was added. Methyl chloroformate (48 μl, 0.62 mmol) was 
added and the mixture was allowed to warm to r.t. It was then stirred under 
nitrogen for 29 h. pH 7.4 phosphate buffer (0.5 ml, 10 mM) was added and the 
product was extracted into ethyl acetate (1 ml). The organic layer was then washed 
with pH 7.4 phosphate buffer (2 x 0.7ml) and brine (2 x 0.7 ml), dried with MgSO4 
and concentrated in vacuo to yield a yellow oil. This was purified using flash 
chromatography with the column prepped with Et3N and then run with EtOAc-
petrol (30:70) to yield 1,3-bis(BOM)-2-oxo-imidazolin-4-methyl methyl carbonate 
75 (3.5 mg, 3.0 %, 0.18 in 50 % EtOAc-petrol); δH (400 MHz, CDCl3) 3.69 (3 H, s, 
OCH3), 4.49 (4 H, s, 2 CH2 (BOM)), 4.95 (2 H, s, CH2 (BOM)), 5.03 (2 H, s, CH2 
(BOM)), 5.18 (NCCH2), 6.43 (1 H, s, NCH), 7.18-7.34 (10 H, m, ArH (BOM)); 
m/z (ESI) found: 413.1704 (M + H
+
) (C22H25N2O6 requires 413.1707). 
 
2-Acetamido-2-[1,3-bis(benzyloxymethyl)5-methyl-2-oxo-2,3-dihydro-1H-
imidazol-4-yl]-malonic acid diethyl ester 77 
 
 
 
 
 
 
Sodium hydride (60 % dispersion in mineral oil, 2.64 mg, 0.11 mmol) was washed 
with petroleum ether. The washed NaH was suspended in anhydrous DMF (1.6 ml) 
under a nitrogen atmosphere. Diethyl acetamidomalonate 71 (23.9 mg, 0.11 mmol) 
was added and the mixture was left stirring at r.t. for 10 min. (S)-(-)-BINAP 
(6.29 mg, 0.01 mmol was then added followed by 
1,3-bis(BOM)-2-oxo-imidazolin-4-methyl methyl carbonate 75 (40 mg, 
0.11 mmol). Finally [Pd(allyl)Cl]2 (0.92 mg, 2.53 μmol) was added. The flask was 
then evacuated and back-filled three times with nitrogen before heating to 80 ° C 
for 5 h. The flask was then cooled to r.t.. Water (2.5 ml) was added and the product 
was extracted into ethyl acetate (5 ml). The organic layer was washed with 
potassium -hydroxide solution (2 x 5 ml, 1 M), HCl (2 x 5 ml, 1 M) and brine 
(BOM)N N(BOM)
O
Me
HN
Me
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OEt
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(3 x 5ml). This layer was then dried with MgSO4 and concentrated in vacuo to 
yield a crude product which was then purified thrice using flash chromatography, 
twice with EtOAc-petrol (40:60 to 80:20 and then 40:60 to 100:0) and then with 
EtOAc-DCM (20:80) to yield 2-acetamido-2-[1,3-bis(benzyloxymethyl)5-methyl-
2-oxo-2,3-dihydro-1H-imidazol-4-yl]-malonic acid diethyl ester 77 (5.1 mg, 8.4 %, 
Rf 0.26 in 30 % EtOAc-DCM); νmax(ATR)/cm
−1
 3319 (NH), 1747 (CO), 1670 
(2 CO);
 
 δH (400 MHz, CDCl3) 1.21 (3 H, t, J 7.2 Hz, CH2CH3), 1.78 (3 H, s, CH3), 
2.05 (3 H, s, CH3), 4.12 – 4.28 (4 H, m, 2 CH2CH3), 4.51 (2 H, s, CH2), 4.59 (2 H, 
s, CH2), 5.06 (2 H, s, CH2), 5.13 (2 H, s, CH2), 7.22 – 7.32 ( 10 H, m, 2 Ph), 7.89 
(1 H, s, br, NH); m/z (ESI) found: 554.2494 (M + H
+
) (C29H36N3O8 requires 
554.2497). 
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